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The role of non-genetic variability in Acute Myeloid Leukaemia 
 
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells 
with a dismal survival. It has a strong reliance on epigenetic and transcriptional factors for disease 
progression. Accordingly, my lab has previously identified KAT2A, a histone acetyl-transferase, as a 
requirement for AML maintenance, where chemical inhibition of KAT2A promotes differentiation of 
AML cell lines (Tzelepis et al., 2016). More recently, using a conditional knockout mouse model for 
Kat2a our lab showed that it sustains KMT2A/MLLT3 AML stem cells. Kat2a is a classical regulator of 
transcriptional variability, its loss leading to cell-to-cell heterogeneity in transcription levels, including 
from genes involved in ribosomal biogenesis and translation (Domingues et al., 2020). No recurrent 
mutations in the KAT2A gene have been described in AML, and it is unclear if and how it participates 
in pre-leukaemia-to-AML progression. In this thesis, I studied Kat2a loss in 2 mouse models of AML 
representing forms of human disease with a prolonged pre-leukaemia phase which typically require 
additional mutations for leukaemia progression. Specifically, I analysed the biology of RUNX1-
RUNX1T1(9a) and Idh1R132H-initiated AML in a conditional Kat2aKO background and observed 
consistent acceleration of leukaemia initiation and progression with perpetuation of transformed 
Kat2aKO cells in vivo. Single-cell RNA sequencing (scRNA-seq) of early-stage Kat2aWT and 
Kat2aKO RUNX1-RUNX1T1(9a) pre-leukaemia, suggested an increase in transcriptional variability 
upon Kat2a loss, which was accompanied by diversification of cell fates towards B-lymphocytes and 
monocytes. Furthermore, pseudo-temporal ordering of single Kat2aKO cells revealed a highly branched 
trajectory populated with intermediate stages of transformation, including accumulation of leukaemia 
progenitors with RUNX1-RUNX1T1 signature. In contrast, Kat2aWT cells displayed a linear 
haematopoiesis trajectory with minimal branching, and an abrupt transition towards the candidate 
leukaemia progenitor state. Pathway analysis combined with functional studies indicate a mechanistic 
contribution of cytoplasmic translation and ribosomal biogenesis-associated genes towards leukaemia 
progression in both models of pre-leukaemia. Taken together, my work suggests that loss of Kat2a 
results in accelerated pre-leukaemia transformation accompanied with diversification of cell fate 
transitions including with increased accessibility to cell states prone to transformation. Furthermore, 
transformation-prone cells may benefit from low biosynthetic activity to progress to a leukaemic state. 
I hypothesize that Kat2a loss may function similarly in the context of other malignancies. In the future, 
this knowledge may aid in the development of early diagnostic tools and suggest bespoke therapeutic 
interventions. 



























I feel humbled and grateful to acknowledge all those who have helped me to frame ideas concretely. I 
am grateful to my supervisor Dr. Cristina Pina for providing me the opportunity to work on this study 
and would like to thank her for constructive comments during thesis writing. I express my warmest 
gratitude to Dr. Gos Micklem for accepting me as his nominal student since August 2019 and am 
indebted to him for his time and efforts in ensuring my well-being and for providing constructive 
suggestions whenever needed. I appreciate the help and support received from my previous advisor Dr. 
Sudhakaran Prabakaran during the first year of my PhD and would remain thankful to him for 
introducing me to the basics of next-generation sequencing technology and terminologies.  
 
I would like to thank our collaborator Prof. George Vassiliou (WT Sanger Institute) for sharing 
Idh1R132H mouse model for this study and his lab member Dr. Oliver Dovey for developing the model. 
I feel delighted to have worked with Oliwia Cyran, placement student from King’s College London 
who worked towards the in vitro pre-leukaemia studies of Idh1R132H mouse model with assistance 
from Ryan J. Asby (Huntly group, Department of Haematology). I am also thankful to Caitlin Cash, 
student at Brunel University, London, for working towards leukaemia analysis of Idh1R132H mouse 
model while I’ve been working from my home country during the pandemic. I would like to thank Ana 
Filipa Domingues (ex-member Pina group) and George Giotopolous (Huntly group) for working on the 
preliminary set-up of the RUNX1-RUNX1T1(9a) mouse model before I joined the group. I would like 
to extend my gratitude towards Dr. Roberto Bandiera (Frye group) for sharing reagents for the OP-Puro 
experiment and providing his help in experimental set up. I would further like to thank Dr. Shabana 
Vohra (Huntly group) for running some pre-processing steps on single cell ATAC sequencing data 
before my lab joining and to Dr. Matt Wayland (Department of Zoology) for providing high 
performance computing resources to run the CellRanger pipeline for single-cell RNA sequencing data. 
I am grateful to Joana Ceveira (Flow cytometry manager, Department of Pathology) for being extremely 
helpful and teaching me how to operate the Attune flow analyzer in a short period of time.   
 
I would like to express my sincere gratitude to my previous supervisor (2013-2015), Dr. Sweta 
Srivastava (Assistant Professor, St. John’s Medical College Hospital, India) for her guidance and 
motivation, which encouraged me to follow a scientific career. I am thankful to her for inculcating in 
me the importance of laboratory management, experimental planning, multi-tasking, and teamwork 
skills which proved vital in finishing my thesis work. In particular, I am grateful for the education I 
received from her which helped me navigate challenging circumstances in a new country, which 




during the stage of thesis conclusion. I will remain indebted to her for helping me become an 
independent researcher and I feel lucky to have the chance to be associated with someone like her in 
my life. 
 
I express my heartfelt gratitude to my Graduate Tutor, Dr. Emma Cahill (Murray Edwards College) for 
her constant encouragement and support, especially during challenging times. I can’t thank her enough 
for her insightfulness and empathy which helped me in finishing my thesis. I would like to extend my 
gratitude towards my General Practitioner, Dr. Rebecca Towl and Ms. Esther at University Counselling 
Services for their excellent care and lending an ear when in need.  
 
I owe my gratitude to my partner Easwaran Ramamurthy (PhD student, Carnegie Mellon University, 
USA). His constant encouragement helped me keep pursuing my interest in Science. Considering the 
lack of computational guidance and environment in my lab, his availability despite the time zone 
difference to answer my questions helped me pick up R, Python, and UNIX which I used for analysing 
sequencing data in this thesis. His care and support during this time have helped me get through difficult 
times. 
 
I could not have asked for better lab members than Keti, Liliana, and Wade who went through hard 
times together, cheered me on, and celebrated each accomplishment. Their timely help and friendship 
will always be remembered. I would also like to thank members from neighbouring labs including 
Chapman group (Haematology), Ferguson Smith group and Imbeault group (Genetics) for their help 
whenever needed.  
 
I am extremely thankful to my friends Shilpa, Akshit, Ying, Chilombo, Amit, Pallavi, Radhika, 
Avinash, Grace, Shalini, and Elizabeth for their love, care and compassionate friendship. I will always 
cherish the warmth shown by them. I am also grateful to Sarah Horton (Huntly group), Rachel Lyne 
(Micklem group) and Susanne van den Brink (van Oudenaarden group, Hubrecht Institute) for their 
comments and suggestions which helped me improve my thesis. 
 
This work wouldn’t have been possible without the prompt support received from the administrative 
staff at Department of Haematology, Department of Genetics, and Murray Edwards College. I would 
especially like to thank Martin Dawes for his truly professional support.   
 
I feel a deep sense of gratitude for my parents who formed part of my vision and taught me good values 
and about the things that matter in life. Their infallible love and support have always been my strength. 




grateful to my brother Ankur for his unconditional trust, timely encouragement, and support despite the 
long distance between us, and to my niece Anvika for her cheerfulness. 
 
I acknowledge Lady Tata Memorial Trust, Trinity Henry Barlow Trust, Cambridge Commonwealth, 
European and International Trust and Murray Edwards College for believing in my work and providing 



















Table of Contents 
List of Figures ....................................................................................................................... xiv 
List of Tables ......................................................................................................................... xix 
List of Abbreviations ............................................................................................................ xxi 
1 Introduction ................................................................................................................... 15 
1.1 Cancer Evolution ..................................................................................................... 15 
1.2 Models of cancer evolution ..................................................................................... 18 
1.3 Mechanisms driving cancer evolution ..................................................................... 23 
1.3.1 Genetic variability ............................................................................................... 23 
1.3.2 Epigenetic variability ........................................................................................... 27 
1.3.3 Transcriptional variability ................................................................................... 32 
1.4 Single-cell technology as a means to quantify cell-to-cell transcriptional variability
 ……………………………………………………………………………………..38 
1.5 Acute Myeloid Leukaemia- a cancer model to study the dependency on non-genetic 
variability ............................................................................................................................. 47 
1.6 Genetic, Epigenetic and Transcriptional variability in Acute Myeloid Leukaemia 48 
1.7 Pre-Leukaemia ......................................................................................................... 53 
1.7.1 RUNX1-RUNX1T1(9a) model ........................................................................... 55 
1.7.2 Idh1R132H model ............................................................................................... 59 
1.8 MLL-AF9 model- a maintenance model of leukaemia ........................................... 62 
1.9 Ribosomal Biogenesis ............................................................................................. 64 
1.10 Lysine acetyltransferase 2a Kat2a/KAT2A- a tool to study non-genetic variability
 ……………………………………………………………………………………..66 
1.11 Hypothesis and Rationale ........................................................................................ 71 
1.12 Objectives ................................................................................................................ 72 
1.13 Thesis Structure ....................................................................................................... 73 




2.1 Kat2a conditional knock-out model ........................................................................ 76 
2.2 Generation of Idh1R132H Kat2a fl/fl mice model .................................................. 77 
2.3 Genotyping .............................................................................................................. 78 
2.3.1 DNA Extraction ................................................................................................... 78 
2.3.2 Polymerase Chain Reaction for Mx1-Cre, Idh1 and Kat2a ................................. 79 
2.4 Idh1R132H recombination confirmation ................................................................ 81 
2.5 Kat2a excision confirmation ................................................................................... 83 
2.6 Bones and spleen processing ................................................................................... 85 
2.7 Lineage depletion .................................................................................................... 86 
2.8 Retroviral Transduction ........................................................................................... 87 
2.9 RUNX1-RUNX1T1(9a) experiment set-up .............................................................. 88 
2.10 Flow Cytometry analysis ......................................................................................... 88 
2.11 Colony Formation assay .......................................................................................... 89 
2.12 Peripheral Blood analysis ........................................................................................ 90 
2.13 Maintenance experiment ......................................................................................... 90 
2.14 Idh1R132H experiment set-up ................................................................................ 91 
2.15 Idh1R132H haematopoietic compartment staining ................................................. 91 
2.16 Single-cell RNA sequencing ................................................................................... 92 
2.16.1 Strategy and sample preparation ..................................................................... 92 
2.16.2 Quality Control (QC) and generation of gene-cell matrix ............................... 94 
2.16.3 Differential expression analysis ...................................................................... 98 
2.16.4 Gene Ontology analysis ................................................................................... 98 
2.16.5 Molecular Signature Database (MSigDB) ....................................................... 98 
2.16.6 Pseudotemporal ordering and construction of single-cell trajectory ............... 99 
2.16.7 Transcriptional variability measurement ....................................................... 100 
2.17 Single-cell ATAC sequencing ............................................................................... 101 
2.17.1 Sample preparation ........................................................................................ 101 
2.17.2 Matrix generation, pre-processing and filtering of data ................................ 102 




2.17.4 Differential accessibility analysis .................................................................. 103 
2.17.5 Dimensionality reduction analysis and k-medoid clustering ......................... 103 
2.17.6 Genomic Regions Enrichment of Annotations Tool (GREAT) .................... 103 
2.17.7 Annotation of peaks ....................................................................................... 104 
2.17.8 Transcriptional variability calculation ........................................................... 104 
2.18 Generation of MLL-AF9 primary cell lines ........................................................... 104 
2.19 Mitochondrial analysis .......................................................................................... 107 
2.20 Tigecycline inhibition ............................................................................................ 109 
2.21 O-propargyl-puromycin (OP-Puro) assay ............................................................. 110 
2.22 S6K1 inhibition ..................................................................................................... 111 
2.23 Statistical Analysis ................................................................................................ 112 
3 Functional characterization of RUNX1-RUNX1T1(9a) and Idh1R132H leukaemia in 
a Kat2a knockout genetic background ............................................................................... 114 
3.1 Loss of Kat2a promotes pre-leukaemia to leukaemia acceleration in RUNX1- 
RUNX1T1(9a) model of leukaemia ................................................................................... 115 
3.2 Kat2a loss aids in the survival of RUNX1-RUNX1T1(9a) transformed cells at pre-
leukaemia stage .................................................................................................................. 119 
3.3 RUNX1-RUNX1T1(9a) transformed cells show an increase in self-renewal capacity 
upon loss of Kat2a ............................................................................................................. 122 
3.4 Kat2a loss does not impact any haematopoietic compartment in Idh1R132H pre-
leukaemia ........................................................................................................................... 125 
3.5 Loss of Kat2a aids in Idh1R132H transformation during pre-leukaemia ............. 129 
3.6 Idh1R132H animals showed myeloproliferation but did not develop leukaemia . 130 
3.7 Kat2a loss promotes enrichment of c-Kit+Mac1- progenitor cells in Idh1R132H 
transplants .......................................................................................................................... 136 
3.8 Loss of Kat2a does not impact DNA damage in Idh1R132H pre-leukaemia ....... 138 
4 Identification of transcriptional programmes associated with Kat2a loss in RUNX1-




4.1 Single-cell RNA sequencing of RUNX1-RUNX1T1(9a) transformed Kat2a WT and 
Kat2a NULL pre-leukaemia cells ...................................................................................... 149 
4.1.1 Gel Bead-In-EMulsions (GEMs) generation and Barcoding ............................ 149 
4.1.2 Post GEM-RT clean up and cDNA amplification ............................................. 149 
4.1.3 Library construction .......................................................................................... 150 
4.1.4 Sequencing libraries .......................................................................................... 150 
4.2 Single-cell RNA sequencing- pre-processing, filtering and normalization ........... 151 
4.3 Dimensionality reduction analysis ........................................................................ 158 
4.3.1 Principal Component Analysis (PCA) ............................................................... 158 
4.3.2 t-Distributed Stochastic Neighbour Embedding (t-SNE) .................................. 164 
4.4 Kat2a loss leads to global downregulation of gene expression ............................. 166 
4.5 The downregulated genes were enriched in mitochondrial ATP synthesis, ribosomal 
biogenesis and cytoplasmic translation pathways ............................................................. 170 
4.6 Time series progression of Kat2a WT and Kat2a NULL suggest an early metabolic 
configuration, which may be accelerated by Kat2a loss ................................................... 178 
4.7 Mitochondrial ATP synthesis pathway was associated with pre-leukaemia 
transformation of Kat2a WT cells ..................................................................................... 180 
5 Mechanistic investigation of Kat2a associated transcriptional programmes in 
RUNX1-RUNX1T1(9a) and Idh1R132H pre-leukaemia ................................................... 193 
5.1 Kat2a loss downregulates mitochondrial activity in RUNX1-RUNX1T1(9a) pre-
leukaemia ........................................................................................................................... 194 
5.2 MLL-AF9 transformed Kat2a WT cells with low mitochondrial mass phenocopy 
some of the characteristics of Kat2a NULL cells .............................................................. 198 
5.3 Inhibition of mitochondrial translation in MLL-AF9 transformed Kat2a WT cells 
phenocopies Kat2a NULL phenotype ............................................................................... 205 
5.4 Inhibition of mitochondrial translation during RUNX1-RUNX1T1(9a) transformation 
selects for primitive cells ................................................................................................... 208 
5.5 Loss of Kat2a inhibits protein synthesis during Idh1R132H pre-leukaemia 




5.6 Inhibition of protein synthesis in RUNX1-RUNX1T1(9a) and Idh1R132H model aids 
in pre-leukaemia transformation ........................................................................................ 215 
6 Analysis of the role of transcriptional variability upon Kat2a loss in RUNX1-
RUNX1T1(9a) pre-leukaemia ............................................................................................. 225 
6.1 Single- cell pseudotime trajectory analysis highlights that Kat2a NULL cells follow 
a dispersed trajectory ......................................................................................................... 225 
6.2 Single-cell trajectory coincides with haematopoietic hierarchy ............................ 229 
6.3 Loss of Kat2a promotes differentiation towards B-cell lineage during pre-leukaemia 
transformation .................................................................................................................... 232 
6.4 Loss of Kat2a promotes monocytic differentiation during pre-leukaemia 
transformation .................................................................................................................... 235 
6.5 Kat2a loss aids in accumulation of transformed pre-leukaemic cells ................... 239 
6.6 Loss of Kat2a increases transcriptional variability during pre-leukaemia progression
 ……………………………………………………………………………………245 
6.7 Inhibition of KAT2A rearranges chromatin accessibility pattern in Kasumi-1 cells
 ……………………………………………………………………………………249 
6.8 MB-3 treated cells possess differential chromatin accessibility pattern ................ 254 
6.9 Increase in transcriptional variability may be consequential to differential chromatin 
accessibility ....................................................................................................................... 255 
7 Discussion ..................................................................................................................... 265 
7.1 Kat2a loss may serve as a tool to study the process of transformation in other pre-
malignancies ...................................................................................................................... 266 
7.2 Kat2a loss may serve as a tool to study mitochondrial metabolism ...................... 273 
7.3 Kat2a loss may serve as a model to study ribosomopathies ................................. 282 
7.4 Loss of Kat2a promotes cellular diversification with an increase in transcriptional 
variability ........................................................................................................................... 285 
7.5 Increase in transcriptional variability upon Kat2a loss may be consequential to 




8 References .................................................................................................................... 306 
Annexure-A: Analysis Scripts ............................................................................................ 362 
A.1 Single-cell RNA sequencing analysis ......................................................................... 362 
Pre-processing and filtering ........................................................................................... 362 
Detection of variable genes ........................................................................................... 363 
Differential expression calculation using DESeq2 ........................................................ 363 
Linear Dimensionality reduction analysis ..................................................................... 363 
Graph based clustering analysis .................................................................................... 364 
Non-linear dimensionality reduction analysis ............................................................... 364 
Creation of Cell Data Set object for pseudotime analysis using Monocle v3.0 ............ 364 
Performing dimensionality reduction analysis .............................................................. 366 
Pseudotime trajectory analysis ...................................................................................... 366 
Pairwise distance calculation ......................................................................................... 367 
A.2 Single-cell ATAC sequencing analysis ...................................................................... 368 
Filtering the lower quality cells ..................................................................................... 368 
Jaccard distance calculation .......................................................................................... 370 
Dimensionality reduction analysis using tSNE ............................................................. 371 
k-medoid clustering ....................................................................................................... 373 
Projection of clusters on tSNE plot ............................................................................... 373 
Calculation of differential accessibility peaks ............................................................... 374 
Annexure-B .......................................................................................................................... 378 
B.1: Definition of haematopoietic compartments for flow cytometry .............................. 378 
B.2: Primers for Genotyping ............................................................................................. 378 
B.3: Primers to confirm excision/mutation recombination ............................................... 378 
B.4: List of antibodies and fluorescent dyes ...................................................................... 379 
B.5: List of cell culture reagents ........................................................................................ 380 










List of Figures 
Figure 1.1: Schematic representing theory of clonal evolution of cancer led by Nowell (Nowell, 
1976). ....................................................................................................................................... 16 
Figure 1.2: Models of tumour evolution. ................................................................................. 23 
Figure 1.3: Types of epigenetic variability bases on relationship with genotype. .................. 29 
Figure 1.4: Relationship between epigenetic variability and transcriptional variability. ........ 31 
Figure 1.5: Intrinsic and extrinsic contributions to gene expression variability. .................... 36 
Figure 1.6: Two-state model of transcriptional bursting. ........................................................ 37 
Figure 1.7: Single cell analysis reveals variability in gene expression patterns. ..................... 39 
Figure 1.8: Schematic of single cell RNA sequencing as described by Tang et al., 2009. ..... 41 
Figure 1.9: Genes recurrently mutated in AML belong to distinct functional groups or 
pathways. ................................................................................................................................. 49 
Figure 1.10: Enhanced transcriptional variability during intermediate stage of cellular 
differentiation process. ............................................................................................................ 52 
Figure 1.11: Recurrent mutations in different cytogenetic and mutational backgrounds in AML.
 ................................................................................................................................................. 53 
Figure 1.12: Genomic structure of t(8;21). .............................................................................. 57 
Figure 1.13: Structure of the full-length RUNX1-RUNX1T1 protein and truncated protein. 57 
Figure 1.14: Chemical reactions catalyzed by the wild-type IDH enzymes and tumour-derived 
IDH1/2 mutants. ...................................................................................................................... 59 
Figure 1.15: TCGA analysis on recurrent mutations in 200 AML patient samples. ............... 61 
Figure 1.16: Schematic of KAT2A-containing complexes and their functions and implications 
in diseases. ............................................................................................................................... 69 
Figure 1.17: Kat2a WT and Kat2a knockout MLL-AF9 primary leukaemias have unique 
differentiation trajectories. ...................................................................................................... 70 
Figure 2.1: Kat2afl/fl conditional knockout mouse model. ....................................................... 76 
Figure 2.2: Generation of Idh1R132H Kat2a fl/fl model. ....................................................... 78 
Figure 2.3: Representative gel images for genotyping from a single run. ............................... 81 
Figure 2.4: Idh1R132H recombination analysis. ..................................................................... 83 
Figure 2.5: Kat2a excision analysis. ........................................................................................ 84 
Figure 2.6: Tissue Processing. ................................................................................................. 86 




Figure 2.8: Single cell RNA sequencing strategy and sample preparation. ............................ 94 
Figure 2.9: Quality Control. .................................................................................................... 95 
Figure 2.10: Generation of gene-cell matrix using Cellranger aggr pipeline. ......................... 97 
Figure 2.11: Pre-processing using Monocle v3.0. ................................................................... 99 
Figure 2.12: Transcriptional variability measurement. ......................................................... 101 
Figure 2.13: Sample preparation and generation of count matrix from scATAC-seq data. .. 102 
Figure 2.14: Characterization of MLL-AF9 primary cell lines. ............................................. 107 
Figure 2.15: Mitochondrial analysis and gating strategy. ..................................................... 108 
Figure 2.16: Schematic for Tigecycline experiment. ............................................................ 110 
Figure 2.17: Gating strategy for OP-Puro analysis. .............................................................. 111 
Figure 2.18: Experimental strategy for S6K1 inhibition experiment. ................................... 112 
Figure 3.1: Functional characterization of RUNX1-RUNX1T1(9a) leukaemia. .................... 117 
Figure 3.2: Peripheral blood analysis and terminal leukaemia burden study. ....................... 119 
Figure 3.3: In vivo analysis of RUNX1-RUNX1T1(9a) pre-leukaemia. ................................ 122 
Figure 3.4: Colony forming unit analysis. ............................................................................. 124 
Figure 3.5: Functional characterization of Idh1R132H model. ............................................. 128 
Figure 3.6: Spleen and liver weight during Idh1R132H pre-leukaemia. .............................. 129 
Figure 3.7: Colony forming unit analysis for Idh1R132H pre-leukaemia. ........................... 130 
Figure 3.8: Peripheral blood analysis. ................................................................................... 132 
Figure 3.9: Flow cytometry analysis of Idh1R132H transformed Kat2a HET and Kat2a NULL 
animals. .................................................................................................................................. 136 
Figure 3.10: Functional characterization of Idh1R132H transplants. ................................... 137 
Figure 3.11: DNA damage assay for Idh1R132H pre-leukaemia. ........................................ 142 
Figure 4.1: Visualization of gene and cell counts using Seurat v2.4. ................................... 153 
Figure 4.2: Relationship between UMI counts, gene counts and mitochondrial content using 
Seurat v2.4. ............................................................................................................................ 156 
Figure 4.3: Detection of variable genes across single cells. .................................................. 157 
Figure 4.4: Dimensionality reduction using Principal Component Analysis. ....................... 160 
Figure 4.5: Jackstraw plot for identification of significant PCs. ........................................... 162 
Figure 4.6: Visualization of PCs. .......................................................................................... 164 
Figure 4.7: Dimensionality reduction analysis using t-distributed stochastic neighbouring 
method. .................................................................................................................................. 166 




Figure 4.9: DESeq2 analysis for Kat2a WT vs Kat2a NULL global comparison. ............... 172 
Figure 4.10: DESeq2 analysis for Kat2a WT vs Kat2a NULL 2months comparison. ......... 174 
Figure 4.11: DESeq2 analysis for Kat2a WT vs Kat2a NULL 4months comparison. .......... 176 
Figure 4.12: DESeq2 analysis for common set of genes downregulated in Kat2a NULL with 
respect to Kat2a WT at respective time points. ..................................................................... 177 
Figure 4.13: DESeq2 analysis for Kat2a WT 2 months vs 4months comparison. ................ 180 
Figure 4.14: DESeq2 analysis for Kat2a NULL 2 months vs 4months comparison. ........... 182 
Figure 4.15: DESeq2 analysis for Kat2a WT 4 months vs Kat2a NULL 2 months comparison.
 ............................................................................................................................................... 184 
Figure 4.16: DESeq2 analysis for common set of genes downregulated in Kat2a NULL vs 
Kat2a WT at 2 months with Kat2a WT 2 months vs 4 months. ........................................... 185 
Figure 5.1: Mitochondrial mass and potential analysis for RUNX1-RUNX1T1(9a) and MLL-
AF9 transformed cells. ........................................................................................................... 198 
Figure 5.2: Colony forming assay for in vitro MLL-AF9 transformed Kat2a WT and Kat2a 
NULL BM cells sorted on the basis of mitochondrial mass. ................................................ 203 
Figure 5.3: Single cell clonal expansion assay for in vitro MLL-AF9 transformed Kat2a WT 
and Kat2a NULL BM cells sorted on the basis of mitochondrial mass. ............................... 205 
Figure 5.4: Inhibition of mitochondrial translational activity in in vitro MLL-AF9 transformed 
Kat2a WT BM cells. .............................................................................................................. 208 
Figure 5.5: Inhibition of mitochondrial translational activity during RUNX1-RUNX1T1(9a) 
transformation of Kat2a WT BM cells in vitro. .................................................................... 209 
Figure 5.6: OP-Puro analysis for RUNX1-RUNX1T1(9a) transformed Kat2a WT and Kat2a 
NULL BM cells. .................................................................................................................... 214 
Figure 5.7: OP-Puro analysis for Idh1R132H transformed Kat2a WT and Kat2a NULL BM 
cells. ....................................................................................................................................... 215 
Figure 5.8: OP-Puro analysis for RUNX1-RUNX1T1(9a) transformed Kat2a WT cells treated 
with S6K1 inhibitor. .............................................................................................................. 217 
Figure 5.9: Colony forming assay upon S6K1 inhibition. ..................................................... 219 
Figure 6.1: Pseudotime trajectory analysis for single cells using Monocle 3.0. ................... 228 
Figure 6.2: Representation of markers of haematopoietic hierarchy. .................................... 232 
Figure 6.3: B-cell differentiation marker analysis. ................................................................ 235 
Figure 6.4: Monocyte marker analysis. ................................................................................. 239 




Figure 6.6: Pseudotime trajectory plots highlighting different population of cells. .............. 245 
Figure 6.7: Pairwise correlation measure for transcriptional variability. .............................. 248 
Figure 6.8: Single cell ATAC sequencing pre-processing and filtering. .............................. 251 
Figure 6.9: GREAT analysis for region-gene associations. .................................................. 253 
Figure 6.10: k-medoid clustering analysis. ............................................................................ 255 
Figure 6.11: Gene ontology analysis and integration with scRNA-seq data. ........................ 260 
Figure 7.1 : Proposed model depicting transcriptional variability consequent to differential 









List of Tables 
Table 1.1: Summary of current scRNA-seq methods (Modified from (Hedlund and Deng, 
2017)) ...................................................................................................................................... 42 
Table 4.1: Data summary post pre-processing and filtering steps ......................................... 166 
Table 4.2: DESeq2 analysis for different comparisons with numbers representing upregulated 
and downregulated genes with p-adj <0.05. Numbers inside the brackets represent minimum 









List of Abbreviations 
AF  Alexa Fluor 
AF9  ALL1-Fused gene from chromosome 9 
ALL  Acute Lymphoblastic Leukaemia 
AML  Acute Myeloid Leukaemia 
AML1  Acute Myeloid Leukaemia 1 
ASPA  Animal Scientific Procedures Act 1986 
ATAC  Ada Two A Containing 
AWERB Animal Welfare and Ethical Review Body 
BCL  Base Call Files 
BE  Branching Evolution 
BED  Browser Extensible Data 
BM  Bone Marrow 
BRD  Bromodomain 
BSA  Bovine Serum Albumin 
CDS  Cell Data Set 
cDNA  complimentary DNA  
CE  Convergent Evolution 
CEL-seq Cell Expression by Linear Amplification Sequencing 
CFC  Colony Forming assay 
CFP  Cyan Fluorescent Protein 
CFU-E  ColonyForming Unit-erythroid 
CFU-G Colony Forming Unit-Granulocyte 
CFU- GEMM Colony Forming Unit- Granulocyte Erythroid Macrophage Megakaryocyte 
CFU-GM Colony Forming Unit-Granulocyte Macrophage 
CLL  Chronic Lymphoid Leukaemia 
CO2  Carbon Dioxide 
CNV  Copy-Number Variation 
CTC  Circulating Tumour Cell 
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats 





DBA  Diamond-Blackfan anaemia 
DLBCL Diffuse Large B-cell Lymphoma 
DMEM Dulbecco's Modified Eagle's medium 
DM  Distance to Median 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
DUB  Histone Deubiquitinase  
EDTA  Ethylenediaminetetraacetic Acid 
ETO  Eight Twenty One 
FACS  Fluorescence Activated Cell Sorting 
FBS  Fetal Bovine Serum 
FDR  False Discovery Rate 
FLT3  Fms-Related Tyrosine Kinase 3 
Gcn5  General control nonderepressible 5  
GFP  Green Fluorescent Protein 
GREAT Genomic Regions Enrichment of Annotations Tool 
GNAT  Gcn5-related N-acetyltransferase 
G&T-seq Genome and Transcriptome sequencing 
HAT  Histone Acetyl Transferase 
HDAC  Histone Deacetylase 
HEK  Human Embryonic Kidney 
HGB  Haemoglobin 
HIF1α  Hypoxia inducible factor 1 α 
I20  IMDM + 20% FBS + 2 mg/mL L-Glutamine, 1% PSA 
IMDM  Iscove's Modified Dulbecco's Medium 
IRES  Internal Ribosome Entry Site 
iPSCs  induced Pluripotent Stem Cells 
IVT  in vitro transcription 
Kat2a  Lysine Acetyltransferase 2a 
KO/NULL Knockout 
LE  Linear Evolution 
log2 FC log2 fold change 




LT-HSC Long-Term reconstituting Haematopoietic Stem Cell 
M  Macrophage 
M-MLV Moloney murine leukaemia virus 
MALBAC Multiple Annealing and Looping-Based Amplification Cycles 
MARS-seq Massively Parallel RNA Single-cell sequencing  
MB-3  α-methylene-γ-butyrolactone 3 
mIL-3  mouse Interleukin-3 
mIL-6  mouse Interleukin-6 
MLL  Mixed Lineage Leukaemia 
MMHCC Mouse Model of Human Cancers Consortium 
MOMP Mitochondrial Outer Membrane Permeabilization 
mRNA  messenger RNA 
mSCF  mouse-Stem Cell Factor 
MSigDB Molecular Signature Database 
NaCl  Sodium Chloride 
NAD+  Nicotinamide adenine dinucleotide 
NADP+ Nicotinamide Adenine Dinucleotide Phosphate 
NAT  N-terminal and Ada-Two interaction domain 
NE  Neutral Evolution 
NGS  Next Generation Sequencing 
NHR  Nervy homology regions 
NOD/SCID  Nonobese diabetic/severe combined immunodeficiency 
NPM1  Nucleophosmin 1 
NRAS  Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog 
OP-Puro O-propargyl-puromycin 
OXPHOS Oxidative Phosphorylation 
PAGA  Partition-based Graph Abstraction 
PANTHER Protein Analysis through Evolutionary Relationships 
PBE  Phosphate Buffer Saline + 0.5M EDTA + 2% BSA  
PBS  Phosphate Buffer Saline 
PCA  Principal Component Analysis 
PCR  Polymerase Chain Reaction 




PE  Punctuated Evolution 
PFA  Paraformaldehyde 
pIpC  Polyinosinic polycytidylic acid 
PKA  Protein Kinase A 
PKA RIIalpha PKA regulatory subunit 
PLT  Platelets  
PSA  Penicillin-Streptomycin Antibiotic 
PCAF  p300/CBP-associated factor 
QC  Quality Control 
qRT-PCR Quantitative Reverse Transcription Polymerase Chain Reaction 
R20  RPMI + 20% FBS 
RBC  Red Blood Cell 
RNA  Ribonucleic acid 
Rpm  Rotations per minute  
RPMI 1640 Roswell Park Memorial Institute 1640 
rRNA  ribosomal RNA 
S6K1  p70 ribosomal S6 kinase 
scATAC-seq Single cell sequencing Assay for Transposase-Accessible Chromatin 
sequencing 
scM&T-seq Single cell genome-wide Methylome and Transcriptome sequencing 
scRNA-seq Single cell RNA sequencing 
scTrio-seq Single cell Triple Omics sequencing 
SDS  Sodium dodecyl sulphate 
SMART Switching Mechanism At 5′ end of RNA Template 
SNV  Single Nucleotide Variation 
SPF  Specific Pathogen Free 
SAGA  Spt-Ada-Gcn5 acetyltransferase 
T-ALL  T-cell acute lymphoblastic leukaemia 
TAF  TATA-binding protein associated factor 
TCA  Tricarboxylic Acid  
TCGA  The Cancer Genome Atlas 
TET  Ten-eleven translocation  




Tris-Cl  Tris(hydroxymethyl)aminomethane hydrochloride 
TRRAP Transformation/Transcription domain-Associated Protein 
tSNE  t-distributed stochastic neighbour embedding 
UMAP  Uniform Manifold Approximation and Projection 
UMI  Unique Molecule Identifier 
WBC  White Blood Cell 
WGS  Whole-genome sequencing 
WT  Wild type 
YFP  Yellow fluorescent protein 
α-KG  α-Ketoglutarate 











































1.1 Cancer Evolution  
 
Cancer is a disease with dysregulated growth and survival. It is the second leading cause of 
death globally with 1 in 6 deaths occurring due to cancer (Roth et al., 2018). There were 17 
million cases of cancer diagnosed around the world, including 9.5 million deaths, in the year 
2018 and the global burden of new cancer cases is expected to reach 27.5 million including 
16.2 million cancer deaths by 2040 (Bray et al., 2018). About 20% of the cancer cases are 
found to be in low- and medium Human Development Index Countries which have scarcity of 
medical resources and lack of supportive health system to circumvent the disease burden. One 
of the major reasons for this high mortality rate is the high failure rates in oncological drug 
discovery for targeted and personalized medicine development. Despite the advent of high- 
throughput tumour analytical techniques, biomarker validation and clinical qualification of 
such biomarkers remains challenging. Unfortunately, less than 1% of all reported cancer 
biomarkers enter clinical practice (Kern, 2012). The challenges posed by difficulties in 
biomarker research can be approached by studying the cancer disease progression from an 
evolutionary perspective.  
 
In this context, the theory of natural selection laid by Charles Darwin suggesting “the fittest 
will survive, and a race will be eventually produced adapted to the conditions in which it lives” 
(Gerlinger, Marco,Nicholas Mcgranahan, 2014) is a paramount in understanding the concept 
of evolution in more detail. The fundamental principles of Darwinian evolution were originally 
framed in relation to the evolution of unicellular or multicellular organisms within a given 
population until Peter C. Nowell explained that the evolutionary concept is equally valid in the 
context of cancer evolution (Nowell, 1976). He suggested that acquired genetic lability permits 
stepwise selection of variant sublines and underlies tumour progression (Fig 1.1). His 
hypothesis that natural selection occurs in cancer in the form of clonal selection which develops 
from a single cell of origin leading to constant evolutionary change and possibly drug 
resistance, gained a widespread audience. Evolutionary studies of clonal cancer development 
have since been conducted, allowing remarkable biological inferences to be made (Gerlinger 







Figure 1.1: Schematic representing theory of clonal evolution of cancer led by Nowell (Nowell, 
1976).  
 
Clonal evolution of cancer is primarily shaped by the following fundamental forces- 
1. Mutation 
2. Genetic drift 
3. Selection 
 
Mutation is a stochastic process by which a change in genetic code is introduced into the given 
population of cells. Genetic drift is a consequence of mutational events and describes the 
stochastic changes in clone size due to random effects that lead to cancer cell growth or death. 
Selection is deterministic and is the fixation of a mutation and its associated clonal 
characteristics, which happen if they result in adaptive advantage (Szendro et al., 2013). 
 
Mutation is crucial for the evolution of cancer, as the diversity generated as a result of somatic 
genetic aberrations in cancer cells enables selection. These mutations may vary from point 
mutations to insertion/ deletion of several base pairs or rearrangements of entire chromosomal 
segments and can modify the protein-coding regions modifying the resultant protein with 
altered function or making it non-functional. Based on their contribution to cancer cell fitness, 
these mutations can be defined as driver or passenger aberrations. Driver mutations, as the 







effect on cellular fitness at a given time point during the process of cancer evolution and 
progression. Driver aberrations are generally required for tumour growth and contribute 
towards disease progression. The cancer driver aberrations can be identified based on most 
affected genomic regions which are frequently mutated, rearranged or reflecting copy number 
gains or losses in a particular cancer type (Wood et al., 2007)(Lawrence et al., 2014). The 
number of driver mutations required for cancer to reach malignancy is still debatable but is 
generally considered to be in between 2 and 20 in most solid cancers (Beerenwinkel et al., 
2007) whereas in the case of certain subtypes of Acute Myeloid Leukaemia (AML), it can be 
as low as one driver mutation (TCGA, 2013a). Difficulties in the identification of subclonal 
driver mutations due to spatial heterogeneity (Gerlinger et al., 2012a) and their tendency to 
follow diverse genetic pathways makes it cumbersome to completely characterize the driver 
aberration landscapes (Wood et al., 2007). 
 
A large number of passenger mutations are associated with driver mutations. For example, 
studies conducted in AML have revealed that the majority of passenger mutations were present 
before the cell of origin was transformed into a cancerous cell (Welch et al., 2012a). However, 
passenger aberrations can also be acquired during the process of cancer evolution and 
progression (clonal selection during evolution) (Gerlinger et al., 2012a). Overall, the 
distinction between driver and passenger mutations during cancer may be dynamic as the fittest 
genotype may not be the same in all cancers or at all places or at all times because the selection 
is environment-dependent (Yap et al., 2012). In certain cases, late-stage cancer may not always 
rely on an early driver event. As certain passenger events perhaps act as driver events in these 
cancer cells (Feldser et al., 2010). However, for some driver mutations, environmental 
variation may matter less because such mutations almost invariably confer a selective 
advantage. For example, p53 mutation is found in various types of cancers however, they are 
not always the initiating mutations driving the cancer progression. They are sometimes selected 
once a particular stage of evolution has been reached (Rivlin et al., 2011). In some cases, 
changes in environmental conditions may influence on which genetic changes are selected. 
This is evident from the fact that many cancer genes only drive the disease when they are 
mutated in the germline (Amberger et al., 2015). These examples indicate that mutational 







1.2 Models of cancer evolution 
 
To further understand the consequence of mutations, it is quite important to study the 
evolutionary trajectory of cancer cells at different time points during the process of disease 
progression. However, the central problem of such approaches is that patients cannot be 
ethically biopsied at multiple time points during the disease development. Analysing patient 
samples at a single time point leads to an incomplete picture of different stages of cancer 
progression specially if intermediate or transient clones are involved during the process. On 
the other hand, static analysis provides a snapshot of the disease development which can be 
taken at different time points during the course of evolution in order to develop a better 
understanding of the disease evolution. Another issue is associated with the fact that early 
stages of cancer are often silent clinically and either not detectable or detected by chance in 
apparently healthy individuals (Busque et al., 2012; Laurie et al., 2012; Genovese et al., 2014; 
Martincorena and Campbell, 2015). Although the general representative models of cancer 
evolution are still debatable, following are the competing models which were broadly proposed 
(Davis, Gao and Navin, 2017) – 
 
1. Linear Evolution (LE) 
2. Branching Evolution (BE) 
3. Neutral Evolution (NE) 
4. Punctuated Evolution (PE) 
 
LE is the most commonly proposed model of cancer evolution suggesting that mutations were 
acquired early in a stepwise manner consequently leading to more malignant stages of cancer 
(Fearon and Vogelstein, 1990). LE model posited that new driver mutations outcompete all 
previous clones by providing strong selective advantage (also known as selective or clonal 
sweep) during the process of cancer evolution (Fig 1.2A). Experimental evidence of LE was 
originally found in the case of X-inactivation in cancer where human cancer cells showed 
inactivation of single clonal X-allele throughout the cancer mass due to selection of dominant 
clone (Linder and Gartler, 1965). Another example of LE was further shown by Fearon and 
Vogelstein where their work suggested that colon cancer progresses through stepwise 






malignant stages of cancer growth (Fearon and Vogelstein, 1990). Overall, LE model suggests 
a stepwise acquisition of mutations consequentially leading to metastasis and more advanced 
stages of disease progression. However, most studies suggesting LE pattern of clonal selection 
lack the measurement of genome-wide markers, indicating that some of the heterogeneous 
mutations defining different clones during the process of disease progression may have been 
missed.  
 
BE represents another model of cancer evolution where clones diverge from an ancestor and 
evolve in parallel during disease progression, leading to multiple clonal lineages (Fig 1.2B). In 
contrast to LE model of evolution, the selection sweep is not reported as the clones can have 
similar levels of fitness. BE has been reported in many cancer types, including, leukaemia 
(Gawad, Koh and Quake, 2014), breast cancer (Nik-Zainal, Van Loo, et al., 2012), liver cancer 
(Ling et al., 2015), colorectal cancer (T. M. Kim et al., 2015), ovarian cancer (McPherson et 
al., 2016), prostate cancer (Boutros et al., 2015), melanoma (Harbst et al., 2016) and brain 
cancer (Sottoriva et al., 2013).  Although these studies confirm the presence of BE model of 
cancer evolution, unfortunately, they differ in the number of clones reported. The number of 
such clonal populations in BE also varies among the patients having the same cancer. For 
example, a deep-sequencing based study conducted on over hundred triple-negative breast 
cancer patient samples identified 1 to 19 subclones per patient (Shah et al., 2012). These kind 
of variability in the genomics data can be consequential to the number of cells sequenced, the 
location of the tumour from where cells were obtained or to the sequencing depth. A typical 
feature of BE includes clonal evolution, where a particular driver mutation gets accumulated 
gradually over the process of development and further leads to clonal expansion within the 
tumour. This kind of selection process during the continuous clonal evolution is supported by 
sub-clonal driver mutations or convergent evolution. Sub-clonal driver mutations have been 
usually reported from single cell analysis on multi-region sampling. For example, in case of a 
multi-region sequencing conducted on breast cancer patient cohort, 13 out of 50 patients 
reported the presence of sub-clonal driver mutations (Yates et al., 2015). Another line of 
selection during clonal evolution can be seen in cases of convergent evolution (CE). CE is a 
model of cancer evolution where two independent lineages of cancer progression have 
mutation in the same driver gene, leading to different clonal expansions. Certain cases of lung 






the disease progression (De Bruin et al., 2014). These examples clearly indicate that subclones 
can co-exist and expand in parallel to each other without outcompeting each other unlike in 
case of LE model of evolution. 
 
NE represents another model of evolution which is basically an extreme case of BE. NE is 
based on the assumption that no selection or fitness change is observed during most of the 
lifetime of cancer evolution (Fig 1.2C). NE model of evolution basically hypothesizes that 
during the process of cancer progression, random mutations accumulate over the period of time 
leading to a genetic drift. NE was also proposed originally in the case of species evolution, 
strongly challenging the theory of natural selection laid by Darwin (Kimura, 1983). As 
discussed above in BE, natural selection is observed in cancer cells due to the presence of sub-
clonal driver mutations and convergent evolution. However, there are certain cases of cancer 
evolution providing evidence for NE. For example, in a study involving The Cancer Genome 
Atlas (TCGA) data analysis conducted by Williams et al., a model of NE was applied to study 
the sub-clonal allele frequencies. The study provided an evidence that one-third of the 
examined cancer cases follow NE model of cancer evolution (Williams et al., 2016). These 
studies indicate the presence of NE model of evolution; however, this evidence also have 
limitations associated with an identification of sub-clonal mutations perhaps due to poor 
sequencing quality or low sequencing depth or may also suggest that non-genetic mechanisms 
have a role during cancer evolution.        
 
The models of evolution mentioned above are based on the assumption that mutations are 
acquired sequentially over the period of cancer progression. However, in certain cases of 
cancers, it has been observed that a large number of genomic aberrations may occur at very 
early stages of cancer progression, during short bursts of time period (Fig 1.2D). The term 
‘Punctuated Evolution’ was proposed as ‘Punctuated Equilibrium’ by Gould and Eldredge in 
1970 which challenged the longstanding paradigm of Darwinian evolution (Gould and 
Eldredge, 1993). PE evolutionary model is fundamentally different from other models of 
evolution as in this case, the assumption is based on the fact that cancer cells are pre-
programmed at the earliest stages of cancer development and are destined to become invasive, 






rely on point mutations, PE model of cancer evolution has been reported in studies indicating 
DNA copy number aberrations and chromosomal structural rearrangements.  
 
PE has been evidenced in two groups of studies- one involving localized phenomenon on single 
chromosomes and the other leading to aneuploidy consequential to whole genome 
rearrangements. One such phenomenon involving localized chromosome rearrangements is 
known as ‘chromothripsis’. Chromothripsis can be defined as a single catastrophic event 
involving shattering and reassembly of a chromosomal arm (Williams, Sottoriva and Graham, 
2019) and is more specifically defined by many oscillating copy number states in which 
breakpoints map between adjacent segments on a single chromosome, and has been reported 
in many cancer types including colorectal cancer (Kloosterman et al., 2011), prostate cancer 
(Berger et al., 2011), etc. Another group of studies where PE has been found to be implicated 
is the genesis of genome-wide aneuploidy. In a study involving 57 patients of prostate cancer, 
a phenomenon called ‘chromoplexy’ was reported where genome wide translocations and copy 
number alterations were interdependent and occurred concurrently in short periods of time 
(Baca et al., 2013). Overall, these studies indicate that chromosomal rearrangements and copy 
number alterations may evolve through PE model of tumour progression.  
 
Ultimately, all these models are variations of the same, nuanced by the initial, detectable event 
where either the clone gain a selective advantage or diverge from the ancestral clone during 


































Figure 1.2: Models of tumour evolution.  
Illustration of tumour evolution models showing dynamic changes in clonal frequencies over time. This 
figure is based on the original study (Marusyk and Polyak, 2010) and derived from (Davis, Gao and 
Navin, 2017). (A) Linear Evolution (B) Branching Evolution (C) Neutral Evolution (D) Punctuated 
Evolution. Colours indicate clones with different genotypes. 
 
1.3 Mechanisms driving cancer evolution 
1.3.1 Genetic variability 
 
One of the mechanisms underlying clonal evolution of cancer is the continuous acquisition of 
somatic mutations contributing towards genetic variability. This genetic variability could be 
allelic or locus-specific. Allelic variability represents different variants at a single gene locus 
leading to similar phenotypic expressions of disease whereas locus-specific variability occurs 
when variants at different gene loci lead to similar disease phenotype. Genetic variability may 
be consequential to development of a genetically distinct subclonal population of cells followed 
by selective outgrowth of clones having a phenotype advantage within a given 
microenvironment as discussed above (Nowell, 1976). In case of selective sweep, as mentioned 
above, whereby a new clone takes over the entire population by replacing any ancestral clones, 
leads to a homogeneous cell population. In case of LE, if a new clone fails to outcompete its 
predecessor, a degree of genetic variability will be observed (Welch et al., 2012b). However, 
in case of BE, the evolution of subclonal population in parallel results in extensive subclonal 
diversity. In certain cases of Acute Lymphoblastic Leukaemia (ALL) following BE, a 
heterogeneity was observed between leukaemia propagating cells (Anderson et al., 2011). 
However, the phenomenon of genetic variability has a clearer topography in solid tumours. In 
certain cases of clear-cell renal cell carcinoma which followed branched evolutionary 
trajectory, spatial separation of tumour subclones was observed. These spatially separated 
subclones were found to harbour heterogeneous somatic mutations and copy number events 
leading to genetic variability (Gerlinger et al., 2012b). In certain cases of breast cancer (Shah 
et al., 2009), pancreatic cancer (Campbell et al., 2010) and medulloblastoma (Wu et al., 2012) 
there is evidence for clonal diversity between primary and metastatic site. The genetic variation 
between primary and metastatic tumour sites may be attributed to the selection pressure 






individual niche evolve independently relative to each other (Junttila and De Sauvage, 2013).  
These intermingled heterogeneous clones obtained from the same biopsy may display 
amplification of different proteins, some of which regulate key signalling processes and whose 
dysregulation may impact cancer development, for example, receptor tyrosine kinases (Snuderl 
et al., 2011). The genetic diversity observed at this intercellular level may be a consequence of 
genomic instability. This genomic instability leads to intercellular variability which increases 
phenotypic variation by broadening the pool of cells subjected to selection and further leading 
to the emergence of complex subclonal architecture (Cahill et al., 1999). 
 
The Deoxyribonucleic Acid (DNA) replication machinery in a genome works at a high 
precision where the genome is replicated and divided with high fidelity. This high accuracy 
rate results in a very low endogenous mutation rate in somatic cells which is estimated to be 
0.77*10-9 per site per cell division (Lynch, 2010). Similar to this observation, the errors in 
chromosome aggregation are also very rare which happen roughly at a rate of 1 per 100 cell 
divisions and poorly tolerated in non-transforming cells (Thompson and Compton, 2008). 
Disruption of mechanisms which maintain the integrity of the genome or exposure to any form 
of exogenous mutagens will elevate the genomic aberration rate. Most of the solid tumours as 
well as haematopoietic malignancies are found to have at least one form of genomic instability 
(Gordon, Resio and Pellman, 2012). Despite the clear association of genomic instability and 
cancer, the fact whether elevated mutation rates are required for cancer evolution, still remains 
debatable (Tomlinson, Novelli and Bodmer, 1996). The mutational burden within a large 
population of cancer cells is likely to be extensive even in the presence of normal somatic 
mutation rate (Tomlinson, Novelli and Bodmer, 1996). In accordance with this, certain studies 
supported by mouse models have revealed that genomic instability increases the risk of cancer 
progression (Weaver et al., 2007).  
 
Different genetic lesions ranging from point mutation frequency to small insertions and 
deletions, large-scale chromosomal rearrangements and alterations in ploidy may lead to 
genomic instability (Table 1.1). The different genetic lesions may have distinct phenotypic 
penetrance, for example, most of the point mutations are neutral whereas a chromosome gain 
or loss may likely have functional consequences. As different patterns of genomic instability 






shaped tumour evolution using sequencing technology (discussed later) and copy-number data 
analysis (Nik-Zainal, Alexandrov, et al., 2012). A recent study provided a deep insight into 30 
different mutations in different cancer types and unravelled 20 distinct signatures of process 
that mutate DNA (Alexandrov et al., 2013). In addition to the observation of mutational 
patterns impacting global genomic architecture, specific mutations may occur at higher 
frequency in the context of a particular instability mechanism. One such example is lung cancer 
where smoking increases mutation rate and the frequency of C.G ® A.T transversions. This 
observation led to the inference that mutations in TP53 can be attributed to DNA damage from 
cigarette smoke carcinogens (Pfeifer et al., 2002). 
 
The increase in the frequency of point mutations may be attributed to different exogenous 
factors (Alexandrov et al., 2013) along with defects in DNA repair pathways including, base- 
excision repair and mismatch repair (Shah, Hile and Eckert, 2010). Apart from seeing this 
hypermutation effect, mismatch repair is also associated with expansion and contraction of 
repetitive tracts of DNA (microsatellite instability), leading to an increased frequency of 
frameshift mutations (Shah, Hile and Eckert, 2010). Different mechanisms impacting gross 
chromosome structure, such as DNA replication stress (Nikolaev et al., 2012), defects in 
homologous recombination and domains that loop together in the interphase nucleus may also 
lead to an increase in point mutation frequency (Yang et al., 2011). 
 
Different mechanisms of genomic instability can contribute towards distinct pattern of point 
mutations- replication stress is associated with an enrichment of mutations in large genes 
(Nikolaev et al., 2012) whereas microsatellite instability, depending upon the nucleotide 
composition of a particular set of genes, may affect specific genes more frequently than others 
(Shah, Hile and Eckert, 2010). A recent study has highlighted the importance of considering 
variation in mutation rate across the genome when identifying putative driver mutations where 
the authors have found that the mutation frequency across the genome is strongly correlated 
with DNA replicating timing and transcriptional activity (Lawrence et al., 2013a). 
 
One of the most common forms of genomic instability is chromosomal instability which occurs 
at high frequencies across many cancer types and is associated with aggressiveness, drug 






any type of karyotypic abnormalities which may not be restricted to translocation, inversions 
and deletions and may also include an increased rate of change in chromosome number or 
structure. A certain proportion of chromosomally unstable tumours also show increased ploidy, 
suggesting that genome doubling could act as precursor to chromosomal instability (Ganem, 
Storchova and Pellman, 2007). From a mechanistic point of view, chromosomal instability has 
been found to be driven by mitotic defects in chromosome attachment which further leads to 
DNA damage and structural rearrangements by entrapment of chromosomes during cytokinesis 
(Janssen et al., 2011) or through aberrant replication or fragmentation of micronuclei (Crasta 
et al., 2012). On the other hand, structural chromosomal aberrations can also compromise the 
accuracy of chromosome aggregation during mitosis (Chan, North and Hickson, 2007). 
Overall, the impact of structural chromosomal aberrations generated from mitotic and pre-
mitotic defects, on chromosomal instability in cancer still needs to be explored.  
 
It is worth noting that a high number of mutations or chromosomal rearrangements do not 
necessarily imply ongoing genomic instability but could reflect a historical prolonged period 
of mutational acquisition or the occurrence of transient mutational bursts (Stephens et al., 
2011). The evolution of cancer does not only proceed gradually through clonal selection of 
point mutations or chromosomal alterations but could also be subjected to certain punctuated 
phases like chromothripsis as described above. Another such example is telomere dysfunction, 
catalysed by eroded chromosome ends, contributing towards genomic instability (Artandi and 
DePinho, 2009). These punctuated events are likely to contribute towards cancer evolution. 
The observations of active DNA damage response and variation in chromosome copy number, 
suggest that ongoing instability occurs in a substantial proportion of tumours (Gorgoulis et al., 
2005). 
 
There are increasing number of studies suggesting the requirement of identification of low-
frequency genetically and functionally distinct subclones at diagnosis (Landau et al., 2013). 
One such study conducted on Chronic Lymphocytic Leukaemia (CLL) suggested the presence 
of distinct subclones that harbour distinct driver events during therapy. In this study, the 
patients harbouring a particular subclonal driver in their pre-treatment samples showed a 
shorter time to re-treatment or death as compared to the patients without any evidence of 






longitudinal tumour sampling over the disease course and throughout the treatment as the 
subclonal driver event may not be detectable in a single biopsy or even in multiple biopsies 
collected before treatment. The ultimate challenge is in identifying the subclones with 
prognostic power that bias therapeutic choices. 
 
It is also worth appreciating that phenotypic divergence cannot be solely attributed to genetic 
variability. In certain cases, genetically homogeneous subclones have been found to have 
distinct functional trajectories after exposure to chemotherapy, sometimes dependent on the 
presence of quiescent cells surviving the cytotoxic pressure (Kreso et al., 2013a). Distinct 
phenotypic outcomes cannot be solely determined through genetic variability between 
subclones, but also through stochastic events in gene expression and protein stability as well 
as epigenetic divergence and microenvironmental fluctuations (Kreso et al., 2013a). 
 
1.3.2 Epigenetic variability 
 
While genetic variability has been the most studied mechanism of clonal evolutionary 
development of cancer, it is widely recognized that epigenetic modifications are likely to play 
an important role in ultimately affecting fitness (Clark and Melki, 2002) (Baylin and Jones, 
2011). The presence of phenotypic variation in genetically uniform cells, in terms of essential 
properties such as survival capacity and proliferative potential, strengthens the existing 
epigenetic variation (Kreso et al., 2013b) (Spencer et al., 2009). The term epigenetics originally 
referred to the stable heritability of a phenotype that results from changes in chromosome 
without any alterations in DNA sequence (Berger et al., 2009). However, a more widespread 
usage of the term also includes DNA methylation, histone modifications, the transcriptional 
effects of RNA interference and nuclear organisation (Bird, 2007). Epigenetic mechanisms 
achieve diverse stable phenotype in genetically identical cells by controlling the abnormal 
transcriptional activation/repression of genes, referred to as ‘Epimutation’ (Holliday, 1987). 
These epimutations are heritable and together with genetic landscape, affect the process of 
cancer evolution (Richards, 2006).  
 
Based on the range of autonomy of epigenetic variability in relationship to genotype context, 






1. Obligatory epigenetic variation 
2. Facilitated epigenetic variation 
3. Pure epigenetic variation 
 
Obligatory epigenetic variation (Fig 1.4A), as the name indicates, is completely dependent on 
genetic variation. In this case, there is a strict one-to-one correspondence between the 
epigenotype and either cis- or trans-acting genetic variation (Richards, 2006). Some of the 
examples include transposon-associated alleles where the presence of transposon is strictly 
associated with epigenetic silencing of coding sequence present in its vicinity (Lippman et al., 
2004). 
 
Facilitated epigenetic variation (Fig 1.4B), on the other hand, is more of genotype directed 
mechanism where genotype potentiates the epigenotype in a probabilistic but not deterministic 
manner. Examples include the formation of epialleles in DNA methylation mutant background 









Figure 1.3: Types of epigenetic variability bases on relationship with genotype.  
The horizontal axis distinguishes between two genotypes that are represented by alleles x and y. At a 
genomic location either in cis or in trans (dashed line), two alternative epigenetic states are depicted as 
either open or filled red boxes. (A) Obligatory type, where the epigenotype of the locus is strictly 
determined by genotype, (B) Facilitated epigenetic variation (epiallele formation: open box–red box) 
that can occur, in a probabilistic manner, only in the context of genotype y, (C) Pure phenotype, where 
stochastic events generate alternative epialleles at some finite frequency regardless of the genotype. 
Adapted from (Richards, 2006). 
 
Pure epigenetic variation (Fig 1.4C), however, is generated by stochastic events which are 











in propagating silent genetic states after DNA replication and the targeting of silent chromatin 
to ectopic genomic locations. One such striking example with consistent stochastic alterations 
leading to epigenetic variation is the growing divergence in epigenotype in monozygotic twins 
during ageing (Fraga et al., 2005).  
 
The very first observation of the presence of an epimutation in genotype context leading to 
cancer was aberrant methylation of the maternal allele of the imprinting control region (ICR) 
of the H19 gene in the normal kidney parenchyma of patients with Wilms tumour. This resulted 
in the loss of imprinting of the closely linked, reciprocally imprinted, H19 and insulin-like 
growth factor 2 (IGF2) genes (Moulton et al., 1996). Another example of epimutation was 
MLH1 in Lynch syndrome, which was the first epimutation to be observed in a non-imprinted 
gene. In this case, an aberrant methylation in MLH1 promoter was observed, accounting for 1–
10% of cancer patients who meet the clinical diagnostic criteria for Lynch syndrome with a 
loss of MLH1 expression in their tumours. MLH1 epimutations were characterized by soma-
wide monoallelic methylation of the MLH1 CpG island promoter accompanied by allelic 
transcriptional inactivation (Hitchins et al., 2007). 
 
These examples indicate the presence of locally disordered methylation patterns which is one 
of the epigenetic mechanisms leading to alternative epigenetic states known as epialleles, 
thereby, contributing towards epigenetic variability. Although global hypomethylation of 
cancer was described in early 1980s, with frequent focal hypermethylation of key regulatory 
regions (Jones, 1999), recent literature has indicated the presence of stochasticity in DNA 
methylation patterns (Landau et al., 2014). Studies conducted in diffuse large B-cell lymphoma 
(DLBCL) associate the presence of differential methylation patterns with relapse and indicate 
that the epigenomic variation in the form of heterogeneous methylation pattern can be used as 
a predictive marker in case of DLBCL (Pan et al., 2015).   
 
Another study performed on chronic lymphocytic leukaemia (CLL) suggested the presence of 
stochastic patterns of DNA methylation during the process of disease evolution. The increase 
in locally disordered methylation was found to be associated with adverse clinical outcome. 
The authors also proposed that stochastic methylation alterations enhance epigenetic plasticity 






fitness trajectories (Landau et al., 2014). They proposed a model associating epigenetic 
landscape with genetic diversification where cellular populations with a preserved epigenetic 
landscape showed a limited capability of genetic diversification. However, the population of 
cells with a more malleable epigenetic landscape gave birth to new subclones leading to 
enhanced genetic diversity and poor clinical outcome. 
 
 
Figure 1.4: Relationship between epigenetic variability and transcriptional variability.  
(A) PDR and expression variability as measured with coefficient of variation (CV) of 5,874 transcribed 
genes. Black circles (brackets)-- mean CV (95% CI) for genes within PDR bins (number of genes per 
bin in blue). Red line - cubic smoothing spline of CV and PDR values (unbinned) (modified from 
(Landau et al., 2014) , (B) Violin plots of transcript expression level variance as measured by single 
cell RNA-sequencing (AML_130 relapse sample) and association (ANOVA test, p < 2.2×1016) with 
low (< 0.05), intermediate (0.050.2) and high (0.21) epiallele shift within respective gene promoters. 
Wilcoxon signed rank tests and ANOVA test: p < 0.001*** (modified from (Li et al., 2016)).   
 
It is worth noting that locally disordered methylation is associated with variability in 
transcriptional landscape with a decoupling of the relationship between promoter methylation 
and gene expression (Landau et al., 2014) (Fig 1.4A). This observation was compatible with 
another study conducted on AML where the genes downstream of the promoters associated 
with epiallele shifts, also showed variability in gene expression at single-cell level (Li et al., 
2016) (Fig 1.4B). These observations imply that apart from genetic and epigenetic variability 
























































transcriptional variability may also contribute mechanistically during the process of cancer 
evolution. 
 
1.3.3 Transcriptional variability 
 
The concept of cell-to-cell transcriptional variability was first highlighted by Novick and 
Weiner in 1957, who showed that the production of beta-galactosidase in individual cells was 
highly variable and random, where the process of induction led to an increase in the proportion 
of cells expressing the enzyme rather than increasing every cell's expression level equally 
(Novick and Weiner, 1957). The cell-to-cell transcriptional variability reflects the variability 
in the number of mRNA molecules produced from a given locus at a certain time point (Ko, 
1991) (Mcadams and Arkin, 1997). This is important for stochastic fate specification which 
complements lineage- and signalling-based mechanisms to further diversify cell types during 
development (RJ and C, 2010). However, to date, the mechanisms contributing towards 
transcriptional variability still remain under exploration (Urban and Johnston, 2018).  
 
The very first attempt at understanding the mechanisms behind transcriptional variability was 
made by Elowitz et al. who introduced the concepts of intrinsic and extrinsic sources of 
transcriptional variability (Elowitz et al., 2002). For this, the authors quantified the variability 
in the expression from a promoter in E. coli by introducing two copies of the same promoter 
into the genome of E. coli, one driving the expression of cyan fluorescent protein (CFP) and 
the other driving the expression of yellow fluorescent protein (YFP). The authors suggested 
that extrinsic fluctuations are those that affect the expression of both copies of the gene equally 
in a given cell (Fig 1.5A). However, intrinsic fluctuations are those due to the randomness 
inherent to transcription and translation and thus should affect each copy of the gene 
independently (Fig 1.5A), adding uncorrelated variations in levels of CFP and YFP (Fig 1.5B). 
The authors found that both sources of noise can be significant depending on the promoter, the 
key regulatory region in bacteria. The observation that the time scale for intrinsic noise 
fluctuations is much shorter (~9 minutes) than that for extrinsic noise (~40 minutes) suggests 
that extrinsic noise may affect cellular phenotypes more strongly than intrinsic noise, at least 






who also quantified noise in gene expression in the prokaryote Bacillus subtilis (Ozbudak et 
al., 2002). 
 
These studies highlight that gene expression variability can be majorly subdivided into two 
types- 
 
1. Extrinsic variability 
2. Intrinsic variability 
 
Extrinsic gene expression variability arises from heterogeneous environmental conditions 
surrounding the cell (Chalancon et al., 2012). It may also be due to asymmetric cell divisions 
or variability in abundance of gene expression machineries like cell-to-cell variation in 
ribosome abundance or any changes in the local distribution and concentration of general 
transcription factors or other proteins. Extrinsic variability varies from cell-to-cell but has the 
potential to affect all genes and is therefore a gene-independent characteristic.  
 
Conversely, intrinsic source of gene expression variability can be attributed to variation in 
chromatin modifier binding at individual gene loci and binding of transcription factors 
(Chalancon et al., 2012). Other factors which may impact intrinsic variability include promoter 
architecture, rate of protein synthesis/ degradation inside a cell as well as transcriptional 
bursting (discussed later). Thus, intrinsic variability is considered a gene-dependent 
characteristic because its effects vary from gene-to-gene and cell-to-cell. 
 
One of the major reasons for gene expression variability is the occurrence of transcription in 
the form of transcriptional ‘burst’ (Cai, Friedman and Xie, 2006). Transcriptional burst is the 
phenomenon by which mRNA is produced from the promoter of a gene, in the form of bursts, 
switching between periods of prolonged inactive (or ‘off’) states and short-lived active (or ‘on’) 
states (Thattai and Van Oudenaarden, 2001). The perturbation in dynamics and frequency of 
the pre-initiation complex (PIC) assembly is one of the reasons for transcriptional bursting (Raj 
and Van Oudenaarden, 2009). Transcriptional bursting is one of the major mechanisms 







1. TATA-box- a DNA binding motif present in the gene-promoters. The variation in the actual 
DNA sequence of the motif impacts the stability of PIC and hence contributes towards 
transcriptional bursting (Lam, Steger and O’Shea, 2008; Corrigan et al., 2016; Ochiai et al., 
2020). 
 
2. Nucleosome occupancy and positioning- in a given population of cells, the nucleosome 
occupancy and positioning at a particular genomic coordinate influences transcriptional 
bursting (Blake et al., 2003). 
 
3. Transcriptional pausing- the presence of polymerase pause sites may impact bursting by 
either stalling polymerases or causing premature termination (Ribeiro et al., 2010)(Larsson et 
al., 2019). 
 
4. Chromatin epigenetics- Histone modifications and DNA methylation can be added and 
removed in a switch-like manner and may impact bursting kinetics (Lim and Van Oudenaarden, 
2007; Miller-Jensen et al., 2011; Larsson et al., 2019) 
 
One of the models which is majorly studied to understand the mechanism of transcriptional 
bursting is called ‘two-state’ model (Peccoud and Ycart, 1995). The model is based on the 
observation that transcriptional bursting occurs when a gene promoter fluctuates between an 
“on” and “off” state for different periods of time. Each time the promoter switches to an “on” 
state, a burst of transcription is produced (Kumar, Singh and Kulkarni, 2015). The majority of 
intrinsic gene expression variability arises from stochastic production of mRNA due to the 
random binding of transcription factors and other transcriptional machinery to the DNA, along 
with the turnover of mRNA and protein at a certain point of time (Raser and O’Shea, 2004a). 
The rate of binding at the promoter or enhancer is termed as Kon, whereas rate of dissociation 
is termed as Koff (Fig 1.6A). These rates of binding and dissociation are majorly dependent on 
protein availability and the presence of other bound proteins. Extrinsic fluctuations produce 
variability in the local concentrations of proteins, leading to alterations in the probability of 
protein binding over time. Gene expression variability also arises from variation in the 






































Figure 1.5: Intrinsic and extrinsic contributions to gene expression variability.  
(A) Schematic depiction of the temporal behaviours of extrinsic noise (upper) and intrinsic noise 
(lower). Adapted from (Elowitz et al., 2002), (B) Expected cell-to-cell variations when fluctuations are 
intrinsic, extrinsic or both. Adapted from (Raj and van Oudenaarden, 2008). 
 
While the two-state model describes the phenomenon of transcriptional bursting and the gene-
independent mechanisms contributing towards this, it does not take the gene-architecture into 
consideration. As mentioned above, The TATA box is a critical determinant of gene expression 
variability, where genes lacking a TATA box are associated with lower variability, while the 
presence of a TATA box promotes higher variability (Blake et al., 2006a). In addition to 
promoter architecture, the interactions between enhancer-promoter also act as gene-dependent 
regulators of transcriptional bursting. One of the mechanisms by which enhancers may affect 
bursting is through enhancer-promoter looping (Fukaya, Lim and Levine, 2016a). The 
fluctuations in the kinetics of the cellular environment, such as changes in the concentration 
and distribution of transcription factors, change the probability of enhancer-promoter contact 
from cell-to-cell. These alterations in enhancer-promoter interactions lead to differences in 













Figure 1.6: Two-state model of transcriptional bursting.  
(A) The two-state bursting model suggests that a gene switches between an ‘inactive’ and ‘active’ state 
at a particular rate, Kon and Koff. In the ‘active’ state RNA transcripts are produced at a rate (u) and 
degraded at a rate (δ), (B) Transcriptional bursting parameters where each burst occurs for a particular 
duration (period of time) with a distinct amplitude (strength) and at a particular frequency. Modified 
from (Urban and Johnston, 2018). 
 
Apart from promoter architecture and enhancer-promoter looping, the chromosome 
organization in topologically associated domains (TADs) may also be associated with the 
phenomenon of transcriptional bursting. Since these TADs facilitate DNA binding with 
proteins like cohesins and CTCF, the depletion of these proteins may subsequently lead to 
dysregulation of gene expression (Dixon, Gorkin and Ren, 2016). Literature suggests that intra-
TAD CTCF binding promotes and stabilizes enhancer-promoter interactions which further 
result in a decrease in transcriptional bursting and variability (Ren et al., 2017a). In addition to 
this, certain histone modifications, including H3K27ac as well as H3K36me3 have been shown 
to be positively correlated with burst frequency (Larsson et al., 2019; Ochiai et al., 2020). 
These examples shed some light on how gene-specific regulatory mechanisms in combination 
with transcriptional bursting may play a significant role in contributing towards transcriptional 
variability. It’s worth understanding how this variability in gene expression may be 
consequential to stochastic cell fate specification further leading to diversification of cell fates. 
 
One such example highlighting stochastic gene expression linked to cell fate decision is 
photoreceptor expression in Drosophila eyes. The Drosophila eye consists of a large number 
of optical units called ommatidia, each of which contains two cells that in turn express one of 
the specific pairs of photoreceptors, either Rh3 and Rh5 (for blue sensitive ommatidia) or Rh4 
and Rh6 (for yellow sensitive ommatidia). Wernet et al., showed that this decision is almost 
exclusively due to the stochastic expression of the spineless gene during mid-pupation, with 
stochastically large levels of spineless expression resulting in the adoption of the yellow fate 
in roughly 70% of the ommatidia (Wernet et al., 2006). 
 
Another example of stochastic cellular differentiation is haematopoietic system where 
progenitor stem cells differentiate into different types of blood cells (Enver, Heyworth and 






gene expression variability. The authors showed that the fates of haematopoietic cells are 
influenced by the expression levels of the cell surface receptor Sca-1. Noise in the levels of 
Sca-1 partitions these cells into high-expressing erythroid fates and low-expressing myeloid 
fates (Chang et al., 2008). These few examples further strengthen the notion that stochastic cell 
fate choices can be made by a particular cellular system in the presence of the source of 
transcriptional variability. With advances in genomics and single-cell studies, it is now possible 
to understand the role of transcriptional dynamics underlying cell-to-cell variability in different 
biological mechanisms including development and disease progression.  
 
1.4 Single-cell technology as a means to quantify cell-to-cell transcriptional variability 
 
As discussed in the previous section, transcription of a gene is carried out inside a cell in the 
form of transcriptional bursts, (Raj and van Oudenaarden, 2008), and individual genes may 
exhibit different pattern of burst kinetics. This difference in the pattern of burst kinetics 
contributes towards variability in gene expression, between individual cells of a population, 
both in terms of which genes they express and the level of expression. In order to understand 
the stochasticity or mechanistic regulation of the cell-to-cell transcriptional variability, it is 
quite important to understand the coregulation of transcription factors (TFs) and their 
expression level in a given population of single cells. Population studies did not only contribute 
towards masking of molecular and functional variability but also enforced an assumption 
towards individual cell behaviour by extrapolating the bulk studies data to single-cell level. 
This extrapolation of population studies suggested that all cells of a population express similar 
levels of a given gene (Fig 1.7A) and that co-expression of multiple genes in a given population 
of cells corresponds to co-expression in the individual cells (Fig 1.7B). However, studies 
conducted to date have indicated that often neither of these assumptions hold true at the single-










Figure 1.7: Single cell analysis reveals variability in gene expression patterns.  
(A) Single cell analysis can distinguish whether all cells of a population express a similar level of a 
transcript (top left) or whether a small number of cells account for most of the expression (top right), 
which cannot be determined from population studies. In single cell studies, a homogeneous population 
would give a single expression distribution (bottom left) while a heterogeneous population would give 
a broader distribution, or multiple distributions (bottom right). In population studies, both sets of cells 
would seem to have the same level of expression (red lines), (B) Single-cell analysis can reveal whether 
co-expression observed at the population level actually occurs within the same single cells (left) or not 
(right). (Adapted from (Moignard and Göttgens, 2014)). 
 
The first evidence of sequencing transcriptome at single-cell level was mentioned by Eberwine 
et al., (Eberwine et al., 1992) along with Iscove and colleagues (Brady, Barbara and Iscove, 
1990) where they pioneered the expansion of complementary DNAs (cDNA) from a single-
cell using linear amplification by in vitro transcription and exponential amplification by PCR, 
respectively. These methodologies were further applied at a commercial scale level by making 









sequencing (scRNA-seq) (Klein et al., 2002)(Kurimoto et al., 2006). Guided by these studies, 
the first description of scRNA-seq based on a next-generation sequencing platform (NGS) was 
available in the year 2009, where the study described the characterization of cells from early 
developmental stages (Tang et al., 2009) (Fig 1.8). Since then several studies have proven the 
potential of scRNA-seq technology to identify the rare subset of population of cells which may 
have potential implications for furthering our understanding of drug resistance and relapse in 
cancer treatment (Shaffer et al., 2017).  
 
Since the first description of scRNA-seq by Tang and colleagues, a massive expansion in 
method development has been witnessed (Table 1.1). Such efforts are crucial as each method 
has distinct advantages and applicability. ScRNA-seq, in general, is composed of four steps 
(Hedlund and Deng, 2018)- 
 
1. Single-cell isolation, capture and lysis 
2. Reverse transcription 
3. cDNA amplification 
4. Sequencing library preparation 
 
Isolation of single cell is the first critical step for obtaining the transcriptome information from 
an individual cell. One of the most commonly used technique is, fluorescence activated cell 
sorting (FACS), which has become quite a popular technique to isolate single-cells (Julius, 
Masuda and Herzenberg, 1972; Hwang, Lee and Bang, 2018). This method utilizes a 
fluorescent tagged antibody with which cells are tagged. These antibodies further recognize 
specific surface markers and enable sorting of distinct populations. In this case, cells are 
isolated magnetically, based on predetermined fluorescent parameters where a charge is 
applied to a cell of interest using an electrostatic deflection system. The same technique can be 
used for index sorting, widely used for single-cell based studies. However, FACS requires large 
starting volumes which makes it difficult to isolate cells from low input numbers (<10,000). 
Another method for isolation of single-cell from a solid sample is laser capture microdissection, 








Figure 1.8: Schematic of single cell RNA sequencing as described by Tang et al., 2009.  
A single cell is manually picked under a microscope and lysed. Then mRNAs are reverse-transcribed 
into cDNAs using a poly(T) primer with anchor sequence (UP1) and unused primers are digested. 
Poly(A) tails are added to the first-strand cDNAs at the 3′ end, and second-strand cDNAs are 
synthesized using poly(T) primers with another anchor sequence (UP2). Then cDNAs are evenly 
amplified by PCR using UP1 and UP2 primers, fragmented, and P1 and P2 adaptors are ligated to the 
ends. Finally, emulsion PCR is performed by mixing libraries with 1 μm diameter beads with P1 primers 
covalently attached to their surfaces. 
 
Microfluidic technology is another promising method for isolation of single cells (Whitesides, 
2006). This technology has gained wide popularity due to low sample volume required and low 






technology. The platform provides automated single-cell lysis, RNA extraction, and cDNA 
synthesis for up to 800 cells in parallel on a single chip and offers lower false positives and 
less bias than tube-based technologies. However, its major drawbacks include the number of 
cells (>1000) required for capture and the homogeneous size limit of the cells being analyzed. 
Microdroplet-based microfluidics circumvent some of these challenges (Utada et al., 2005). 
The technology allows monodispersion of aqueous droplets in a continuous oil phase. The 
lower volume required by this system compared to standard microfluidic chambers enables the 
manipulation and screening of thousands to millions of cells at a reduced cost. The commercial 
chromium system from 10X genomics based on this technology, offers high-throughput 
profiling of 3′ ends of RNAs of single cells with high capture efficiency, further enabling the 
analysis of rare cell types in a sufficiently heterogeneous biological space. Another 
methodology to isolate circulating tumour cells (CTCs) has been developed by CellSearch. The 
technology uses a magnet conjugated with antibodies to detect CTCs of epithelial origin in 
patient blood samples. 
 
Table 1.1: Summary of current scRNA-seq methods (Modified from (Hedlund and Deng, 
2017)) 
 
Methods Captured RNAs cDNA coverage Amplification technology 
    
Homopolymer tailing based-PCR 
    
Tang 
2009 
polyA+ RNAs Full-length with 3' 
biased 
PCR after poly A tailing 
Quartz-
seq 
polyA+ RNAs Full-length with 3' 
biased 
PCR after poly A tailing 
SC3-seq polyA+ RNAs Full-length with 3' 
biased 
PCR after poly A tailing 
SUPeR-
seq 
polyA+ RNAs and 
polyA- RNAs 
Full-length PCR after poly-dA tailing 
MATQ-
seq 
polyA+ RNAs and 
polyA- RNAs 






    
Switching mechanism at 5' end of RNA Template (SMART)-based PCR 
    
STRT-seq polyA+ RNAs 5'Tag(TSS) Template switching-based PCR 
Smart-seq polyA+ RNAs Full length with 
weak 3'-biased 
Template switching-based PCR 
Smart-
seq2 
polyA+ RNAs Nearly full-length Template switching-based PCR 
Drop-seq polyA+ RNAs 3' tag (UTR) Template switching-based PCR 
Patch-seq polyA+ RNAs Nearly full-length 5' 
tag (TSS) 
Template switching-based PCR 
    
in vitro transcription-based linear amplification 
    
CEL-seq polyA+ RNAs 3' tag (UTR) in vitro transcription  
CEL-seq2 polyA+ RNAs 3' tag (UTR) in vitro transcription and random 
primer based PCR 
MARS-
seq 
polyA+ RNAs 3' tag (UTR) in vitro transcription  
inDrops polyA+ RNAs 3' tag (UTR) in vitro transcription  
    
Designed primers-based PCR 
    
DP-seq polyA+ RNAs Specific gene-region PCR using designed heptamers 
Cyto-seq polyA+ RNAs 3' tag (UTR) gene-specific primer based PCR 
MALBA
C RNA 
polyA+ RNAs Full-length Quasilinear PCR with 7 random 
MALBAC primers 
 
The generation of scRNA-seq libraries require cell lysis, reverse transcription into first-strand 
cDNA, second-strand synthesis, and cDNA amplification. Generally, the cells are lysed in a 
hypotonic buffer, and poly(A)+ selection is performed using poly(dT) primers to capture 
mRNAs. Due to the selection step based on poly(dT) primers, non-polyadenylated RNA 






established that due to Poisson sampling, only 10–20% of transcripts will be reverse transcribed 
at this stage (Islam et al., 2014a). This low mRNA capture efficiency is an important challenge 
that remains in existing scRNA-seq protocols and necessitates a highly efficient cell lysing 
strategy.  
 
Next step in the process of scRNA-seq is preparation of cDNA. The first strand synthesis for 
cDNA preparation is done by an engineered version of the reverse transcriptase isolated from 
Moloney murine leukaemia virus (M-MLV) having low RNase H activity and increased 
thermostability (Arezi and Hogrefe, 2009). Once the first strand synthesis is done, second 
strand synthesis can be achieved using either poly(A) tailing (Sasagawa et al., 2013) or by a 
template-switching mechanism also known as SMART technology (switching mechanism at 
5′ end of RNA template) (Islam et al., 2011). The SMART technology approach ensures 
uniform coverage without loss of strand-specificity compared to the former. Some of the 
scRNA-seq methods which follow SMART technology include Smart-seq (Switch Mechanism 
at the 5' End of RNA Templates sequencing), Smart-seq2 and STRT (Single-cell tagged reverse 
transcription sequencing).  
 
Another approach ligates the 5’ end of cDNA with either poly(A) or poly(C) to build common 
adaptors for PCR amplification. However, the exponential amplification generated by PCR can 
potentially skew the representation of gene expression profiles towards shorter and less G-C 
rich amplicons. To avoid these drawbacks, CEL-seq (Cell Expression by Linear Amplification 
Sequencing) method was devised (Hashimshony et al., 2012), which is the first method based 
on in vitro transcription (IVT). Although this method allows linear amplification of templates, 
it is quite time consuming, as it requires an additional reverse transcription, which may lead to 
3′ coverage biases (Morris, Singh and Eberwine, 2011). In addition to this, another method for 
cDNA amplification is based on Multiple Annealing and Looping-Based Amplification Cycles 
(MALBAC) which uses quasilinear instead of exponential amplification to amplify and 
sequence the transcriptomes of single cells (Zong et al., 2012). The MALBAC primers generate 
amplicons to have complementary ends that loop and prevent DNA from being copied 







Next step in scRNA-seq is the preparation of sequencing library. As mentioned in Table 1.1, 
there are several methods which have been developed for scRNA-seq. These methods can be 
generally divided into two types- full-length and tag-based. Full-length methods are 
advantageous in achieving a uniform gene body read coverage and increase the number of 
mappable reads. Such broad coverage is required for the analyses of the data for isoform 
discovery, splicing events and SNP identification for allelic gene expression. However, one of 
the major drawbacks of full-length methods is that it was not possible to multiplex and pool all 
samples for one tube preparation of Illumina sequencing libraries, which increased cost and 
labour. Most scRNA-seq methods are tag-based and can be further divided into two categories 
depending on if they utilize a 3´ (e.g CEL-seq/CEL-seq2, MARS-seq) or a 5′ tag (e.g STRT). 
One of the advantages of tag-based methods is that these can be combined with Unique 
Molecule Identifiers (UMIs), which is a sequence of several nucleotides which can be 
integrated into each transcript by reverse transcription (Kivioja et al., 2012).  This enables 
multiplexing of more samples and improvement of gene-level quantification and throughput. 
So far, tag-based methods have relatively low sensitivity as mappable reads are restricted to 
one end of the transcript. Thus, tag-based methods are mostly used for gene expression 
quantification and cannot be utilized for isoform identification or splicing. 
 
Due to stochasticity in transcription and the scarcity of RNA material in an individual cell, 
scRNA-seq data often face challenges in determining cell-to-cell transcriptional variability. 
While some of this variability may be inherent due to biological factors such as stochastic gene 
expression, different cell cycle state, cell size etc., the observed variability may also be 
attributed to technical factors such as RNA capture efficiency, random dropouts during library 
preparation or varying sequencing depth. Further, experimental batch effects may be 
introduced during sample handling steps, capturing of single cells, sequencing at various 
sequencing depths using different lots of experiments involving several biological specimens 
(Leek et al., 2010). One way to identify the presence of batch effects, is to visualize the data 
using principal component analysis (PCA) and observe if cells are grouped by their 
experimental origin. Furthermore, multiple batch correction methods have been established to 
deal with these issues (Johnson, Li and Rabinovic, 2007). Addition of spike-in RNA standards 
of known abundance to the endogenous samples has also become a common practice to better 






(Baker et al., 2005). However, the ideal concentration of spike-in RNA standards is also cell-
type specific and may not be the same for control and perturbation samples. 
 
Despite the above discussed challenges in analyzing scRNA-seq data, the technology has been 
successfully implemented in understanding cell-to-cell transcriptional variability during the 
development of drug tolerance in cancer cells (K. T. Kim et al., 2015) and in reconstructing 
clonal and phylogenetic relationships, during the process of cancer evolution, by modelling 
transcriptional kinetics (Müller et al., 2016). In addition to these, scRNA-seq has been recently 
proven to have potential in performing lineage tracing during evolution by reconstructing 
lineage phylogeny over many generations (Frieda et al., 2017). As sequencing costs decrease, 
it will be possible to routinely analyze more than a million cells within the next 5 years 
(Svensson, Vento-Tormo and Teichmann, 2018). The Human Cell Atlas aims to map 35 trillion 
cells from the human body and then use gene expression profiles to classify and identify new 
cell types (Regev et al., 2017). Recent progress in overcoming the challenges in different single 
cell profiling datasets have allowed the integration of scRNA-seq with epigenomic profiling 
such as scATAC-seq (Mezger et al., 2018) which has enhanced our understanding of 
correlating transcriptional variability with differential chromatin accessibility patterns at 
single-cell level (Stuart et al., 2019). Another example of recent development in the field of 
single cell analysis is the idea of an elegant methodology named “spatial transcriptomics”. In 
this method, the transcriptome can be analyzed in intact tissues sections on slides, without the 
need for cell isolation (Ståhl et al., 2016).  
 
Future advancements may involve combined profiling of genome, epigenome, transcriptome 
and/or protein from the same single cell. This will enable a comprehensive understanding of 
each cell by integrating information from DNA, RNA, protein as well as epigenetic 
modifications and would enable identification of a rare subset of population contributing 
towards disease evolution. Few examples of such methods that have already been developed 
to achieve this include G&T-seq (genome and transcriptome sequencing) for genomic and 
transcriptomics analyses (Macaulay et al., 2015), scTrio-seq (single-cell triple omics 
sequencing) for genomic, transcriptomic analyses together with DNA methylome (Hou et al., 
2016), scM&T-seq (single-cell genome-wide methylome and transcriptome sequencing) for 






transcriptome simultaneously can correlate chromosomal CNVs (copy-number variations), 
chromosome fusion and SNVs (single nucleotide variations) in regulatory elements with the 
corresponding gene expression level. Such studies can also reveal clonal structure and cell 
subtypes within the population, which directly links genotype variation with phenotype 
outcomes (Macaulay et al., 2015). On the other hand, incorporation of transcriptomic and 
methylomic analysis would reveal how the degree of epigenetic variability in the form of DNA 
methylation of different functional elements in the genome may reflect cell-to-cell gene 
expression variability in single cells during disease development. 
 
1.5 Acute Myeloid Leukaemia- a cancer model to study the dependency on non-genetic 
variability 
 
Acute Myeloid Leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic 
progenitor cells (‘blasts’) which lose the ability to differentiate normally and to respond to 
normal regulators of proliferation (Lowenberg, Downing and Burnett, 1999). The abnormal 
differentiation of myeloid cells results in enhanced production of immature malignant cells 
with fewer differentiated red blood cells (RBCs), white blood cells (WBCs) and platelets. AML 
is more prevalent in adults who are 65 years or old with a dismal prognosis of <30% 5-year 
survival (National Cancer Institute). A better understanding of how AML evolves using 
recently developed next-generation sequencing technologies, can help us devise strategies to 
improve the therapy and prognosis of AML patients. 
 
Haematopoietic Stem Cells (HSCs), like other stem cells, are undifferentiated long-lived cells 
capable of asymmetric division, facilitating both self-renewal and the generation of 
differentiated progeny. Additionally, these cells can undergo either self-renewing (clonal 
expansion) or differentiating (clonal extinction) symmetric division (Pina and Enver, 2007). 
On an average, human HSCs undergo cell division once every 40 weeks (Catlin et al., 2011). 
However, blood cell production is a continuous process throughout life, with an adult human 
producing an estimated 1011 cells daily (Beerman et al., 2010). These properties make HSCs, 
like other tissue stem cells, prime targets for malignant transformation. On the other hand, the 
fact that some mutations can transform differentiating cells as well suggests that HSCs might 






1.6 Genetic, Epigenetic and Transcriptional variability in Acute Myeloid Leukaemia 
 
As discussed previously that somatic mutations get accumulated during the course of disease 
development and are the source of genetic variability amongst a given population of cells over 
a period of time. It is worth noting that AML has one of the lowest number of mutational load 
per case of any adult cancer studied to date where the range varies widely between individual 
cases  (Lawrence et al., 2013b). However, the number of mutations in an individual HSC 
increases almost linearly with age and is very similar to that found in de novo AML, suggesting 
that AML develops stochastically in a cell, which fortuitously accrues a transforming 
combination of mutations (Welch et al., 2012c).  
 
AML has relatively well-defined set of recurrent mutations, most of which fall into functional 
categories (TCGA, 2013b; Papaemmanuil et al., 2016). A study conducted by The Cancer 
Genome Atlas (TCGA) in 2013 on 200 AML patient samples suggested the presence of at least 
one recurrent mutation in 199 (>99%) samples (TCGA, 2013b). These mutations were found 
to be present in one of the nine categories that were defined according to biological function 
and which have a putative role in AML pathogenesis: transcription-factor fusions (18% of 
cases), the gene encoding nucleophosmin (NPM1) (27%), tumour-suppressor genes (16%), 
DNA-methylation–related genes (44%), activated signalling genes (59%), chromatin-
modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex genes 









Figure 1.9: Genes recurrently mutated in AML belong to distinct functional groups or pathways. 
The most prominent functional groups and genes associated with these are listed. The proportion of 
AMLs with mutations affecting each of these groups is displayed. Adapted from (Grove and Vassiliou, 
2014), based on the data obtained from (TCGA, 2013b). 
The somatic mutations in AML can be divided into two categories based on their functions. 
The first class of mutations mainly enhance proliferation and survival of haematopoietic 
progenitors through the activation of signalling pathways. Few examples include Fms-Related 
Tyrosine Kinase 3 (FLT3), C-Kit, and Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog 
(NRAS). On the other hand, the second class of mutations mainly occur in transcription factors 
such as RUNX1, CEBPa and RARA, where these mutations hinder cell differentiation and 
create an accumulation of immature progenitors. Based on the frequent observation of 
mutations in each of these two classes in AML, Gilliland & Griffin proposed a ‘double-hit’ 
model of leukaemogenesis (Kelly, Clark and Gilliland, 2002). They proposed that either class 
of mutations is insufficient to cause malignant transformation of haematopoietic stem cells on 
its own. Only the co-occurrence of a class I and class II mutations would cooperate to form 
leukaemia. However, there were certain limitations to the double-hit model, where not every 
AML harboured the mutations that strictly correspond to these two classes. This was in-line 
with a recent epigenomics study which specifically showed that the combination of Tet2 loss 
with expression of FLT3ITD results in synergistic and gain-of-function effects on the epigenetic 
state and on transcription. Overall, the study showed that combination of a class I and class II 






induce distinct epigenetic and transcriptional programming effects than what was caused by 
either mutation alone (Shih et al., 2015). 
 
AML has been observed as a disease model with a complex mosaic of cells containing different 
combinations of genetic lesions and epigenetic variants (Ding et al., 2012; Li et al., 2014; 
Paguirigan et al., 2015). The clonal evolutionary dynamics in AML is marked by continuous 
acquisition and loss of specific mutations, sometimes occurring at different timepoints which 
lead to simultaneous evolutionary convergence and divergence among particular clones and 
subclones during the course of disease (Ding et al., 2012; Paguirigan et al., 2015; Wu et al., 
2020). Exposure to chemotherapy regimens places an enormous stress on AML cell 
populations and may be more toxic to certain clones than others. Remarkably, it has been 
observed that clonal composition of AMLs can change quite markedly after therapy in relapsed 
disease, with selection occurring at both the genetic and epigenetic levels (Ding et al., 2012; 
Li et al., 2014). These observations highlighted the functional significance of the genetic 
composition of clones. Certain clones within the same AML patient have been characterized 
by distinct morphology, differentiation markers, and engraftment potential in 
immunocompromised mice (Klco et al., 2014). These characteristics of AML cells suggest the 
fact that the subpopulation of more immature leukaemia stem cells may have the potential to 
perpetuate and repopulate the disease, and these cells are more chemotherapy resistant. Hence 
leukaemia stem cell functionality may be a reflection of subclonal combinations of specific 
mutations, with the emergence of chemoresistance and/or tumour changes potentially driven 
by these clonality shifts (Li et al., 2014). 
 
Apart from these clonal shifts, the variability in the order of acquisition of mutations also 
contributes towards AML pathogenesis. Somatic mutations in the epigenetic modifiers 
DNMT3A, IDH1/2 and TET2 are initiating mutations in AML, especially those with normal 
karyotype (Welch et al., 2012c; Shlush et al., 2014a; Xie et al., 2014). Mutations of the NPM1 
gene that encode the aberrant NPM1c protein have also been described as initial hits (Welch et 
al., 2012c). However, clonal evolution analysis of AML patients at relapse suggests that, in the 
AML cases having both DNMT3A and NPM1, the DNMT3A mutations may precede NPM1 
(Krönke et al., 2013) since DNMT3A mutation persisted at relapse in cases where NPM1 






sequential order of mutation acquisition whereby DNMT3A and IDH2 mutations exist in pre-
leukaemic HSCs and precede NPM1c and FLT3-ITD (Shlush et al., 2014a). In-line with this, 
Corces-Zimmerman et al. also found that somatic mutations in epigenetic modifiers which 
regulate cytosine methylation occur early in pre-leukaemia cells and persist once AML goes in 
remission, whereas somatic mutations in signalling pathways that drive proliferation are later 
events in AML transformation (Corces-Zimmerman et al., 2014a). These data suggest that 
disruption of epigenetic patterning is likely an early and prominent event during 
leukaemogenesis. On similar lines, somatic mutations in transcription regulators including 
NPM1, FLT3, IDH1, N/KRAS, RUNX1, CEBPA, WT1, PTPN11, c-KIT are observed quite 
often. For example, NPM1 occurs in 27% of de novo AML cases. Likewise, chromosomal 
translocations (often a fusion of a transcription factor gene with another gene) occur frequently 
in de novo AML (18%). Examples include fusion of genes such as RUNX1 with ETO, PML 
with RARA, CBFB with MYHII, as well as fusion of MLL with various partner genes (TCGA, 
2013b; Koeffler and Leong, 2017). These findings overall indicate that early disruption in 
transcriptional landscape is a common hallmark in AML. This was compatible with the 
findings on transcriptional variability suggested by Pina et al. in haematopoietic system (Fig 
1.10A) and Buganim et al. in induced Pluripotent Stem Cells (iPSCs) obtained from fibroblasts 
(Fig 1.10B), where the authors had shown that early committed progenitors show higher 
variability in their transcriptional programmes compared to the multipotent self-renewing cells 
(Pina et al., 2012) (Buganim et al., 2012). These findings altogether strongly suggest that 
epigenetic and transcriptional reprogramming are key mechanisms during the early stage of 









Figure 1.10: Enhanced transcriptional variability during intermediate stage of cellular 
differentiation process.  
(A) Principal component analysis (PCA) plots of single-cell quantitative reverse transcription PCR data 
for cultured, primary mouse bone marrow (BM) cells in two different cytokine conditions, undergoing 
erythroid commitment and differentiation decisions (data obtained from (Pina et al., 2012)). The plot 
highlights the point that early committed cells, pre-megakaryocytic/erythroid progenitors (preMegE), 
are more heterogeneous in their transcriptional programmes than the multipotent self-renewing cells 
including long-term reconstituting haematopoietic stem cells (LT-HSCs) and short-term HSCs (ST-
HSC) they originate from, or the differentiated progeny, colony forming unit- erythroid (CFUe) they 
give rise to. Adapted from (Moris, Pina and Arias, 2016a), (B) PC projections of individual cells, 
coloured by their sample identification. The blue circle surrounds fibroblasts population and the red 
circle surrounds iPSCs. The orange dotted circle surrounds a third intermediate population with 
enhanced transcriptional variability. Modified from (Buganim et al., 2012). 
 
Based on the above inferences that epigenetic and transcriptional variability may act at early 
stages of AML progression, I focussed on the AML mouse models, which require cooperating 













Figure 1.11: Recurrent mutations in different cytogenetic and mutational backgrounds in AML. 
Recurrent tier 1 mutations in 200 AML patient samples. For each set of data, the middle horizontal line 
indicates the mean, and the shaded area indicates ±1 SD. P values are shown for the groups that had 
significant differences from the mean number of recurrent tier 1 mutations in all samples. NK denotes 




Pre-Leukaemia or pre-leukaemic phase is defined as the sequential acquisition of mutations in 
functionally normal HSCs which give rise to pre-leukaemic HSCs. These pre-leukaemic HSCs 
are capable of increased cell proliferation or self-renewal but retain normal multilineage 
potential and possess a high risk of leukaemic transformation (P.Greenberg, 1983; Jacobs, 
1985). The term ‘pre-leukaemia’ was first coined by Block et al. in 1953, where it was defined 
as heterogeneous group of haematopoietic disorders associated with a block in myeloid 
differentiation and chronic cytopenias (Block, Jacobson and Bethard, 1953). Pre-leukaemia 
was initially reported in concordant twins with ALL, whose haematopoietic cells shared a 
unique somatic rearrangement involving the MLL gene (Ford et al., 1993). The current model 
of pre-leukaemic HSCs has been defined on the basis of various scientific evidence which 
suggest that first leukaemogenic mutation must either occur in a cell that is capable of self-
renewal or confer self-renewal upon the cell. If the first mutation fails to meet one of these two 







The term pre-leukaemia has undergone a major evolution since its inception by Block et al. in 
1953. The term also refers to the heterogeneous group of haematopoietic disorders associated 
with a block in myeloid differentiation and chronic cytopenias, known as myelodysplastic 
syndromes (MDS) (Haferlach et al., 2014). As the population ages, the prevalence of these 
abnormalities markedly increases, where about 75 new patients per 100,000 individuals per 
year over the age of 65 years develop MDS. About 20–30% of these individuals do indeed 
progress to AML; and thus, these individuals might justifiably be known as preleukaemic 
(Koeffler and Leong, 2017).  
 
Another scenario where the existence of pre-leukaemic clones has been reported is the X-
inactivation during blastogenesis which usually results in equal inactivation of the maternal 
and paternal X chromosomes in the female (Gale et al., 1993). Few studies have indicated that 
older individuals have haematopoietic cells that favour usage of one X allele. This has been 
explained by unequal exhaustion of haematopoietic stem cells as individuals age. This 
observation was buttressed by genomically marking murine haematopoietic stem cells and 
using them for complete haematopoietic transplantation. Multiple clones of haematopoiesis 
initially developed in these transplanted animals; but as the mice aged, oligoclonal 
haematopoiesis predominated, suggesting that with age, certain haematopoietic clones can 
predominate (Williams et al., 1984).  
 
The presence of inherited germline mutations of one of several transcription factors (RUNX1, 
GATA2 or CEBPA) in certain individuals has been shown to have an increased propensity to 
develop AML over their life (Smith et al., 2004; Wlodarski et al., 2016). Other inherited 
germline mutations that can also predispose to MDS include Diamond–Blackfan anaemia (20% 
risk of MDS/AML), dyskeratosis congenita (disorder of telomere maintenance, 30% risk 
MDS/AML), Fanconi anaemia (40% risk), severe congenital neutropenia (20–40% risk), 
Shwachman-Diamond syndrome (10–35% risk), mutations of the SRP72 gene (increased risk 
of aplastic anaemia or MDS), Bloom syndrome (25% risk for MDS/AML), Li-Fraumeni 
syndrome (p53 mutation) (5–7% risk) and familial monosomy (Babushok and Bessler, 2015). 
For each of these inherited germline mutations, their progression to frank AML requires the 







The presence of pre-leukaemic clones has also been reported in certain AML patients who 
achieved complete morphologic remission by chemotherapy and continued to have an 
abnormal clone (Fialkow, Janssen and Bartram, 1991). This observation suggested that 
preleukaemic clone can be used to describe the loss of the major phenotype of AML, including 
driver mutations associated with AML blast cells, but where the clonal haematopoiesis 
persisted, and could evolve into relapse AML (Koeffler and Leong, 2017). Ley and colleagues 
had reported that ~50% of the individuals whose AML cells carried DNMT3A, TET2 or 
IDH1/2 mutations at diagnosis, continued to have the same mutation in >5% of the 
haematopoietic cells at complete morphologic remission, but the classical driver mutations (for 
example, NPM1, FLT3 and RAS) found at diagnosis, were not detectable at remission (Klco 
et al., 2015). Another study performed by Dick’s group on a cohort of individuals whose AML 
blast cells had mutations of DNMT3A and NPM1 at both diagnosis and relapse, indicated the 
presence of only DNMT3A mutation upon morphologic complete remission (Shlush et al., 
2014b). 
 
In conclusion, pre-leukaemia might be defined as a condition that has modifying mutations in 
the bone marrow that either cause MDS or cause clonal haematopoietic expansion initially 
without disease but associated with progression to AML (Koeffler and Leong, 2017). 
 
During the course of my PhD, I focussed on two different mouse models of pre-leukaemia- 
 
1.7.1 RUNX1-RUNX1T1(9a) model 
 
RUNX1-RUNX1T1 (aka AML1-ETO) is characterized by chromosomal translocation, 
t(8;21)(q22;q22), and is one of the most common genetic abnormalities in AML, identified in 
15% of the cases in AML (Miyoshi et al., 1991). Since the discovery of pre-leukaemia clones 
in monozygotic twins with ALL, the clonotypic RUNX1–RUNX1T1 fusion sequences were 
also detected in Guthrie spots in cases of childhood AML (Wiemels et al., 2002). The 
prevalence of detectable RUNX1–RUNX1T1 in cord blood is 100-fold greater than the risk of 
the corresponding leukaemia, and the frequency of positive cells (10-4 to 10-3), indicating 
substantial clonal expansion of the abnormal progenitor population of cells (Mori et al., 2002). 






disease development, as indicated by protracted post-natal latencies, non-concordant 
phenotypes in monozygotic twins (Wiemels et al., 2002) and the lack of overt leukaemia in 
transgenic mice (Rhoades et al., 2000). Therefore, secondary genetic events appear necessary 
for tumour development.  
 
The RUNX1-RUNX1T1 fusion with breaks at 8q22 and 21q22.3 was first reported by Dr Janet 
Rowley in 1973 during the analysis of a leukaemia patient sample (Rowley, 1973). Both the 
RUNX1 and ETO genes were identified subsequently by several groups in the early 1990s 
(Gao et al., 1991; Miyoshi et al., 1991). RUNX1 (also known as AML1, CBFα2 or PEBP2αB) 
gene belongs to the family of Runt-related transcription factors (RUNXs) (Van Wijnen et al., 
2004). It is known as acute myeloid leukaemia 1 (AML1) as its gene sequence was discovered 
from a human patient with AML (Miyoshi et al., 1991). The expression of RUNX1 marks the 
earliest haematopoietic precursor cells (T North, 1999). Mice haploinsufficient for RUNX1 
displayed a reduced number of HSCs defined by Lineage- Sca1+ Ckit+ (LSK) (Sun and 
Downing, 2004). RUNX1 gene is found to be highly mutated in AML patients and is the most 
common target of chromosomal rearrangements in AML (Osato et al., 1999). RUNX1T1 gene 
(also known as ETO or MTG8), on the other hand, is mainly characterized by its four Nervy 
homology regions (NHRs), which are homologous to Drosophila nervy protein (Feinstein et 
al., 1995). These NHRs define the domains of ETO gene that mediate interactions with other 
proteins. NHR1 share high similarity with TATA-binding protein associated factor (TAF) 
proteins and inhibits the ability for E proteins to recruit co-activator molecules like p300/CBP 
(Eriksson, Lennartsson and Lehmann, 2015)(Peterson and Zhang, 2004). NHR2 can mediate 
homo- and hetero- oligomerization of ETO and can interact with co-repressors like Histone 
deacetylases (HDACs) (Liu et al., 2006). NHR3 shares structural homology with Protein 
Kinase A (PKA) and binds to PKA regulatory subunit (PKA RIIalpha) (Fukuyama et al., 2001). 
NHR4 contains a zinc chelating motif and interacts with co-repressors NCoR/SMRT (Liu et 
al., 2007). 
 
The RUNX1-RUNX1T1 fusion occurs in intron 5 of the RUNX1 locus and in either intron 1a 
or 1b of the ETO locus (Tighe and Calabi, 1995; Tighe, Daga and Calabi, 1995; Zhang et al., 
2002) (Fig 1.12). The fusion protein consists of 752 amino acids involving N-terminal portion 






(Miyoshi et al., 1993) (Fig 1.13A). Although the presence of RUNX1-RUNX1T1 leads to 
alteration of gene expression and haematopoietic cell proliferation, its expression does not lead 
to development of leukaemia (Peterson and Zhang, 2004). This is indicative of the weakly 
oncogenic effect of RUNX1-RUNX1T1, which require cooperating mutations in order to 
develop leukaemia.  
 
 
Figure 1.12: Genomic structure of t(8;21). 
The translocation occurs in intron 5 of AML1 and intron 1a or 1b of ETO gene. Modified from (Yan et 
al., 2006). 
 
An alternatively spliced isoform of the RUNX1-RUNX1T1 transcript, RUNX1-RUNX1T1 
(9a) was identified (Yan et al., 2006) which includes an extra exon, exon 9a, of the RUNX1T1 
gene. RUNX1-RUNX1T1(9a) encodes a C-terminally truncated RUNX1-RUNX1T1 protein 
of 575 amino acids (Fig 1.13B). Expression of RUNX1-RUNX1T1(9a) leads to rapid 
development of leukaemia in a mouse retroviral transduction–transplantation model (Yan et 
al., 2006).  
 
 
Figure 1.13: Structure of the full-length RUNX1-RUNX1T1 protein and truncated protein.  
(A) Structure of full length RUNX1-RUNX1T1 encoding for 752 amino acids, (B) Structure of 
truncated RUNX1-RUNX1T1 with ETO exon 9a product encoding for 575 amino acids. The number 
after the “+” sign indicates the number of extra amino acids that were not included in the original 








Subsequent to the identification of the spliced form of RUNX1-RUNX1T1, namely RUNX1-
RUNX1T1(9a), Chen and colleagues explored the presence of mutations in C-KIT gene and 
expression in t(8;21) leukaemogenesis (Wang et al., 2005; Jiao et al., 2009). They found that 
C-KIT was highly expressed in 81.3% of patients with t(8;21) compared to patients with other 
leukaemias. Further, among patients with t(8;21) and mutated C-KIT, most of the leukaemic 
cells at disease presentation harboured both of the genetic alterations, whereas in three such 
cases investigated during complete remission, only t(8;21), but not mutated C-KIT, could be 
detected, suggesting that mutated C-KIT should be a subsequent event on the basis of t(8;21).  
 
The epigenomics studies performed on deciphering the molecular pathogenesis of RUNX1-
RUNX1T1 suggested depletion of RUNX1-RUNX1T1 affects transcriptional programmes 
associated with myeloid differentiation, proliferation and self-renewal, in addition to those 
promoting cell cycle progression and DNA synthesis (Ptasinska et al., 2012). RUNX1-
RUNX1T1 cells were found to require active RUNX1 where RUNX1 knockdown in Kasumi-
1 cells resulted in apoptosis (Schnittger et al., 2011). Another study demonstrated that RUNX1-
RUNX1T1 transformed cells require a functional RUNX1 to maintain adequate PU.1 levels, 
which is critical for RUNX1-RUNX1T1 leukaemia development in mouse transplantation 
models (Ben-Ami et al., 2013; Nafria et al., 2020). Increasing evidence suggests that the early 
presence of RUNX1-RUNX1T1 may promote mutagenesis. Several studies showed that 
RUNX1-RUNX1T1 downregulates genes involved in base-excision repair mechanism (BER) 
as well as in homologous recombination (HR) (Krejci et al., 2008; Forster et al., 2016) 
suggesting that RUNX1-RUNX1T1 may compromise genome integrity by impairing DNA 
stress monitoring and DNA repair capabilities. RUNX1-RUNX1T1 has been also found to be 
capable of recruiting the histone acetyltransferase (HAT) p300/CBP complex. RUNX1-
RUNX1T1 changes the local nucleosomal environment by acetylating histone lysine residues 
and recruiting the transcriptional machinery thus playing an essential role in gene regulation in 
normal haematopoiesis (Kasper et al., 2002; Rebel et al., 2002). Another recent study identified 
the role of RUNX1-RUNX1T1 in contributing to high order cis regulatory interactions by 
making use of Promoter Capture Hi-C (CHi-C) method in Kasumi-1 cells. The depletion of 
RUNX1-RUNX1T1 led to a rewiring of promoter-enhancer interactions, which was driven by 
increased C/EBPα and loss of AP-1 binding after knockdown (Ptasinska et al., 2019). Overall, 






leukaemia progression and maintenance, however, the detailed molecular mechanism 
underlying stepwise RUNX1-RUNX1T1(9a) progression still remain unexplored and further 
studies are needed to understand the RUNX1-RUNX1T1(9a) pathogenesis.  
 
1.7.2 Idh1R132H model 
 
Isocitrate Dehydrogenase 1 (IDH1) is a key metabolic enzyme and belongs to one of the three 
isoforms of IDH enzymes present in eukaryotes. IDH1 and IDH2 are homodimeric and 
dependent on Nicotinamide adenine dinucleotide phosphate (NADP+), while IDH3 is a 
structurally distinct heterotetrameric enzyme that utilizes Nicotinamide adenine dinucleotide 
(NAD+) as a co-factor (Fig 1.14). The cytoplasmic IDH1 contributes to the metabolic 
regulation of cells by catalyzing the oxidative decarboxylation of isocitrate to produce carbon 
dioxide (CO2) and α-ketoglutarate (α-KG) in a NADP+ dependent manner (Yang et al., 2012a). 
Whereas the IDH1 present in peroxisomes is responsible for providing reducing equivalents to 




Figure 1.14: Chemical reactions catalyzed by the wild-type IDH enzymes and tumour-derived 
IDH1/2 mutants.  
The only structural difference between α-KG and D-2-HG is the replacement of the 2-ketone group in 
α-KG by a hydroxyl group in 2-HG. ICT- Isocitrate, α-KG- α-ketoglutarate and D-2-HG- 2-







IDH1/2 mutations were first identified in colorectal cancer, and later, were also identified in 
brain tumours, with >70% incidence in secondary gliomas (Yan et al., 2009). Whole-genome 
sequencing analysis (WGS) of AML patients indicated the presence of IDH1/2 mutations in 
12-18% of AML cases (Mardis et al., 2009). Following the discovery of IDH1/2 mutations in 
glioma and AML, these were found in several different cancers, including thyroid cancer, 
intrahepatic cholangiocarcinoma, cartilaginous tumour, and some other cancers (Mi et al., 
2009; Hemerly, Bastos and Cerutti, 2010; Amary et al., 2011; Wang et al., 2013). Recently, 
IDH1/2 mutations have been identified as an important regulator in promoting cardiac arrest 
as well (Kattih et al., 2020). This studies altogether suggested the significant relevance of these 
mutations in disease and in particular, in cancer development. 
 
The most common IDH1 mutations are found on a single amino acid residue, Arg 132 (R132) 
which are heterozygous (Yan et al., 2009) and believed to have a dominant-negative effect 
(Zhao et al., 2009). IDH1 R132 mutant gains a neomorphic activity and convert α-KG to D-2-
Hydroxyglutarate (D-2-HG or 2-HG), (also known as R(-)-2-hydroxyglutarate) by utilizing 
NADPH, a key component of cellular anti-oxidation systems (Dang et al., 2009). 2-HG is 
maintained at very low levels in normal cells and tissues and is not known to have any 
significant role in any metabolic pathway. The cancer cells harbouring IDH1 mutant have up 
to ~100-fold greater 2-HG levels as compared to wild type hence, termed as an 
‘oncometabolite’ (Dang et al., 2009). 
 
2-HG and α-KG share highly identical structure. As α-KG apart from playing a crucial role in 
Krebs cycle, is also involved in other biochemical pathways, including glutamate synthesis, 
transamination of amino acids, generation of NADPH and a cofactor for dioxygenase enzymes, 
the structural similarity of 2-HG and α-KG may lead to competitive inhibition of several other 
α-KG dependent dioxygenases (Xu et al., 2011). Some of these dioxygenases include Ten-
eleven translocation (TET) family, Jumonji-C domain-containing histone demethylases, 
cytochrome C oxidase and Hypoxia inducible factor 1 α (HIF1α) (Figueroa et al., 2010; Xu et 
al., 2011). Since these enzymes are responsible for epigenetic modifications in normal cells, 
alteration in these in cancer cells due to accumulation of 2-HG may constitute a key hallmark 







IDH1/2 mutations have been identified as recurrent mutations in case of normal cytogenetic 
AML (NC-AML) which may lead to leukaemogenesis (Mardis et al., 2009). These mutations 
were found to have increased frequency with increasing age (Fathi et al., 2015) where mutant 
NPM1 and FLT3 were identified as their potential collaborators. However, the presence of 
IDH1/2 mutations mutually exclusively of the transcription-factor fusions, suggests that these 
mutations may have functions in the initiation of AML that are similar to the functions of fusion 
genes (TCGA, 2013b) (Fig 1.15). IDH1 mutations most often involve a cysteine (R132C) or 
histidine (R132H) substitution for arginine at R132. To date, the only in vivo study conducted 
by Sasaki et al. on Idh1 R132H mutant knock-in mouse model suggested the development of 
haematologic abnormalities including anaemia, splenomegaly and extramedullary 
haematopoiesis. The proportion of progenitor population of cells characterized by Lineage- 
Sca1+ Kit+, in the BM was expanded by about 5-fold in 42-46 week old mice, but the proportion 
of common myeloid progenitors (CMPs), granulocyte monocyte progenitors (GMPs), 
megakaryocyte erythrocyte progenitors (MEPs), and common lymphoid progenitors (CLPs) in 
the bone marrow remained unaffected (Sasaki et al., 2012a). Progression to acute leukaemia 
was not reported, indicating that additional collaborating mutations are required in-line with 
the model utilised in this thesis work. 
 
 
Figure 1.15: TCGA analysis on recurrent mutations in 200 AML patient samples.  
The plot shows significantly mutated genes and the number of samples with each mutation. Adapted 






Further studies have also found that these mutations are acquired early in the progression from 
normal haematopoietic stem/progenitor cells to form leukaemia (Corces-Zimmerman et al., 
2014b; Shlush et al., 2014c) and are stable during the evolution (Chou et al., 2010), indicating 
that a population of IDH1 mutant cells survive initial chemotherapy and contribute to relapse. 
Due to the recent discovery of recurrent IDH1 mutations in AML and unavailability of 
sufficient data on understanding the disease progression, it is quite important to understand the 
stepwise progression of this disease with the contribution of genetic and non-genetic factors 
during the course of disease evolution. 
 
1.8 MLL-AF9 model- a maintenance model of leukaemia 
 
Mixed lineage leukaemia gene (MLL or KMT2A) is located on 11q23 which is commonly 
involved in rearrangements (Djabali et al., 1992). MLL rearrangements fuse the N-terminus of 
MLL to a fusion partner protein and constitute >70% of infant ALL and between 35-50% of 
infant AML; MLL translocations also occur in leukaemias of older children and adults, overall 
accounting for 10% of cases (Krivtsov and Armstrong, 2007). Generally, patients with MLL 
rearrangements have a poor prognosis and are treated according to high-risk protocols, 
depending on the translocation partner fused to MLL gene (Meyer et al., 2009). In a genomic 
study conducted by TCGA in 2013, the group of patients with MLL fusions had the fewest 
recurrent tier 1 mutations, suggesting that MLL fusions require fewer cooperating mutations 
than other AML-initiating events (TCGA, 2013b) (MLL-X in Fig 1.11).  
 
MLL is expressed in most tissues, including myeloid and lymphoid cells, and positively 
regulates expression of the clustered Hox genes through histone H3 lysine 4 (H3K4) 
methyltransferase activity (Milne et al., 2002). Knockout studies in mice show that Mll is 
important for the maintenance of Hox gene expression. The expression of Hox genes is initiated 
normally in Mll knockout mice but is not properly maintained (Yu et al., 1995). Further 
analysis of the role of Mll in haematopoietic system revealed that Mll is necessary for the 
proliferation and/or survival of the HSC and progenitor compartment in both the developing 







ALL1-fused gene from chromosome 9 (AF9) is one of the most common fusion partners of 
MLL1, and this fusion arise from the t(9;11)(p22,q23) translocation (Meyer et al., 2013). The 
MLL-AF9 fusion protein consequential to t(9;11) arrangement is found in about 2-5% of all 
AML and up to 25% of de novo AML in children (Huret et al., 2000). MLL-AF9 induced 
leukaemia has an aggressive phenotype with median survival for de novo cases being only ~4 
years (Huret et al., 2000). The first MLL–AF9 fusion knock-in mouse model was made in 1996 
by Corral and colleagues. The model constitutively expressed MLL–AF9 under the control of 
the endogenous MLL promoter and developed AML (Corral et al., 1996). Subsequently, 
another conditional knock-in model was developed that showed MLL-AF9 expression in long-
term haematopoietic stem cells (LT-HSC) and in vitro resulted in dispersed clonogenic growth 
and expression of genes involved in migration and invasion (Stavropoulou et al., 2016) 
 
Delving deeper into the mechanistic understanding of MLL-AF9 pathogenesis, Somervaille 
and colleagues had shown that the strong oncogenic activity of MLL-AF9 cells aided in 
immortalization of colony-forming cells and displayed high leukaemia maintenance potential 
(Somervaille and Cleary, 2006). This was confirmed based on mice transplantation experiment 
using in vitro MLL-AF9 transformed colonies maintained in a semi-solid medium. All of the 
animal recipients injected with MLL-AF9 transformed cells developed AML with a median 
latency of 84.5 days demonstrating the fact that strong oncogenicity of MLL-AF9 transformed 
cells could aid in maintaining the leukaemia initiating cells (Somervaille and Cleary, 2006). 
These observations were further confirmed by another study conducted by Horton et al., where 
the authors found that the immortalization of leukaemogenic population of cells was dependent 
on constitutive MLL-AF9 expression (Horton et al., 2013). 
 
These observations of immortalization of AML transformed cells in the presence of strong 
oncogenic effect of MLL-AF9 fusion protein, makes it an excellent model to study AML 
maintenance in contrast to the pre-leukaemia models, namely RUNX1-RUNX1T1(9a) and 









1.9 Ribosomal Biogenesis 
 
The eukaryotic ribosome is a complex macromolecular machine made of 4 rRNA species and 
80 ribosomal proteins (RPs) (Warner, 1999). The mature ribosome is composed of 2 subunits, 
the small 40S ribosomal subunit containing the 18S rRNA and 33 RPs and the large 60S 
ribosomal subunit containing the 28S, 5.8S, and 5S rRNAs and 47 RPs. Ribosome biogenesis, 
one of the most complex and energy consuming process in the cell (Warner, 1999; Ben-Shem 
et al., 2011), involves the coordinated work of the three RNA polymerases (RNA pol) and the 
assistance of more than 200 protein co-factors (Henras et al., 2008). This stepwise journey 
commences in the nucleolus with the synthesis by RNA pol I of a large RNA transcript, the 
45S pre-rRNA, which encodes three of the mature rRNA species (18S, 5.8S, and 28S rRNAs). 
The 5S rRNA is transcribed in the nucleoplasm by RNA Pol III and imported to the nucleolus. 
These rRNAs are then engaged in a series of modifications comprising nucleolytic processing 
steps and successive recruitment of RPs (transcribed by RNA pol II) in order to shape precursor 
ribosomal particles. Then, following further nucleoplasmic maturation steps, pre-60S and pre-
40S ribosomes are eventually translocated to the cytoplasm where they undergo final 
maturation steps to form the mature 40S and 60S ribosomal subunits and achieve translation 
competence (Tschochner and Hurt, 2003). Ribosome biogenesis is directly regulated by the 
extracellular environment and stresses, nutrient availability, and cell proliferation and has been 
extensively studied in yeast as well as in higher eukaryotes, both in normal and pathological 
contexts (Bastide and David, 2018; Klinge and Woolford, 2019). 
 
In mammalian cells, RP expression varies greatly among tissues and even from one cell type 
to another (Bortoluzzi et al., 2002; Kondrashov et al., 2011a; Signer et al., 2014). This suggests 
that RPs expression pattern may evolve along cell differentiation, concomitantly with the 
acquisition of specialized functions. This is exemplified by RPL38 tissue-specific expression 
pattern during murine embryogenesis, which correlates with tissues that are affected by the loss 
of function of this protein (Kondrashov et al., 2011a). A recent study performed on similar 
lines also showed that the protein synthesis is dynamically controlled in a cell-type- and the 
developmental stage-specific manner in the haematopoietic system (Magee and Signer, 2021). 
Adult HSCs depend on maintaining low protein synthesis (Signer et al., 2014, 2016), and 






biogenesis of misfolded proteins (Hidalgo San Jose et al., 2020). Whereas fetal HSCs maintain 
relatively high protein synthesis, yet they retain self-renewal capacity, suggesting that they can 
cope with misfolded proteins more effectively than adult HSCs (Magee and Signer, 2021). 
 
Ribosome biogenesis and protein synthesis are involved in a considerable number of 
components and events and are highly regulated in order to efficiently respond to extrinsic 
demands. In cancer cells, disruption of ribosome biogenesis and protein synthesis is associated 
with altered expression of key genes encoding translation initiation factors and proto-
oncogenes such as mTOR, c-MYC, and RAS (Ruggero et al., 2004; Rosen and She, 2006; 
Markman, Dienstmann and Tabernero, 2010). One of the most striking examples connecting 
RP haploinsufficiency with elevated cancer incidence are ribosomopathies, a collection of 
disorders, in which genetic abnormalities trigger impaired ribosome biogenesis and function 
(De Keersmaecker, Sulima and Dinman, 2015). These syndromes result in specific clinical 
phenotypes that can be categorized as cellular hypoproliferative defects, often involving bone 
marrow failure and/or craniofacial or other skeletal defects. Remarkably, some of these 
diseases are associated with increased cancer risk, although the type and frequency vary 
significantly (De Keersmaecker, Sulima and Dinman, 2015). The best-studied ribosomopathy 
is named Diamond-Blackfan anemia (DBA) and characterized by bone marrow failure 
syndrome with a severe erythroid defect. Although this disease was first associated with 
recurrent mutations in RPS19 gene, further studies identified mutations or deletions in other 
RPs (Sulima et al., 2017). DBA patients show a predisposition, particularly, towards 
Myelodysplastic syndrome (MDS) or AML development (Vlachos et al., 2012a). Other 
congenital disorders have been associated with defective ribosome biogenesis and cancer 
predisposition, including Schwachman–Diamond syndrome, Dyskeratosis Congenital (DC), 
cartilage hair hypoplasia, and Treacher Collins syndrome (Narla and Ebert, 2010). In the 5q 
syndrome, a subtype of adult myelodysplastic syndrome, the long arm of chromosome 5 is 
deleted, resulting in RPS14 haploinsufficiency and subsequent severe refractory anaemia 
(Mills and Green, 2017). 
 
Quite often, mutation or alteration of a single ribosomal component triggers global changes of 
ribosome-related genes expression. Although such changes may reflect a mere necessity to 






predictive values. For example, translational profiling analysis of chronic lymphocytic 
leukaemia (CLL) patients led to the identification of a ribosome-related translational signature 
comprising RPs, translation initiation factors, and DKC1. The authors showed that decreased 
DKC1 expression observed in CLL was associated with reduced synthesis of certain RPs, 
which in turn promoted translatome alteration and the acquisition of an aggressive phenotype 
(Sbarrato et al., 2016). 
 
Ribosome alteration can arise following somatic mutation of RP gene or as an indirect 
consequence of changes in ribosome-related genes' expression. Recently, genome-wide 
analysis of tumour samples with next generation sequencing technologies revealed frequent 
somatic defects in multiple RP genes. In T-cell acute lymphoblastic leukaemia (T-ALL), 
somatic mutations and deletions of RP encoding genes have been reported in about 20% cases, 
the most frequent ones on RPL10 (8% of pediatric T-ALL cases) and RPL22 (10%), with rare 
defects in RPL5 (2%) and RPL11 (1.4%) (De Keersmaecker et al., 2013a; Tzoneva et al., 
2013a). In aggressive CLL, somatic missense mutations of RPS15 occur in 10–20% of patients 
(Landau et al., 2015; Ljungström et al., 2016a).  
 
Ribosomal alteration may also trigger translational dysfunction, which will have an impact on 
gene expression. For instance, the T-ALL-associated RPL10-R98S mutation triggers profound 
structural, biochemical, and translational fidelity defects that may drive cancer evolution 
through gene expression reprogramming (Ljungström et al., 2016a). Given its role in driving 
cancer evolution, it would be worth understanding whether attenuation in ribosomal 
biosynthetic programmes also alter gene expression landscape during pre-leukaemia 
transformation. 
 
1.10 Lysine acetyltransferase 2a Kat2a/KAT2A- a tool to study non-genetic variability 
 
Lysine Acetyltransferase 2a or Kat2a is a histone acetyl transferase (HAT) which belongs to 
Gcn5-related N-acetyltransferase (GNAT) superfamily (Neuwald and Landsman, 1997). Kat2a 
is one of the mammalian homologous (other one is Kat2b) orthologues of yeast General control 
nonderepressible 5 (Gcn5) which was the first histone specific HAT to be isolated from 






(Brownell et al., 1996). Kat2a is mostly abundant in haematopoiesis, neural tissue and has a 
role in development (Yamauchi et al., 2000). It plays an important role in developing embryo 
where it is ubiquitously expressed between E7.5 and E9.0, however, its expression decreases 
after E16.5 indicating the minimal requirement of Kat2a during terminal differentiation (Xu et 
al., 2000a). Kat2a null mice die at E10.5, with extensive mesodermal apoptosis; suggesting 
that Kat2a is important during embryonic development (Xu et al., 2000b). Kat2a is also 
required in pluripotent stem cells system not from the maintenance perspective but for the 
stabilization of pluripotency gene regulatory networks, as our lab has shown previously (Moris 
et al., 2018a).  
 
There is literature on associating the role of Kat2a in cancer, however, the mechanistic link of 
Kat2a during tumour progression still needs to be unravelled. The expression of KAT2A is 
found to be associated with poor prognosis in breast cancer (Chen et al., 2010), non-small cell 
lung carcinoma (N-SCLC) (Chen et al., 2013), colon cancer (Yin et al., 2015) and renal cell 
carcinoma (Hong et al., 2020). The poor prognosis is majorly associated with histone 
acetylation-mediated co-activation of E2F and MYC transcriptional targets to maintain cell 
proliferation and survival (Yin et al., 2015). Increased expression of KAT2A also associates 
with poor survival in renal cell carcinoma, on contrary to this, overexpression of KAT2A in 
pancreatic adenocarcinoma and glioma provides a survival advantage to the cells (Arede and 
Pina, 2020). A recent study has linked the KAT2A succinylation activity to maintenance of 
pancreatic adenocarcinoma cell lines, overall raising the possibility of the contrasting role of 
KAT2A in a cancer stage-specific manner, as shown for other epigenetic regulators (Basheer 
et al., 2019). It is worth noting that till date no recurrent mutations in KAT2A have been 
described in any cancer type suggesting hijacking of KAT2A at an epigenetic level for the 
establishment or maintenance of cancer. 
 
Kat2a forms a crucial part of Spt-Ada-Gcn5 acetyltransferase (SAGA) which is a 
multifunctional co-activator with distinct activities including HAT, a histone deubiquitinase 
(DUB), and an activator-binding module (Lee et al., 2011). Kat2a was identified not only in 
SAGA, but also as a subunit of a second co-activator complex with HAT activity in Drosophila 
and mammals, named Ada Two A Containing (ATAC) (Guelman et al., 2006). The 






structural modules namely, the HAT module, central core of SAGA including SPT and TAF 
module and DUB module (Fig 1.16). The HAT module which is also shared with ATAC 
consists of KAT2A (or KAT2B, mutually exclusive to each other), SGF29, TADA3 and a 
complex-specific ADA2 variant –ADA2B in SAGA and ADA2A in ATAC. SGF29 is 
responsible for recruiting KAT2A on active promoters marked by H3K4 tri or di-methylation 
(Bian et al., 2011). TADA3 is a transcriptional activator adaptor required for transcriptional 
activity (Martinez et al., 2001) whereas ADA2B is a zinc finger protein which is capable of 
binding double-stranded DNA (Zhang et al., 2019). TAF5L and TAF6L present in the central 
core of SAGA and are specific to SAGA, whilst the other TAFs are shared with TFIID 
complex, the RNA Polymerase II (Pol II) General Transcription Factor. TRRAP is a large 
transcription factor interaction module present in SAGA complex and was originally identified 
as cofactor of c-Myc and E2F proteins (McMahon et al., 1998). Finally, the DUB module 
present in SAGA complex is catalyzed by USP22, which targets H2B and H2A as well as non-
histone proteins (Armour et al., 2013). All 4 members of the DUB module – USP22, 















Figure 1.16: Schematic of KAT2A-containing complexes and their functions and implications in 
diseases.  
This figure only summarizes the presence of subunits, not their arrangement within ATAC. The 
modules are indicated by the following colour codes: red, HAT module; blue, DUB module; orange, 
SPT module; grey, TAF module; and green, ATAC-specific unit. DUB: Deubiquitination; HAT: 
Histone acetyltransferase; TF: Transcription factor. Modified from (Wang and Dent, 2014). 
 
KAT2A is present as a subunit in another complex known as ATAC which includes YEATS2, 
DR1 (NC2β), ATAC1 (ZZZ3), WDR5, MBIP and ATAC2 (KAT14) within the ATAC subunit 
(Fig 1.16). YEATS2 reads H3K27 acetylation mark which allows for integration of additional 
transcription activation signals (Mi et al., 2017). DR1 is a member of NC2 complex, which 
heterodimerizes with YEATS2 to interact with TBP. ATAC1 is a zinc finger protein that 
specifically binds H3 tails (W. Mi et al., 2018) and WDR5 which has been identified as a 
candidate therapeutic target in CEBPA N-terminal leukaemia (Grebien et al., 2015). MBIP is 
a MAP3K regulator present only in mammalian cell complexes (Wang et al., 2008) whereas 
ATAC2 is responsible for a second HAT activity in this complex (Guelman et al., 2009). 
YEATS2, MBIP and KAT14 are required for complex integrity (Guelman et al., 2009).  
 
The yeast orthologue of Kat2a, known as Gcn5, is a classical regulator of transcriptional 
variability (Raser and O’Shea, 2004b) as it’s loss promotes cell-to-cell transcriptional 
variability (Weinberger et al., 2012a). As discussed above, transcriptional variability is 
inherent to the phenomenon known as transcriptional bursting which depends on various 
factors including variability in TATA-box, nucleosome positioning. Cell-to-cell transcriptional 
variability is one of the non-genetic mechanisms which lead to imbalance between self-renewal 
and cellular differentiation, thereby may contribute towards cancer evolution.  
 
Delving deeper into understanding the role of KAT2A, our lab has recently shed some light on 
its role in AML. Using a  Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)-dropout screen of AML cell lines, KAT2A was identified as a genetic vulnerability 
in AML (Tzelepis et al., 2016). Our lab has shown that the acetyltransferase activity of KAT2A 
is responsible for maintaining undifferentiated cultured and patient-derived human AML cells 
in vitro. Further, our lab studied the MLL-AF9 leukaemia using a conditional Kat2a knockout 






term preservation of functional leukaemia stem-like cells (LSC). Further, the Kat2a-depleted 
LSCs lost repopulating capacity and did not fully progress through myelo-monocytic 
differentiation. Upon performing scRNA-seq of Kat2a wild-type (WT) and knockout (KO) 
leukaemia, an increase in cell-to-cell transcriptional variability was observed in KO, supporting 
a role of KAT2A in transcriptional stability. Additionally, upon learning the differentiation 
trajectories from leukaemia stem cells to differentiated leukaemia cells, the single-cell 
trajectory analysis performed on WT and KO cells highlighted an almost linear trajectory for 
WT MLL-AF9 cells, whereas Kat2a KO leukaemia cells were distributed along multiple 
discontinuous differentiation trajectories (Fig 1.17). Overall, this suggested that Kat2a KO 
cells had multiple uncoordinated routes into cell fate decision-making, which were initiated 
but not coherently completed by cells depleted of stem cell potential. These set of observations 
were interesting as they suggest cell-to-cell transcriptional variability as a mechanism where 
the leukaemia transformed cells lose the capability of maintaining a balance between self-
renewal and differentiation, thereby setting up a paradigm of utilising Kat2a as a tool to 
understand cell-fate decisions in a given disease model. 
 
 
Figure 1.17: Kat2a WT and Kat2a knockout MLL-AF9 primary leukaemias have unique 
differentiation trajectories.  
(A) Monocle pseudotime trajectory of MLL-AF9 transformed Kat2a WT cells, (B) Monocle pseudotime 
trajectory of MLL-AF9 transformed Kat2a NULL cells. Adapted from Domingues and colleagues 







1.11 Hypothesis and Rationale 
 
The central role of non-genetic mechanisms, in particular cell-to-cell transcriptional variability 
in impacting the cell-fate decision process during disease progression independent of genetic 
blueprint is evident from the literature. The fact that Acute Myeloid Leukaemia does not 
possess high mutational burden and has a strong dependency on epigenetic and transcription 
factors for disease progression makes it an excellent model to study the contributions of non-
genetic variability during leukaemia propagation. The Pina lab has previously shown that 
KAT2A/Kat2a inhibition enhances transcriptional variability in mouse embryonic stem cells 
(Moris et al., 2018a), a finding that is recapitulated in the MLL-AF9 leukaemia model 
(Domingues et al., 2020). While transcriptional variability may be disadvantageous to MLL-
AF9 transformed cells, which are abnormally retained in leukaemia self-renewal through the 
activity of the fusion protein, I propose that variability in gene expression may equally promote 
transition from pre-leukaemia towards leukaemia just as achieved by accumulation of 
mutational events. To test this hypothesis, I have made use of RUNX1-RUNX1T1(9a) and 
Idh1R132H mouse models of pre-leukaemia, which are normally reliant on additional 
mutational hits for full leukaemia transformation. Specifically, I analysed the biology of 
RUNX1-RUNX1T1(9a)-initiated and Idh1R132H-initiated AML in a conditional Kat2a 
knockout background. In order to study the potential link between loss of Kat2a, its consequent 
increase in gene expression variability, and pre-leukaemia progression, I performed single-cell 
RNA sequencing (scRNA-seq) of early-stage Kat2a WT and Kat2a NULL RUNX1-
RUNX1T1(9a) pre-leukaemia samples. The scRNA-seq analysis was utilized to study the 
transcriptional programmes impaired upon loss of Kat2a during pre-leukaemia transformation 
which were further validated experimentally and contrasted with MLL-AF9 model of 
leukaemia. Further, to study the lineage dependencies and cell fate decisions during pre-
leukaemia progression upon loss of Kat2a, pseudo-temporal ordering analyses were 
performed. Overall, Kat2a depletion portrays an interesting model of perturbation of AML 
progression that can either prevent or accelerate leukaemia progression depending on 











In order to test the mechanistic contributions of cell-to-cell transcriptional variability 
consequent to Kat2a loss during leukaemia initiation, I aimed to answer the following 
questions- 
 
1. Does Kat2a play a functional role in leukaemia initiation? Specifically, is leukaemia 
initiation impacted in RUNX1-RUNX1T1(9a) (aka AML1-ETO9a) and Idh1R132H mice 
models of leukaemia with a Kat2a conditional knockout background? 
 
2. What are the transcriptional programmes impacted upon loss of Kat2a? Do these 
programmes coincide with the general process of pre-leukaemia transformation?  
 
3. How do these transcriptional programmes affect pre-leukaemia transformation in RUNX1-
RUNX1T1(9a) and Idh1R132H pre-leukaemia models in contrast to MLL-AF9 leukaemia? 
 
4. What is the role of these transcriptional programmes in carrying out cellular variability 
during the process of pre-leukaemia progression? Is this cell-to-cell transcriptional variability 



















1.13 Thesis Structure 
 
Following the literature review in the ‘Introduction’ chapter, the thesis work begins with 
Chapter-2 which describes the experimental design and methodology of the experiments, 
which are further discussed in detail in the results section. The methodology section includes 
descriptions of the Kat2a conditional knockout mouse model as well as the setting up and 
validation of Idh1R132H colony in a conditional Kat2a knockout background. The 
computational pipelines and algorithms followed for single-cell RNA sequencing analysis are 
also described in this section. 
 
The results from the analysis and experiments are then divided amongst the next four chapters. 
Chapter-3 describes the functional characterization of RUNX1-RUNX1T1(9a) and Idh1R132H 
pre-leukaemia in a Kat2a conditional genetic background. The functional analysis of RUNX1-
RUNX1T1(9a) model suggested an accelerated leukaemia progression upon loss of Kat2a. The 
pre-leukaemia analysis further showed perpetuation of RUNX1-RUNX1T1(9a) transformed 
Kat2a knockout cells with an enhanced self-renewal capacity in vitro. Similar analysis was 
performed on Idh1R132H model where progression to leukaemia was not observed, suggesting 
requirement of additional incorporating events. However, an increase in progenitor cell 
population was observed, consistent with RUNX1-RUNX1T1(9a) model. The pre-leukaemia 
analysis highlighted an increase in self-renewal capacity in vitro during early stages of pre-
leukaemia progression.  
 
In Chapter-4, I discuss the single-cell RNA sequencing analysis of RUNX1-RUNX1T1(9a) 
time-series pre-leukaemia in order to study the potential link between loss of Kat2a and the 
consequent increase in gene expression variability. The chapter first describes the pre-
processing steps performed, which include filtering of poor-quality cells and genes and 
normalization to exclude bias introduced by variable sequencing depth. The chapter also 
describes dimensionality reduction analysis performed using principal component analysis and 
t-distributed stochastic neighbour embedding to define a robust gene set for downstream 
analysis. I then discuss the transcriptional programmes which were impacted upon Kat2a loss, 
where the analysis identified an alteration specifically in mitochondrial bioenergetics and 






Chapter-5 discusses the mechanistic contribution of transcriptional programmes altered during 
pre-leukaemia transformation in RUNX1-RUNX1T1(9a), Idh1R132H and contrasts it with 
MLL-AF9. Specifically, the chapter describes the analysis of self-renewal potential and 
clonogenic capacity in MLL-AF9 transformed primary cells segregated on the basis of high and 
low mitochondrial mass. The analysis suggested that Kat2a WT cells with low mitochondrial 
content may phenocopy some of the characteristics of Kat2a NULL cells. This chapter also 
details the analysis of protein synthesis activity in pre-leukaemia models using the OP-Puro 
incorporation method. A reduction in protein synthesis was observed in Idh1R132H Kat2a 
NULL cells. Further, upon inhibition of protein synthesis using S6K1 inhibitor, the Kat2a WT 
cells transformed with either RUNX1-RUNX1T1(9a) or Idh1R132H showed an enhanced 
colony forming potential, thus phenocopying Kat2a NULL cells. This contrasted with findings 
in the MLL-AF9 model of leukaemia, where a reduction in colony forming potential was 
observed. 
 
Chapter-6 discusses the role of gene expression variability consequent to Kat2a loss in deciding 
lineage dependencies and cellular fate reprogramming during pre-leukaemia progression. The 
single-cell RNA sequencing data described in Chapter-4 was used for this analysis. The analysis 
indicated that Kat2a NULL cells displayed an increase in transcriptional variability, which was 
accompanied by diversification of cell fates towards B-lymphocytes and monocytes. 
Furthermore, pseudo-temporal ordering of single Kat2a NULL cells revealed a highly branched 
trajectory, which was heavily populated with cells at intermediate stages of transformation; 
including accumulation of leukaemia progenitors with RUNX1-RUNX1T1 signature. In contrast, 
Kat2a WT cells displayed a linear normal haematopoiesis trajectory with minimal branching and 
an abrupt transition towards candidate leukaemia progenitor state. This chapter also discusses 
single-cell ATAC sequencing analysis of a representative RUNX1-RUNX1T1(9a) human cell 
line, which suggested that the observed increase in transcriptional variability was a consequence 
of differential chromatin accessibility patterns observed upon inhibition of KAT2A. 
 
Finally, all these findings are discussed together in Chapter-7 where they are critically evaluated 
to draw the main conclusions about how transcriptional variability consequential to differential 







































2 Materials and Methods 
2.1 Kat2a conditional knock-out model 
 
Kat2afl/fl mouse strain was a kind gift from Prof. Sharon Dent, MD Anderson Cancer Centre, 
Smithville, TX, USA. My lab generated a stable mouse line homozygous for the Flox allele, 
by crossing Kat2afl/fl conditional knockout mice (MGI:3801321) (Lin et al., 2008) with 
interferon response-inducible Mx1-Cre+/- transgenic mice (Kühn et al., 1995a) in a C57Bl/6 
background (Fig 2.1). Kat2a locus excision was obtained through the treatment of experimental 
(Kat2a excised-NULL) and control (Kat2a floxed- Kat2a WT) mice with intra-peritoneal 
polyinosylic-polycytidylic (pIpC) acid (Chan et al., 2011). 
 
After generating Kat2afl/fl conditional knockout mouse model, my lab further confirmed that 
Kat2a deletion does not perturb normal haematopoiesis and thus preserves candidate 
progenitor cells-of-origin for leukaemia transformation (Domingues et al., 2020). 
 
 
Figure 2.1: Kat2afl/fl conditional knockout mouse model.  
Schematic representing conditional Kat2a floxed (WT) and Kat2a-excised (NULL) alleles and resultant 
transcript and protein generated. PCAF- p300/CBP-associated factor, NAT- N-terminal and Ada-Two 
interaction domain, BRD- Bromodomain. 





2.2 Generation of Idh1R132H Kat2a fl/fl mice model 
 
Mx1-Cre inducible Idh1R132H mouse model (Fig 2.2A) was a kind gift from our collaborator 













Figure 2.2: Generation of Idh1R132H Kat2a fl/fl model.  
(A) Idh1R132H conditional knock-in mouse model representing Mx1-Cre inducible R132H mutation 
in exon 3, (B) Schematic representing crossing strategy between Idh1 mut/WT Kat2a WT/WT and Idh1 
WT/WT Kat2a fl/fl leading in order to obtain Kat2a Het- Idh1 mut/WT Kat2a fl/WT and Kat2a NULL- 
Idh1 mut/WT Kat2a fl/fl. 
 
In order to generate Mx1-Cre inducible mouse colony with Idh1mut/WT and Kat2a floxed 
allele, Idh1mut/WT Kat2a WT/WT Cre +/- male was crossed with Idh1 WT/WT Kat2a fl/fl 
Cre -/- female. The first-generation offspring obtained had a Kat2a fl/WT genotype (referred 
as Kat2a Het) with either Idh1 WT/WT or Idh1mut/WT and a heterozygous Cre allele. 
 
These off-springs having Idh1 WT/WT Kat2a fl/WT and Idh1mut/WT Kat2a fl/fl were crossed 
in order to obtain experimental genotypes referred to as Kat2a HET- Idh1mut/WT Kat2a fl/WT 
and Kat2a NULL- Idh1mut/WT Kat2a fl/fl with heterozygous Cre allele (Fig 2.2B). 
 
2.3 Genotyping 
2.3.1 DNA Extraction 
 
Ear clippings were collected from 4-5 weeks old mice and immediately stored in 500µl of lysis 
buffer having following composition- 
 
50mM Sodium Chloride (NaCl) 
50mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-Cl)  
5mM Ethylenediaminetetraacetic acid (EDTA) 
20% Sodium dodecyl sulphate (SDS) 
0.5mg/ml Proteinase K 
 
The lysis step was performed overnight at 55°C, 750rpm using a Thermoshaker (BioSan). 
Following day, the lysates were centrifuged at 13,000rpm for 5 minutes (tabletop centrifuge, 
eppendorf). The supernatant obtained was transferred to a fresh 1.7ml microtube having 500µl 
of Isopropanol. The microtubes were shaken gently until a white precipitate was observed and 
centrifuged at 13,000rpm for 5 minutes. The supernatant was discarded and the pellet was 





washed with 700µl of 70% ethanol. The pellet was centrifuged twice at 13,000rpm for 5 
minutes to remove excess ethanol and was further air-dried for 20 minutes and then 
resuspended in 20µl of Tris-EDTA (TE) buffer (10mM Tris, 1mM EDTA). The resuspended 
pellet was then incubated at 55°C, 750rpm for 10 minutes. The DNA obtained was quantified 
using NanodropTM Lite Spectrophotometer (Thermo Scientific) and stored at -20°C for long 
term storage. 
 
2.3.2 Polymerase Chain Reaction for Mx1-Cre, Idh1 and Kat2a   
 
The DNA samples extracted from the above step was utilised for Polymerase Chain Reaction 
(PCR) analysis using primers mentioned in Table B.2 (Annexure-B). The PCR master mix was 
prepared with the following composition- 
 
7.5µl HotStarTaq Plus Master Mix 2X (Qiagen) 
0.1µl Forward Primer 100µM 
0.1µl Reverse Primer 100µM 
2µl DNA template (50ng equivalent)     
5.3µl RNase free water (Qiagen) 
 
The PCR reaction set-up was as follows- 
 
Initial Denaturation- 95°C for 5 minutes 
Denaturation- 94°C for 30 seconds 
Annealing- 60°C for Mx1-Cre and Kat2a, 57°C for Idh1 for 30 seconds                    40 cycles 
Elongation- 72°C for 30 seconds for Kat2a and Idh1, for 90 seconds for Mx1-Cre 
Final Elongation- 72°C for 10 minutes 
 
After PCR reaction was completed, 15µl of PCR product was mixed with 4X gel loading dye 
and loaded on a 1.5% agarose gel (Fig 2.3A, B). The band sizes were estimated based on 1kb 
Plus DNA ladder (New England BioLabs). The following were the corresponding band size 
for each genotype- 
 





Mx1-Cre -/-  ~1kb 
Mx1-Cre +/-  ~700bp and ~1kb 
Kat2a fl/fl- 310bp 
Kat2a fl/wt- 310bp and 210bp 
Idh1 wt/wt - 675bp 

















Figure 2.3: Representative gel images for genotyping from a single run.  
(A) Gel image representing PCR products for 9 mice for Mx1-Cre and Kat2a where NTC represents 
No Template Control, (B) Gel image representing PCR products for Kat2a and Idh1. 
 
2.4 Idh1R132H recombination confirmation 
 
In order to confirm the recombination event leading to the activation of Idh1R132H, peripheral 
blood sampling was conducted post pIpC injections, using saphenous vein method (Fig 2.4A). 
Blood sampling was done every 2 weeks post pIpC injections and DNA extraction was 
performed as per manufacturer’s instructions (PureLink Genomic DNA Mini Kit, Thermo 
Fisher Scientific). DNA was eluted in 20 µl of elution buffer and quantified using NanodropTM 
Lite Spectrophotometer (Thermo Scientific). 
 
Next to assess the recombination event, 25ng of DNA sample was taken for PCR reaction (total 
volume- 15µl) along with primers designed specifically for Idh1R132H mutation (Table B.3 
(Annexure-B)). 
 
7.5µl HotStarTaq Plus Master Mix 2X (Qiagen) 
0.1µl Forward Primer 100µM 
0.1µl Reverse Primer-1 100µM 
0.1µl Reverse Primer-2 100µM 
2µl DNA template (50ng equivalent)     
5.2µl DNase RNase free water (Qiagen) 
 
The PCR reaction set-up was as follows- 
 
Initial Denaturation- 95°C for 5 minutes 
Denaturation- 94°C for 30 seconds 
Annealing- 57°C for 30 seconds       40 cycles 
Elongation- 72°C for 30 seconds  
Final Elongation- 72°C for 10 minutes 
 































Figure 2.4: Idh1R132H recombination analysis.  
(A) Schematic for peripheral blood sampling post 2/4/6 and 8 weeks of pIpC treatment. DNA extraction 
was performed from peripheral blood and PCR was performed to confirm the activation of Idh1R132H 
mutation, (B) Representative gel electrophoresis images for Idh1R132H at different sampling time 
points.  
 
After PCR reaction was completed, 15µl of PCR product was added to 4X gel loading dye and 
loaded on a 1.5% agarose gel. The band sizes were visualized using AlphaImager UV 
transilluminator (Protein Simple) estimated based on 1kb Plus DNA ladder (New England 
BioLabs). 
 
A recombination event highlighting activation of Idh1R132H mutation corresponds to an 
additional band size of ~700bp (Fig 2.4B).  
 
2.5 Kat2a excision confirmation 
 
To confirm the excision levels of Kat2a floxed allele, the DNA samples obtained from the 
above step were utilised for Quantitative Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR). The following reaction was prepared in triplicates for each sample- 
 
10µl 2X Takyon Low Rox SYBR Mastermix dTTP Blue (Eurogentec)  
0.1µl Forward Primer 100µM 
0.1µl Reverse Primer 100µM 
2µl DNA template (40 ng equivalent) 
7.8µl RNase- free water 
 
Primers were designed in two different pairs, where one pair was designed to amplify the 
excised region of Kat2a, referred to as Kat2a-IN, whereas the second pair was designed to 
amplify the region distal to the second loxP site, referred to as Kat2a-OUT (Fig 2.5A) (Table 
B.3 (Annexure-B)). Standards were prepared ranging from 0.8ng- 80ng along with a no 
template control. The reaction conditions were as follows- 
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Figure 2.5: Kat2a excision analysis.  
(A) Primer designing strategy depicting WT and Kat2a fl/fl to confirm Kat2a excision Kat2a IN (In11, 
within the excised region) and Kat2a OUT primers (Out18, downstream of the excised region), (B) 
qRT-PCR analysis to confirm Kat2a excision from peripheral blood sample (n=3 for Kat2a WT and 
n=5 for Kat2a NULL), (C) qRT-PCR analysis comparing excision between Kat2a WT (n=3) with 
Kat2a Het (n=2).  
 
Initial denaturation- 95°C for 3 minutes 
Denaturation- 95°C for 10 seconds      40 cycles      
Annealing- 60°C for 1 minute 
Final cycle- Denaturation 95°C for 60 seconds, Annealing 55°C for 30 seconds 
 
The expression levels were calculated by the Pfaffl method (Pfaffl, 2001) following 
normalization with respect to Kat2a-OUT (Fig 2.5B, C). 
 

































2.6 Bones and spleen processing 
 
Experimental animals were culled by cervical dislocation method, one of the schedule 1 
method of euthanasia. Before dissection, the animal was cleaned by spraying 70% ethanol. 
Animal was dissected, flesh was removed using forceps and scalpel in order to collect leg 
bones, femur, tibia and spleen in I10 (Iscove's Modified Dulbecco's Medium (IMDM) 
supplemented with 10% Heat inactivated- Fetal Bovine Serum (FBS), 2mg/mL L-Glutamine, 
1% Penicillin-Streptomycin Amphothericin (PSA)) for further processing. For histological 
assessment, liver, lungs, sternum, a portion of spleen, heart, kidneys, intestine were collected, 
weighed and immediately stored in formalin. 
 
Extraction of bone marrow (BM) and spleen cells was done separately using mortar and pestle 
(Fig 2.6). The resultant extract was filtered using 40µM cell strainer (Fisher Scientific) to 
obtain a homogeneous suspension. The cells were centrifuged at 2000rpm for 5 minutes 
(refrigerated centrifuge, eppendorf). Post removal of the supernatant, cells were resuspended 
in 2ml of Red Blood Cell (RBC) lysis buffer and incubated for 5 minutes. The reaction was 
terminated by adding 10ml of I10 medium. The cells were again centrifuged at 2000rpm for 5 
minutes. The supernatant was decanted and cells were resuspended in 20ml of Phosphate 
Buffer EDTA containing PBS + 2mM Ethylenediaminetetraacetic Acid (EDTA) + 0.5% 
Bovine Serum Albumin (BSA). The cells were counted, of which 1*106 cells/ sample were 
kept for flow cytometry analysis (described below), 50,000 cells/ sample were utilised for 
colony-forming assay (described below). Rest of the cells were cryopreserved with two vials 
each for BM and spleen. For cryopreservation, cells were centrifuged at 2000rpm for 5 min, 
supernatant was removed and the pellet was resuspended in 1ml of I10 medium with 1ml of 
freezing medium having 80% FBS and 20% Dimethylsulfoxide (DMSO). Each cryovial 
containing 1ml of this cell suspension was stored in Mr. Frosty freezing container (Thermo 
Scientific) at -80°C for up to 3 days and transferred to liquid nitrogen tank for long term 
storage.    
 
For pre-leukaemia studies, animals were processed in the same manner at pre-decided time 
points post transplantation. Leukaemia was determined on the basis of the presence of clinical 









Figure 2.6: Tissue Processing.  
Schematic representing the processing of tissue samples obtained post Schedule 1 and further used for 
in vitro experiments. 
 
2.7 Lineage depletion 
 
Lineage depletion was done to enrich for progenitor population of cells using a cocktail of 
biotinylated antibodies including B220, Ter119, Cd11b, Gr1 and Cd3e as mentioned in Table 
B.4 (Annexure-B). For this, primary BM cells obtained from mouse were resuspended in 100µl 
of PBE and a total of 10µl lineage cocktail antibodies were added to the cell suspension. The 
cell suspension having antibodies was incubated for 15 minutes on ice. Post incubation, the 
cell suspension was centrifuged at 2000rpm for 5 minutes and supernatant was removed. The 
pellet was resuspended in 100µl PBE along with magnetic Streptavidin Nanobeads 
(BioLegend) at a ratio of 10µl of beads for every 107 cells. The cell suspension was incubated 
with beads for 15 minutes on ice and washed post incubation. The pellet was resuspended in 
5ml of ice-cold PBE and cell suspension was transferred to polystyrene tube (Fisher Scientific) 
compatible with magnetic separation. The tube was placed inside the magnet (MojoSort 
Magnet, BioLegend) for 5 minutes. Post incubation, the cell suspension was poured out and 
collected. The magnetic separation steps were repeated in order to obtain a pool of two 
separations. Cells obtained were counted and further utilised for retroviral transduction. 
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2.8 Retroviral Transduction 
 
For overexpression of RUNX1-RUNX1T1(9a) fusion protein, retroviral particles expressing the 
fusion protein were produced using Human Embryonic Kidney (HEK) 293T cells. For this, 
2.5*106 of HEK 293T cells were cultured in a 10 cm dish in D10 (DMEM supplemented with 
10% Hi- FBS, 2mg/mL L-Glutamine, 1% PSA) at 37°C in CO2 incubator for overnight. Next 
day, the cells were transfected using the following transfection mix for each plate-  
 
47.5µl of TransIT (Mirus) 
5µg of psi Eco vector (packaging plasmid) 
5µg of RUNX1-RUNX1T1(9a) retroviral plasmid (MSCV-AML1/ETO-IRES-GFP)  
600µL of Opti-MEM Medium (Gibco) 
 
This transfection mix was added dropwise to HEK 293T cells followed by plate swirling and 
cultured overnight at 37°C in CO2 incubator. Following the day of transfection, the medium 
was replaced with R20 (Rosewell Park Memorial Institute 1640 (RPMI-1640) medium 
supplemented with 20% Hi- FBS, 2mg/mL L-Glutamine, 1% PSA, Table B.5 (Annexure-B)). 
After 24 hours and 48 hours of medium replacement, medium was collected and filtered using 
0.45μM syringe filter (Merck Millipore). The viral supernatant collected was immediately used 
for transduction or stored at -20°C for long term storage. 
 
For viral transduction, BM cells freshly isolated/ thawed were maintained at a density of 1*106 
cells/ml in R20 supplemented with 20ng/ml of mouse-Stem Cell Factor (mSCF), 10ng/ml of 
mouse Interleukin-3 (mIL-3), 10ng/ml of mouse Interleukin-6 (mIL-6) (Table B.5 (Annexure-
B)) in a 6-well plate for overnight at 37°C, 5% CO2. The next day, BM cells were briefly 
centrifuged at 2000 rpm for 5 minutes and viral supernatant supplemented with 20ng/ml of 
mSCF, 10ng/ml of mIL-3, 10ng/ml of mIL-6 and 10µg/ml of polybrene (Sigma) (Table B.5 
(Annexure-B)) was added to cells at a density of 1*106 cells/ml. Post viral addition, cells were 
centrifuged at 2000 rpm at 25°C for 1 hour and kept overnight at 37°C 5% CO2. A second round 
of viral transduction was performed the following day in a similar manner. Post two rounds of 
viral transductions, cells were collected, washed twice with PBS and once with R20 medium. 





The cell pellet obtained was resuspended back in R20 medium and GFP levels were assessed 
by Gallios Flow Cytometer (Beckman Coulter) and data was analysed using Kaluza software. 
 
2.9 RUNX1-RUNX1T1(9a) experiment set-up 
 
For RUNX1-RUNX1T1(9a) leukaemia and pre-leukaemia studies, three animals each of Kat2a 
WT and Kat2a NULL cohort were intraperitoneally injected with pIpC (Sigma) for 5 alternate 
days (10 days duration) at 300 µg/injection. After 4-6 weeks of the last pIpC injection, animals 
were culled following schedule 1 method of euthanasia and BM cells were isolated from 
individual animals as mentioned above. The BM cells obtained were enriched for lineage 
depletion markers and retrovirally transduced with RUNX1-RUNX1T1(9a) overexpressing 
plasmid as described above. Post transduction, Green Fluorescent Protein (GFP) levels, 
representative of transduction efficiency, were assessed using Gallios Flow Cytometer 
(Beckman Coulter). 
 
For the experimental set-up, separate pool of Kat2a WT and Kat2a NULL BM cells were made 
post in vitro transduction from three animals each. C57/BL6 mice, >8 weeks old, were lethally 
irradiated (2*5.5 Gy), weighed and injected with 1*106 cells/recipient from WT or NULL pool 
cells (n= 17 mice/group) intravenously. Pre-leukaemic mice were processed 2 months (n= 
3/group) and 4 months (n= 2/group) post-transplantation. Leukaemia studies were performed 
on the rest of the transplants where mice were collected based on the presence of clinical 
symptoms of hunched posture, inappetence and lethargy.      
 
Mice were kept in a Specific Pathogen Free (SPF) animal facility, and all experimental work 
was carried out under UK Home Office regulations. Animal research was regulated under the 
Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical 
review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). 
 
2.10 Flow Cytometry analysis  
 
Cell surface staining for both BM and spleen obtained from pre-leukaemia and leukaemia 
animals was performed using a panel of antibodies which included Cd117/ c-Kit-APCC7, 





Cd11b/ Mac1-AF700, Sca1-PEC7, Gr1-PB, Cd34-APC and Cd16/32/Fc𝛾𝑟-PE. The dilutions 
used and respective clones for each antibody is mentioned in Table B.4 (Annexure-B). For this, 
1*106 cells/ sample were resuspended in 100µl of PBE and antibody cocktail was added. 
Unstained sample and respective single colour controls were prepared to define positive gates. 
The samples were incubated for 20 minutes on ice and the reaction was terminated by adding 
500µl of R20 media. The samples were then centrifuged at 2000 rpm for 5 minutes and further 
resuspended in 200µl of R20 media for analysis. Acquisition was performed on Gallios Flow 
Cytometer (Beckman Coulter), gating was done on GFP+ population and data was analysed 
using Kaluza software.  
 
For surface marker studies during in vitro transformation of Kat2a WT and NULL with 
RUNX1-RUNX1T1(9a), same protocol was followed for a panel of antibodies including B220-
APCCy7, F4/80 PE, CD14-PECy7 (BioLegend). The cells were acquired on Attune NxT Flow 
Cytometer (Thermo Scientific) and analysed using Attune Nxt Software version 3.2.1. 
 
2.11 Colony Formation assay 
 
For analysis of pre-leukaemia samples from RUNX1-RUNX1T1(9a) and Idh1R132H, 50,000 
cells/ condition isolated from BM were plated in duplicates in MethoCult M3434 (Stem Cell 
Technologies) and colonies (a colony is defined as the presence of more than 25 cells present 
in close proximity to each other) were scored after 7-10 days. The colonies were categorized 
as Granulocyte (G), Erythroid (E), Macrophage (M), Granulocyte Macrophage (GM) and 
Granulocyte Erythroid Macrophage Megakaryocyte (GEMM). Further, re-platings were done 
with 10,000 cells/condition in duplicates until no colonies were discovered in order to assess 
the self-renewal potential of transformed cells. 
 
In case of MLL-AF9 transformed primary mouse BM cells, 10,000 cells/ condition were plated 
as mentioned above and colonies were scored after 5-7 days. The colonies were categorized as 
compact, mixed and dispersed. Further re-platings were done with 2,000- 4,000 cells/ condition 
to obtain transformed cells. 
 





2.12 Peripheral Blood analysis 
 
To study the progression of leukaemia, blood sampling was done every 4-5 weeks post 
transplantation using saphenous vein method. To start with, animals were warmed at 37°C in 
a temperature-regulated chamber for 10-15 minutes in order to dilate the blood vessel before 
bleeding. After this, the individual animal was placed in a restraining device in order to access 
the tail vein. The vein was punctured using 30G needle (VWR) and sample was collected in 
capillary action collection tube (Sarstedt). The samples collected were analysed for different 
haematological parameters using a Vet abc automated counter (Scil Animal Care, Viernheim, 
Germany).  
 
For analysing GFP population, 50µl of blood sample was diluted in 1:1 ratio with PBS. RBC 
lysis was performed for 10 minutes and cells were resuspended in 100µl of PBS post 
centrifugation at 200rpm for 5 minutes. The cells were acquired on Gallios Flow Cytometer 
(Beckman Coulter) and data was analysed using Kaluza software.  
 
2.13 Maintenance experiment 
 
To study the self-renewal potential of RUNX1-RUNX1T1(9a) transformed Kat2a WT and 
Kat2a NULL cells in a maintenance set-up, bone marrow cells were collected from 12 weeks 
old Kat2a -/- Mx1-Cre -/- animals and the cells obtained from three such animals were pooled 
together. The pooled cells obtained were then retrovirally transduced with RUNX1-
RUNX1T1(9a) as mentioned above. Post retroviral transduction, three rounds of plating were 
done as colony forming assay with 4000 cells utilised for each plating. Re-platings were done 
10 days post previous plating. Post plating 2, the cells were collected and then transduced 
retrovirally with MIGR-Cre-OP-Puro where MIGR-OP-Puro served as control, as mentioned 
above. The transduced cells were then selected using puromycin selection for 48 hours in liquid 
culture medium. The selected cells were then again plated as colony forming assay with 4000 
cells/condition in the presence of puromycin. The number of colonies obtained were scored 
and reported. 
 





2.14 Idh1R132H experiment set-up 
 
For Idh1R132H pre-leukaemia and leukaemia studies, 8-weeks old mice with required 
genotypes i.e., Idh1R132H Kat2a wt/fl (Kat2a HET) and Idh1R132H Kat2a fl/fl (Kat2a 
NULL) were subjected to pIpC injections intraperitoneally for 5 alternate days at 300 µg/dose. 
To study the phenotypic characterization of Kat2a HET and NULL carrying Idh1R132H during 
pre-leukaemia, mice were culled post 4-weeks and 20-weeks of pIpC injections following 
schedule 1 method of euthanasia (n= 3/ group for each time point) and BM cells were extracted 
using same procedure mentioned above. 50,000 cells/ condition were maintained in CFC assay 
with scoring and re-plating the colonies every 7-10 days as mentioned above. Rest of the 
samples were cryopreserved as described above.  
 
For leukaemia studies, the BM cells collected post 20-weeks of pIpC injections were thawed 
and counted. 1*106 cells/ recipient were injected into sub-lethally irradiated (1*5.5 Gy) CD45.1 
animals (n= 8/group). Leukaemia was determined on the basis of the presence of clinical 
symptoms of hunched posture, inappetence and lethargy, and animals were processed as 
mentioned above.  
 
2.15 Idh1R132H haematopoietic compartment staining 
 
To study the impact of Kat2a NULL on different haematopoietic compartments in Idh1R132H 
mice, BM cells obtained from 4-weeks and 20-weeks post pIpC were thawed and recovered in 
R20 medium. 1*106 cells/ sample was taken for cell surface staining whereas 0.2*106 cells were 
taken for each unstained/ single colour control and Fluorescence minus one (FMO) for Cd135 
and Cd34. Surface staining was performed using Cd16/32- FITC, Cd135-PE, Cd117/C-Kit- 
APCCy7, Sca1-PECy7, Cd34-APC as mentioned in Table B.4 (Annexure-B). Lineage 
exclusion cocktail included B220, Ter119, Cd11b, Gr1 and Cd3e biotinylated antibodies along 
with streptavidin-conjugated Brilliant Violet 510 as mentioned in Table B.4 (Annexure-B). 
The samples were acquired on Gallios Flow Cytometer (Beckman Coulter) and data was 
analysed using Kaluza software based on the gating strategy mentioned in Fig 2.7. 
 






Figure 2.7: Flow cytometry analysis for normal haematopoietic compartments.  
Gating strategy for different haematopoietic compartments in Kat2a HET and Kat2a NULL with 
Idh1R132H. The populations including HSC, LMPP, MPP, GMP, CMP and MEP are defined in Table 
B.1 (Annexure-B). 
 
2.16 Single-cell RNA sequencing  
2.16.1 Strategy and sample preparation 
 
Single cell RNA sequencing (scRNA-seq) was performed for RUNX1-RUNX1T1(9a) pre-
leukaemia BM samples collected post 2 months and 4 months of transplantation. For this, one 
representative BM sample of each genotype for individual time point was taken for further 
analysis. The samples were selected based on the percentage GFP population as well as self-
renewing capacity as studied in vitro using CFC assay (Fig 2.8A).  
 
These BM cells which were cryopreserved immediately after processing were thawed and 
recovered in R20 medium. In order to enrich for progenitor-like population, 107 cells/ sample 
were resuspended in 200 µl PBE and stained with Cd117/ c-Kit- APCCy7 for 30 minutes on 
ice. After incubation, cells were washed and resuspended in R20 medium with Hoescht58 (as 
mentioned in Table B.4 (Annexure-B)) in order to exclude dead cells. The stained cells were 
subjected to Fluorescence Activated Cell Sorting (FACS) for GFP+Cd117+ population based 
on the gating strategy in Fig 2.8B. The sorting was performed at NIHR Cambridge BRC Cell 
Phenotyping Hub situated in the Department of Medicine, Addenbrookes Hospital. 
 
 









     
                
 
 





Figure 2.8: Single cell RNA sequencing strategy and sample preparation.  
(A) Sample preparation strategy for single-cell RNA sequencing obtained from RUNX1-RUNX1T1(9a) 
pre-leukaemia post 2 and 4 months of transplantation and sorted for GFP+c-Kit+ (B) Gating strategy for 
sorting mouse bone marrow cells for single cell RNA sequencing highlighted in red gate along with 
sorting layout for individual samples. 
 
Each sample was sorted following the above gating strategy in order to obtain ~2000 
cells/sample (Fig 2.8B). The sorted cells were collected in 500 µl of R20 medium. The cells 
were washed and counted post-sorting. 2000 cells/sample were resuspended in 34µl of R20 
medium and sent for library preparation using 10X genomics technology at Genomics Core 
Facility in Cancer Research UK Cambridge Institute.  
 
The library preparation involves the association of all cDNA molecules arising from a single 
cell with a unique barcode using gel bead-in emulsions. These barcodes are 10bp long and 
called unique molecule identifier (UMI). Broadly, the library preparation was done using 10X 
genomics 3’ mRNA v2 chemistry with steps involving capturing cells with beads, release 
RNA, oligo- dT primed cDNA to get a 3’ mRNA seq library. The libraries obtained were 
subjected to paired-end sequencing with 26 base pair (bp) read length using Hi Seq 4000.  
 
2.16.2 Quality Control (QC) and generation of gene-cell matrix 
 
In order to understand the quality of reads generated post sequencing, FastQC report generated 
post Illumina sequencing was studied where quality scores across all bases were observed using 


















Figure 2.9: Quality Control.  
(A) Plot representing quality score per base where x-axis represents the position in base pair and y-axis 
shows quality scores, (B) Plot representing the distribution of quality score over all sequences. 
 
The plot in (Fig 2.9A) represents an overview of the range of quality values across all bases at 
each position in the FastQ file. For each position a BoxWhisker type plot is drawn where the 
central red line is the median value, the yellow box represents the inter-quartile range (25-
75%), the upper and lower whiskers represent the 10% and 90% points, the blue line represents 
the mean quality. The y-axis on the graph shows the quality scores. The higher the score the 





better the base call. The per sequence quality score report allows us to see if a subset of the 
sequences have universally low-quality values (Fig 2.9B). Ideally, these should represent only 
a small percentage of the total sequences.  
 
Post QC, Cell Ranger (v2.2) pipeline developed by 10X genomics was followed in order to 
align reads and generate gene-cell matrix. The process was initiated by cellranger mkfastq 
which was used to demultiplex raw base call (BCL) files generated by Illumina sequencing 
into FASTQ files. These FASTQ files obtained were further fed into cellranger count pipeline 
which performs alignment, filtering, barcode counting, and UMI counting. mm10 was used as 
a reference genome for alignment. These two pipelines were run individually for each sample 
in order to obtain good quality reads for further analysis.  
 
For analysing all of the samples together, a combined gene- barcode matrix was generated 
using cellranger aggr pipeline (Fig 2.10A). This pipeline normalised all four samples to the 
same sequencing depth then recomputed the gene-barcode matrices and performed analysis on 
the combined data (Fig 2.10B, C, D). The gene- barcode matrix generated had 1767 cells in 
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Figure 2.10: Generation of gene-cell matrix using Cellranger aggr pipeline.  
(A) Tabular representation of different parameters corresponding to individual sample resulting from 
Cellranger aggr pipeline where median number of genes and UMIs per cell are highlighted in red, (B) 
Barcode versus UMI plot highlighting events considered as single cell in green whereas technical noise 
is considered background and highlighted in grey, (C) Distribution of total UMI counts per cell post 
normalization (D) Distribution of number of genes detected per cell post normalization. 
 





2.16.3 Differential expression analysis 
 
Differential expression analysis was done using DESeq2 tool (Love, Huber and Anders, 2014) 
integrated in Seurat v2.4. DESeq2 estimates variance-mean dependence and calculates 
differential expression based on a model using negative binomial distribution. For genes with 
adjusted p-value =< 0.05, differential expression was calculated using log2 fold change (log2 
FC) where |log2 FC| >= 0.26 was considered a significant upregulation/ downregulation, 
corresponding to a 20% change in average fold difference.  
 
2.16.4 Gene Ontology analysis 
 
The differentially expressed genes obtained from DESeq2 analysis were further studied for 
biological processes enrichment. For this, Panther analysis (version 14.0) (H. Mi et al., 2018) 
was done where enrichments were calculated based on Fischer’s exact test and adjusted p-
values were obtained upon Bonferroni correction for multiple testing. 
 
2.16.5 Molecular Signature Database (MSigDB) 
 
In order to understand the molecular function of the differentially expressed genes of respective 
WT and NULL comparisons obtained from DESeq2 analysis, an overlap of these genes with 
C2 (MF) datasets available on MSigDB v7.1 (Subramanian et al., 2005, Liberzon et al., 2015) 
was computed and top 10 gene sets with False Discovery Rate (FDR) less than 0.05 were 
represented.  
 
For highlighting the processes specific for each cellular compartment, an overlap was 
performed with C7 dataset highlighting immunologic signatures and top 10 gene sets with FDR 









2.16.6 Pseudotemporal ordering and construction of single-cell trajectory 
 
In order to study the transcriptional dynamics during the process of leukaemia transformation, 
Monocle (v3.0) (Trapnell et al., 2014) was used. To start with, a cell data set (CDS) object was 
created from raw data having expression matrix, cell metadata and gene annotations. After this, 
pre-processing was done by normalizing the data by log and size factor to address depth 
differences. Post normalization, PCA analysis was done in order to study the variance 




Figure 2.11: Pre-processing using Monocle v3.0. 
Principal Component Analysis was done in order to observe the variance contributed by each PC and 
utilize this information to visualize cells in a reduced dimensional space. 
 
To visualize the cells in a lower dimensional space, Uniform Manifold Approximation and 
Projection (UMAP) method was used which is integrated in Monocle 3. Further, cells were 
divided into larger well separated groups called partitions following Partition-based Graph 
Abstraction (PAGA) algorithm integrated in Monocle3 (Wolf et al., 2019) and visualized on 
UMAP plot obtained from previous step. After grouping the cells, a principal graph was fitted 
for these partitions and further, each cell was ordered according to it’s progress along the 
learned trajectory. This alignment of cells as a function of progress along the trajectory is 
termed ‘pseudotime’.  
 





For ordering the cells along pseudotime, the beginning of the biological process, termed as 
‘root’ was defined by a region where most of the WT-2 months cells were present. For 
individual WT or Kat2a NULL cells trajectories, the root was defined by WT/ Kat2a NULL-2 
months cells. After defining the root, each cell was ordered in pseudotime space with respect 
to the root.  
 
The cellular compartments were identified by differential expression performed using DESeq2 
as described above and further by performing Gene Ontology analysis using Panther. 
 
2.16.7 Transcriptional variability measurement 
 
For measuring transcriptional variability, pairwise distance method was used (Mohammed et 
al., 2017). In order to measure this, top 500 variable genes from each subset under comparison 
were identified based on Distance to Median (DM) and correlation measures were calculated 
for these. These correlation measures were further converted into distance using equation 
below- 
 
𝑑 = 	√[(1 − 	𝜌)/2] 
 
d = transcriptional variability 
𝜌 = Spearman’s correlation coefficient 
 
The distance values representing transcriptional variability were plotted in the form of violin 
plot (Fig 2.12).  






Figure 2.12: Transcriptional variability measurement.  
Schematic representing heterogeneous transcription which can be measured by pairwise correlation 
method. 
 
2.17 Single-cell ATAC sequencing 
2.17.1 Sample preparation 
 
The sample preparation (Fig 2.13) including building up of libraries for single-cell ATAC 
sequencing were done by members of Pina group prior to my joining. For this, the Kasumi-1 
cells were taken and subjected to treatment with 100 µM MB-3 where 0.1% DMSO served as 
control. The cells were cultured the day before at 7*105/ml, treated on D0 and collected 24 
hours later (D1). The library preparation was done using C1 Single-Cell Auto Prep System 














Figure 2.13: Sample preparation and generation of count matrix from scATAC-seq data. 
Schematic describing the different steps involved in generating scATAC-seq data, starting from the 
treatment of Kasumi-1 cells with KAT2A inhibitor MB-3 where DMSO served as control, these cells 
were then subjected to scATAC-seq library preparation using Fluidigm C1 system, the raw reads 
generated upon sequencing were then subjected to alignment and further utilised for peak calling in 
order to generate a workable matrix. 
 
2.17.2 Matrix generation, pre-processing and filtering of data 
 
The sequencing data generated was aligned using hg19 as reference genome and peak calling 
was done using MACS2 (Zhang et al., 2008). This led to 74,284 peaks in DMSO and 111,898 
peaks in MB-3 in the form of binary measure where 0 and 1 corresponds to the absence and 
the presence of a peak, respectively. These peaks were merged using Bedtools 2.27.0 (Quinlan 
and Hall, 2010) and filtered for the peaks which were present in at least 15 % of the cells. The 
strict filtering was done to avoid any false positive peaks and to balance the number of peaks 
obtained from higher number of MB-3 cells sequenced (50 vs. 38 in DMSO). Post-filtering, 
4157 peaks were obtained in total which were subjected to differential accessibility analysis 
based on Fisher exact test and information gain as mentioned above. The p-values generated 
were corrected for the mean number of comparisons using Bonferroni (Haynes, 2013) and 
Benjamini Hochberg (Benjamini and Hochberg, 1995) correction method. The combined 
measure of frequency of peaks in DMSO and MB-3 cells and differential analysis resulted in 
50 peaks which were characterized as DMSO unique, 520 peaks which were characterized as 
MB-3 unique and 3587 peaks which were attributed as common set of peaks. 
 
2.17.3 Jaccard distance calculation 
 
After obtaining the peak accessibility matrix, Jaccard distance method (Jaccard, 1901) was 
used to quantify the dissimilarity in which two cells vary in their peak accessibility. The Jaccard 
distance was calculated as the ratio between the number of peaks that are unique to a cell 
against all the peaks that are open in two cells. 
 





2.17.4 Differential accessibility analysis 
 
Differential accessibility analysis was done for a common subset of peaks in order to calculate 
statistical significance for quantitative changes in chromatin accessibility between DMSO and 
MB-3 treated cells. For this, two different approaches were followed- Information Gain and 
Fisher exact test. 
 
Information gain is a measure of homogeneity and calculates the reduction in entropy based on 
which it suggested the peaks which differentiate MB-3 from DMSO. The information gain was 
calculated as-  
 
 
Where P is collection of all data, PG1 represents cells in G1 and PG2 represents cells in G2. 
 
Fisher exact test was run on a peak-by-peak basis by organizing the open and closed (1’s and 
0’s) for each peak in a 2 × 2 contingency table. The p-values obtained were then corrected for 
multiple comparisons using Bonferroni correction.  
 
2.17.5 Dimensionality reduction analysis and k-medoid clustering 
 
For easy visualization and downstream analysis, dimensionality reduction analysis was 
performed using tSNE. The cells were further clustered using k-medoid algorithm which 
breaks the dataset into different partitions and attempts to minimize the distance between points 
assigned in a cluster and a point designated as the centre of that cluster. 
 
2.17.6 Genomic Regions Enrichment of Annotations Tool (GREAT) 
 
In order to model the regulatory landscape corresponding to DMSO and/or MB-3 specific 
peaks, GREAT analysis (Mclean et al., 2010) was done. The tool calculated region-gene 
associations for each subset of peaks with respect to hg19 species assembly.  





2.17.7 Annotation of peaks 
 
Annotation of different subset of peaks was done using HOMER (Duttke et al., 2019). The 
peaks were provided in the form of Browser Extensible Data (BED) format having information 
about chromosome, starting/ending position and strand (+/-) specificity. The peaks were 
annotated using hg19 as reference genome. 
 
2.17.8 Transcriptional variability calculation 
 
Transcriptional variability measurement was done using pairwise distance method mentioned 
above. For this, the peaks which were found to have higher accessibility in MB-3-I cluster as 
compared to DMSO or MB3-II were annotated for closest genes using HOMER as mentioned 
above. In order to measure transcriptional variability using scRNA-seq from RUNX1-
RUNX1T1(9a) pre-leukaemia, the genes obtained post annotation were converted to mouse 
homolog using BioMart (Smedley et al., 2009). 
 
Pairwise correlation was calculated using top 500 variable genes for each subset, calculated as 
mentioned above.   
 
2.18 Generation of MLL-AF9 primary cell lines 
 
MLL-AF9 primary cultures were set-up using Kat2a WT and Kat2a NULL BM cells obtained 
from mice and transduced with MLL-AF9 in vitro as described above. The cells obtained were 
enriched for transformants by three rounds of serial re-plating in MethoCult M3434. These 
transformed cells were then cultured in R20 supplemented with 20ng/ml each of mSCF, mIL-
3, mIL-6 at a density of 0.2*106 cells/ ml and passaged when they reached a density of 
1*106cells/ ml.   
 
The primary cell lines generated in vitro were then carefully observed to study any differences 
in growth patterns (Fig 2.18A). Live and dead cell counting was performed every alternate day 
for both genotypes.  
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Figure 2.14: Characterization of MLL-AF9 primary cell lines.  
(A) Growth curve representing number of cells (per 1*106) for both Kat2a WT and Kat2a NULL at 
each passage (mean ± SD), (B) Cell cycle profile obtained for both genotypes using flow cytometry 
analysis for Hoescht 33342 representing G0/G1, S and and G2/M phase of cell cycle, (C) Proportion of 
cells in each phase of cell cycle for both genotypes (n=3/genotype, mean ± SD, Student’s t-test 
p<0.05*), (D) Flow cytometry plots representing early and late apoptosis marked by Annexin V and 
Hoescht58 for both genotypes, € Representative plot for early apoptotic population of cells for both 
genotypes (n=3/genotype, mean ± SD, Student’s t-test p<0.05 *), (F) Representative plot for late 
apoptotic population of cells for both genotypes (n=3/genotype, mean ± SD, Student’s t-test p<0.01**). 
 
Post three passages, cell cycle analysis was done to see any differences during different phases 
of cell cycle (Fig 2.18B). For this, 1*106 cells of both Kat2a WT and Kat2a NULL cells were 
incubated in R20 medium with Hoescht33342 (2µg/ml) at 37°C for 2 hours and cells were 
acquired on Gallios Flow Cytometer (Beckman Coulter) and data was analysed using Kaluza 
software suggesting a reduction in S phase in Kat2a NULL cells (Fig 2.18C). 
 
Apoptosis studies were also done in parallel for both Kat2a WT and Kat2a NULL cells (Fig 
2.18D). The cells were incubated in 5µl of Annexin V APC (BioLegend) for 15 minutes and 
resuspended in Hoescht33258 (1:10000). Acquisition was done on Gallios Flow Cytometer 
(Beckman Coulter) and data was analysed using Kaluza software suggesting an increase in 
both early and late apoptosis in Kat2a NULL cells (Fig 2.18E, F). 
 
2.19 Mitochondrial analysis  
 
For mitochondrial analysis, 105 cells/ sample were resuspended in 100µl of R20 medium 
supplemented with 10ng/ µl mIL-3, 10ng/ µl mIL-6 and 20ng/ µl mSCF as mentioned above. 
Unstained and single colour controls were prepared from a pool of all samples with 105 cells/ 
control and resuspended in same media. For each sample and control, 1µl of Mitotracker- Deep 
Red and Mitostatus- Tetramethylrhodamine ethyl ester (TMRE) were added to obtain a final 
concentration of 500nM and 100nM respectively. The addition of dyes was performed in dark. 
The cells were incubated for 30 minutes at 37°C in CO2 incubator. Post incubation, 700µl of 
R20 was added and the cells were centrifuged at 2000 rpm for 5 minutes. The supernatant was 
removed, and samples were resuspended in 200µl of R20 supplemented with cytokines as 





mentioned above and Hoescht58 at a dilution of 1:10000. The samples were acquired on 
Gallios Flow Cytometer (Beckman Coulter) at low/ medium speed, gating was done on GFP+ 
for RUNX1-RUNX1T1(9a) and YFP+ for MLL-AF9 transformed cells and data was analysed 





                            
Figure 2.15: Mitochondrial analysis and gating strategy.  
(A) Experimental strategy for Mito hi/Mito lo analysis where MLL-AF9 transformed cells were stained 
with mitochondrial dyes and sorted as Mito hi and Mito lo, (B) Gating strategy for defining low and 
high population for WT and Kat2a NULL cells transformed with MLL-AF9.  
 
In order to study the phenotypic differences between high mitochondrial mass (Mito hi) and 
low mitochondrial mass (Mito lo), MLL-AF9 mBM transformed cells post staining with 
Mitostatus and Mitotracker were sorted based on mitochondrial mass high/ low (Fig 2.19A, 
2.19B). Index sorting was done for both Kat2a WT and Kat2a NULL where single cell was 
collected in each well of a 96-well plate from Mito hi, Mito lo and Mito total fractions in 200 
µl of R20 medium supplemented with cytokines. These single cell clonal cultures were kept at 
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37°C in CO2 incubator and tracked for cell counts in each well for 7 days in order to visualize 
any differences in clonal expansion abilities of these cells.  
 
The cells were also sorted in bulk in order to study any differences in self-renewal potential of 
the mitochondrial fractions in both genotypes. The sorted cells ~2000 cells/ sample were 
maintained in the form of CFC assays in technical duplicates as mentioned above. The colonies 
obtained were scored after 5 days. 
 
2.20 Tigecycline inhibition 
 
To study whether inhibition of mitochondrial translation activity in Kat2a WT cells 
phenocopies that of Kat2a NULL cells, Kat2a WT BM cells transformed with MLL-AF9 were 
taken and treated with 2.5µM and 5µM of Tigecycline where R20 medium served as control. 
3.3µl of Tigecycline (equivalent to respective concentrations) or medium was added directly 
to MethoCult M3434 and vortexed thoroughly. 10,000 cells/condition were added to the 
medium and plated in duplicates. The colonies obtained were scored after 5-7 days of plating 
and analysed for cell surface marker, Cd117/ c-Kit using Gallios Flow Cytometer (Beckman 
Coulter). The data obtained was analysed using Kaluza software. 
 
Further, to study the effect of mitochondrial translation inhibition during leukaemia 
transformation, 50,000 cells each of Kat2a WT BM cells transduced with RUNX1-
RUNX1T1(9a) were treated with 2.5µM of Tigecycline (Tocris) where R20 medium served as 
control. Colonies were scored after 7-10 days of plating and further re-plated with 10,000 
cells/condition for plate 2 and 4,000 cells/condition for further platings in presence of 
Tigecycline. The colonies obtained at plate 5 were analysed using flow cytometry following 
the procedure described above for c-Kit (Fig 2.16). 
 
 






Figure 2.16: Schematic for Tigecycline experiment.  
Experimental strategy for studying the effect of mitochondrial translation inhibition upon RUNX1-
RUNX1T1(9a) transformation using Tigecycline and performing flow cytometry analysis. 
 
2.21 O-propargyl-puromycin (OP-Puro) assay 
 
OP-Puro assay was done in order to study differences in protein synthesis. For this, Kat2a WT 
and Kat2a NULL cells transformed with RUNX1-RUNX1T1(9a) or having Idh1R132H, 20-
weeks post pIpC were serially re-plated during colony forming assays as described above. At 
each plating, 1*106 cells each of Kat2a WT and NULL cells were taken where 0.8*106 cells 
were cultured in R20 medium supplemented with 20ng/ml of mSCF, 10ng/ml of mIL-3 and 
10ng/ml of mIL-6 having 12.5 µM OP-Puro (Thermo Scientific). Rest 0.2*106 cells were 
cultured in the same medium where OP-Puro was replaced with PBS. The cells were kept in 
culture for 1 hour in CO2 incubator. Post incubation, cells were washed, resuspended in PBE 
and surface staining was done with c-Kit-APCC7, Sca1-PC7, CD11b-Biotin, Gr1-Biotin, 
Streptavidin Brilliant Violet 605 (all BioLegend) as described above. Respective single colour 
controls were prepared with a pool of treated and non-treated cells. Post staining, each sample 
was resuspended in 500µl of 1% Paraformaldehyde (PFA), vortexed thoroughly and incubated 
for 20 min at 4°C for fixation. The cells were washed twice with PBS post fixation and 
resuspended in 200µl of cold permeabilization buffer (PBS +3% FBS +0.1% saponin) for 5 
minutes in dark. Post incubation, samples were centrifuged, supernatant was removed and 
immediately proceeded for Azide-Alkyne Cycloaddition reaction. Each sample was 
resuspended in 500µl of following reaction mixture- 
 
440µl 1x Reaction Buffer (component A; Click-iT Cell Reaction Buffer Kit, Life 
Technologies)  
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10µl CuSO4 (component B)  
1µl Alexa Fluor 647-Azide (AF647-Azide) (Life Technologies) 




Figure 2.17: Gating strategy for OP-Puro analysis.  
Gating strategy differentiating OP-Puro low (Lo) and high (Hi) population based on unstained and 
single colour controls for both RUNX1-RUNX1T1(9a) or Idh1R132H. 
 
The samples were thoroughly vortexed and incubated for 30 minutes in dark at room 
temperature. Post incubation, samples were washed twice with 1ml of ice cold permeabilization 
buffer and resuspended in 200ul of PBS. All centrifugation steps were done at 2000 rpm for 5 
minutes at 4°C. The samples were acquired on Attune NxT Flow Cytometer (Thermo 
Scientific) and analysed using Attune Nxt Software version 3.2.1. Gating strategy was based 
on unstained and single colour control defining OP-Puro low and high populations (Fig 2.21). 
 
2.22 S6K1 inhibition 
 
Functional studies on protein synthesis ablation were done using p70 ribosomal S6 kinase 
(S6K1) inhibitor (Tocris). For this, Kat2a WT BM cells transduced with RUNX1-
RUNX1T1(9a) or having Idh1R132H, 4-weeks post pIpC, were treated with either 3.3	µl of 
control DMSO or S6K1 inhibitor (equivalent to final concentration of 10µM). The inhibitor or 
DMSO was directly added to MethoCult M3434 and vortexed thoroughly to which cell 
suspension with 10,000 cells/ condition were added and plated. The colonies were scored after 





7-10 days and single cell suspensions obtained were subjected to OP-Puro analysis similarly 
as mentioned above (Fig 2.22). 10,000 cells/ condition were re-plated and the same procedure 
was repeated until third plating. 
  
 
Figure 2.18: Experimental strategy for S6K1 inhibition experiment.  
Kat2a WT cells transformed with RUNX1-RUNX1T1(9a) or Idh1R132H were treated with S6K1 
inhibitor with DMSO as vehicle. Colony scoring and OP-Puro analysis was done at each plating. 
 
2.23 Statistical Analysis 
All experiments were done in triplicates except where mentioned. The data is plotted as Mean 
± Standard deviation and Student’s t-test was performed using Graphpad Prism 8.0 software. 
In case of scRNA-seq and scATAC-seq analysis, adjusted p-value was calculated using 



















3 Functional characterization of RUNX1-RUNX1T1(9a) and 
Idh1R132H leukaemia in a Kat2a knockout genetic background 
In this chapter, I studied the functional role of Kat2a, an established regulator of cell-to-cell 
transcriptional variability, in a disease initiation set-up. Herein, I describe the experiments 
which were conducted in order to study the impact of Kat2a loss in 2 mouse models of AML, 
namely, the ones initiated by RUNX1-RUNX1T1(9a) and Idh1R132H. These models typically 
require additional mutations for leukaemia progression and thus, represent forms of human 
disease with a prolonged pre-leukaemia phase. In order to study the role of Kat2a in these 
disease models, I made use of Kat2a conditional knockout mice model, available in the lab, 
(MGI:3801321) (Lin et al., 2008) with interferon response-inducible Mx1-Cre+/-  (Kühn et al., 
1995a) in a C57Bl/6 background. The method utilizes interferon g (IFNg)-inducible Mx 
dynamin-like GTP-ase 1 (Mx1) promoter which controls Cre recombinase expression (Kühn 
et al., 1995b), activation of which allows targeted silencing of Kat2a in vivo in haematopoietic 
system. Kat2a locus excision was obtained through the treatment of experimental (Kat2a 
excised- Kat2a NULL or Kat2a knockout) and control (Kat2a floxed- Kat2a WT) mice of both 
genotypes with intra-peritoneal polyinosylic-polycytidylic (pIpC) acid (Chan et al., 2011). My 
lab has confirmed previously that Kat2a deletion does not perturb normal haematopoiesis and 
thus, preserves candidate progenitor cells-of-origin for leukaemia transformation (Domingues 
et al., 2020). In line with this, I studied RUNX1-RUNX1T1(9a) pre-leukaemia by making use 
of bone marrow (BM) cells retrovirally transduced with RUNX1-RUNX1T1(9a) and injected 
back into C57/BL6 mice. For studying Idh1R132H pre-leukaemia, I crossed Idh1R132H 
conditional knock-in model (obtained from a collaborator as described in Methods) with 
Kat2afl/fl mouse in order to generate a conditional Idh1R132H Kat2a fl/fl mouse model which 
was further utilized for pre-leukaemia studies. The pre-leukaemia cells were collected at 
different time points post RUNX1-RUNX1T1(9a) transduction or Idh1R132H mutation 
activation and were phenotypically characterized using flow cytometry analysis, colony 
forming replating assay, and peripheral blood sampling during the course of pre-leukaemia 
progression, as described in detail in this chapter. 
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3.1 Loss of Kat2a promotes pre-leukaemia to leukaemia acceleration in RUNX1- 
RUNX1T1(9a) model of leukaemia 
To study the loss of Kat2a in RUNX1-RUNX1T1(9a) model, BM cells were extracted from 
Kat2a WT and Kat2a NULL animals post 4-6 weeks of pIpC treatment (Methods). The BM 
cells obtained were enriched for lineage depleted cells (B220-, Ter119-, Cd11b-, Gr1- and Cd3e-
) and transduced with RUNX1-RUNX1T1(9a) overexpressing plasmid in vitro. These 
transduced BM cells were injected into lethally irradiated C57/BL6 animals as described in 
methods in order to study differences in leukaemia progression in vivo upon Kat2a loss (Fig 
3.1A). There were 17 animals injected for BM cells from each genotype, of which 5 animals 
per genotype were utilized for pre-leukaemia studies. The animals were routinely observed for 
the presence of clinical symptoms of hunched posture, inappetence, and lethargy, indicative of 
leukaemia development. The first Kat2a NULL animal died of leukaemia post 104 days of 
transplantation. In contrast, the first Kat2a WT animal to develop leukaemia did so post 171 
days of transplantation. Overall, an acceleration in leukaemia progression was observed in 
Kat2a NULL animals compared to Kat2a WT, suggesting that loss of Kat2a promotes RUNX1-
RUNX1T1(9a) leukaemia progression (Fig 3.1B). The analysis includes animals having 
developed leukaemia until 405 days of transplantation which is when the experiment was 
terminated. The animals which died of reasons other than leukaemia were excluded from the 
statistical analysis.  
Animals that developed leukaemia were inspected for the presence of RUNX1-RUNX1T1(9a) 
transformed cells. For this, the animals were culled using schedule 1 method of euthanasia; 
BM cells and spleen cells were isolated and stained with a cocktail of antibodies (Methods). 
Flow cytometry analysis suggested that 30-60% of the total population was GFP+ indicating 
RUNX1-RUNX1T1(9a) mediated transformation (Fig 3.1C and 3.1D). A significant proportion 
of these transformed cells were c-Kit+ indicating the presence of early progenitor cells in 
leukaemic animals irrespective of genotypes (Fig 3.1C and 3.1D). The gating set-up was done 
on the basis of unstained and single colour controls for the individual experiment. 
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Figure 3.1: Functional characterization of RUNX1-RUNX1T1(9a) leukaemia.  
(A) Schematic diagram representing experimental set-up. Bone marrow cells from Kat2a WT and 
Kat2a NULL animals were transformed with RUNX1-RUNX1T1(9a) overexpression plasmid having 
GFP reporter and transplanted into lethally irradiated CD45.1 animals (n=17 animals/genotype). Pre-
leukaemia studies were done 2 months (n= 3/genotype) and 4 months (n=2/genotype) post-
transplantation, (B) Survival curve representing percentage survival with respect to the number of days 
post transplantation for CD45.1 animals transplanted with Kat2a WT and Kat2a NULL cells (n=12 
animals/genotype, Log rank test, p=0.0105), (C) Representative flow cytometry analysis of bone 
marrow cells obtained from one of the Kat2a WT animals which developed leukaemia. The plot 
highlights GFP+ cells indicating RUNX1-RUNX1T1(9a) transformation, (D) Representative flow 
cytometry analysis of bone marrow cells obtained from for one of the Kat2a NULL animals which 
developed leukaemia.  
 
The leukaemia studies were complemented by terminal peripheral blood analysis to understand 
differences in haematological parameters in Kat2a NULL animals over the period of leukaemia 
development (Fig 3.2). For this, blood sampling was done prior to culling for all the animals, 
irrespective of leukaemia induced death and samples were analysed using Vet abc automated 
counter (Methods). Kat2a NULL and Kat2a WT samples displayed no significant differences 
in any of the haematological parameters including WBC (Fig 3.2A), RBC (Fig 3.2B), and 
Haemoglobin (Fig 3.2C). Further, liver and spleen size and weight were measured between the 
genotypes to assess infiltration of the disease. There was no significant difference observed 
when comparing liver weight between the genotypes (Fig 3.2D left). Similar results were 
observed when the analysis was restricted to the animals which developed leukaemia (Fig 3.2D 
right). Similarly, no significant differences were observed for spleen size upon loss of Kat2a 
(Fig 3.2E left). Again, similar results were observed when the analysis was restricted to animals 
which developed leukaemia (Fig 3.2E right). 
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Figure 3.2: Peripheral blood analysis and terminal leukaemia burden study.  
Peripheral blood analysis to study different haematological parameters including, (A) White Blood 
Cells, (B) Red Blood Cells, (C) Haemoglobin, for both Kat2a WT and Kat2a NULL animals (plots 
represent analysis for n=6 animals for Kat2a WT and n=5 animals for Kat2a NULL, mean ± SD, 
Student’s t-test) (D) Comparison of liver weight between Kat2a WT and Kat2a NULL animals (left) 
(plots represent analysis for n=10 animals for Kat2a WT and n=12 animals for Kat2a NULL, mean ± 
SD), Comparison of liver weight between Kat2a WT and Kat2a NULL animals which developed 
leukaemia (plots represent analysis for n=3 animals for Kat2a WT and n=7 animals for Kat2a NULL, 
mean ± SD, Student's t-test) (right) (E) Comparison of spleen weight between Kat2a WT and Kat2a 
NULL animals (plots represent analysis for n=10 animals for Kat2a WT and n=12 animals for Kat2a 
NULL, mean ± SD, Student’s t-test) (left), Comparison of spleen weight between Kat2a WT and Kat2a 
NULL animals which developed leukaemia (plots represent analysis for n=3 animals for Kat2a WT and 
n=7 animals for Kat2a NULL, mean ± SD, Student’s t-test) (right). 
 
3.2 Kat2a loss aids in the survival of RUNX1-RUNX1T1(9a) transformed cells at pre-
leukaemia stage 
To understand whether accelerated leukaemia progression upon loss of Kat2a is a consequence 
of advantageous transformation events at pre-leukaemic stages, peripheral blood sampling was 
done on a regular basis post transplantation in C57/BL6 mice injected with RUNX1-
RUNX1T1(9a) transduced BM cells. Mononuclear cells extracted from peripheral blood 
samples were analysed for GFP+ population which is representative of RUNX1-RUNX1T1(9a) 
transformed cells. Blood sampling was performed on 10 animals for each genotype starting 
from 5 weeks post transplantation until 48 weeks.  Kat2a NULL animals showed an increase 
in RUNX1-RUNX1T1(9a) transformed cell population after 12 and 17 weeks of transplantation. 
This population remained stable at later stages of sampling suggesting a perpetuation of the 
transformed population which leads to accelerated leukaemia progression (Fig 3.3A, Two-way 
ANOVA analysis, p= 0.001***). On the other hand, Kat2a WT animals did not show any 
changes in accumulation of transformed cells suggesting the event is Kat2a specific.  
 
In addition to the above, the collected blood samples were also analysed for various 
haematological parameters during disease progression. In general, there was a steady increase 
in WBCs until 17 weeks which remained stable until 48 weeks post transplantation (Fig 3.3B). 
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The proportion of HGB remained stable over the period of disease development (Fig 3.3C). 
The number of PLT were slightly reduced over the period, potentially due to aging (Fig 3.3D). 
However, there was a sharp reduction at 17 weeks which is likely due to presence of technical 
artifact since both the genotypes responded in similar manner. Overall, there were no genotype 
specific differences in haematological parameters over the period of disease progression, 
suggesting no leukaemia associated phenotypic changes upon Kat2a loss.  
 
To assess whether these in vitro observations of fixation of RUNX1-RUNX1T1(9a) transformed 
cells replicated in vivo, Kat2a WT and Kat2a NULL animals were culled using schedule 1 
method of euthanasia 2 months and 4 months post transplantation to study differences during 
pre-leukaemia transformation (n=3/genotype at 2 months and n=2/genotype at 4 months). The 
time points chosen reflected the in vitro fixation of the transformed population of cells. BM 
and spleen cells were isolated and stained with a cocktail of antibodies including CD117/ c-Kit 
(early progenitor marker), Cd11b/ Mac1 (monocyte/lin+ marker), Sca1 (stem cell marker), Gr1 
(granulocyte/ lin+ marker/), CD34 (haematopoietic stem cell marker) and CD16/32/FC𝛾𝑅 
(myeloid progenitor marker) (Methods). The combination of markers was selected in order to 
define stem and progenitor markers in these RUNX1-RUNX1T1(9a) transformed BM cells 
obtained from pre-leukaemia animals (Weissman and Shizuru, 2008) (Doulatov et al., 2012). 
The combined flow cytometry analysis for pre-leukaemia samples collected at both time points 
indicated a significant increase in the primitive population represented by GFP+ Kit+ FCgR+ 
indicative of myeloid progenitors in Kat2a NULL animals, (Fig 3.3E) in line with the in vitro 
observations obtained from peripheral blood sampling and suggesting perpetuation of RUNX1-
RUNX1T1(9a) transformed pre-leukaemia clones. 
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Figure 3.3: In vivo analysis of RUNX1-RUNX1T1(9a) pre-leukaemia.  
(A) Flow cytometry analysis representing GFP+ population in mononuclear cells extracted from 
peripheral blood post 5, 8, 12, and 17 weeks of transplantation from both Kat2a WT and Kat2a NULL 
animals (n=10/genotype at 5 and 8 weeks, n=7/genotype at 12 and 17 weeks, mean ± SD, Student’s t-
test, p=0.0408* at 12 weeks and p=0.0438* at 17 weeks), Similar analysis to study any variations in 
haematological parameters between Kat2a WT and Kat2a NULL animals post 5, 8, 12, 17, 27, 36, 44 
and 48 weeks of transplantation, (B) White blood cells, (C) Haemoglobin, (D) Platelets, (n=10 
animals/genotype at 5, 8, 12 weeks, n=7 animals/genotype at 17 weeks, n=5 animals/genotype from 27 
weeks onwards) (E) Flow cytometry analysis for pre-leukaemia animals processed post 2 and 4 months 
of transplantation. The plot represents leukaemic engraftment as defined by GFP+ c-Kit+ FCγR+ 
population in spleen cells from pre-leukaemia animals (n=3 animals/genotype for 2 months and n=2 
animals/genotype for 4 months, mean ± SD, Student’s t-test, p=0.0467*). 
 
3.3 RUNX1-RUNX1T1(9a) transformed cells show an increase in self-renewal capacity 
upon loss of Kat2a 
After confirming perpetuation of RUNX1-RUNX1T1(9a) transformed cells in Kat2a NULL 
animals during pre-leukaemia, I wanted to study whether there are any differences in self-
renewal capacity of these cells during the process of transformation in vivo. To assess this, 
serial re-plating colony assay was performed. I started with BM cells obtained from both Kat2a 
WT and Kat2a NULL (n=3/genotype) at 2 months as mentioned above. Initial plating was done 
with 50,000 cells/sample in technical duplicates and the colonies were scored after 7-10 days 
of plating. Serial re-plating was done using 10,000 cells/condition until no colonies were 
discovered, which allowed studying the serial replating capacity, an indicator of self-renewal 
potential of RUNX1-RUNX1T1(9a) transformed cells. The colonies were categorized as 
Granulocyte (G), Erythroid (E), Macrophage (M), Granulocyte Macrophage (GM), and 
Granulocyte Erythroid Macrophage Megakaryocyte (GEMM), where GM and GEMM 
colonies indicate the significant expansion of transformants (Methods). There was no 
significant difference between the genotypes in terms of re-plating potential at 2 months (Fig 
3.4A). However, a trend towards enhanced self-renewal in Kat2a NULL at plate 4 
(n=1/genotype at plate 4) was observed. This indicated that while it is possible that RUNX1-
RUNX1T1(9a) transformed Kat2a NULL cells may have enhanced self-renewal potential, 2 
months post transplantation may be too early to capture this. Therefore, study of pre-leukaemia 
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at a later time point is required. In line with this, similar analysis was performed for pre-
leukaemia BM cells collected at 4 months (n=2/genotype done in technical duplicates). There 
was a trend towards enhanced self-renewal capacity of Kat2a NULL cells from plate 1 onwards 
and a significant increase at plate 3, indeed suggesting that loss of Kat2a promotes self-renewal 
potential of RUNX1-RUNX1T1(9a) transformed cells in vivo (Fig 3.4B).  
 
To study whether a similar trend in enhanced self-renewal exists in vitro, an in vitro colony 
forming assay was performed prior to my joining in the lab. The experiment was conducted on 
Kat2a WT and Kat2a NULL BM cells (n=3/genotype) isolated from Kat2afl/fl mice post 6-8 
weeks of Mx1-Cre activation, which coincides with the time when stable locus excision is 
achieved based on previous laboratory observations. The cells were enriched for lineage 
depletion and transduced with RUNX1-RUNX1T1(9a) overexpression plasmid as described in 
methods. Post transduction, the cells were washed and maintained in colony forming assay at 
4,000 cells/sample in technical duplicates and the colonies were scored after 7-10 days of 
plating. Serial re-plating was done again using 4,000 cells/condition until plating 5. Again, 
there was an increase in self-renewal capacity in Kat2a NULL at plate 4 and plate 5 in line 
with the in vivo experiments thus strengthening the finding that loss of Kat2a enhances colony 
forming potential of RUNX1-RUNX1T1(9a) transformed cells (Fig 3.4C).  
 
After confirming enhanced self-renewal potential in Kat2a NULL cells during disease 
initiation, my lab members sought to understand if there were any changes in a maintenance 
set up. For this, RUNX1-RUNX1T1(9a) transduction was done on BM cells carrying 
conditional Kat2a floxed allele prior to Cre recombinase activation. Post transduction, cells 
were washed with media and 50,000 cells/condition were maintained in colony forming assay. 
After re-plating the obtained colonies twice, the cells were transduced with Cre recombinase 
expressing vector in order to generate Kat2a NULL phenotype or with empty vector (EV) 
which served as control. Post transduction, cells were maintained in colony forming set up 
where Kat2a NULL cells showed reduced colony forming potential as compared to control 
both at plate 1 and plate 2 (Fig 3.4D). This observation suggested that enhanced self-renewal 
capacity of Kat2a NULL cells observed in vitro and in vivo was a consequence of loss of Kat2a 
during early stages of leukaemia transformation. On the other hand, once the cells are 
transformed, not having Kat2a is disadvantageous for the re-plating potential of these cells.  
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Figure 3.4: Colony forming unit analysis.  
(A) Serial re-plating of colony forming cell assay from pre-leukaemia bone marrow cells obtained from 
Kat2a WT and Kat2a NULL animals post 2 months of transplantation (n=3 animals/genotype at P1, 
n=1 animal/genotype at P4, mean ± SD), (B) Serial re-plating of colony forming cell assay from pre-
leukaemia bone marrow cells obtained from Kat2a WT and Kat2a NULL animals post 4 months of 
transplantation (n=2 animals/genotype at P1, n=1 animal for Kat2a WT and n=2 animals for Kat2a 
NULL at P4, mean ± SD), (C) Serial re-plating of colony forming cell assay from in vitro transformed 
RUNX1-RUNX1T1(9a) bone marrow cells obtained from Kat2a WT and Kat2a NULL cells (n=3 
animals/genotype at each plating, mean ± SD, Student’s t-test p=0.02* at P4 and p=0.07 at P5), (D) 
Serial re-plating of colony forming cell assay from in vitro transformed RUNX1-RUNX1T1(9a) bone 
marrow cells obtained from Kat2a WT where Kat2a floxed allele was obtained by in vitro transducing 
the cells with Cre recombinase expressing CRE plasmid where Empty vector (EV) served as control 
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This was in line with the previous observation in the lab, where MLL-AF9 transformed 
leukaemia cells, representative of a leukaemia maintenance model, showed enhanced 
differentiation upon loss of Kat2a (Domingues et al., 2020).     
 
3.4 Kat2a loss does not impact any haematopoietic compartment in Idh1R132H pre-
leukaemia 
Pre-leukaemia studies performed on RUNX1-RUNX1T1(9a) model in a conditional Kat2a 
genetic background suggested that loss of Kat2a aids in perpetuation of the transformed 
population of cells which have enhanced self-renewal capacity. To understand the general role 
of Kat2a in pre-leukaemia, it was important to understand whether these observations can be 
replicated in other pre-leukaemia models. For this, I studied Idh1R132H (Idh1mut) model 
developed in George Vassiliou’s laboratory (Wellcome Trust Sanger Institute). Idh1R132H 
represents another model with a prolonged pre-leukaemia requiring incorporation of additional 
mutations (Introduction). The present model has a 30% leukaemia incidence 1-year post-
mutation activation. To start, crossings were set up with Kat2a conditional knockout model in 
order to generate Idh1mut knock-in mice with conditional Kat2a allele dependent on Mx1-Cre 
activation. The activation of Idh1 mutation and Kat2a excision were confirmed at different 
time points post pIpC injections as described in Methods. 
 
In order to study the role of Kat2a in Idh1R132H leukaemia biology, it was important to 
investigate differences in various haematopoietic compartments in Idh1mut model upon Kat2a 
loss. For this, Kat2a HET and Kat2a NULL animals with Idh1mut were studied 4 weeks and 
20 weeks post pIpC treatment (Fig 3.5A), reflecting pre-leukaemia development at two time 
points (n=3/genotype for each time point). The animals were sacrificed using schedule 1 
method of euthanasia and were further utilized to study the cell populations belonging to 
different haematopoietic compartments. The combination of markers was selected in order to 
define stem and progenitor markers in Idh1R132H transformed BM cells obtained from pre-
leukaemia animals (Weissman and Shizuru, 2008) (Doulatov et al., 2012) (Sasaki et al., 
2012b). BM cells obtained were stained using a cocktail of antibodies including CD16/32- 
FITC, CD135-PE, CD117/C-Kit- APCCy7, Sca1-PECy7, CD34-APC as mentioned in Table 
B.4 (Annexure-B). Lineage exclusion cocktail included B220, Ter119, CD11b, Gr1, and CD3e 
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biotinylated antibodies along with streptavidin-conjugated Brilliant Violet 510 were also added 
as mentioned in Table B.4 (Annexure-B). The gating strategy for different cell populations 
including HSC, LMPP, MPP, GMP, CMP, MEP is described in methods. The experiments on 
these cells were performed by Oliwia Cyran, a placement student in the lab mentored by me 
whereas I performed the analysis.  
 
Post 4 weeks of mutation activation, there were no significant differences between the two 
genotypes in any of the haematopoietic compartments including HSCs, suggesting that loss of 
Kat2a at early stages of leukaemia progression doesn’t impact the BM cellularity (Fig 3.5B). 
Similarly, there were no significant changes post 20 weeks of mutation activation between the 
genotypes supporting the observation in 4 weeks samples (Fig 3.5C). However, between 4 
weeks to 20 weeks, I observed an increasing trend in overall cellularity, in particular for the 
CMP and GMP population. This trend was observed irrespective of genotype but was not 
statistically significant. Further, I looked at KSL and KL populations where no significant 
differences were found between the genotypes at 4 weeks (Fig 3.5D) and 20 weeks (Fig 3.5E), 
however, there was a slight increasing trend in KSL in Kat2a NULL cells. While comparing 
these populations from 4 weeks to 20 weeks, there was an increasing trend in KL at 20 weeks 
indicating putative pre-leukaemia progression. Overall, loss of Kat2a did not impact any 
haematopoietic compartment in Idh1R132h leukaemia model, consistent with previous 
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Figure 3.5: Functional characterization of Idh1R132H model.  
(A) Schematic diagram representing experimental set-up. Bone marrow cells from Idh1R132H Kat2a 
HET and Idh1R132H Kat2a NULL animals post 20 weeks of pIpC treatment were transplanted into 
lethally irradiated CD45.1 animals (n=8 animals/genotype). Pre-leukaemia studies were done post 4 
and 20 weeks of weeks of pIpC treatment (n=3/genotype at each time point), Flow cytometry analysis 
for bone marrow cells obtained from Idh1R132H Kat2a HET and Idh1R132H Kat2a NULL animals at 
(B) 4 weeks post pIpC (n=3/ genotype, mean ± SD), (C) 20 weeks post pIpC (n=3/genotype, mean ± 
SD) representing different compartments of haematopoietic hierarchy, Separate plot representing 
different lineage negative populations from the same flow cytometry analysis post (D) 4 weeks of pIpC 
(n=3/genotype, mean ± SD), (E) 20 weeks of pIpC (n=3/genotype, mean ± SD). (HSC- Lin-
Kit+Sca1+CD34-CD135-, MPP- Lin-Kit+Sca1+CD34+CD135-, LMPP- Lin-Kit+Sca1+CD34+CD135+, 
CMP- Lin-Kit+Sca1-CD34+/lowCD16/32low, GMP- Lin-Kit+Sca1+CD34+CD16/32high, MEP- Lin-
Kit+Sca1+CD34-CD16/32-, KSL- Lin-Kit+Sca1+, KL- Lin-Kit+). 
 
The flow cytometry pre-leukaemia analysis for Idh1mut transformed cells was complemented 
with measurement of spleen and liver weights in order to assess early pre-leukaemia infiltration 
events (Fig 3.6). At 4 weeks post pIpC (n=3 for Kat2a HET and n=2 for Kat2a NULL), no 
differences in spleen weights were observed upon loss of Kat2a indicating no differences in 
pre-leukaemia burden (Fig 3.6A). This finding was recapitulated at 20 weeks post pIpC 
(n=3/genotype), where again no differences were observed in spleen weight upon Kat2a loss 
(Fig 3.6A). However, combining the analyses from 4 weeks and 20 weeks post pIpC, there was 
an increasing trend in spleen weight from 4 weeks to 20 weeks irrespective of genotype (Fig 
3.6A), compatible with the inferences from Sasaki and colleagues, where a gain in spleen 
weight was observed with pre-leukaemia progression (Sasaki et al., 2012b). Similarly, 4 weeks 
post pIpC (n=2/genotype), no changes were observed in liver weight upon loss of Kat2a (Fig 
3.6B), similar to the findings at 20 weeks post pIpC (n=3/genotype) (Fig 3.6B). In contrast to 
the findings for spleen weight, no such trend was observed for alteration in liver weight with 
pre-leukaemia progression (Fig 3.6B). 
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Figure 3.6: Spleen and liver weight during Idh1R132H pre-leukaemia. 
Spleen weight at (A) 4 and 20 weeks (n=3 for Kat2a HET at both time points, n=2 for Kat2a NULL at 
4 weeks, mean ± SD), (B) 4 and 20 weeks (n=3/genotype at each time point, mean ± SD), post pIpC. 
 
3.5 Loss of Kat2a aids in Idh1R132H transformation during pre-leukaemia  
As loss of Kat2a aids in self-renewal of RUNX1-RUNX1T1(9a) pre-leukaemia, we wanted to 
study whether this observation can be recapitulated in Idh1mut model. For this, BM cells 
obtained from Kat2a HET and Kat2a NULL animals with Idh1mut at 4 weeks and 20 weeks 
post pIpC treatment were maintained in a colony forming assay at 50,000 cells/condition in 
technical duplicates (n=3/genotype for each time point). The colonies were scored every 7-10 
days and re-plated serially at 10,000 cells/condition. There was an increase in re-plating 
efficiency in Kat2a NULL cells post 4 weeks pIpC suggesting that Kat2a plays a general role 
in promoting self-renewal of transformed cells at early pre-leukaemia stage (Fig 3.7A). On the 
other hand, post 20 weeks of pIpC, the difference in self-renewal potential between Kat2a 
NULL and Kat2a HET was lost suggesting that it was an early effect of the loss of Kat2a (Fig 
3.7B).  
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Figure 3.7: Colony forming unit analysis for Idh1R132H pre-leukaemia.  
(A) Serial re-plating of colony forming cell assay from pre-leukaemia bone marrow cells obtained from 
Idh1R132H Kat2a HET and Idh1R132H Kat2a NULL animals post 4 weeks of pIpC treatment (n=3 
animals/genotype, mean ± SD, Student’s t-test p=0.037*) (B) Serial re-plating of colony forming cell 
assay from pre-leukaemia bone marrow cells obtained from Idh1R132H Kat2a HET and Idh1R132H 
Kat2a NULL animals post 20 weeks of pIpC treatment (n=3 animals/genotype, mean ± SD) 
 
3.6 Idh1R132H animals showed myeloproliferation but did not develop leukaemia  
To understand whether the gain in self-renewal at early stages of pre-leukaemia transformation 
impacts overall leukaemia progression, I started with Kat2a HET and Kat2a NULL bone 
marrow cells (n=3/genotype) studied at 4 weeks post pIpC. 1*106 cells from each of the Kat2a 
HET and Kat2a NULL animals were injected into each lethally irradiated CD45.1 recipient 
such that there were 3 representative recipients from each donor. Unfortunately, most of the 
animals lost >50% of weight after -experimental set up and the experiment had to be terminated 
as per the study plan regulations. Further, an attempt was made by making use of Kat2a HET 
and Kat2a NULL BM cells (n=3/genotype) studied post 20 weeks of pIpC. The transplants 
were set up in a similar manner with recipients being sub-lethally irradiated.  
 
To study differences in various haematological parameters upon loss of Kat2a during disease 
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increasing trend in WBC 38 weeks post transplantation in Idh1R132H Kat2a NULL animals 
compared to Idh1R132H Kat2a HET animals, perhaps highlighting an acceleration in disease 
progression (Fig 3.8A). However, the number of WBCs were found to be lower at 51 weeks 
post transplantation in both the genotypes which may indicate a technical bias. In contrast to 
this, the HGB levels remained stable post transplantation in both the genotypes with a slight 
increase at 10 weeks post transplantation in both the genotypes (Fig 3.8B). The levels of 
platelets in the peripheral blood were mostly fluctuating with a slight increase at 10-, 15- and 
38-weeks post transplantation. This could be a result of technical issues while analysing the 
samples. Overall, no differences were observed in platelets levels in both genotypes (Fig 3.8C). 
Altogether, the peripheral blood analysis suggested that loss of Kat2a did not lead to any 
changes in the blood composition during the progression of Idh1R132H pre-leukaemia. This 
finding was in line with the insights obtained from RUNX1-RUNX1T1(9a) model.  
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Figure 3.8: Peripheral blood analysis.  
Peripheral blood analysis to study different haematological parameters, including, (A) White Blood 
Cells, (B) Haemoglobin, (C) Platelets for both Idh1mut Kat2a HET and Idh1mut Kat2a NULL animals 
(plots represent analysis for n=6 animals for Idh1mut Kat2a HET and n=3 animals for Idh1mut Kat2a 
NULL at 10 weeks post-transplantation, mean ± SD).  
After transplantation, the animals were routinely observed for the presence of clinical 
symptoms of hunched posture, inappetence and lethargy, indicative of leukaemia development. 
However, none of the animals developed such symptoms until 52 weeks post transplantation. 
The animals which died of reasons other than leukaemia during this period were excluded from 
further analysis. The animals which were alive until 52 weeks post transplantation were culled 
using schedule 1 method of euthanasia; BM cells and spleen cells were isolated and stained 
with a cocktail of antibodies and flow cytometry analysis was performed (Methods) 
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(n=3/genotype). These antibodies include CD45.1 (recipient animals), CD45.2 (donor 
animals), lineage cocktail (Mac1, Gr1, CD3e, Ter119, B220) to exclude terminally 
differentiated cells, Sca1, c-Kit, to identify stem and progenitor compartment of cells, FcgR 
(myeloid marker) and Cd34 to identify HSCs and Flt3 which is short term HSCs/multipotent 
progenitor marker. The experiment was performed by Caitlin Cash, a master’s student in Pina 
group. 
The flow cytometry analysis suggested that majority of cells present in the bone marrow were 
CD45.2 positive rather than being CD45.1 positive, highlighting successful transplantation of 
Idh1R132H transformed cells in both Kat2a HET and Kat2a NULL animals (Fig 3.9A.I, B.I). 
All the animals transplanted with Idh1R132H transformed cells either with Kat2a HET or 
Kat2a NULL showed more than 50% of the bone marrow cells which were CD45.2 positive. 
We then focussed on CD45.2 positive cells for further analysis. In order to understand whether 
these cells have enrichment for terminally differentiated cells, we looked at lineage markers 
which suggested nearly 40-50% of the cells were lineage negative in case of both Kat2a HET 
or Kat2a NULL animals (Fig 3.9A.II, B.II) and thus indicate presence of early progenitor cells 
in the bone marrow. We then further narrowed down our analysis to look at the presence of c-
Kit and Sca-1 marker expression specifically within the lineage negative compartment of cells 
in order to distinguish between progenitor and stem cells. We observed the presence of 
progenitor cells characterized by Lin-c-Kit+Sca1- (KL) which are further capable of expansion, 
compared to Lin-c-Kit+Sca1+ (KLS) population representing stem compartment of cells (Fig 
3.9A.III, B.III). The KL population of cells were further segregated on the basis of the presence 
of FcgR and Cd34 expression in these cells. The presence of FcgR+Cd34+ population of cells 
would have indicated GMP-like population, however, Cd34 expression was not observed in 
these cells, compatible with the absence of leukaemia phenotype. This was consistent in both 
Idh1R132H transformed Kat2a HET and Kat2a NULL cells. However, both genotypes showed 
an enrichment in FcgR+ population of cells suggesting an accumulation in myeloid progenitors 
and indicative of myeloproliferation (Fig 3.9A.IV, B.IV).  
Functional characterization of RUNX1-RUNX1T1(9a) and Idh1R132H leukaemia in a 
























Functional characterization of RUNX1-RUNX1T1(9a) and Idh1R132H leukaemia in a 












































Functional characterization of RUNX1-RUNX1T1(9a) and Idh1R132H leukaemia in a 





Figure 3.9: Flow cytometry analysis of Idh1R132H transformed Kat2a HET and Kat2a NULL 
animals.  
(A) Flow cytometry schematic control plots for Idh1R132H transplants, (B) Flow cytometry plots for 
Idh1R132H transformed Kat2a HET cells 52 weeks post transplantation highlighting plots between 
CD45.1 and CD45.2 (I), c-Kit and Lineage (II), Sca-1 and c-Kit (III) and Cd34 and FcgR (IV), (C) 
Flow cytometry plots for Idh1R132H transformed Kat2a NULL cells 52 weeks post transplantation 
highlighting plots between CD45.1 and CD45.2 (I), c-Kit and Lineage (II), Sca-1 and c-Kit (III) and 
Cd34 and FcgR (IV) (KLS- Lin-c-Kit+Sca1+, Lin- Lineage), (Plots mentioned in II, III and IV represent 
percentage population of cells within CD45.2 population). 
Overall, the phenotypic characterization of cells did not reveal any significant differences upon 
loss of Kat2a along with any changes in disease progression suggesting that loss of Kat2a is 
not sufficient to carry out leukaemia development. Nonetheless, the analysis confirmed that 
Idh1 mutation represents pre-leukaemia phase which requires the presence of collaborating 
mutations for leukaemia development.  
 
3.7 Kat2a loss promotes enrichment of c-Kit+Mac1- progenitor cells in Idh1R132H 
transplants 
After characterizing the phenotype of Idh1R132H transformed Kat2a HET and Kat2a NULL 
transplanted cells using flow cytometry, we then studied the self-renewal potential of these 
cells in order to understand whether Kat2a NULL cells show an advantage in their replating 
capacity. For this, both Kat2a HET and Kat2a NULL cells transformed with Idh1R132H were 
plated into methylcellulose based semi-solid medium at 10,000 cells/condition (n=3 
animals/genotype) and colonies were scored after 7-10 days. As mentioned earlier, the present 
model has a 30% leukaemia incidence 1-year post-mutation activation, so the bone marrow 
cells obtained from Idh1R132H leukaemia animals from collaborators at Sanger institute 
served as control. At plating one, there was an increasing trend in colony forming potential in 
Idh1R132H transformed Kat2a NULL cells compared to Kat2a HET. On the other hand, 
leukaemia cells had highly variable colony forming potential in different replicates (Fig 
3.10A). However, at plating 2 there was an increase in colony forming potential upon Kat2a 
loss in Idh1R132H transformed cells compared to Kat2a HET (Fig 3.10A) suggesting that loss 
of Kat2a provides a self-renewal potential to these transplanted cells. Moreover, the self-
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renewal potential observed in Kat2a NULL cells transformed with Idh1R132H was 
comparable to the colony forming potential of Idh1R132H leukaemia cells, altogether 
suggesting that although we did not capture leukaemia progression in our transplants, loss of 
Kat2a provides a self-renewal advantage to Idh1R132H transformed cells which may 
consequentially lead to an accelerated leukaemic progression. 
 
 
Figure 3.10: Functional characterization of Idh1R132H transplants.  
(A) Serial re-plating of colony forming cell assay using bone marrow cells obtained from Idh1R132H 
transformed Kat2a HET and Kat2a NULL animal transplants (n=3/genotype) along with Idh1R132H 
leukaemia animals (n=2) (mean ± SD, Student’s t-test p=0.0398* for Kat2a HET vs Kat2a NULL), (B) 
Proportion of c-Kit+ Mac1- cells in cells obtained from Idh1R132H transformed Kat2a HET and Kat2a 
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cytometry plots highlighting c-Kit and Mac1 cell population in Idh1R132H transformed Kat2a HET 
and Kat2a NULL bone marrow cells at plating 1. 
 
To characterize the progenitor population of cells contributing to the colony forming potential, 
we performed flow cytometry analysis from the cells obtained after plating one. The flow 
cytometry analysis was gated on cells which were characterized as donor cells based on 
CD45.2 expression. The cells were stained with all the lineage markers as well as c-Kit marker 
in order to assess presence of a progenitor phenotype. Overall, no differences were observed 
in any of the haematopoietic compartments upon Kat2a loss, however, a combined analysis of 
proportion of c-Kit+Mac1- population with the colony forming cells obtained after plating one 
suggested an increase in c-Kit+Mac1- population of cells upon loss of Kat2a (Fig 3.10B). The 
representative plots for c-Kit+Mac1- population in Idh1R132H transformed Kat2a HET and 
Kat2a NULL cells are shown in Fig 3.10C. 
 
3.8 Loss of Kat2a does not impact DNA damage in Idh1R132H pre-leukaemia 
Combined observations from RUNX1-RUNX1T1(9a) and Idh1R132H pre-leukaemia models 
suggested that loss of Kat2a at early stages of disease progression aids in transformation by 
increasing self-renewal capacity of these cells. This enhanced self-renewal capacity is overall 
advantageous in accelerating pre-leukaemia to leukaemia progression. Since these models are 
dependent on the acquisition of incorporating mutations, it was important to study whether loss 
of Kat2a is accelerating disease progression by increasing genomic instability. 
 
For this, DNA damage analysis was conducted in the lab on Idh1mut transformed BM cells 
with Kat2a HET or Kat2a NULL genotype collected at 4 weeks and 20 weeks post pIpC 
treatment (n=3/genotype at each time point). For this, the collected BM cells were thawed and 
irradiated to induce DNA damage. Non-irradiated cells served as control. Cells were recovered 
post irradiation and subsequently stained with anti-phospho-Histone H2AX (gH2AX) along 
with Alexa Fluor 594 rabbit anti-mouse as a secondary control. gH2AX is formed upon 
phosphorylation of Ser140 as a functional consequence of the DNA damage response and act 
as a surrogate for DNA double stranded breaks (Horton, 2017). DAPI was used as a nuclei 
stain and acquisition was done on a confocal microscope (Methods). Cells were categorized 
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into ones with 0 foci, 1-5 foci, or more than 5 foci. Cells with 0 foci represent ones with no 
DNA damage observed, 1-5 foci represent cells with moderate DNA damage, and more than 5 
foci represent cells with high DNA damage. At least 100 cells were scored for each sample 
from three individual replicates. 
 
Upon irradiation, there was an increase in the cell population with more than 5 foci compared 
to the non-irradiated cell population confirming the DNA damage induced by irradiation (Fig 
3.11A and 3.11C). However, there were no significant differences in the number of cells 
showing more than 0 foci in Kat2a NULL as compared to Kat2a HET at both 4 weeks (Fig 
3.11A and 3.11B) and 20 weeks post pIpC (Fig 3.11C and 3.11D). This suggested the potential 
involvement of non-genetic factors in accelerating leukaemia progression upon loss of Kat2a. 
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Figure 3.11: DNA damage assay for Idh1R132H pre-leukaemia.  
(A) Plot representing proportion of cells with γH2AX foci upon irradiation with 0 foci/cell, 1-5 foci/cell 
and >5 foci/cell in bone marrow cells obtained from Idh1R132H Kat2a HET and Idh1R132H Kat2a 
NULL animals post 4 weeks of pIpC treatment where non-irradiated cells served as control (n= 3 
animals/genotype, mean ± SD), (B) Representative microscopic images of γH2AX foci in Idh1R132H 
Kat2a HET and Idh1R132H Kat2a NULL animals post 4 weeks of pIpC treatment, (C) Plot 
representing proportion of cells with γH2AX foci upon irradiation with 0 foci/cell, 1-5 foci/cell and >5 
foci/cell in bone marrow cells obtained from Idh1R132H Kat2a HET and Idh1R132H Kat2a NULL 
animals post 20 weeks of pIpC treatment (n=3 animals/genotype, mean ± SD), (D) Representative 
microscopic images of γH2AX foci in Idh1R132H Kat2a HET and Idh1R132H Kat2a NULL animals 
post 20 weeks of pIpC treatment. (Idh1R132H Kat2a HET- HET, Idh1R132H Kat2a NULL- NULL) 
 
In this chapter, I have studied the functional consequences of loss of Kat2a during RUNX1-
RUNX1T1(9a) and Idh1R132H pre-leukaemia progression. The loss of Kat2a was found to 
promote the RUNX1-RUNX1T1(9a) leukaemia progression with a significant number of cells 
being c-Kit+, suggesting the presence of early progenitor cells prone to leukaemic 
transformation. The leukaemia analysis was performed in two separate cohorts of animals with 
varying transduction efficiency, however, in both cases a consistent observation of accelerated 
leukaemia progression was observed upon Kat2a loss. Phenotypic characterization of 
individual leukaemia animals highlighted a different proportion of leukaemia markers 
including presence of stem (c-Kit+Sca1+) and progenitor cells (c-Kit+Sca1-), confirming the 
multi-hit requirement for RUNX1-RUNX1T1(9a) leukaemia progression. The infiltration of 
leukaemia cells was observed in spleen as well as in liver in some cases. Strikingly, terminal 
blood analysis did not reflect any differences in leukaemia burden upon loss of Kat2a, 
compatible with our previous lab observation in MLL-AF9 leukaemia (Domingues et al., 2020).  
 
Upon studying RUNX1-RUNX1T1(9a) pre-leukaemia stages, a perpetuation in RUNX1-
RUNX1T1(9a)+ pre-leukaemia clones was observed in the peripheral blood 12 weeks and 17 
weeks post-transplantation. Due to a smaller number of animals left post 17 weeks of 
transplantation, the analysis could not be performed with confidence, however, an increasing 
trend in GFP+ population was observed upon loss of Kat2a. In line with this, the flow cytometry 
characterization of pre-leukaemia animals 2 months and 4 months post transplantation 
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indicated an increase in GFP+c-Kit+FcgR+ cell population upon Kat2a loss, indicative of 
accumulation of myeloid progenitor cells. The accumulation of myeloid progenitors was 
compatible with the gradual progression of RUNX1-RUNX1T1(9a) pre-leukaemia. However, 
the haematological parameters obtained from peripheral blood sampling did not show any 
difference upon loss of Kat2a, suggesting that loss of Kat2a does not have any impact on 
haematological parameters globally. However, the variability observed at different time points 
may be suggestive of technical bias during sampling, given that it follows similar trend in both 
the genotypes. 
 
The pre-leukaemia cells obtained from both Kat2a WT and Kat2a NULL cells 2 months and 4 
months post transplantation were assessed for their self-renewal potential using colony forming 
assay. The analysis suggested an increase in colony forming potential associated with Kat2a 
NULL cells compared to Kat2a WT cells with a trend at 2 months and at 4 months post 
transplantation. The variability in colony forming efficiency observed at 2 months was due to 
the varying GFP levels in individual samples. Similar analysis was performed using spleen 
cells obtained from Kat2a WT and Kat2a NULL animals 2 months post transplantation and an 
increase in colony forming potential was observed in Kat2a NULL cells, compatible with the 
observations from bone marrow cells (data not shown). Similar insights were obtained from 
colony forming assay performed on Kat2a WT and Kat2a NULL cells transformed with 
RUNX1-RUNX1T1(9a) in vitro. Interestingly, the pro-leukaemogenic effect of Kat2a loss was 
specific to disease initiation as the ablation of Kat2a in established RUNX1-RUNX1T1(9a) 
AML cells resulted in reduced maintenance of transformed cells, in line with my lab’s 
observations in AML cell lines (Tzelepis et al., 2016) and the mouse MLL-AF9 AML 
(Domingues et al., 2020). 
 
In order to study whether the functional consequences associated with Kat2a loss observed in 
RUNX1-RUNX1T1(9a) pre-leukaemia are model specific, another model of pre-leukaemia, 
namely Idh1R132H was studied in a Kat2a conditional knockout background.  The Idh1R132H 
pre-leukaemia analysis was performed 4 weeks and 20 weeks post initiation of mutation 
recombination event as confirmed by PCR (Methods). Phenotypic characterization of pre-
leukaemia bone marrow cells revealed no significant differences upon loss of Kat2a at both 4-
week and 20-week time points, suggesting that loss of Kat2a does not impact overall bone 
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marrow cellularity during Idh1R132H pre-leukaemia, an observation in line with observations 
in models previously studied in the lab, which include RUNX1-RUNX1T1(9a) as well as MLL-
AF9 model of leukaemia. There were no significant changes in proportion of HSCs upon Kat2a 
loss in Idh1R132H pre-leukaemia at both time points. However, between 4 weeks to 20 weeks, 
an increasing trend in overall cellularity was observed, in particular for the CMP and GMP 
population irrespective of genotype. Similarly, no significant differences were found between 
the genotypes at 4 weeks and 20 weeks in KSL and KL populations, suggesting that loss of 
Kat2a does not impact stem and progenitor compartment during Idh1R132H pre-leukaemia 
progression. However, while comparing these populations from 4 weeks to 20 weeks, there 
was an increasing trend in KL at 20 weeks indicating putative pre-leukaemia progression. This 
observation was compatible with the increase in GFP+c-Kit+FcgR+ from 2 months to 4 months 
during RUNX1-RUNX1T1(9a) pre-leukaemia progression. Although no infiltration of pre-
leukaemia cells was observed in spleen and liver, however, an increasing trend in spleen weight 
from 4 weeks to 20 weeks was observed irrespective of genotype, potentially indicative of pre-
leukaemia burden. 
 
The pre-leukaemia cells obtained from Kat2a WT and Kat2a NULL cells 4 weeks and 20 
weeks post transplantation were assessed for their self-renewal potential using colony forming 
assay. An increase in colony forming efficiency was observed upon Kat2a loss 4 weeks post 
initiation of mutation recombination event. This gain in self-renewal potential was not 
maintained until 20 weeks. This analysis could have benefitted from including pre-leukaemia 
analysis at a time point between 4 weeks and 20 weeks of pre-leukaemia progression to 
understand the hierarchical progression of gain in self-renewal upon Kat2a loss during 
Idh1R132H pre-leukaemia progression. Nonetheless, the analysis altogether suggested that 
loss of Kat2a aids a transient increase in colony forming potential during early stages of pre-
leukaemia. 
 
In order to understand whether the gain in self-renewal at early stages of pre-leukaemia 
transformation impacts overall leukaemia progression, CD45.1 animals were transplanted with 
Idh1R132H transformed Kat2a HET and Kat2a NULL bone marrow cells. An increase in 
WBCs was observed at 10 weeks in both the genotypes with an increasing trend specifically in 
Kat2a NULL cells at 38 weeks, perhaps indicating the accelerated establishment of leukaemia 
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upon loss of Kat2a. In contrast, the HGB levels and platelets remained stable post 
transplantation in both genotypes. Altogether, the peripheral blood analysis suggested that loss 
of Kat2a did not lead to any changes in the blood composition during the progression of 
Idh1R132H pre-leukaemia. This finding was in line with insights obtained from RUNX1-
RUNX1T1(9a) model. Flow cytometry based phenotypic characterization of Idh1R132H Kat2a 
HET and Kat2a NULL animals did not show changes in any of the haematopoietic 
compartments suggesting that loss of Kat2a does not impact overall cellularity upon 
Idh1R132H mediated transformation which was compatible with pre-leukaemia analysis. None 
of the animals progressed to leukaemia but showed a development of myeloproliferation, 
suggesting the requirement of additional incorporating mutations for leukaemia progression, 
in line with the only model published so far (Sasaki et al., 2012b). However, combining the 
serial replating assay with flow cytometry characterization, we observed an increase in c-
Kit+Mac1- population of cells upon Kat2a loss, suggesting that loss of Kat2a may promote the 
enrichment of progenitor cells which are likely capable of expansion during the process of 
leukaemia progression. 
 
Since both RUNX1-RUNX1T1(9a) and Idh1R132H models of pre-leukaemia are described as 
multi-hit haematological malignancies which require incorporation of additional mutations in 
order for leukaemia establishment, we further studied whether loss of Kat2a accelerates disease 
progression by causing genomic instability. Upon irradiation, there was an increased 
population of cells having gH2AX foci indicating the induction of DNA damage upon 
irradiation. However, no significant differences were observed in Kat2a NULL cells 
transformed with Idh1R132H compared to Kat2a HET cells at both 4 weeks and 20 weeks 
suggesting that loss of Kat2a does not increase DNA damage by inducing double strand breaks. 
The analysis altogether indicated that the accelerated pre-leukaemia progression upon loss of 
Kat2a is likely due to the potential involvement of non-genetic factors.  The next chapter 
discusses the single cell RNA sequencing (scRNA-seq) performed on RUNX1-RUNX1T1(9a) 
pre-leukaemia cells studied 2 months and 4 months post transplantation. The chapter highlights 
the scRNA-seq pre-processing, filtering, and analysis in order to study the transcriptional 
programmes impacted by loss of Kat2a during RUNX1-RUNX1T1(9a) pre-leukaemia. 
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4 Identification of transcriptional programmes associated with 
Kat2a loss in RUNX1-RUNX1T1(9a) pre-leukaemia 
 
The previous chapter discussed the functional role of Kat2a in promoting pre-leukaemia 
transformation in vivo in both RUNX1-RUNX1T1(9a) as well as Idh1R132H models of AML. 
The in vitro analysis of these pre-leukaemia clones highlighted a perpetuation of these 
population of cells upon loss of Kat2a. These pre-leukaemia clones were further found to be 
associated with an enhanced self-renewal capacity suggesting these cells have the capability to 
maintain the transformants, which may have further expanded and consequently led to an 
accelerated leukaemia progression as evidenced in the RUNX1-RUNX1T1(9a) model. As 
discussed previously, in order to understand whether this accelerated leukaemia progression is 
also a consequence of an increased DNA damage, gH2AX staining was done in Idh1R132H 
transformed Kat2a HET and Kat2a NULL cells. The analysis did not provide evidence for an 
increase in DNA damage upon Kat2a loss in case of Idh1R132H model, suggesting that 
genomic instability may not be the underlying cause of this accelerated leukaemia progression. 
These observations further highlighted the importance of understanding the role of non-genetic 
mechanisms during the process of pre-leukaemia transformation. Since Kat2a loss is central to 
an increase in cell-to-cell transcriptional variability (Moris et al., 2018b; Domingues et al., 
2020), I tested the hypothesis by studying the potential link between loss of Kat2a, the 
associated increase in transcriptional variability, and accelerated pre-leukaemia progression 
using single cell RNA sequencing (scRNA-seq) of RUNX1-RUNX1T1(9a) pre-leukaemia cells. 
This chapter describes the scRNA-seq analysis, in particular the pre-processing of raw data 
obtained from scRNA-seq and further filtering and normalization steps which were required to 
generate a workable gene-expression matrix which contained high quality cells representing 
gene expression levels beyond the level of technical noise. Further, this chapter also includes 
the various differential gene expression comparisons between genotype-specific samples as 
well as different time points within the same genotype in order to identify instability in 
transcriptional programmes induced upon loss of Kat2a during pre-leukaemia progression. 
 






4.1 Single-cell RNA sequencing of RUNX1-RUNX1T1(9a) transformed Kat2a WT and 
Kat2a NULL pre-leukaemia cells   
 
In order to study a potential link between loss of Kat2a, the associated increase in 
transcriptional variability, and accelerated pre-leukaemia progression, scRNA-seq was 
performed on Kat2a WT and Kat2a NULL cells transformed with RUNX1-RUNX1T1(9a), 
collected 2 months and 4 months post transplantation. scRNA-seq was performed using 10X 
genomics technology with 3’ chemistry (v2). The single cell 3’ expression profiling can be 
divided into four steps- 
 
4.1.1 Gel Bead-In-EMulsions (GEMs) generation and Barcoding  
 
The single cell 3’ expression profiling utilizes a microfluidic platform for digital gene 
expression profiling by making use of 10X GemCode technology. It does so by partitioning 
thousands of cells into nanolitre-scale Gel Bead-In-EMulsions (GEMs), where all generated 
cDNA share a common 10X barcode sequence. Libraries are generated and sequenced from 
the cDNA and the 10X barcodes are used to associate individual reads back to the individual 
partitions. To achieve single cell resolution, the cells are delivered at a limiting dilution, such 
that the majority (~90-99%) of generated GEMs contain no cells, while the remainder largely 
contain a single cell. Upon dissolution of the single cell 3’ Gel Bead in a GEM, primers 
containing (i) an Illumina R1 sequence (read1 sequencing primer), (ii) a 16 nt 10X barcode, 
(iii) a 10 nt Unique Molecular Identifier (UMI), and (iv) a poly-dT primer sequence are released 
and mixed with cell lysate and master mix. Incubation of the GEMs then produces barcoded, 
full-length cDNA from poly-adenylated mRNA. After incubation, the GEMs are broken, and 
the pooled fractions are recovered. 
 
4.1.2 Post GEM-RT clean up and cDNA amplification 
 
Silane magnetic beads are used to remove leftover biochemical reagents and primers from the 
post GEM reaction mixture. Full length barcoded cDNA is then amplified by PCR to generate 
sufficient mass for library construction. 






4.1.3 Library construction 
 
Enzymatic fragmentation and size selection are used to optimize the cDNA amplicon size prior 
to library construction. R1 (read 1 primer sequence) are added to the molecules during GEM 
incubation. Primers used in Illumina bridge amplification (P5, P7), a sample index, and R2 
(read 2 primer sequence) are added during library construction via end repair, A tailing, adaptor 
ligation, and PCR.  
 
4.1.4 Sequencing libraries 
 
The single cell 3’ protocol produces Illumina-ready sequencing libraries. A single cell 3’ 
library comprises standard Illumina paired-end constructs which begin and end with P5 and 
P7. The single cell 3’ 16 bp 10X barcode and 10 bp UMI are encoded in Read 1, while Read 2 
is used to sequence the cDNA fragment. Sample index sequences are incorporated as the i7 
index read. Read 1 and Read 2 are standard Illumina sequencing primer sites used in paired-
end sequencing. 
 
The sequencing of a single cell 3’ library produced a standard Illumina raw Base Call (BCL) 
data output folder. The BCL data included the paired-end Read 1 (containing the 16 bp 10x 
Barcode and 10 bp UMI) and Read 2, and the sample index in the i7 index read. In order to 
assess the quality of these BCL files, I conducted quality control using FastQC (Wingett and 
Andrews, 2018), filtering based on Phred score (Ewing and Green, 1998). As described in 
methods, a plot representing quality scores across individual bases was studied in order to get 
an overview of the range of quality values across all bases at each position in the FastQC file. 
The higher the score across the bases, the better the base call. In addition to this, the per 
sequence quality score report was also studied, which allowed identification of sequences 
having universally low-quality values. Post QC, the CellRanger (v2.2) pipeline developed by 
10X genomics was followed in order to align reads and generate the gene-cell expression 
matrix. The process was initiated by running the cellranger mkfastq command which 
demultiplexes raw base call (BCL) files generated by Illumina sequencing into FASTQ files. 
These FASTQ files were further fed into the cellranger count pipeline which performs 






alignment, filtering, barcode counting, and UMI counting. mm10 was used as a reference 
genome for alignment. These two pipelines were run individually for each sample in order to 
obtain good quality reads for further analysis.  
 
In total, 1767 cell barcodes were subjected to sequencing: 379 cells from Kat2a WT at 2 
months, 369 cells from Kat2a NULL at 2 months, 518 cells from Kat2a WT at 4 months, and 
501 cells from Kat2a NULL at 4 months. Post QC and filtering, all 1767 cells were retained 
for downstream processing. Once the reads from these cell barcodes were aligned to the mm10 
mouse reference genome using the cellranger count (v2.2) command 
(https://support.10xgenomics.com/single-cell-gene-expression/software/overview/welcome), 
the cellranger aggr command was used to normalise all four samples to the same sequencing 
depth and recompute the gene-barcode matrices. The gene-barcode matrix generated had 1767 
cells in total, 174770 mean reads per cell with 1575 median genes detected per cell. This 
resultant matrix was then used for further processing and analysis.  
 
4.2 Single-cell RNA sequencing- pre-processing, filtering and normalization 
 
Although cellranger differentiated between cells and technical noise and helped in removing 
background noise and dropout events from the gene expression matrix, certain biological 
parameters still needed to be imposed. For example, filtering parameters like the minimum 
number of cells expressing a gene or the minimum number of genes expressed in a cell could 
be varied to ensure stringent filtering for downstream analysis.  
 
To ensure the gene-barcode matrix retains good quality cells and gene expression values, I 
imposed two different types of filtering- 
 
1. First, I set the minimum number of genes expressed in a cell to 500 based on a previous lab 
study (Domingues et al., 2020), where each cell that expressed less than 500 genes was 
considered a poor quality cell. 
 
 

































































































Figure 4.1: Visualization of gene and cell counts using Seurat v2.4.  
(A) Violin plot representing distribution of number of genes in cells in the dataset after imposing a cut-
off of each gene being expressed in at least 2% of cells (left), 3% of cells (middle), and 4% of cells 
(right), and each cell having at least 500 genes, where each data point represents an individual cell, (B) 
Violin plot representing distribution of number of UMI molecules in the dataset after imposing a cut-
off of each gene being expressed in at least 2% of cells (left), 3% of cells (middle) and 4% of cells 
(right), and each cell having at least 500 genes, where each data point represents an individual cell (C) 
Violin plot representing percentage of mitochondrial genes after imposing a cut-off of each gene being 
expressed in at least 2% of cells (left), 3% of cells (middle) and 4% of cells (right), and each cell having 
at least 500 genes, where each data point represents an individual cell. 
 
2.  Second, to remove technical noise in gene expression values, I imposed a cut-off where 
each gene is considered to have a significant expression in the given biological system only if 
a minimum number of cells express it. Since this is a critical step for obtaining rare cell 
populations which may have distinct gene expression signatures during pre-leukaemia 
progression, I started with 3 such cut-offs of 2% (36 cells), 3% (53 cells), and 4% (71 cells) for 
downstream analysis and decided the ideal cut-off for capturing such cell populations based on 
cell visualization and effective separation using dimensionality reduction analysis.    
 
After imposing the filtering criteria described above, I visualized the gene and UMI counts 
along with the percentage of mitochondrial genes (Fig 4.1) using Seurat v2.4 (Butler et al., 
2018) (Methods). The distribution of genes had a range from 500 to 5000 genes in an individual 
cell with a median count of 1575 genes per cell (Fig 4.1A) for a cut-off of 2% (left), 3% 
(middle) and 4% (right) of cells. Visualization of UMI counts reflected individual cells with 
UMI counts having a range from 1000 to 30000 with a median UMI count of 5939 at different 
cut-offs of 2% (left), 3% (middle) and 4% (right) of cells (Fig 4.1B). After looking at the 
technical parameters of gene-barcode matrix, I looked at the percentage of mitochondrial genes 
present in the dataset. An outlier level of mitochondrial content is deterministic of poor 
biological quality of the cells sequenced.  The percentage of mitochondrial content was found 
to be within 0-0.1% range at different cut-offs of 2% (left), 3% (middle) and 4% (right) of cells 
(Fig 4.1C), suggesting that very few cells subjected to scRNA-seq were of poor quality.  






Having visualized the distribution of gene and UMI counts along with mitochondrial content 
in the processed matrix, I further studied the relationship of gene counts and UMI counts with 
respect to mitochondrial content. The plots depicting these relationships aided in defining 
outlier cells having high mitochondrial gene expression and/or low UMI count. A subset of 
cells having unique gene counts greater than 4500, which did not follow a linear relationship 
between UMI and gene count, were excluded for downstream analysis at each cut-off of 2% 
(Fig 4.2A left), 3% (Fig 4.2B left) and 4% (Fig 4.2C left), as recommended by Seurat authors. 
These outliers may reflect potential doublets and hence, were filtered out for the downstream 
analysis. To further exclude any biological artifacts, cells having mitochondrial content of more 
than 0.1% were filtered out for each cut-off of 2% (Fig 4.2A right), 3% (Fig 4.2B right) and 
4% (Fig 4.2C right). 
 
After filtering the outliers, 1739 cells and 1675 cells were obtained at the 2% and 3% cut-offs 
respectively, whereas the 4% cut-off yielded 1599 cells. 
 
After removing technical and biological artifacts from the dataset, the gene expression 
measurements were normalized for sequencing depth using the log transformation in Seurat 
v2.4. This method normalizes individual gene expression values by the total gene expression 
measurement of a cell and then log-transforms the result after multiplying by a scaling factor 
of 10,000 by default.   
 
 

















































Figure 4.2: Relationship between UMI counts, gene counts and mitochondrial content using 
Seurat v2.4.  
Visualization of relationships between UMI and gene counts (left), and UMI counts and percentage 
mitochondrial content to identify and filter outlier cells at different cut-off levels imposed on the 
percentage of cells that each gene is expressed in (A) 2%, (B) 3%, (C) 4% of cells. A single cut-off of 
each cell having at least 500 genes was imposed to filter cells. The cells highlighted within the red box 
were filtered out post analysis.  
 
After filtering and normalization of data to the same depth, highly variable genes were 
calculated using Seurat v2.4 and analysed further. These highly variable genes strictly define 
gene–gene similarities or cell–cell similarities, which provide a basis for imputing dropouts 
with appropriate values. Several pipelines built for scRNA-seq analysis utilize highly variable 
genes as these are less affected by dropouts, and this approach has been proven effective 
because the cell-to-cell variability of major phenotypes can often be captured by genes 
exhibiting high variability (Qiu, 2020). For this, each gene was placed in a bin and a z-score 
was calculated for individual bin to plot a relationship between average expression and 
dispersion (Fig 4.3). These plots were created for the three different cut-offs of 2% (Fig 4.3A), 
3% (Fig 4.3B) and 4% (Fig 4.3C) and 2063, 1844, and 1184 highly variable genes were 
identified for the respective cut-offs (Fig 4.3D). Since Seurat aims to identify nearly 2000 
highly variable genes at a given cut-off, the output of 1184 variable genes at 4% cut-off 
indicated that was a stringent cut-off which may lead to the filtering out of rare cell populations. 
 
 







Figure 4.3: Detection of variable genes across single cells.  
Plot between dispersion and average expression of individual genes based on z-score of dispersion for 
each bin, where genes are divided into bins based on their mean expression. This was done for different 
cut-offs for the percentage of cells in which a gene expressed (A) 2%, (B) 3%, (C) 4% of cells. Cells 
were filtered using a single cut-off of having at least 500 genes, (D) Tabular representation of number 
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4.3 Dimensionality reduction analysis 
4.3.1 Principal Component Analysis (PCA) 
 
After filtering, normalization, and detection of sources of variability in the sequenced data, the 
next step was to visualize the data in a reduced dimensional space. Prior to that, it was important 
to remove unwanted sources of technical and biological noise to improve downstream analysis. 
For doing this, I made use of the ScaleData function implemented in Seurat v2.4, which 
constructs linear models of gene expression estimation and generates a z-scale score for the 
same. This regresses out noisy signals from the data. Then, I performed linear dimensionality 
reduction analysis using Principal Component Analysis (PCA) taking variable genes found in 
Figure 4.3 as an input for individual cut-off. Representative PCA plots based on scores for PC1 
and PC2 are shown in Figure 4.4 where (A), (C) and (E) represent PC plots for cut-off of 2%, 
3% and 4% respectively. To overcome the extensive technical noise associated with a particular 
gene in the dataset, the cells were visualized using a clustering method which employed PC 
scores as a correlation measure. To determine how many PCs to be included in downstream 
analysis, Elbow plot analysis (Cattell RB, 1966) was done. The analysis took standard 
deviation of each PC into consideration to determine the significant number of PCs. In case of 
2% cut- off, there were 12 significant PCs (Fig 4.4B) whereas in case of 3% and 4% cut-off, 
the number of significant PCs were 10 and 8 respectively (Fig 4.4D and 4.4F). Another 
approach known as the Jackstraw plot approach was followed to determine the significant 
number of PCs. The JackStrawPlot function provided a visualization tool for comparing the 
distribution of p-values for each PC against a uniform distribution (dashed line). Significant 
PCs showed a strong enrichment of genes with low p-values (solid curve above the dashed 
line). Based on jackstraw approach I found all 12 PCs to be significant for all individual cut-
offs including 2% (Fig 4.5A), 3% (Fig 4.5B), and 4% (Fig 4.5C). In order to study the 
association of sets of genes with respective PCs, VizPCA function implemented in Seurat was 
utilised, which allowed easy exploration of genes which tend to be the primary source of 
variability within the dataset for cut-off of 2% (Fig 4.6A), 3% (Fig 4.6B) and 4% (Fig 4.6C).   
 




























Figure 4.4: Dimensionality reduction using Principal Component Analysis.  
Principal Component analysis in order to visualize data in lower dimensional space (left) and PC Elbow 
plot for identification of significant PCs based on their standard deviation (right) for different cut-offs 
of (A) and (B) 2%, (C) and (D) 3%, (E) and (F) 4% of cells expressing a particular gene. 
 




























Figure 4.5: Jackstraw plot for identification of significant PCs.  
Jackstraw plot for comparing the distribution of p-values for each PC against a uniform distribution 
(dashed line). Significant PCs showed a strong enrichment of genes with low p-values (solid curve 
above the dashed line), (A) Jackstraw plot for 2% cut-off, (B) Jackstraw plot for 3% cut-off and (C) 
Jackstraw plot for 4% cut-off. 
C
PC10 1.71e-20 PC11 5.19e-25 PC12 1.66e-16
PC7 6.72e-28 PC8 2.02e-69 PC9 8.1e-60
PC4 6.16e-87 PC5 4.18e-91 PC6 1.58e-42
PC1 6.91e-301 PC2 2.24e-131 PC3 2.56e-150

























































Figure 4.6: Visualization of PCs.  
Genes associated with PC1 and PC2 for (A) 2% cut-off, (B) 3% cut-off, and (C) 4% cut-off. 
 
4.3.2 t-Distributed Stochastic Neighbour Embedding (t-SNE) 
 
After determining significant PCs using Elbow plot, I looked at how these PCs may aid in 
visualization of data by separating the cells into different clusters. For this, graph- based 
clustering approach implemented in Seurat v2.4 was followed, based on above defined PCs. 
Briefly, the graph-based clustering approach followed K-nearest neighbour algorithm (KNN) 
(Sieranoja, 2018), where edges were drawn between cells with similar gene expression patterns 
and grouped based on a modularity optimization technique, the Louvain algorithm (Blondel, 
2008), which iteratively grouped cells together. In order to lay over the clusters obtained in a 
low dimensional space, t-Distributed Stochastic Neighbour Embedding (tSNE) tool (Van Der 
Maaten and Hinton, 2008) was used which places cells with similar local neighbourhoods in 
C






the high-dimensional space together in the low-dimensional space (Fig 4.7). I obtained 5 
clusters, with less defined boundaries in low dimensional space for the 2% cut-off (Fig 4.7A), 
whereas well-segregated clusters were obtained for 3% (6 clusters, Fig 4.7B) and 4% cut-offs 
(8 clusters, Fig 4.7C). Although both 3% and 4% cut-off led to well defined clusters of cells in 
lower dimensional space, however, 4% cut-off had much lower number of cells (1599 cells in 
4% compared to 1675 cells in 3%) indicative of really strict filtering. Therefore, I utilized the 
gene-barcode matrix obtained upon applying the 3% cut-off for further downstream analysis. 
 
 











Figure 4.7: Dimensionality reduction analysis using t-distributed stochastic neighbouring 
method.  
tSNE representation of graph-based clusters obtained based on significant PCs for different cut-offs 
where each gene is expressed in at least, (A) 2%, (B) 3%, (C) 4% of cells that express a minimum of 
500 genes. 
 
4.4 Kat2a loss leads to global downregulation of gene expression  
 
After initial pre-processing steps including filtering and normalization, the gene-barcode 
matrix obtained had 1675 cells; 361 cells from Kat2a WT at 2 months, 331 cells from Kat2a 
NULL at 2 months, 502 cells from Kat2a WT at 4 months, and 481 cells from Kat2a NULL at 
4 months, representing transcript levels of 8603 genes normalized to the same sequencing 
depth. These cells had a median gene count of 1575 and median UMI count of 5939 (Table 
4.1). 
 










To study the effect of Kat2a loss on global gene expression, I performed differential expression 
analysis to identify genes expressed differentially upon loss of Kat2a at different time points. 
For this, DESeq2 method (Love, Huber and Anders, 2014) integrated in Seurat v2.4 was 
employed which identifies differentially expressed genes based on a negative binomial 
distribution (Methods). I started by comparing Kat2a WT cells from both 2 months and 4 
months time-points against Kat2a NULL cells from both time points. This global comparison 
revealed that Kat2a NULL leads to an overall downregulation of gene expression, with 811 
genes (p-adj <0.05) being downregulated compared to 70 genes being upregulated (p-adj 
<0.05) (Table 4.2). Interestingly, the global comparison also suggested that only 82 (7+75) 
genes out of 881 (811+70) displayed a higher than 20% change in gene expression upon Kat2a 
loss, suggesting that loss of Kat2a may be contributing towards transcriptional instability of 
gene expression programmes during pre-leukaemia progression rather than a mere 
downregulation of genes as evident from the log2 fold change differences. 
 
Table 4.2: DESeq2 analysis for different comparisons with numbers representing upregulated 
and downregulated genes with p-adj <0.05. Numbers inside the brackets represent minimum 20% 




After performing the global comparison, I compared gene expression in Kat2a NULL cells 
against Kat2a WT cells at individual time points, where the comparison between 2 months 






samples would indicate Kat2a associated transcriptional changes during pre-leukaemia 
initiation and the comparison between 4 months samples would indicate the transcriptional 
changes associated with Kat2a loss during pre-leukaemia maintenance. Downregulated genes 
upon loss of Kat2a at each time point again outnumbered the upregulated genes, consistent 
with the global comparison (Table 4.2). There were 551 downregulated and 48 upregulated 
genes upon loss of Kat2a at 2 months, whereas 118 genes were downregulated and 39 genes 
were upregulated upon loss of Kat2a at 4 months post transplantation. This indicated that Kat2a 
loss may potentially impact gene expression during early stages of pre-leukaemia 
transformation (Table 4.2). Comparing the genes downregulated in the global as well as the 
respective time point comparisons, only 52 genes displayed consistent downregulation (Fig 
4.8A). Next, I compared the transcriptional changes in Kat2a WT occurring between 2 months 
and 4 months and Kat2a NULL occurring between 2 months and 4 months separately. Kat2a 
WT cells showed a downregulation of 600 genes at 4 months compared to 2 months, whereas 
1325 genes were downregulated in Kat2a NULL cells at 4 months compared to 2 months 
(Table 4.2). The higher number of downregulated genes in Kat2a NULL time-series 
comparison may indicate that Kat2a loss leads to downregulation of a specific set of genes 
during the process of pre-leukaemia progression and further suggests that downregulation of 
gene expression is a hallmark of pre-leukaemia progression. Only 38 genes were common to 
the set of genes downregulated in time series comparison and the set of genes downregulated 
in the global comparison (Fig 4.8B).  
 
Since the combined in vitro and in vivo analysis suggested an accelerated RUNX1-
RUNX1T1(9a) leukaemia progression upon Kat2a loss (Chapter-3), I wanted to compare the 
leukaemia progression hierarchy in Kat2a WT cells at 4 months and Kat2a NULL cells at 2 
months. For this, I looked at differentially expressed genes in Kat2a NULL cells at 2 months 
post transplantation compared to Kat2a WT cells at 4 months post transplantation. There were 
493 genes downregulated and 123 genes upregulated in Kat2a NULL at 2 months post 
transplantation highlighting gene expression programmes specific to Kat2a loss during the pre-
leukaemia transformation process (Table 4.2). 
 








Figure 4.8: Venn diagram for common set of downregulated genes.  
(A) Venn diagram highlighting common set of genes among global Kat2a WT and Kat2a NULL 
differential comparison along with the Kat2a WT vs NULL comparison at respective time points, (B) 
Venn diagram highlighting common set of genes among global Kat2a WT and Kat2a NULL differential 
comparison along with time point comparisons for respective genotypes. 
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4.5 The downregulated genes were enriched in mitochondrial ATP synthesis, ribosomal 
biogenesis and cytoplasmic translation pathways 
 
Having observed that loss of Kat2a leads to global downregulation of gene expression, I next 
wanted to study the gene expression pathways enriched upon Kat2a loss. For this, I started 
with the list of genes which were significantly downregulated upon loss of Kat2a in a global 
comparison, using the DESeq2 method mentioned previously (Fig 4.9A). The 811 genes which 
were downregulated in Kat2a NULL cells, were subjected to Panther (version 14.0) enrichment 
analysis (H. Mi et al., 2018) (Methods). The two major enriched categories were associated 
with translation/ribosome biogenesis and mitochondrial ATP synthesis pathways (Fig 4.9B). 
Some of the other enriched categories included protein stabilization, ubiquitination, splicing, 
protein folding, apoptosis etc., highlighting that loss of Kat2a may exert its effect through 
general pathways rather than leukaemia specific ones. This observation was in line with a 
previous study conducted in our lab (Domingues et al., 2020). I used another approach to 
conduct pathway enrichment analysis, specifically, by overlapping these downregulated genes 
with MSigDB (Subramanian et al., 2005; Liberzon et al., 2015) (Methods). The top 10 gene 
sets with FDR q< 0.05 were enriched in translational activity/ribosomal structure and 
mitochondrial activity, consistent with the results obtained from Panther enrichment analysis 
(Fig 4.9C).  
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Figure 4.9: DESeq2 analysis for Kat2a WT vs Kat2a NULL global comparison.  
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a WT (2 
months + 4 months) vs Kat2a NULL (2 months + 4 months) cells. The genes present above the grey 
line (p-adj=0.05) are significant and highlighted in red, (B) Gene Ontology analysis using PANTHER 
v14 representing significantly enriched categories (p-adj <0.05) based on Fisher’s exact test with 
Bonferroni correction, where pink highlights genes associated with translation/ribosome biogenesis, 
and green highlights mitochondrial ATP synthesis associated genes, (C) MSigDB v7.1 overlap with C2 
dataset highlighting top 10 gene sets with FDR less than 0.05. 
 
After performing pathway enrichment analysis for the global Kat2a NULL versus Kat2a WT 
comparison, I performed similar analysis for genes downregulated at individual time-points. 
The comparison between 2 months samples would indicate Kat2a associated gene expression 
pathways affected during pre-leukaemia initiation whereas comparison between 4 months 
samples would indicate the transcriptional programmes associated with Kat2a loss during pre-
leukaemia maintenance. There were 599 significantly differentially expressed genes in Kat2a 
NULL compared to Kat2a WT at 2 months post transplantation, out of which 551 genes were 
downregulated (Fig 4.10A). Gene ontology analysis using Panther indicated enrichment of 
similar gene expression programmes as global comparisons, namely translation/ribosomal 
biogenesis and mitochondrial ATP synthesis (Fig 4.10B). However, unlike the global 
comparison, this analysis did not capture other protein modification processes, highlighting the 
importance of these 2 pathways during leukaemia initiation upon Kat2a loss. This observation 
was consistent with MSigDB overlap where translation/ribosomal biogenesis and 
mitochondrial ATP synthesis pathways were prominently enriched (Fig 4.10C). 
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Figure 4.10: DESeq2 analysis for Kat2a WT vs Kat2a NULL 2months comparison.  
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a WT vs 
Kat2a NULL cells (2 months). The genes present above the grey line (p=0.05) are significant and 
highlighted in red, (B) Gene Ontology analysis using PANTHER v14 representing significantly 
enriched categories (p-adj<0.05) based on Fisher’s exact test with Bonferroni correction, where pink 
highlights genes associated with translation/ribosome biogenesis and green highlights mitochondrial 
ATP synthesis associated genes, (C) MSigDB v7.1 overlap with C2 dataset highlighting top 10 gene 
sets with FDR less than 0.05.  
 
Further, I looked at the pathways enriched in Kat2a NULL at 4 months post transplantation. 
There were 157 genes in total which were differentially expressed at 4 months (Fig 4.11A), a 
number much lower than the 599 differentially expressed genes at 2 months, indicating that 
loss of Kat2a leads to transcriptional changes at early stages of RUNX1-RUNX1T1(9a) 
leukaemia transformation. The 118 downregulated genes out of the 157 genes were subjected 
to Panther gene ontology enrichment analysis, which suggested overrepresentation of genes 
related to translation and ribosome biogenesis (Fig 4.11B). Unlike previous comparisons 
performed globally and at 2 months, no other categories were enriched, perhaps indicating that 
those pathways were specifically required at early stages of transformation whereas 
translation/ribosome biogenesis were continually required for pre-leukaemia maintenance. 
This was consistent with previous lab observations (Domingues et al., 2020). However, this 
may also indicate that the time point at 4 months post transplantation may be too late to capture 
alterations in the pathways which were enriched globally and at 2 months. Further, I looked at 
the enrichment of gene expression pathways using the MSigDB overlap approach. The findings 
were in-line with the Panther gene ontology analysis with enrichment in ribosomal structural 
biogenesis genes (Fig 4.11C). 
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Figure 4.11: DESeq2 analysis for Kat2a WT vs Kat2a NULL 4months comparison. 
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a WT vs 
Kat2a NULL cells (4 months). The genes present above the grey line (p= 0.05) are significant and 
highlighted in red, (B) Gene Ontology analysis using PANTHER v14 representing significantly 
enriched categories (p-adj <0.05) based on Fisher’s exact test with Bonferroni correction, where pink 
highlights genes associated with translation/ribosome biogenesis, (C) MSigDB v7.1 overlap with C2 
dataset highlighting top 10 gene sets with FDR less than 0.05.  
 
To study the common set of genes which are differentially expressed upon Kat2a loss at both 
2 months and 4 months post transplantation, an intersection was performed between the 
downregulated genes at both the time points, which yielded 90 genes in common (Fig 4.12A). 
These 90 genes were fed into Panther gene ontology enrichment analysis, which confirmed the 
downregulation of translation and ribosomal biogenesis pathway associated genes, in line with 
the observations in previous comparisons (Fig 4.12B). This was further confirmed using 
MSigDB overlap, where downregulation of ribosomal structural genes was observed (Fig 
4.12C). These observations strengthened the finding that the translation/ribosomal structural 
constituent genes, mainly Rpl and Rps gene family, are downregulated upon loss of Kat2a. The 
downregulation of these genes is putatively important for early RUNX1-RUNX1T1(9a) 
leukaemia transformation as well as during leukaemia maintenance.  
 







Figure 4.12: DESeq2 analysis for common set of genes downregulated in Kat2a NULL with 
respect to Kat2a WT at respective time points.  
(A) Venn diagram highlighting 90 common genes downregulated in Kat2a NULL compared to Kat2a 
WT at the respective time points, (B) Gene Ontology analysis using PANTHER v14 representing 
significantly enriched categories (p-adj<0.05) based on Fisher’s exact test with Bonferroni correction 
where pink highlights genes associated with translation/ribosome biogenesis, (C) MSigDB v7.1 overlap 
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4.6 Time series progression of Kat2a WT and Kat2a NULL suggest an early metabolic 
configuration, which may be accelerated by Kat2a loss  
 
After looking at the gene expression signatures attributed to loss of Kat2a, I wanted to study if 
there are any differences in time series progression of Kat2a WT and Kat2a NULL. For this, I 
started with Kat2a WT and performed differential expression analysis using DESeq2 at 4 
months compared to 2 months post transplantation. There were in total 621 differentially 
expressed genes, out of which 600 were downregulated, indicating loss of gene expression 
during RUNX1-RUNX1T1(9a) pre-leukaemia progression in Kat2a WT cells (Fig 4.13A). 
Panther gene ontology analysis suggested an enrichment in mitochondrial ATP synthesis 
pathway genes indicating an early metabolic reconfiguration during RUNX1-RUNX1T1(9a) 
pre-leukaemia transformation which may be accelerated upon loss of Kat2a (Fig 4.13B). This 
was consistent with MSigDB overlap approach where pathways associated with 
oxidoreductase activity, ATPase activity, and proton transmembrane activity were enriched 
(Fig 4.13C). Other enriched gene expression programmes were found to be associated with 
regulation of cell cycle genes and post-transcriptional regulatory processes like alternative 
splicing, along with protein ubiquitination (Fig 4.13B and C).    
 
After comparing the gene expression programmes impacted during RUNX1-RUNX1T1(9a) 
pre-leukaemia progression in Kat2a WT cells, similar analysis was done for Kat2a NULL cells. 
Differential expression analysis using DESeq2 yielded 1325 downregulated genes and 79 
upregulated genes (Fig 4.14A). Based on Panther enrichment analysis, the downregulated 
genes were broadly enriched for categories related to regulation of gene expression, including 
alternative splicing, cis-splicing along with cell cycle regulation, protein modifications, and 
chromatin organization (Fig 4.14B). This was consistent with the insights from MSigDB 
overlap, where genes related to RNA binding, transcription factor binding, and protein 
modifications were enriched (Fig 4.14C). These observations altogether suggested that unlike 
in Kat2a WT cells which mostly have an impact on genes associated with mitochondrial 
alterations during pre-leukaemia development, Kat2a NULL cells follow pre-leukaemia 
hierarchy by impacting post-transcriptional and epigenetic regulatory mechanisms during the 
process of pre-leukaemia maintenance.  
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Figure 4.13: DESeq2 analysis for Kat2a WT 2 months vs 4months comparison.  
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a WT 2 
months vs 4 months. The genes present above the grey line (p= 0.05) are significant and highlighted in 
red, (B) Gene Ontology analysis using PANTHER v14 representing significantly enriched categories 
(p-value adj<0.05) based on Fisher’s exact test with Bonferroni correction, where green highlights 
mitochondrial ATP synthesis associated genes, (C) MSigDB v7.1 overlap with C2 dataset highlighting 
top 10 gene sets with FDR less than 0.05.  
 
4.7 Mitochondrial ATP synthesis pathway was associated with pre-leukaemia 
transformation of Kat2a WT cells 
 
Having studied gene expression programmes associated with time series progression 
individually for both Kat2a WT and Kat2a NULL cells transformed with RUNX1-
RUNX1T1(9a), I wanted to understand the gene expression programmes during pre-leukaemia 
transformation between Kat2a NULL at 2 months and Kat2a WT at 4 months post 
transplantation. This comparison would allow to gain insight into the underlying differences 
between their pre-leukaemia progression hierarchy. I performed differential expression 
analysis using DESeq2 which gave 493 downregulated and 123 upregulated genes in Kat2a 
NULL cells at 2 months (Fig 4.15A). The downregulated genes were significantly enriched in 
mitochondrial ATP synthesis and translation/ribosome biogenesis associated gene expression 
programmes (Fig 4.15B). This was in agreement with MSigDB overlap (Fig 4.15C). Overall, 
these observations were in-line with the previous observations suggesting an early metabolic 
reconfiguration which may be accelerated upon loss of Kat2a along with translation/ribosome 
biogenesis associated genes having a role in pre-leukaemia maintenance.  
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Figure 4.14: DESeq2 analysis for Kat2a NULL 2 months vs 4months comparison.  
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a NULL 2 
months vs 4 months. The genes present above the grey line (p= 0.05) are significant and highlighted in 
red, (B) Gene Ontology analysis using PANTHER v14 representing significantly enriched categories 
(p-value adj <0.05*) based on Fisher’s exact t-test with Bonferroni correction, (C) MSigDB v7.1 
overlap with C2 dataset highlighting top 10 gene sets with FDR less than 0.05.  
 
Finally, I studied the common gene expression pathways expressed differentially in Kat2a 
NULL at 2 months or Kat2a WT at 4 months, compared to Kat2a WT at 2 months. This 
comparison would develop an understanding of the gene expression programmes specifically 
associated with pre-leukaemia transformation of Kat2a WT cells at 2 months. For this, I 
performed an intersection between the list of downregulated genes for the two comparisons 
(Fig 4.16A). The intersection resulted in a list of 262 genes which were majorly enriched in 
mitochondrial ATP synthesis processes, highlighting the regulatory role of these processes 
during pre-leukaemia progression in both Kat2a WT at 4 months and Kat2a NULL at 2 months 
(Fig 4.16B and C). The observation of presence of early metabolic reconfiguration during the 
process of pre-leukaemia transformation was consistent with previous comparisons. However, 
the fact that this comparison did not capture genes associated with translation/ribosome 
biogenesis, highlighted the specificity of transcriptional instability in these programmes upon 
loss of Kat2a. 
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Figure 4.15: DESeq2 analysis for Kat2a WT 4 months vs Kat2a NULL 2 months comparison.  
(A) Volcano plot representing differentially expressed genes obtained from comparing Kat2a WT 4 
months vs Kat2a NULL cells 2 months. The genes present above the grey line (p= 0.05) are significant 
and highlighted in red, (B) Gene Ontology analysis using PANTHER v14 representing significantly 
enriched categories (p-adj<0.05) based on Fisher’s exact test with Bonferroni correction, where pink 
highlights genes associated with translation/ribosome biogenesis, (C) MSigDB v7.1 overlap with C2 
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Figure 4.16: DESeq2 analysis for common set of genes downregulated in Kat2a NULL vs Kat2a 
WT at 2 months with Kat2a WT 2 months vs 4 months.  
(A) Venn diagram highlighting 262 common genes downregulated in Kat2a NULL vs Kat2a WT at 2 
months with Kat2a WT 2 months vs 4 months, (B) Gene Ontology analysis using PANTHER v14 
representing significantly enriched categories (p-adj <0.05) based on Fisher’s exact test with Bonferroni 
correction where green highlights genes associated with Mitochondrial ATP synthesis, (C) MSigDB 
v7.1 overlap with C2 dataset highlighting top 10 gene sets with FDR less than 0.05.  
 
In this chapter, I discussed the single-cell RNA sequencing of early-stage RUNX1-
RUNX1T1(9a) transformed Kat2a WT and Kat2a NULL pre-leukaemia using 10X genomics 
technology. The samples for scRNA-seq were prepared from frozen bone marrow samples 
collected from both Kat2a WT and Kat2a NULL pre-leukaemia animals 2 months and 4 
months post transplantation. In total, 1739 cells were subjected to sequencing with 174,770 
mean reads per cell. The cell capture efficiency was ~21.73%, which is low compared to the 
expected 50-65% (Ziegenhain, Vieth, Parekh, Reinius, et al., 2017). This could be attributed 
to poor sample quality post sorting or limitations associated with library preparation. With 
recent advancements in 10X technology with v3 being the latest version of the technology, the 
cell capture efficiency has been improved to ~70%. I obtained 8-10 million reads/sample, much 
higher than the recommended 1 million (Ziegenhain, Vieth, Parekh and Heyn, 2017), 
suggesting that the sequencing was performed to a reasonable level of saturation. For individual 
sample, the number of reads mapped to the genome had fallen in the range of 94-95%, 
highlighting that it was wise to select mm10 as reference genome. More than 90% of the reads 
in individual sample were confidently mapped to the genome confirming a good separation 
from background technical noise. Nearly 70% of the reads in each sample corresponded to 
transcriptomic region validating the 10X transcriptomics methodology however, it’s worth 
appreciating that the transcripts captured would map to the 3’ end of the due to oligodT 
selection step. Taking the number of detected genes per cell as a measure of sensitivity, I found 
that individual sample from this study had a median number of genes falling in the range of 
1000-2000 genes. One of the major reasons for such low number of detected genes is the fact 
that the cells utilized for sequencing were cryopreserved for several months and weren’t 
transcriptionally active. This number was of course relatively much lower compared to rest of 
the single-cell transcriptomics technology where Drop-seq and MARS-seq are capable of 






detecting ~5000 median genes per cell whereas Smart-seq/C1 is capable of capturing ~7500 
median genes per cell. On the other hand, recently developed Smart-seq2 is capable of 
detecting up to ~9100 median genes per cell, becoming the most sensitive technique amongst 
all (Ziegenhain, Vieth, Parekh and Heyn, 2017). However, after comparing the total number of 
genes detected across many cells, all of these methods including 10X genomics technology 
were capable of capturing majority of the genes (~13000 genes) where method-specific genes 
were detected in very few cells (87% of genes occur in one or two cells) (Ziegenhain, Vieth, 
Parekh and Heyn, 2017). These indications overall highlighted that although 10X genomics 
doesn’t seem comparable to other methods in terms of sensitivity, however, given that the 
method is capable of detecting majority of the genes, it’s highly unlikely that the impact of low 
median gene count on conclusions drawn from scRNA-seq data will be significant. 
 
It is worth noting that the Kat2a NULL sample collected 2 months post transplantation, unlike 
other samples, did not have a clear distinction between the cells detected and background noise 
with merely 2753 median UMI counts per cell as opposed to more than 6000 UMI counts per 
cell in other samples. I hypothesize that this not-so-clear distinction could be due to higher 
percentage of terminally differentiated cells in the sample, which may not acclimatize to the 
freezing-thawing cycle very well, and hence, the sample quality may not be comparable to the 
rest of the samples. Again, with recent developments and an improved CellRanger pipeline, 
these challenges associated with clear distinction between cells and noisy background along 
with dropout rates have been addressed remarkably.  
 
Due to inherent noisiness of scRNA-seq data (Hwang, Lee and Bang, 2018), owing to various 
technical and biological factors, I first performed a clean-up of the scRNA-seq data obtained 
above (Butler et al., 2018). For this, I started with imposing two different types of cut-offs, 
first, by keeping the minimum number of genes to 500, in-line with the previous lab study 
(Domingues et al., 2020), where each cell having gene expression values for less than 500 
genes was considered a poor quality cell. Secondly, a cut-off was imposed on number of cells, 
where each gene was considered to have a significant expression in the given biological system 
if a minimum number of cells showed expression for it. To begin with, three such different cut-
offs (2%, 3% and 4%) for minimum number of cells were imposed for downstream analysis. 
Then, I excluded the cells with compromised viability as highlighted by high mitochondrial 






gene expression, which is indicative of apoptotic or necrotic cells. Further, potential doublets 
or multiplets were filtered out based on abnormal gene counts represented by a barcode 
representative of gene expression data from more than a single cell. Post-filtering, 
normalization was performed to account for any cell-specific bias and zero-inflated counts due 
to reasons such as dropout or transient gene expression (Hwang, Lee and Bang, 2018). The 
normalization was performed using log-transformation method and a scaling factor which is 
estimated by standardizing across the given cells, assuming that most genes are not 
differentially expressed. Although, log-normalization, so-far has been the most reliable method 
for researchers handling scRNA-seq data, however, it’s worth considering that certain factors 
including differences in cell lysis, reverse transcription efficiency, and stochastic molecular 
sampling during sequencing also contribute significantly towards technical bias and may 
potentially impact downstream analysis (Hafemeister and Satija, 2019). The data variability 
due to confounding technical challenges associated with PCR has somewhat been resolved by 
the incorporation of unique molecular identifiers (UMI) in scRNA-seq (Islam et al., 2014b). 
However, the potential for combining within-sample and between-sample normalization 
methods still largely remains unexplored and an active area of research that will require 
rigorous testing. 
 
Post-filtering and normalization of scRNA-seq data, I focussed on highly variable genes for 
further downstream analysis. I used a function implemented in Seurat v2.4 which calculates 
the average expression and dispersion for each gene, places these genes into bins, and then 
calculates a z-score for dispersion within each bin. This function gave an output of ~2000 genes 
at the individual cut-off imposed at the beginning of filtering process. The 4% cut-off yielded 
only 1,184 highly variable genes, indicating that this cut-off may not be able capture rare-cell 
populations compared to the 2% and 3% cut-off, which yielded 2,063 and 1,844 highly variable 
genes. These highly variable genes thus obtained were utilised for performing linear 
dimensionality reduction analysis using Principal Component Analysis (PCA). PCA helped in 
defining the significant principal components contributing towards gene expression variability, 
thus identifying the true dimensionality of the dataset.  
 
Based on the significant principal components identified using PCA, a graph-based clustering 
approach was followed. The cells were further clustered using a modularity optimization 






technique, the Louvain algorithm (default) which iteratively grouped cells together, with the 
goal of optimizing the standard modularity function (Vincent D Blondel et al., 2008). This is 
an improved approach compared to conventional approaches which follow Euclidean norm or 
cosine distance, as these are not effective enough for high-dimensional data with few objects. 
(Beyer et al., 1998).  
 
In order to lay over the clusters obtained in a low dimensional space, t-Distributed Stochastic 
Neighbour Embedding (t-SNE) (Van Der Maaten and Hinton, 2008) was used which placed 
the cells with similar local neighbourhoods in high-dimensional space together in low-
dimensional space. The reduced dimensional data thus obtained had 5 clusters with less well- 
defined boundaries in case of the 2% cut-off, whereas well-segregated clusters were obtained 
in case of the 3% (6 clusters) and 4% cut-offs (8 clusters). Combining information from highly 
variable genes and obtained clusters, I utilised 3% cut-off for downstream analysis in order to 
obtain high confidence rare cell populations without losing informative genes. Overall, the pre-
processing of scRNA-seq data obtained from early-stage RUNX1-RUNX1T1(9a) transformed 
Kat2a WT and Kat2a NULL pre-leukaemia animals yielded a gene expression matrix of 1675 
cells with 1575 median genes having 5939 median UMI counts per cell.  
 
After performing the clean-up steps on raw scRNA-seq data, the transcriptional programmes 
associated with Kat2a loss were studied and correlated with pre-leukaemia progression. 
Differential expression analysis was performed using DESeq2 (Love, Huber and Anders, 
2014). The global comparison of Kat2a NULL with respect to Kat2a WT, revealed that loss of 
Kat2a leads to an overall downregulation of gene expression, with 811 genes (p-adj <0.05) 
being downregulated compared to 70 genes being upregulated (p-adj <0.05). Interestingly, the 
global comparison also suggested that there were only 82 genes out of 881 having more than 
20% change in gene expression upon Kat2a loss. These observations were compatible with the 
acetyltransferase activity of Kat2a, playing an important role in promoting transcriptional 
stability (Hebbes, Thorne and Crane-Robinson, 1988)(Turner BM, 1993). Altogether, these 
inferences from literature are held in conjunction with the observation that loss of Kat2a 
promotes transcriptional instability during RUNX1-RUNX1T1(9a) pre-leukaemia 
transformation.  
 






After looking at the global comparison, gene expression changes were studied upon Kat2a loss 
by comparing Kat2a NULL cells to Kat2a WT cells at individual time points. A comparison 
between 2 months samples would indicate Kat2a associated transcriptional changes during pre-
leukaemia initiation whereas comparison between 4 months samples would indicate 
transcriptional changes associated with Kat2a loss during pre-leukaemia maintenance. There 
were 551 downregulated and 48 upregulated genes upon loss of Kat2a at 2 months and 118 
downregulated and 39 upregulated genes upon loss of Kat2a at 4 months post transplantation. 
These analyses highlighted loss of Kat2a may potentially impact gene expression during early 
stages of pre-leukaemia transformation. I also compared the transcriptional changes in Kat2a 
WT occurring between 2 months and 4 months and Kat2a NULL occurring between 2 months 
and 4 months separately. Kat2a WT cells showed a downregulation of 600 genes at 4 months 
compared to 2 months, whereas 1,325 genes were downregulated in Kat2a NULL cells at 4 
months compared to 2 months. The higher number of downregulated genes in Kat2a NULL 
time-series comparison may indicate that Kat2a loss leads to downregulation of specific sets 
of genes during the process of leukaemia progression. This also suggested that downregulation 
of gene expression programmes may be associated with pre-leukaemia transformation. This 
observation may not be surprising given that pre-leukaemic clones contribute towards disease 
relapse which may be a consequence of reduced transcription of genes (Lee et al., 2006; Majeti 
et al., 2009). 
 
I then sought to understand the pathways associated with Kat2a loss at a global scale, 
Translation/ribosome biogenesis and mitochondrial ATP synthesis pathways were found to be 
the two major enriched categories. These observations were compatible with a previous study 
conducted in our lab on MLL-AF9 leukaemia, where loss of Kat2a downregulated gene 
expression pathways associated with translation/ribosome biogenesis and mitochondrial ATP 
synthesis (Domingues et al., 2020). These findings altogether suggested that loss of Kat2a may 
exert its effect through general pathways rather than leukaemia specific ones. Similar analysis 
was performed for genes downregulated at individual time-points. There were 599 significantly 
differentially expressed genes in Kat2a NULL compared to Kat2a WT at 2 months post 
transplantation, out of which 551 genes were downregulated. Gene ontology analysis indicated 
enrichment of similar gene expression programmes as global comparisons, namely 
translation/ribosomal biogenesis and mitochondrial ATP synthesis, highlighting their 






importance in pre-leukaemia transformation. Similarly, I looked at the pathways enriched in 
Kat2a NULL at 4 months post transplantation. There were 157 genes in total which were 
differentially expressed at 4 months, a number much lower than the 599 differentially 
expressed genes at 2 months, indicating that loss of Kat2a leads to transcriptional changes at 
early stages of RUNX1-RUNX1T1(9a) pre-leukaemia transformation. The 118 downregulated 
genes out of the 157 genes were subjected to gene ontology enrichment analysis, which again 
suggested overrepresentation of genes related to translation and ribosome biogenesis. Unlike 
previous comparisons performed globally and at 2 months, no other categories were enriched, 
perhaps indicating that the missing pathways were specifically required at early stages of 
transformation whereas translation/ribosome biogenesis were continually required for pre-
leukaemia maintenance. However, this may also indicate that the time point at 4 months post 
transplantation may be too late to capture alterations in the pathways which were enriched 
globally and at 2 months. Further, 90 genes were found to be differentially expressed upon 
Kat2a loss at both 2 months and 4 months post transplantation. These 90 genes were also 
enriched in translation and ribosomal biogenesis pathway associated genes, in line with the 
observations in previous comparisons. 
 
To understand the time series progression of Kat2a WT cells and Kat2a NULL cells separately, 
differential expression analysis was performed comparing the 4 months time point to the 2 
months time for each genotype separately. In total, there were 621 differentially expressed 
genes in Kat2a WT cells at 4 months, out of which 600 were downregulated indicating loss of 
gene expression during RUNX1-RUNX1T1(9a) leukaemia progression in Kat2a WT cells 
undergoing pre-leukaemia transformation. The gene ontology analysis suggested an 
enrichment in mitochondrial ATP synthesis pathway genes, highlighting the presence of 
metabolic reconfiguration during early stages of pre-leukaemia transformation. These 
metabolic changes may be key to pre-leukaemia progression and are accelerated in the absence 
of Kat2a. On a similar note, another analysis was performed for Kat2a NULL cells comparing 
4 months to 2 months post transplantation. Differential expression analysis yielded a total of 
1325 downregulated genes and 79 upregulated genes which were broadly enriched for 
categories related to regulation of gene expression, including alternative splicing, cis-splicing, 
along with cell cycle regulation, protein modifications, and chromatin organization. The 
analysis highlights that loss of Kat2a impacts translation/ribosomal biogenesis and 






mitochondrial ATP synthesis during early stages of pre-leukaemia transformation and 
potentially needs these processes during pre-leukaemia maintenance. However, once the 
RUNX1-RUNX1T1(9a) pre-leukaemia is established, the disease progression impacts 
transcriptional programmes associated with cell cycle progression, post-transcriptional 
modifications, along with epigenetic instability in the form of chromatin reorganization.   
 
Altogether, the analysis presented in this chapter highlights that enrichment of mitochondrial 
bioenergetics indicate an early metabolic reconfiguration during pre-leukaemia transformation, 
which may be accelerated upon loss of Kat2a. However, the impairment in ribosomal 
biogenesis and translation associated genes is a consequence of loss of Kat2a which maybe 
continually required for pre-leukaemia maintenance. Based on these insights obtained from 
scRNA-seq, I sought to understand their mechanistic contribution by inhibition of these 
pathways individually during the process of RUNX1-RUNX1T1(9a) pre-leukaemia 






























5 Mechanistic investigation of Kat2a associated transcriptional 
programmes in RUNX1-RUNX1T1(9a) and Idh1R132H pre-
leukaemia 
 
In the previous chapter, I identified the prominent gene expression pathways that show 
transcriptional instability upon loss of Kat2a during RUNX1-RUNX1T1(9a) pre-leukaemia, 
including mitochondrial bioenergetics and ribosomal biosynthetic programmes. The 
downregulation of mitochondrial ATP bioenergetics as well as mitochondrial translation 
reflect two different aspects of metabolic reprogramming during early pre-leukaemia 
transformation as a consequence of Kat2a loss.  The consistent attenuation in ribosomal 
biogenesis machinery at both time points, however, indicated that reduced protein synthesis 
may impact RUNX1-RUNX1T1(9a) pre-leukaemia transformation in vivo upon loss of Kat2a. 
In order to validate these observations experimentally in vitro, I made use of RUNX1-
RUNX1T1(9a) and Idh1R132H models of pre-leukaemia to assess the mitochondrial activity 
and protein synthesis. In parallel, I conducted similar experiments on the MLL-AF9 model of 
leukaemia, which represents a strong oncogenic model in contrast to the other two pre-
leukaemia models. As discussed in Chapter-1, MLL-AF9 transformed cells could aid in 
maintenance of the leukaemia by immortalization of leukaemogenic cell populations, which is 
dependent on constitutive MLL-AF9 expression (Somervaille and Cleary, 2006) (Horton et al., 
2013). Previous studies conducted in our lab suggested a depletion of MLL-AF9 leukaemia 
stem-like cells upon loss of Kat2a via promotion of transcriptional instability in mitochondrial 
bioenergetics and ribosomal biosynthetic programmes (Domingues et al., 2020). The 
observations of immortalization of AML transformed cells in the presence of strong oncogenic 
effect of MLL-AF9 fusion protein suggest it is an excellent model of AML maintenance in 
contrast to the pre-leukaemia models, with similar transcriptional programmes being impacted 
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5.1 Kat2a loss downregulates mitochondrial activity in RUNX1-RUNX1T1(9a) pre-
leukaemia  
 
To study the role of mitochondrial activity, I started with collection of BM cells from RUNX1-
RUNX1T1(9a) in vivo transformed Kat2a WT and Kat2a NULL animals at 2 months post 
transplantation. To test whether loss of Kat2a impairs mitochondrial functionality, both Kat2a 
WT and Kat2a NULL BM cells were subjected to staining with two fluorescent dyes, namely 
Mitotracker deep red, and Mitostatus TMRE (Methods). Mitotracker deep red contains a mildly 
thiol-reactive chloromethyl moiety, which passively diffuses across the plasma membrane and 
accumulates in active mitochondria, hence, indicating active mitochondrial content/mass inside 
a cell. On the other hand, Mitostatus TMRE measures mitochondrial membrane potential 
(Δψm) of a cell, which is a measure of oxidative stress, apoptosis, or any other stressful event 
(Scaduto and Grotyohann, 1999). For example, in cells undergoing apoptosis, pro-apoptotic 
Bcl-2 family proteins cause mitochondrial outer membrane permeabilization (MOMP), 
resulting in the release of cytochrome C, and the subsequent activation of caspase-9 and the 
apoptotic cascade (Gottlieb, Vander Heiden and Thompson, 2000) (Lemasters et al., 1998). 
This MOMP often correlates with the loss of inner mitochondrial membrane potential (Δψm), 
which can be detected using Δψm-sensitive dyes. Mitostatus TMRE is one such cationic, 
lipophilic dyes which gets accumulated within the mitochondria of healthy cells, but not within 
mitochondria that have lost Δψm due to induction of apoptosis, or treatment with a 
mitochondrial uncoupler. To avoid confounding effects due to variability in cell size and 
mitochondrial number, cells with similar forward and side scatter profile were included in the 
analysis. I observed that Kat2a NULL cells transformed with RUNX1-RUNX1T1(9a) in vivo 
displayed an increase in a population with low active mitochondrial mass (Mito lo) compared 
to Kat2a WT (Fig 5.1A). A representative flow cytometry plot highlighted the shift in the 
Mitotracker positive population leading to reduced active mitochondrial mass (Fig 5.1B). On 
the other hand, no changes were observed in terms of mitochondrial potential, as indicated by 
Mitostatus TMRE, upon loss of Kat2a (Fig 5.1B).   
 
To understand the general role of Kat2a in leukaemia progression, I also looked at potential 
mitochondrial alterations in MLL-AF9 in vitro transformed Kat2a WT and Kat2a NULL BM 
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cells. MLL-AF9 represents a leukaemia maintenance model requiring fewer cooperating 
mutations, unlike RUNX1-RUNX1T1(9a) and Idh1R132H. Previous work conducted in our lab 
suggested that Kat2a plays a role in MLL-AF9 driven transformation by impacting 
mitochondrial translational machinery and ribosomal biosynthetic programmes (Domingues et 
al., 2020). To investigate this observation mechanistically, I performed the same experiment 
with Mitotracker deep red and Mitostatus TMRE in Kat2a NULL and Kat2a WT cells 
transformed with MLL-AF9 in vitro. As per the findings from single cell RNA sequencing 
(scRNA-seq) on MLL-AF9 transformed Kat2a WT and Kat2a NULL cells, I observed an 
increase in the Mito lo population in Kat2a NULL cells compared to Kat2a WT cells (Fig 
5.1C). This is highlighted by a shift in the Mitotracker positive population, while no changes 
were observed in the Mitostatus TMRE positive population, in line with the RUNX1-
RUNX1T1(9a) pre-leukaemia observations (Fig 5.1D). 
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Figure 5.1: Mitochondrial mass and potential analysis for RUNX1-RUNX1T1(9a) and MLL-AF9 
transformed cells.  
(A) Relative proportion of RUNX1-RUNX1T1(9a) in vivo transformed Kat2a NULL BM cells and 
Kat2a WT BM cells that have low mitochondrial mass at 2 months post transplantation (n= 2/genotype), 
horizontal bars represent mean value  and dots indicate individual data points (B) Representative flow 
cytometry dot plot (left) highlighting mitochondrial mass on x-axis and mitochondrial potential on y-
axis, along with the respective histograms (right) for RUNX1-RUNX1T1(9a) transformed Kat2a WT 
BM cells (top) and Kat2a NULL BM cells (bottom), (C) Relative proportion of MLL-AF9 in vitro 
transformed Kat2a NULL BM cells and Kat2a WT BM cells that have low mitochondrial mass (n= 
2/genotype), (D) Representative flow cytometry dot plot (left) highlighting mitochondrial mass on x-
axis and mitochondrial potential on y-axis along with respective histograms (right) for MLL-AF9 
transformed Kat2a WT BM cells (top) and Kat2a NULL BM cells (bottom). 
 
5.2 MLL-AF9 transformed Kat2a WT cells with low mitochondrial mass phenocopy 
some of the characteristics of Kat2a NULL cells 
 
Having confirmed that loss of Kat2a reduces mitochondrial content in both RUNX1-
RUNX1T1(9a) and MLL-AF9 leukaemia, I wanted to study whether segregating cell 
populations on the basis of mitochondrial content would allow me to dissect the mechanistic 
contribution of mitochondrial activity during leukaemia progression. For this, I made use of 
MLL-AF9 model of leukaemia, due to its impact on immortalization of leukaemia cells which 
allows long term maintenance of these transformed cells in vitro. 
 
I started with MLL-AF9 in vitro transduced Kat2a WT and Kat2a NULL BM cells, which were 
maintained in the form of a colony forming assay (CFC assay) in a semi-solid methylcellulose 
medium supplemented with cytokines, allowing for the maintenance of myeloid progenitor 
cells. The MLL-AF9 in vitro transduced Kat2a WT and Kat2a NULL BM cells were 
maintained in the CFC assay for three rounds of plating, until the colonies obtained were 
enriched in transformed cell populations. These transformed cell populations having either 
Kat2a WT or Kat2a NULL genotype were stained with Mitostatus TMRE and Mitotracker 
deep red fluorescent dye and sorted on the basis of high mitochondrial mass (Mito Hi) and low 
mitochondrial mass (Mito Lo) (gating strategy described in Methods). The different fractions 
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of cells obtained post sorting were namely, Kat2a WT Mito hi, Kat2a WT Mito lo, Kat2a 
NULL Mito hi, and Kat2a NULL Mito lo. These cell populations were subjected to CFC assay 
in order to assess differences in their self-renewal potential. 
 
Globally, the total number of colonies obtained from Kat2a NULL fractions were lower than 
those obtained from Kat2a WT fractions, compatible with the observation in MLL-AF9 model 
(described in detail in Chapter-6, Figure 6.4H). The cells from Mito lo fractions had lower 
number of colonies compared to the respective Mito hi fractions for both genotypes, indicating 
that segregation of cells based on mitochondrial content may not have a genotype-specific 
effect (Fig 5.2A). However, the number of colonies obtained in Kat2a WT Mito lo was 
comparable to that of Kat2a NULL Mito hi and Kat2a NULL Mito lo together, suggesting that 
Kat2a NULL as a whole phenocopies Kat2a WT Mito lo. 
 
I then looked at the colony composition of individual cell subsets based on criteria defined in 
a study by Lavau and colleagues (Lavau et al., 1997), where colonies were subdivided into 
compact, mixed, and dispersed types. As the nomenclature suggests, compact colonies are the 
ones which are compact and do not show any halo of migrating cells, mixed colonies have a 
compact centre with a diffuse halo of differentiating progenitors, and dispersed colonies are 
comprised of large diffuse colonies without a defined centre. Compact colonies are determinant 
of the presence of immature myeloid cells, whereas diffuse components include differentiated 
macrophages. Based on these criteria, looking at the different colony types in these cellular 
fractions, I observed a reduction in compact colonies in Kat2a NULL compared to Kat2a WT 
cells, compatible with the earlier observation (Chapter-6). In line with the reduction in total 
colonies, there was also a significant reduction in compact colonies from Mito hi to Mito lo 
fractions in both genotypes, indicating a reduction in colony forming potential in the Mito lo 
population, irrespective of genotype (Fig 5.2B). Once again, the relative proportion of compact 
colonies from Kat2a WT Mito lo was comparable to that of Kat2a NULL Mito hi and Kat2a 
NULL Mito lo, suggesting that Kat2a NULL as a whole phenocopies Kat2a WT Mito lo, a 
trend compatible with total colonies. Further, I looked at the proportion of mixed and dispersed 
colonies which is determinant of cellular differentiation in all four populations. In line with 
previous observations (Chapter-6), mixed colonies seemed specific to MLL-AF9 transformed 
Kat2a NULL cells and Kat2a NULL Mito hi captured most of these. There was a significant 
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reduction in mixed colony proportion in Kat2a NULL Mito lo cells relative to Kat2a NULL 
Mito hi cells (Fig 5.2C). The proportion of mixed colonies in Kat2a NULL Mito lo was 
comparable to the mitochondrial fractions in Kat2a WT cells. Dispersed colonies were the 
lowest represented colonies in all the samples, consistent with the previous observations 
(Chapter-6), which made it challenging to identify subtle significant differences in the 
proportion of these colonies in different samples. However, there was a trend towards an 
increase in the proportion of dispersed colonies in Kat2a WT Mito lo, comparable with global 
Kat2a NULL cells, again indicating that Kat2a NULL as a whole phenocopies Kat2a WT Mito 
lo (Fig 5.2D).  In summary, this experiment strongly suggests that reduction in active 
mitochondrial mass impacts self-renewal potential of MLL-AF9 transformed Kat2a WT and 
Kat2a NULL mouse bone marrow cells. After segregation based on active mitochondrial mass, 
these cells may lose their colony forming potential as observed in cells with lower 
mitochondrial mass, where loss of Kat2a mimics the replating capacity of Kat2a WT Mito lo 
cells (Fig 5.2E). 
 
After studying the functional impact of loss of Kat2a on active mitochondrial mass and how 
this affects the self-renewal potential of MLL-AF9 transformed Kat2a WT and Kat2a NULL 
cells, I aimed to understand the impact of active mitochondrial mass on clonal expansion of 
MLL-AF9 transformed cells. For this, MLL-AF9 in vitro transformed Kat2a WT and Kat2a 
NULL cells were stained with Mitostatus TMRE and Mitotracker deep red, and further index-
sorted on the basis of Mitotracker deep red fluorescence (active mitochondrial mass). 
Individual cell populations were single-cell sorted in a 96-well plate, giving a total of 6 
samples- Kat2a WT Mito hi, Kat2a WT Mito lo, Kat2a WT total, Kat2a NULL Mito hi, Kat2a 
NULL Mito lo, Kat2a NULL total. The index-sorting technology enabled study of clonal 
expansion capability of individual cells from separate mitochondrial fractions sorted from each 
genotype (Hayashi et al., 2010). The single-cell clonal cultures were maintained for a week 
and cell counting was performed for individual wells on a daily basis. The cell counts thus 
obtained were categorized into 7 intervals, where each interval was coded in a different colour. 
These counts were then organized in the form of a heatmap hierarchically, so that the cells with 
increased clonal expansion capacity can be correlated with their colony forming potential. The 
generated global heatmap suggested a decrease in clonal expansion potential in Kat2a NULL 
cells compared to Kat2a WT as seen from the Mito Total, in line with the observation from 
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colony forming assay (Fig 5.3A). This was also compatible with the insights from colony 
forming assay discussed in Chapter-6. The cells from Mito lo fractions had reduced clonal 
expansion capacity compared to the respective Mito hi fractions for both genotypes, indicating 
that segregation of cells based on mitochondrial content may not have a genotype-specific 
effect (Fig 5.3B). This was again in accordance with the colony forming assay observations 
above, where both Mito lo fractions had reduced colony forming potential compared to their 
respective Mito hi fractions. 
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Figure 5.2: Colony forming assay for in vitro MLL-AF9 transformed Kat2a WT and Kat2a NULL 
BM cells sorted on the basis of mitochondrial mass.  
(A) Colony forming frequency for Kat2a WT mitochondrial mass high (WT Mito Hi), Kat2a WT 
mitochondrial mass low (WT Mito Lo), Kat2a NULL mitochondrial mass high (NULL Mito Hi), Kat2a 
NULL mitochondrial mass low (NULL Mito lo) (n=4/sample, mean ± SD, Nested t-test, p= 0.017* WT 
Mito hi vs lo, p= 0.031* NULL Mito hi vs lo, p= 0.0052** WT Mito hi vs NULL Mito lo), (B) Relative 
frequency of compact colonies (n=4/sample, mean ± SD, Nested t-test, p= 0.0085** WT Mito hi vs lo, 
p= 0.0068** NULL Mito hi vs lo, p= 0.0024** WT Mito hi vs NULL Mito hi, p= 0.0005*** WT Mito 
hi vs NULL Mito lo), (C) Relative frequency of mixed colonies (n=4/sample, mean ± SD, Nested t-
test, p= 0.0045** NULL Mito hi vs lo, p= 0.0029** WT Mito hi vs NULL Mito hi, p= 0.0116* WT 
Mito lo vs NULL Mito hi), (D) Relative frequency of dispersed colonies (n=4/sample, mean ± SD, 
Nested t-test, all comparisons not significant), (E) Relative colony type distribution for each sample 
showing proportion of compact, mixed, and dispersed colonies (n=4/sample, mean ± SD). 
 
Amongst all of the fractions, Kat2a NULL Mito lo showed the least clonogenic potential which 
in conjunction with the observation from serial re-plating assay suggested that this cell 
population is difficult to sustain in in vitro cultures (Fig 5.3B). Further, upon looking at the 
clonal expansion patterns of individual samples, the ability of a single cell to expand clonally 
was comparable in Kat2a WT Mito lo and Kat2a NULL Mito total, again suggesting that Kat2a 
WT Mito lo may potentially phenocopy some aspects of the Kat2a NULL cell population (Fig 
5.3B). This was also compatible with the self-renewal assay analysis discussed above. These 
analyses altogether highlighted that loss of Kat2a leads to reduction in active mitochondrial 
mass, which further impacts self-renewal potential and clonogenic expansion capacity of MLL-
AF9 transformed cells in vitro. 
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Figure 5.3: Single cell clonal expansion assay for in vitro MLL-AF9 transformed Kat2a WT and 
Kat2a NULL BM cells sorted on the basis of mitochondrial mass.  
Heatmap representation of individual wells in a 96-well plate for maintaining single cell culture 
obtained from in vitro MLL-AF9 transformed Kat2a WT and Kat2a NULL cells, (A) Mito total (left-
Kat2a WT, right-Kat2a NULL) (B) Mito hi and Mito lo (left-Kat2a WT, right-Kat2a NULL) cells 
sorted on the basis of high mitochondrial mass, low mitochondrial mass, and total population 
(n=2/sample). The clonal expansion analysis was done on the basis of cell counting on a daily basis for 
7 days. 
 
5.3 Inhibition of mitochondrial translation in MLL-AF9 transformed Kat2a WT cells 
phenocopies Kat2a NULL phenotype 
 
Having studied the impact of Kat2a loss on active mitochondrial mass and consequentially on 
self-renewal and clonogenic expansion capacity of MLL-AF9 transformed cells, I then studied 
the mechanistic association of mitochondrial translational activity on colony forming potential 
of these cells. Mitochondrial ribosomes differ from eukaryotic cytosolic ribosomes (O’Brien, 
2003) where they use unique protein translation machinery. The process of mitochondrial 
translation is important for functional regulation of oxidative phosphorylation (Fukuda et al., 
2007). In order to study the dependency of MLL-AF9 transformed Kat2a WT cells on 
mitochondrial translation suggestive of a consequent dependency on oxidative 
phosphorylation, MLL-AF9 transformed Kat2a WT cells were treated with Tigecycline, an 
inhibitor of mitochondrial translation. Tigecycline is a third generation tetracycline antibiotic 
that interferes with translation by blocking the interaction of aminoacyl-tRNA with the A site 
of the ribosome in mitochondria (Škrtić et al., 2011). Thus, tigecycline is a selective inhibitor 
of eukaryotic mitochondrial protein translation and respiratory complex activity.  
 
To start the experiment, primary cell lines were generated from MLL-AF9 in vitro transformed 
Kat2a WT and Kat2a NULL cells and characterized for differences in cell cycle and apoptosis 
profile (Methods). After four passages, the MLL-AF9 transformed Kat2a WT cells thus 
obtained, were treated with different concentrations of Tigecycline (2.5µM and 5µM), and a 
colony forming assay was performed. Colonies were scored 7 days after plating, and no 
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significant difference was observed in the number of colonies in Tigecycline treated MLL-AF9 
transformed Kat2a WT cells compared to untreated cells, suggesting that these cells might not 
be sensitive towards tigecycline (Fig 5.4A). However, there was a remarkable difference in the 
compact colonies which do not show any halo of migrating cells and represent the presence of 
immature myeloid cells. The reduction was more prominent in MLL-AF9 transformed Kat2a 
WT cells treated with 5µM of tigecycline relative to the cells treated with 2.5µM tigecycline 
(Fig 5.4B). These observations suggested that MLL-AF9 transformed cells may not be sensitive 
to tigecycline in terms of impacting the overall colony numbers, however, tigecycline treatment 
impacts the maintenance of self-renewal potential of these cells, highlighted by the reduced 
number of compact colonies. This reduction in compact colonies was accompanied by a gain 
in the proportion of non-compact colonies indicating that MLL-AF9 transformed Kat2a WT 
cells upon inhibition of mitochondrial translation activity may mimic some of the 
characteristics of Kat2a NULL cells (Fig 5.4C). The non-compact colonies obtained upon 
tigecycline treatment had a characteristic comet shaped morphology due to which mixed and 
dispersed types of colonies couldn’t be distinguished (Fig 5.4D). 
 
To study any changes in the phenotype of the obtained colonies, flow cytometry analysis was 
conducted on both control and tigecycline treated MLL-AF9 transformed Kat2a WT cells. The 
flow cytometry analysis revealed no significant differences in the c-Kit expression levels 
(marker of early progenitors) in tigecycline treated cells compared to control (Fig 5.4E). This 
was compatible with the global observation where no differences in number of colonies were 
observed upon treatment with tigecycline.    
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Figure 5.4: Inhibition of mitochondrial translational activity in in vitro MLL-AF9 transformed 
Kat2a WT BM cells.  
(A) Colony forming assay for MLL-AF9 transformed Kat2a WT BM cells treated with 2.5µM and 5µM 
Tigecycline. Untreated cells served as control (n=3/sample, mean ± SD, Student’s t-test, all 
comparisons non-significant), (B) Proportion of compact colonies (n=3/sample, mean ± SD, Student’s 
t-test, p= 0.0091** control vs Tigecycline 2.5µM, p= 0.045* control vs Tigecycline 5µM), (C) 
Proportion of non-compact colonies (n=3/sample, mean ± SD, Student’s t-test, p= 0.0091** control vs 
Tigecycline 2.5µM, p= 0.045* control vs Tigecycline 5µM), (D) Representative microscopic images of 
colonies at 10X resolution obtained in control, Tigecycline 2.5µM, and 5µM. Tigecycline treated cells 
showed characteristic non-compact colonies, (E) Flow cytometry analysis for c-Kit expression in  
control, Tigecycline 2.5µM, and Tigecycline 5µM treated cells (n=3/sample, mean ± SD, Student’s t-
test, all comparisons non-significant). 
 
5.4 Inhibition of mitochondrial translation during RUNX1-RUNX1T1(9a) 
transformation selects for primitive cells 
 
After studying the impact of inhibition of mitochondrial translation on reducing the self-
renewal potential of MLL-AF9 transformed Kat2a WT cells, I extended this analysis to Kat2a 
WT cells undergoing transformation with RUNX1-RUNX1T1(9a) to understand the role of 
mitochondrial translation in a leukaemia initiation set-up. For this, I started with Kat2a WT 
cells transduced with RUNX1-RUNX1T1(9a) which were maintained in a semi-solid 
methylcellulose medium supplemented with either 2.5µM Tigecycline or control medium in a 
colony forming assay. The colonies obtained at each plating were scored and analysed using 
flow cytometry. A reduced number of colonies were obtained at each plating upon Tigecycline 
treatment, suggesting that the cells undergoing transformation with RUNX1-RUNX1T1(9a) are 
sensitive to the mitochondrial translation inhibitor, Tigecycline.  
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Figure 5.5: Inhibition of mitochondrial translational activity during RUNX1-RUNX1T1(9a) 
transformation of Kat2a WT BM cells in vitro.  
(A) Proportion of colonies obtained at each plating during RUNX1-RUNX1T1(9a) transformation of 
Kat2a WT BM cells treated with control and Tigecycline 2.5µM (n=2/plating, mean ± SD), (B) Flow 
cytometry analysis for c-Kit expression in control and Tigecycline 2.5µM treated cells at plating 4 and 
5. 
 
Interestingly, post plating 3, which is when the percentage of RUNX1-RUNX1T1(9a) 
transformed cells is >99%, the number of colonies upon tigecycline treatment remained 
constant, perhaps indicative of perpetuation of a particular cell population. To characterize this 
cell population, I performed flow cytometry analysis, where I observed an increase in c-Kit 
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expression at plating 4 and plating 5, in contrast to the observation in MLL-AF9 cells, where 
no changes in c-Kit expression was observed. This increase in c-Kit expression in Kat2a WT 
cells undergoing transformation with RUNX1-RUNX1T1(9a) suggested an accumulation of 
immature myeloid progenitor cells, which was contrary to the observations in MLL-AF9 cells 
where an enhanced differentiation was observed upon tigecycline treatment, characterized by 
an increase in proportion of non-compact colonies.  
 
Overall, both Mito hi/lo and tigecycline based approaches indicated that there are aspects of 
low mitochondrial activity in Kat2a WT cells which may capture some of the characteristics 
of Kat2a NULL cells. This was in agreement with observed transcriptional changes in MLL-
AF9 leukaemia based on scRNA-seq (Domingues et al., 2020). 
 
Having studied the role of mitochondrial biogenesis both in terms of active mitochondrial mass 
and mitochondrial translation in Kat2a WT cells transformed with MLL-AF9 or undergoing 
transformation with RUNX1-RUNX1T1(9a), I then studied how attenuation in ribosomal 
biogenesis and cytoplasmic translation machinery associated genes may impact pre-leukaemia 
transformation. 
 
5.5 Loss of Kat2a inhibits protein synthesis during Idh1R132H pre-leukaemia 
transformation 
 
The insights obtained from scRNA-seq analysis performed on RUNX1-RUNX1T1(9a) 
transformed pre-leukaemia cells as described in the previous chapter, indicated that loss of 
Kat2a impacts ribosomal biogenesis machinery and cytoplasmic translation processes during 
the process of pre-leukaemia transformation. To study the mechanistic contribution of these 
processes it was important to first confirm underlying differences in protein synthesis between 
RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells and Kat2a WT cells.   
 
For this, I started with RUNX1-RUNX1T1(9a) in vitro transduced Kat2a WT and Kat2a NULL 
cells where analysis for quantification of protein synthesis was performed at each plating of 
the colony forming assay which maintained RUNX1-RUNX1T1(9a) in vitro transduced Kat2a 
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WT and Kat2a NULL cells in a semi-solid methylcellulose based medium enriched with 
cytokines. The transformed Kat2a WT and Kat2a NULL cells obtained at each plating were 
then utilized for OP-Puro incorporation assay to assess differences in protein synthesis between 
the genotypes. OP-Puro is an alkyne analogue of puromycin which is efficiently incorporated 
into newly translated proteins. The transformed cells obtained at each plating were briefly 
incubated with OP-Puro and then with AF-azide in order to detect differences based on 
fluorescence intensity using flow cytometry. Cells were simultaneously stained for lineage 
markers, Cd11b and Gr1, and the surface marker, c-Kit, (Methods) to study differences in 
protein synthesis in specific cell populations.  
 
Post analysis, I observed a decrease in the OP-Puro high (Hi) population accompanied by an 
increase in the OP-Puro low (Lo) population of cells within Lin-Kit+ cells, in two of the 
biological replicates, whereas the other replicates did not indicate a reduction in protein 
synthesis in RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells (Fig 5.6). The contrasting 
results obtained with individual biological replicate made it difficult to interpret whether the 
indication from scRNA-seq data that RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells 
have reduced protein synthesis holds true in an in vitro set-up. It is possible that the variability 
observed in OP-Puro incorporation may be due to technical bias or differences in the extent of 
transformation on the primary cells utilised for the experiment. However, this variability could 
be attributed to the cellular diversity facilitated by the loss of Kat2a at early stages of RUNX1-
RUNX1T1(9a) pre-leukaemia transformation. As discussed in Chapter-6 in more detail, loss of 
Kat2a specifically at the 2 months time point post transplantation showed cellular 
differentiation towards monocytic and B-cell lymphocyte lineage. This cellular variability 
could lead to differential OP-Puro incorporation and lead to ambiguous results. Although 
RUNX1-RUNX1T1(9a) transformed cells didn’t show a significant change in overall protein 
synthesis upon loss of Kat2a, there was an indication in two of the biological replicates towards 
reduced protein synthesis in Kat2a NULL cells. To investigate this further, I looked at OP-
Puro incorporation in Idh1R132H model.  
 
For this, Idh1R132H cells with either Kat2a HET or Kat2a NULL genotype processed 20 
weeks post pIpC treatment were thawed and maintained in a serial re-plating assay (Methods). 
Similar to the RUNX1-RUNX1T1(9a) methodology, the transformed Idh1R132H Kat2a HET 
Mechanistic investigation of Kat2a associated transcriptional programmes in RUNX1-





and Idh1R132H Kat2a NULL cells obtained at each plating were utilized for OP-Puro 
incorporation assay to assess differences in protein synthesis between the genotypes. The cells 
obtained were briefly incubated with OP-Puro and AF-azide as mentioned previously and 
analysed for OP-Puro incorporation. A significant reduction in OP-Puro high (Hi) population 
was observed within the Lin-c-Kit+ compartment of cells in Kat2a NULL cells transformed 
with Idh1R132H (Fig 5.7A and 5.7B). This was also accompanied by a gain in OP-Puro low 
(Lo) population (Fig 5.7C), suggesting that loss of Kat2a reduces translation rate in Idh1R132H 
pre-leukaemia cells. In contrast to RUNX1-RUNX1T1(9a) model, a combined analysis of all of 
the biological replicates in Idh1R132H model, reached statistical significance (Fig 5.7B and 
5.7C), suggesting that perturbation of ribosomal biosynthetic programmes may play a 
mechanistic role during pre-leukaemia transformation. These findings were compatible with 
reduced protein synthesis observed upon Kat2a loss in MLL-AF9 leukaemia (Domingues et al., 
2020). 
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Figure 5.6: OP-Puro analysis for RUNX1-RUNX1T1(9a) transformed Kat2a WT and Kat2a NULL 
BM cells.  
Flow cytometry histogram plots for Kat2a WT (left) and Kat2a NULL (right) BM cells highlighting 
OP-Puro high (Hi) and OP-Puro low (Lo) cell populations, (A) Biological replicate 1, (B) Biological 
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Figure 5.7: OP-Puro analysis for Idh1R132H transformed Kat2a WT and Kat2a NULL BM cells. 
(A) Representative flow cytometry histogram plots for Kat2a WT (left) and Kat2a NULL (right) BM 
cells highlighting OP-Puro high (Hi) and OP-Puro low (Lo) cell populations, (B) Plot representing 
relative OP-Puro high population in Idh1R132H transformed Kat2a WT and Kat2a NULL BM cells 
(n=4/sample, Nested t-test, p= 0.0267*), (C) Plot representing relative OP-Puro low population in 
RUNX1-RUNX1T1(9a) transformed Kat2a WT and Kat2a NULL BM cells (n=4/sample, Nested t-test, 
p= 0.0353*). 
 
The reduced incorporation of OP-Puro in different models of AML, including RUNX1-
RUNX1T1(9a), Idh1R132H and MLL-AF9 models of leukaemia strengthen previous findings 
from transcriptomics data that loss of Kat2a is associated with reduced protein synthesis and 
the transcriptional programmes associated with ribosomal biogenesis and protein synthesis 
may play a mechanistic role in Kat2a mediated pre-leukaemia transformation.  
 
5.6 Inhibition of protein synthesis in RUNX1-RUNX1T1(9a) and Idh1R132H model aids 
in pre-leukaemia transformation 
 
Having confirmed that loss of Kat2a is associated with reduced protein synthesis, I wanted to 
understand the mechanistic contribution of attenuation of ribosomal biosynthetic programmes 
during pre-leukaemia transformation. To study this, I treated RUNX1-RUNX1T1(9a) in vitro 
transduced Kat2a WT cells with S6K1 inhibitor (control-DMSO) during colony forming assay 
(Methods). The colonies obtained were re-plated in the presence of S6K1 inhibitor or control 
DMSO until three platings. S6K1 inhibitor acts on S6K1 isoform of p70 ribosomal S6 kinase 
and thus inhibits protein synthesis. To mediate its effects on metabolic pathways, S6K1 
phosphorylates a number of downstream substrates including the small ribosomal subunit 
protein S6 (rpS6) (Salmond et al., 2015).  
 
To confirm the activity of S6K1 inhibitor, OP-Puro assay was conducted to assess differences 
in protein synthesis upon S6K1 inhibition. The Kat2a WT cells undergoing transformation 
with RUNX1-RUNX1T1(9a) were treated with 10mM of S6K1 inhibitor with DMSO serving 
as a control. OP-Puro incorporation analysis was done where the cells treated with S6K1 
inhibitor showed a reduction in OP-Puro high (Hi) population with a significant gain in OP-
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Puro low (Lo) population, thus validating the reduction in rate of translation upon S6K1 
inhibition. (Fig 5.7A). This trend was consistent across all biological replicates (Fig 5.7B), 
confirming the functional output of S6K1 inhibitor on Kat2a WT cells.   
 
After confirming the functionality of S6K1 inhibitor, the colonies representative of self-
renewal capacity were scored after each plating. Kat2a WT cells transformed with RUNX1-
RUNX1T1(9a) in vitro were found to have enhanced colony numbers representing an increased 
self-renewal capacity upon S6K1 inhibition compared to control at plate 2 (Fig 5.8A). 
Contrastingly, there was no difference in the number of colonies at plate 3, indicating that 
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Figure 5.8: OP-Puro analysis for RUNX1-RUNX1T1(9a) transformed Kat2a WT cells treated with 
S6K1 inhibitor.  
(A) Representative flow cytometry plot for OP-Puro analysis of RUNX1-RUNX1T1(9a) transformed 
Kat2a WT BM cells treated with control-DMSO (left) and treated with S6K1 inhibitor (right). OP-Puro 
high (Hi) (pink) and OP-Puro low (lo) (green) populations are highlighted, (B) Relative OP-Puro hi 
population (left) and OP-Puro lo population (right) upon S6K1 inhibitor treatment (n=3/sample for each 
comparison, Nested t-test, p= 0.0242* for OP-Puro hi, p= 0.0054** for OP-Puro lo). Horizontal bars 
represent mean value and each dot represents an individual biological replicate. 
 
To test whether this observation is model specific, similar analysis was done using Idh1R132H 
Kat2a WT cells processed 4 weeks post pIpC. There was a significant association of enhanced 
colony forming efficiency at plate 2 upon S6K1 inhibition (Fig 5.8C), which disappeared at 
plate 3 (Fig 5.8D), overall strengthening the findings in RUNX1-RUNX1T1(9a) that inhibition 
of protein synthesis aids in pre-leukaemia transformation which further contributes to 
accelerated leukaemic progression. 
 
Having observed the mechanistic contribution of perturbation of protein synthesis in pre-
leukaemia models, I further investigated its role in the MLL-AF9 leukaemia model. Kat2a WT 
cells transformed with MLL-AF9 in vitro were treated with S6K1 inhibitor and I observed that 
there was a significant reduction in colony forming efficiency overall, indicating a reduction 
in self-renewing capacity of these cells compatible with the phenotype observed in MLL-AF9 
transformed Kat2a NULL cells (Domingues et al., 2020) (Fig 5.8E). The S6K1 inhibition also 
led to a reduction in compact colonies representative of immature myeloid cells, accompanied 
by an increase in proportion of mixed and dispersed colonies, representative of differentiated 
macrophages, again compatible with the MLL-AF9 transformed Kat2a NULL phenotype (Fig 
5.8F). These findings overall suggested a mechanistic role for ribosomal biogenesis and protein 
synthesis machinery associated genes in pre-leukaemic transformation. However, the 
perturbation is context dependent, where reduced expression in pre-leukaemia models 
accelerates pre-leukaemia transformation, whereas in a maintenance model, it leads to 
enhanced cellular differentiation.    
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Figure 5.9: Colony forming assay upon S6K1 inhibition.  
Number of colonies obtained during serial re-plating of RUNX1-RUNX1T1(9a) transformed Kat2a WT 
BM cells treated with S6K1 inhibitor where DMSO served as control at (A) Plate 2 (n=4/sample, mean 
± SD, Nested t-test, p= 0.0117*), (B) Plate 3 (n=4/sample, mean ± SD, Nested t-test, p= 0.1753 n.s.), 
Number of colonies obtained during serial re-plating of Idh1R132H transformed Kat2a WT BM cells 
treated with S6K1 inhibitor where DMSO served as control at (C) Plate 2 (n=4/sample, mean ± SD, 
Nested t-test, p= 0.0056**),  (D) Plate 3 (n=4/sample, mean ± SD, Nested t-test, p= 0.3803 n.s.), (E) 
Number of colonies obtained when MLL-AF9 transformed Kat2a WT BM cells were treated with S6K1 
inhibitor. DMSO treatment served as control (n=3/sample, mean ± SD, Student’s t-test, p= 0.0251*), 
(F) Proportion of colonies obtained when MLL-AF9 transformed Kat2a WT BM cells were treated with 
S6K1 inhibitor. DMSO treatment served as control (n=3/sample, mean ± SD, Student’s t-test, p= 
0.0016** for compact colonies, p= 0.0034** for mixed colonies and p= 0.0048** for dispersed 
colonies). 
 
In this chapter, I discussed the mechanistic association of transcriptional programmes, namely 
mitochondrial bioenergetics, mitochondrial translation, and ribosomal biogenesis/cytoplasmic 
translation which were found to be impacted upon loss of Kat2a during RUNX-RUNX1T1(9a) 
pre-leukaemia transformation. Although mitochondrial bioenergetics mechanism may 
highlight the initial metabolic reconfiguration as a consequence of Kat2a loss, at the early 
stages of pre-leukaemia transformation, I hypothesized that ribosomal biogenesis and 
cytoplasmic translational machinery may reflect the mechanistic association with RUNX1-
RUNX1T1(9a) pre-leukaemia transformation.   
 
I started by looking at the differences in mitochondrial activity in terms of active mitochondrial 
mass and mitochondrial potential in RUNX-RUNX1T1(9a) transformed pre-leukaemia Kat2a 
WT and Kat2a NULL cells.  Since MLL-AF9 transformed cells could aid in leukaemia 
maintenance by immortalization of a leukaemogenic cell population which is dependent on 
constitutive MLL-AF9 expression, I utilized this as a contrasting model to RUNX1-
RUNX1T1(9a) pre-leukaemia model. The reduction in active mitochondrial mass upon loss of 
Kat2a was synergistic in both models, confirming the scRNA-seq insights that Kat2a loss is 
associated with reduction in mitochondrial activity. Surprisingly, no differences were observed 
in terms of mitochondrial potential indicating that the reduction in active mitochondrial mass 
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was subtle and unable to induce any consequent difference in mitochondrial potential. In the 
future, this analysis may be extended by looking at the levels of oxidative phosphorylation in 
terms of the presence of reactive oxygen species. Although the findings were compatible in 
both RUNX-RUNX1T1(9a) pre-leukaemia as well as MLL-AF9 leukaemia model,  the outcome 
in both models upon reduction in mitochondrial activity is different, suggesting that loss of 
Kat2a is merely facilitating rather than determining the fate acquisition which consequently 
leads to its model-specific phenotype. 
 
In order to study the impact of mitochondrial activity on the MLL-AF9 leukaemia 
transformation as well as on self-renewal, the Kat2a WT and Kat2a NULL cells transformed 
with MLL-AF9 were segregated on the basis of active mitochondrial mass and the different cell 
populations obtained post-sorting were maintained in a colony forming assay for a week. The 
colonies obtained suggested a reduction in colony forming potential in Mito lo fraction of cells 
irrespective of the genotype, indicating that reduced mitochondrial mass may impact the self-
renewal potential of MLL-AF9 cells, which could be further extrapolated in other models of 
leukaemia. The reduction in colonies obtained in Kat2a WT Mito lo accompanied by reduced 
compact colonies suggested that Kat2a WT Mito lo may phenocopy Kat2a NULL cells as a 
whole. These experiments were further extended in the bone marrow cells obtained from 
secondary leukaemia, however, an abrupt increase in colony forming efficiency was observed 
in Kat2a NULL Mito hi, perhaps due to variability in primary samples, due to which the 
experiment could not be interpreted. 
 
The experiments on self-renewal were accompanied by the single cell clonal assay where 
individual cells were index sorted from Mito hi and Mito lo cell populations obtained from 
individual genotypes and were assessed for their clonal expansion capacity. The analysis was 
in line with the results obtained from colony forming assay, where cells obtained from Mito lo 
subfraction had reduced clonal expansion capacity compared to their respective Mito hi 
fractions. Once again, the pattern of clonogenicity observed in Kat2a WT Mito lo phenocopied 
that of Kat2a NULL total cells. It would have been interesting to study the phenotype of 
individual clones obtained from these cell fractions using flow cytometry in order to correlate 
their phenotype with MLL-AF9 leukaemic animals. However, due to limited in vitro expansion 
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capacity of RUNX1-RUNX1T1(9a) cells, these assays could not be replicated in a leukaemia 
initiation set up.  
 
Another aspect of mitochondrial bioenergetics was to study the impact of mitochondrial 
translation on leukaemia transformation and self-renewal capacity. To understand the role of 
mitochondrial translation during MLL-AF9 leukaemia, the Kat2a WT cells transformed with 
MLL-AF9 were treated with Tigecycline, an inhibitor of mitochondrial translation. The 
inhibition of mitochondrial translation using tigecycline suggested no difference in global 
colony forming capacity, in contrast to the findings made from Mito/Mito lo assay. These 
contrasting observations could be due to the translation aspect of mitochondrial activity. With 
literature suggesting that AML cells with lower mitochondrial mass are generally resistant to 
tigecycline (Škrtić et al., 2011), it might be worth performing the tigecycline treatment on the 
cell populations segregated on the basis of active mitochondrial mass. This may also be valid 
in case of RUNX1-RUNX1T1(9a) where a selection of tigecycline resistant colonies was 
observed upon treatment with tigecycline. These cells however, represented an early progenitor 
population, unlike MLL-AF9 transformed cells, suggesting perpetuation of early progenitors in 
a reduced mitochondrial translation environment, in line with findings from scRNA-seq data. 
However, this analysis could be repeated with a greater number of biological replicates in order 
to draw stronger conclusions. It would have been interesting to study the role of mitochondrial 
translation in Idh1R132H pre-leukaemia transformation process given the association of Idh1 
mutation with accumulation of 2-hydroxyglutarate (2-HG) which consequently leads to 
metabolic reprogramming in AML. Inhibition of mitochondrial translation in this model would 
also impact the process of oxidative phosphorylation during tricarboxylic acid cycle (TCA) 
which would affect the metabolic landscape and may further impact the process of pre-
leukaemia transformation. 
 
After studying the role of mitochondrial activity and mitochondrial translation in pre-
leukaemia transformation (RUNX1-RUNX1T1(9a)) and leukaemia progression (MLL-AF9), I 
studied the impact of attenuation in translational machinery on these processes. The OP-Puro 
incorporation assay performed to assess any differences in protein synthesis rate upon Kat2a 
loss suggested a reduction in case of Idh1R132H model, contrary to the observations in 
RUNX1-RUNX1T1(9a) where no significant differences were observed globally, except for a 
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slight trend towards reduction in OP-Puro high population in two of the replicates. I attributed 
this variability in OP-Puro incorporation to the enhanced cellular diversity generated upon 
Kat2a loss (Chapter-6). It is worth considering that this variability in OP-Puro incorporation 
wasn’t observed in case of Idh1R132H model, as the cells utilized for OP-Puro incorporation 
assay were not at very early stage of pre-leukaemia transformation, at which time point the 
cellular diversity was observed in case of RUNX1-RUNX1T1(9a) model. Future analysis may 
involve studying the incorporation of OP-Puro in RUNX1-RUNX1T1(9a) Kat2a WT and Kat2a 
NULL animals, which would enable an in-depth analysis of alterations in protein synthesis 
levels during pre-leukaemia progression. 
 
Another approach to study the role of ribosomal biogenesis during RUNX1-RUNX1T1(9a) pre-
leukaemia transformation was to make use of shRNAs against Rpl38 gene, due to its potential 
contribution to Hoxa programmes (Kondrashov et al., 2011b), which could reflect a visible 
difference between MLL-AF9 leukaemia and RUNX1-RUNX1T1(9a) pre-leukaemia set-up. For 
this, the Kat2a WT cells transduced with RUNX1-RUNX1T1(9a) were infected with two 
different shRNAs targeting Rpl38 gene. Post infection, 18-20% of the cells were found to be 
positive for Rpl38 shRNAs as well as control (mCherry reporter). Unfortunately, these 
transduced cells could not be maintained successfully in a colony forming assay set-up, perhaps 
due to the incapability of Rpl38sh cells in promoting expansion of early progenitors 
(Kondrashov et al., 2011b). 
 
After seeing the differences in protein synthesis rate in Kat2a NULL cells transformed with 
Idh1R132H, compatible with previous lab findings in MLL-AF9 model (Domingues et al., 
2020), I sought to associate these findings mechanistically by performing inhibition of protein 
synthesis using S6K1 inhibitor which acts on S6K1 isoform of p70 ribosomal S6 kinase and 
thus inhibits protein synthesis. Upon performing S6K1 inhibition, an enhanced colony forming 
potential was observed at plating 2, in line with the insights from RUNX1-RUNX1T1(9a) 
scRNA-seq analysis, suggesting that impairment of ribosomal biogenesis/cytoplasmic 
translation may contribute towards the acceleration in pre-leukaemia transformation. This 
increase in colony forming potential was lost markedly upon plating 3 indicating that inhibition 
of cytoplasmic translation is beneficial for RUNX1-RUNX1T1(9a) pre-leukaemia progression 
during early stages of transformation. Similar findings were observed in case of Idh1R132H, 
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where an enhanced colony forming potential was observed at plating 2 with no difference at 
plating 3. However, in case of MLL-AF9 model, reduced colony forming potential was 
observed accompanied by a decrease in compact colonies and an increase in mixed and 
dispersed colonies, in line with the scRNA-seq analysis performed on MLL-AF9 leukaemia 
Kat2a WT and Kat2a NULL cells (Domingues et al., 2020). These findings altogether suggest 
that inhibition of cytoplasmic translation in Kat2a WT cells phenocopies some aspects of 
Kat2a NULL cells.  
 
Although the findings from S6K1 inhibition experiment were compatible with scRNA-seq 
insights obtained from individual models at leukaemia and pre-leukaemia stages, however, it 
represents a dichotomy since inhibition of cytoplasmic translation promotes pre-leukaemia 
transformation in RUNX1-RUNX1T1(9a) model, whereas it leads to inhibition of leukaemia 
stem-like cells in case of MLL-AF9 model. These findings reflect that reduction in protein 
synthesis is specifically associated with loss of Kat2a, which facilitates rather than determines 
the cellular state during the process of leukaemia progression. The next chapter in this thesis 
reflects on how loss of Kat2a promotes cellular diversity by increasing cell-to-cell 
transcriptional variability in RUNX1-RUNX1T1(9a) pre-leukaemia cells. 
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6 Analysis of the role of transcriptional variability upon Kat2a 
loss in RUNX1-RUNX1T1(9a) pre-leukaemia  
 
The previous chapters discussed the functional impact of Kat2a loss in RUNX1-RUNX1T1(9a) 
as well as Idh1R132H pre-leukaemia models, where loss of Kat2a accelerates leukaemia 
progression along with perpetuation of pre-leukaemia clones characterized by enhanced self-
renewal capacity. These pre-leukaemia cells benefit from a reduced translational activity as 
well as reduced mitochondrial biosynthetic programmes during different stages of pre-
leukaemia progression and aid in leukaemia development. The process of pre-leukaemia 
development, similar to other developmental processes, require continuous changes in the 
trajectory of a transformed cell. It would be ideal to monitor these changes in a given cell over 
the period of pre-leukaemia progression. Unfortunately, as the cells subjected to single cell 
RNA sequencing (scRNA-seq) are lysed (destroyed) when the RNA is extracted, we are limited 
to studying cell fate trajectory by sampling at multiple time points and obtaining snapshots of 
the gene expression profile of individual cells. Since cells not having Kat2a should proceed 
faster along the pre-leukaemia development trajectory than other cells, each snapshot may 
contain cells at varying points along the developmental progression. This information can 
therefore be analysed using different statistical methods to order cells along one or more 
trajectories which represent the underlying developmental trajectories. Such an ordering is 
often termed as “pseudotime”. As mentioned in Chapter-1, an underlying cause of cell fate 
transitions could be the presence of inherent cell-to-cell transcriptional variability. Given the 
central role of Kat2a in limiting cell-to-cell transcriptional variability (Moris et al., 2018b) 
(Domingues et al., 2020), I further interrogated a potential link between loss of Kat2a, its 
consequent increase in transcription variability, and pre-leukaemia progression, by utilising the 
single-cell transcriptomics data discussed in Chapter-4.  
 
6.1 Single- cell pseudotime trajectory analysis highlights that Kat2a NULL cells follow 
a dispersed trajectory  
 
To study the differences between transcriptional dynamics of Kat2a WT and Kat2a NULL 
cells, I used Monocle 3 (v3.0) (Trapnell et al., 2014) to build trajectories based on time series 






progression data. Single-cell trajectory building was important to capture asynchrony between 
the population of cells of a genotype. Since Monocle 3 works by grouping cells with similar 
gene expression profiles at early stages, I pre-processed the data separately keeping the filtering 
parameters similar to the ones used in Seurat v2.4 analysis (Chapter-4). To start, I created a 
cell data set (CDS) object from raw data containing the expression matrix, cell metadata, and 
gene annotations. After this, I normalized the data by log transformation and size factors to 
address depth differences. Post normalization, I did PCA in order to study the variance 
contributed by each Principal Component (PC) (Methods). I visualized cells in a lower 
dimensional space using Uniform Manifold Approximation and Projection (UMAP) which is 
implemented in Monocle 3 (Methods). Single-cell trajectory building was done by ordering 
each cell captured in scRNA-seq according to its progress along a learned pseudotime 
trajectory. Pseudotime represents the distance between a cell from the start of the trajectory, 
measured along the shortest path. The total length of the trajectory is defined in terms of the 
total amount of transcriptional change that a cell undergoes as it moves from the starting state 
to the end state.  
 
To start, I built a single-cell trajectory for Kat2a WT cells processed at both 2 months and 4 
months post transplantation. For this, I first visualized the cells using UMAP dimensionality 
reduction method. Then, I performed pseudotime temporal ordering (Fig 6.1A) with the root 
node of the trajectory set to the space occupied by Kat2a WT cells processed at 2 months (Fig 
6.1B). The trajectory started from these cells (1-10, white) (Fig 6.1A) and was followed by a 
bifurcation. Going forward, one of the branches is referred to as cellular state 1 (1, grey). The 
other branch which undergoes transcriptional modifications (1-4, black) and subsequently 
leads to a state which is referred to as cellular state 2 (2, grey) (Fig 6.1A). Overall, the Kat2a 
WT cells followed a linear trajectory starting from the root (purple) and ending up at the final 
(yellow) cellular state (Fig 6.1A). The branch defined by cellular state 1 was enriched in Kat2a 
WT cells at 2 months, perhaps indicating an early cell fate during RUNX1-RUNX1T1(9a) 
transformation, whereas cellular state 2 was composed of cells from both the 2 months and 4 
months timepoints (Fig 6.1B).  
 
 











































































































































Figure 6.1: Pseudotime trajectory analysis for single cells using Monocle 3.0.  
(A) Pseudotime trajectory represented on a UMAP plot for Kat2a WT cells, including those collected 
at both 2 months and 4 months post transplantation. The encircled cells (white) represent the start of 
the trajectory highlighted in purple colour, whereas yellow-coloured cells represent the end of the 
trajectory. Cells encircled in black represent a different cellular state, whereas cells encircled in grey 
represent branching, (B) UMAP representation of Kat2a WT cells at both time points of 2 months (blue) 
and 4 months (pink) post transplantation, (C) Pseudotime trajectory representation on a UMAP plot for 
all Kat2a NULL cells including those collected at both 2 months and 4 months timepoints, (D) UMAP 
representation of Kat2a NULL cells at individual time points of 2 months (blue) and 4 months (pink) 
post transplantation, (E) Global pseudotime trajectory represented on a UMAP plot for all Kat2a WT 
and Kat2a NULL cells including both 2 months and 4 months timepoints, (F) Global UMAP 
representation of all Kat2a WT and Kat2a NULL cells at both time points post transplantation,  Kat2a 
WT 2 months (blue), Kat2a WT 4 months (red), Kat2a NULL 2 months (purple) and Kat2a NULL 4 
months (green). 
Similarly, I built a trajectory for Kat2a NULL cells at both 2 months and 4 months post 
transplantation. Pseudotime temporal ordering was done (Fig 6.1C) post UMAP visualization, 


































































































Unlike Kat2a WT cells, Kat2a NULL cells had a branched trajectory with four different 
cellular states (1-4, grey). One of these branches was composed of Kat2a NULL cells at 2 
months exclusively, indicating a cellular state consequential to loss of Kat2a during early 
stages of RUNX1-RUNX1T1(9a) transformation, whereas the rest of the cellular states were 
composed of Kat2a NULL cells from both the 2 months and 4 months timepoints (Fig 6.1D).  
 
After studying differences in individual trajectories in both Kat2a WT and Kat2a NULL cells, 
a global trajectory was built in a similar manner, including all Kat2a WT and Kat2a NULL 
cells at both time points (Fig 6.1E). Pseudotime temporal ordering was performed with the root 
node set to the space occupied by both Kat2a WT and Kat2a NULL cells processed at 2 months 
(1-30, white) (Fig 6.1F). Again, a bifurcation was observed from the root cells (Fig 6.1E), 
where one of these branches was enriched for Kat2a NULL cells at 2 months and Kat2a WT 
cells at 4 months, and the other branch was composed of Kat2a NULL cells at 2 months 
exclusively (Fig 6.1F). This was compatible with the observations from the genotype specific 
trajectories. However, a discontinuity was observed within the trajectory, which may be the 
consequence of an abrupt leukaemia transformation event. This discontinuity in global 
trajectory was in-line with the abrupt transition of cellular state 2 in the Kat2a WT specific 
trajectory. Cell-to-cell correspondence analysis between the genotype-specific and global 
trajectories indicated that the population of cells characterized by cellular state 2 in the 
individual genotype trajectories corresponded to the subset of cells enriched in Kat2a NULL 
cells at 2 months and Kat2a WT cells at 4 months in the global trajectory. Overall, trajectory 
analysis indicated presence of a branched trajectory upon loss of Kat2a, suggestive of 
transcriptional reprogramming at various steps during pre-leukaemia progression contributing 
towards a changing cellular landscape.   
 
6.2 Single-cell trajectory coincides with haematopoietic hierarchy 
 
Having identified differences in progression of Kat2a WT and Kat2a NULL cells, I wanted to 
identify the different cellular states of trajectory. For this, I plotted expression of marker genes 
of cell types in the haematopoietic system on the UMAP plots. These included Ly6e (also 
known as Sca2) (haematopoietic stem cell marker), Fcgr3 (myeloid progenitor marker), Cd34 






(haematopoietic stem cell marker), Flt3 (short term Haematopoietic Stem Cells 
(HSCs)/multipotent progenitor marker- also known as Cd135), Cd48 (lymphocyte marker), 
Cd27 (lymphocyte marker), Cd33 (myeloid marker), Cd14 (monocyte/macrophage marker), 
along with few transcription factors such as Gata2 (haematopoietic stem cell marker), Cebpa 
(myeloid progenitor marker) and Myb (myeloid progenitor marker) (Fig 6.2A).  
 
Since all the cells subjected to scRNA-seq were selected for c-Kit positivity (early progenitor 
marker- also known as Cd117), a combination of c-Kit+Ly6ehiCd34+Flt3+ cells would represent 
a population of Lymphoid-primed multipotential like progenitors (LMPP). Indeed, I was able 
to distinguish an LMPP-like population in our UMAP plots (Fig 6.2B). These cells also had 
higher expression of Gata2 and were Myb positive, compatible with the LMPP-like phenotype 
(Fig 6.2A). Further, cells with Ly6eloCd34+Fcgr3+ expression highlighted a Granulocyte-
Macrophage Progenitor (GMP) like population (Fig 6.2B). This population also had higher 
expression of Cebpa. 
 
After characterizing these cell populations, I looked at the sample-wise composition of each 
population. Strikingly, 44.37% of the LMPP-like population was composed of Kat2a WT cells 
at 2 months post transplantation, whereas the rest of the samples had a contribution of ~15-
20% (Kat2a WT cells 4 months- 15.89%, Kat2a NULL cells 2 months- 20.52%, Kat2a NULL 
cells 4 months- 19.20%). The higher percentage of LMPP-like population in the Kat2a WT 
cells at 2 months post transplantation was compatible with the experimental observation where 
loss of Kat2a accelerates RUNX1-RUNX1T1(9a) leukaemia progression.  
 
Similarly, I looked at the GMP compartment, where 80.68% of the population was comprised 
of cells studied at 4 months from both Kat2a WT and Kat2a NULL genotypes (Fig 6.2D). This 
suggested that the cells collected at later time points follow a gradual leukaemic transformation 
trajectory. On the other hand, Kat2a WT cells and Kat2a NULL cells at the 2 months- time 
point together constituted 19.32% of the GMPs, where only 3.44% of the GMP population 
came from Kat2a NULL cells. This suggested that the Kat2a WT and NULL cells followed an 
abrupt leukaemia transformation trajectory, in line with the observations from genotype-
specific and global single-cell trajectory analysis. 


















































































Figure 6.2: Representation of markers of haematopoietic hierarchy.  
(A) Global UMAP representation of cells with expression of haematopoietic markers indicated, 
enabling identification of LMPP- c-Kit+Ly6e+CD34+Flt3+, and GMP- c-Kit+Ly6e+CD34+Fcgr3+ cell 
populations. The colour represents average gene expression (log10 scale) where blue highlights cells 
with low expression and green represents high expression of the gene, (B) Global UMAP plot 
highlighting LMPP (blue) and GMP (green) population of cells, (C) Percentage composition of LMPP 
cell population by individual sample (Kat2a WT 2 months as WT-2M, Kat2a NULL 2 months as 
NULL-2M, Kat2a WT 4 months as WT-4M, Kat2a NULL 4 months as WT-4M), (D) Percentage 
composition of GMP cell population by individual sample. 
 
6.3 Loss of Kat2a promotes differentiation towards B-cell lineage during pre-leukaemia 
transformation  
 
After characterizing the LMPP-like and GMP populations, I analysed the other arm of 
bifurcation observed from LMPP-like population of cells. This arm also captured Kat2a NULL 
cells exclusively from the 2 months time-point (for simplicity, this population is referred to as 
population ‘a’ going forward) (Fig 6.3A). 77.6% of the population ‘a’ comprised of Kat2a 
NULL cells at the 2 months time-point, indicative of an early consequence of Kat2a loss during 
leukaemia progression (Fig 6.3B). To identify the gene expression programmes characterizing 
population ‘a’, I conducted DESeq2 analysis (Love, Huber and Anders, 2014) to identify 
differentially expressed genes between population ‘a’ and the remaining cells, irrespective of 
genotype. I identified significant genes (p-adj<0.05, Bonferroni correction) which were 
upregulated in population ‘a’ and conducted Panther gene ontology analysis (H. Mi et al., 
2018) on this gene set (see Chapter-2 for methodology). This analysis highlighted pathways 
such as cellular response to Interleukin-7, which are specific to lymphocytes (Fig 6.3C). An 
overlap analysis with the Immunological gene expression signatures in MSigDB (Subramanian 
et al., 2005; Liberzon et al., 2015) also indicated a B-lymphocytes signature upregulated in 
population ‘a’ (Fig 6.3D). To further confirm this, I plotted average expression of B-cell 
surface markers, including Cd79a, Cd19, Igll1, Ebf1, and Il7r on the global UMAP plot (Fig 
6.3D). Population ‘a’ specifically showed a higher average expression of these markers (Fig 
6.3E), suggesting that loss of Kat2a promotes B-cell differentiation during early stages of 
RUNX1-RUNX1T1(9a) leukaemia.  
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Figure 6.3: B-cell differentiation marker analysis.  
(A) UMAP plot highlighting cluster a composed of Kat2a NULL cells at 2 months, (B) Sample-wise 
composition of cluster a, (C) Panther gene ontology analysis for genes upregulated in cluster a, where 
the pathway corresponding to B-cell differentiation is highlighted in purple, (D) Gene ontology analysis 
based on MSigDB overlap, highlighting a subset of genes involved in B-cell differentiation in purple, 
(E) UMAP plot with expression values of markers for B-cells. The log10 scaled expression represents 
average gene expression, where blue highlights cells with low expression and green represents high 
expression for that particular gene, (F) Flow cytometry analysis for B220, a B-cell marker, during 
RUNX1-RUNX1T1(9a) transformation in vitro at plate 2 (n=3/ sample, mean ± SD, Student’s t-test, p= 
0.039*), (G) Flow cytometry analysis for B220 during RUNX1-RUNX1T1(9a) transformation in vitro 
at plate 3 (n=3/ sample, mean ± SD, Student’s t-test, p= 0.56). 
 
To validate this observation functionally, I started with RUNX1-RUNX1T1(9a) in vitro 
transduced Kat2a WT and Kat2a NULL cells. These cells were maintained in the form of 
colony forming assay which allowed selection of transformants with each plating (Methods). 
With each plating, I studied the expression of B220, a B-cell marker individually in both Kat2a 
WT and Kat2a NULL cells using flow cytometry. I observed a significant increase in B220 
expression in Kat2a NULL cells at plating 2 compared to Kat2a WT cells, confirming the 
scRNA-seq observation (Fig 6.3F). Interestingly, this increase in B220 expression was lost at 
plating 3 (Fig 6.3G), indicating that enhanced B-cell differentiation is consequential to early 
loss of Kat2a.  
 
6.4 Loss of Kat2a promotes monocytic differentiation during pre-leukaemia 
transformation  
 
After characterizing population ‘a’, I looked at a second group of cells, hereafter referred to as 
population ‘b’ (Fig 6.4A). This population had a higher percentage of Kat2a NULL cells 
(62.17%) compared to Kat2a WT cells (37.81%) (Fig 6.4B). To identify the gene expression 
programmes characterizing population ‘b’, I conducted DESeq2 analysis to identify 
differentially expressed genes between population ‘b’ and the remaining cells, irrespective of 
genotype. The gene ontology analysis for significantly upregulated genes (p-adj<0.05, 
Bonferroni correction) in population ‘b’ was done using Panther (Methods). This analysis 






indicated an enrichment of genes involved in monocyte/macrophage development (Fig 6.4C). 
Similar observations were obtained upon performing an overlap with MSigDB Immunological 
Signatures database (methodology described previously) (Fig 6.4D). Cell surface markers 
associated with monocyte biogenesis including Cd14, Cd74, Fcgr3, Ccr2, Mafb, and Mafg 
displayed higher average expression in population ‘b’ compared to the rest of the cells (Fig 
6.4E). Overall, the analysis highlighted differentiation of progenitor cells towards a monocytic 
lineage during the process of RUNX1-RUNX1T1(9a) leukaemia transformation.  
 
Since scRNA-seq captured a higher proportion of Kat2a NULL cells differentiating to 
monocytes compared to Kat2a WT cells, I wanted to validate this observation in an 
experimental set-up. For this, I started with RUNX1-RUNX1T1(9a) in vitro transduced Kat2a 
WT and Kat2a NULL cells which were maintained in a colony forming assay (methodology 
described previously). Using flow cytometry analysis, I analysed the expression of F4/80, a 
monocyte-specific cell surface marker, at each plating. I observed a significant increase in 
F4/80 expression in Kat2a NULL cells at plating 2 compared to Kat2a WT cells, supporting 
the observation from scRNA-seq (Fig 6.4F). Similar to the observation for B-cell 
differentiation, there was no change in F4/80 expression at plating 3 (Fig 6.4G). These 
observations altogether validated findings of increased monocyte differentiation along with B-
cell differentiation upon Kat2a loss during RUNX1-RUNX1T1(9a) leukaemia progression.  
 
This is in line with my previous observations in the MLL-AF9 leukaemia model, where loss of 
Kat2a promotes cellular differentiation. This was evident from a significant reduction in 
compact colony type along with an increase in mixed and dispersed colonies (Fig 6.4H). The 
differentiation observed upon Kat2a loss was towards a monocytic lineage based on in vitro 
analysis of primary MLL-AF9 leukaemia cells (Fig 6.4I) (Domingues et al., 2020). It was quite 
interesting to notice the monocytic differentiation associated with Kat2a loss in different 
models of AML, where in case of RUNX1-RUNX1T1(9a) loss of Kat2a accelerates the disease 
progression whereas in case of MLL-AF9, Kat2a loss leads to depletion of leukaemia stem like 
cells. The similarities observed in terms of monocytic differentiation indicates that loss of 
Kat2a enhances the probability of cell fate transitions, resulting in increased molecular 
heterogeneity and stochastic fate choices. This further suggests that Kat2a loss likely facilitates 
rather than determines fate acquisition, which consequently leads to its model-specific role.  
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Figure 6.4: Monocyte marker analysis.  
(A) UMAP plot highlighting cluster b composed of Kat2a NULL cells at 2 months and 4 months, (B) 
Sample-wise composition of cluster b, (C) Panther gene ontology analysis for genes upregulated in 
cluster b, where the pathway corresponding to monocytic differentiation is highlighted in blue, (D) 
Gene ontology analysis based on MSigDB overlap highlighting the set of genes corresponding to 
monocyte differentiation in blue, (E) UMAP plot of cells coloured by average expression of monocyte 
marker genes. The log10 scaled expression represents average gene expression where blue highlights 
cells with low expression and green represents high expression for that particular gene, (F) Flow 
cytometry analysis for F4/80, a monocyte marker, during RUNX1-RUNX1T1(9a) transformation in vitro 
at plate 2 (n=3/ sample, mean ± SD, Student’s t-test, p= 0.0229*), (G) Flow cytometry analysis for 
F4/80 during RUNX1-RUNX1T1(9a) transformation in vitro at plate 3 (n=3/ sample, mean ± SD, 
Student’s t-test, p= 0.8221), (H) Colony forming assay for in vitro MLL-AF9 transformed Kat2a WT 
and Kat2a NULL cells (left) (n=3/ sample, mean ± SD, Student’s t-test, p= 0.0225*); distribution of 
colonies highlighting proportion of compact (n=3/ sample, mean ± SD, Student’s t-test, p= 0.001***), 
mixed (n=3/ sample, mean ± SD, Student’s t-test, p= 0.0292*) and dispersed (n=3/ sample, mean ± SD, 
Student’s t-test, p= 0.0264*) colonies (right), (I) Mean fluorescence intensity of Mac1, a monocyte 
marker, upon flow cytometry analysis of in vitro MLL-AF9 transformed Kat2a WT and Kat2a NULL 
cells (n=3/ sample, mean ± SD, Student’s t-test, p= 0.0005*). 
 
6.5 Kat2a loss aids in accumulation of transformed pre-leukaemic cells 
 
After identifying the cell populations in the RUNX1-RUNX1T1(9a) leukaemia transformation 
trajectory, including LMPP-candidate, GMPs, B-cell and monocytes, I wanted to characterize 
the population of cells which were not part of the global trajectory (Fig 6.1E, highlighted in 

































































candidate to GMP, I hypothesized that the population of cells not forming a trajectory could be 
RUNX1-RUNX1T1(9a) transformed leukaemia progenitor cells. For this, I looked at direct 
target genes of RUNX1-RUNX1T1 based on ChIP-seq analysis in a previous study (Ptasinska 
et al., 2012), and plotted their average expression on the global UMAP plot (Fig 6.5A). 
Interestingly, RUNX1-RUNX1T1 targets had a higher average expression in this compartment 
compared to the remaining cells in the trajectory, suggestive of leukaemia-initiating events. To 
confirm this, I also looked at Kat2a targets based on unpublished ChIP-seq data in Pina lab. 
The ChIP-seq experiment was done on Kasumi-1 cells, which are representative of RUNX1-
RUNX1T1 leukaemia. Kat2a target genes were enriched in gene expression programmes 
related to cytoplasmic translation and ribosome biogenesis, compatible with the observation 
from scRNA-seq data (Chapter-4). These Kat2a target genes were highly expressed in LMPP-
like population of cells, with a gradual reduction in GMPs, and a further reduction in the 
‘Leukaemia Progenitors’ compartment (Fig 6.5B). Further, I looked at the composition of the 
leukaemia progenitor compartment of cells (Fig 6.5C) and found that it was predominantly 
populated with the Kat2a WT and Kat2a NULL cells at 4 months post-transplantation (Fig 
6.5D). The gradual accumulation of leukaemia progenitors with time coincided with the 
progressive RUNX1-RUNX1T1(9a) transformation (Fig 6.5D). The increased accumulation of 
leukaemia progenitors upon Kat2a loss at respective time points was in-line with the in vivo 
observation of accelerated leukaemia progression upon loss of Kat2a.  
 
To further characterize this population of cells, differential gene expression analysis was 
performed using DESeq2, comparing leukaemia progenitor cells against other cells (Fig 6.5E).  
There were 1877 genes (p-adj<0.05, Bonferroni correction) which were differentially 
expressed in leukaemia progenitors compared to the rest of the population. Out of 1877 genes, 
897 genes were upregulated, whereas 980 genes were downregulated (Fig 6.5E). These 
upregulated genes were mostly associated with general gene expression categories such as 
respiratory burst and haematopoietic hierarchy, including leukocyte maintenance and 
differentiation (Fig 6.5F and 6.5G). On the other hand, the downregulated genes captured gene 
signatures associated with Kat2a loss, namely, mitochondrial ATP transport, 
translation/ribosome biogenesis (Fig. 6H), and lymphocyte maintenance (Fig. 6I), which was 
compatible with the observation of Kat2a mediated accumulation of leukaemia progenitors.   
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Figure 6.5: Characterization of leukaemia compartment.  
(A) UMAP plot of cells coloured by average expression of RUNX1-RUNX1T1 target genes obtained 
from a previous study (Ptasinska et al., 2012), (B) Heatmap of gene expression values in different cell 
compartments for Kat2a direct targets identified in an  unpublished ChIP-seq dataset from MB-3 treated 
Kasumi-1 cells available in the lab. Downregulation of genes is highlighted in pink, (C) UMAP plot of 
cells coloured by identified compartments; LMPP (blue), GMP (golden), B-cell progenitors (red), 
Monocyte progenitors (pink), and the leukaemia compartment (green), (D) Composition of leukaemia 
progenitors cells by individual sample (Kat2a WT 2 months as WT-2M, Kat2a NULL 2 months as 
NULL-2M, Kat2a WT 4 months as WT-4M, Kat2a NULL 4 months as WT-4M), (E) Volcano plot 
representing differentially expressed genes in leukaemia compartment (red) with p-adj<0.05*, (F) Gene 
Ontology analysis using Panther 14.0 for upregulated genes in leukaemia compartment obtained from 
DESeq2 analysis (p<0.05*), (G) Gene Ontology analysis based on MSigDB overlap for upregulated 
genes in leukaemia compartment (FDR<0.05), (H) Gene Ontology analysis using Panther 14.0 for 
downregulated genes in leukaemia compartment highlighting translation/ribosome biogenesis (pink) 
and mitochondrial translation (green) (p<0.05*), (I) Gene Ontology analysis based on MSigDB overlap 

























Figure 6.6: Pseudotime trajectory plots highlighting different population of cells.  
Pseudotime trajectory representation on a UMAP plot for (A) Kat2a WT cells, (B) Kat2a NULL cells, 
including cells collected at both 2 months and 4 months post transplantation. Populations of cells 
identified based on cell surface markers, LMPP- c-Kit+Ly6e+CD34+Flt3+, GMP- c-
Kit+Ly6e+CD34+Fcgr3+, Monocytes- Cd14+Cd74+Mafb+, B-cells- Cd79a+Cd19+Il7r+, Leukaemia 
progenitors- c-Kit+FcgR+RUNX1-RUNX1T1+ are highlighted. 
 
Overall, the characterization of different cellular compartments of the trajectory highlighted 
the overall pre-leukaemia transformation process starting from LMPP-like, progressing to 
GMP, and further leading to the accumulation of leukaemia progenitors (Fig 6.6). 
 
6.6 Loss of Kat2a increases transcriptional variability during pre-leukaemia 
progression 
 
After studying the role of Kat2a in promoting cellular variability during leukaemia initiation 
and given its central role in limiting cell-to-cell transcriptional variability, I wanted to 
interrogate a potential link between loss of Kat2a, its consequent increase in transcriptional 
variability, and pre-leukaemia progression. Briefly, as mentioned in Chapter-1, our lab has 
recently deciphered the role of Kat2a in MLL-AF9 leukaemia using a conditional Kat2a 
knockout mice model, where we observed that loss of Kat2a impacts the long-term 
preservation of functional leukaemia stem-like cells (LSC) (Domingues et al., 2020). Upon 
performing scRNA-seq of Kat2a WT and NULL leukaemia, an increase in cell-to-cell 
transcriptional variability was observed in Kat2a NULL cells, suggestive of a role for Kat2a 
in promoting transcriptional stability and altogether, revealing cell-to-cell transcriptional 
variability as a mechanism where leukaemia transformed cells lose the capability to maintain 
a balance between self-renewal and differentiation. 
 
In order to study this in the context of pre-leukaemia, I first compared cell-to-cell 
transcriptional variability at a global scale upon Kat2a loss. Transcriptional variability was 
calculated based on distance to median (DM), which was used to identify the top 500 most 
variable genes in each sample. After defining the top 500 variable genes in each sample, a 






pairwise correlation method was employed which calculated cell-to-cell variability based on a 
Spearman’s correlation coefficient (Mohammed et al., 2017) (Methods). The global analysis 
indicated an increase in transcriptional variability upon loss of Kat2a at respective time points 
(Fig 6.7A) in-line with previous observations in the lab (Domingues et al., 2020). The increase 
in transcriptional variability upon Kat2a loss was more evident at 2 months compared to 4 
months, compatible with the cell fate diversification observed at early stages of leukaemia 
transformation. Further, there was a reduction in transcriptional variability at 4 months 
compared to 2 months in both the genotypes, suggesting that increase in cell-to-cell 
transcriptional variability is a hallmark of early pre-leukaemia transformation event. However, 
it is worth noting that enhanced transcriptional instability consequent to a loss of Kat2a may 
be a reflection of the underlying increase in cellular diversity at the 2 months time point.   
 
After making global comparisons, I wanted to understand whether different compartments of 
cells showed differences in cell-to-cell transcriptional variability. For this, I compared the 
LMPP-like, GMP, and leukaemia progenitor cell populations using Spearman’s correlation. 
Compared to LMPP-candidate, GMPs showed a reduction in transcriptional variability, 
compatible with the cellular fate trajectory observed at early time points of RUNX1-
RUNX1T1(9a) leukaemia initiation (Fig 6.7B). As the haematopoietic hierarchy progresses, 
cells become relatively more committed, and hence, a reduction in transcriptional variability 
was observed in case of GMPs. However, leukaemia progenitor cells showed an increase in 
transcriptional variability, potentially due to the presence of leukaemia-initiating events 
leading to leukaemia establishment (Fig 6.7B). This was in-line with the global comparisons 
which confirmed the role of cell-to-cell transcriptional variability during RUNX1-
RUNX1T1(9a) pre-leukaemia transformation.   
 
 







































































































































































Figure 6.7: Pairwise correlation measure for transcriptional variability.  
(A) Violin plot for global transcriptional variability based on pairwise correlation method 
(p<0.0001**** Kat2a WT 2 months vs Kat2a NULL 2 months, p<0.0001**** Kat2a WT 4 months vs 
Kat2a NULL 4 months), (B) Violin plot representing transcriptional variability based on pairwise 
correlation method for different cell compartments (p<0.0001**** LMPP vs leukaemia, p<0.0001**** 
GMP vs leukaemia), (C) Violin plot for transcriptional variability based on pairwise correlation method 
for samples within LMPP compartment (p<0.0001**** Kat2a WT 2 months vs Kat2a NULL 2 months, 
p<0.0001**** Kat2a WT 4 months vs Kat2a NULL 4 months), (D) Violin plot for transcriptional 
variability based on pairwise correlation method for samples within GMP compartment (p<0.0001**** 
Kat2a WT 2 months vs Kat2a NULL 2 months, p<0.0001**** Kat2a WT 4 months vs Kat2a NULL 4 
months), (E) Violin plot for transcriptional variability based on pairwise correlation method for samples 
within leukaemia compartment (p<0.0001**** Kat2a WT 2 months vs Kat2a NULL 2 months). 
 
Further, I looked at the cell-to-cell transcriptional variability for individual samples within each 
cell compartment. In LMPP candidates, there was an increase in transcriptional variability in 
Kat2a NULL cells compared to Kat2a WT cells, which was more prominent at 2 months (Fig 
6.7C). Overall, a reduction in cell-to-cell transcription variability was observed from 2 months 
to 4 months, compatible with the global observation for each genotype. I extended the analysis 
for GMPs, where I observed a similar reduction in cell-to-cell transcriptional variability (Fig 
6.7). Again, the genotype-specific differences were more prominent at 2 months compared to 
4 months. Finally, in case of leukaemia progenitors, there was again an increase in cell-to-cell 
variability at 2 months upon Kat2a loss, followed by a reduction between 2 months and 4 
months (Fig 6.7). However, no differences in cell-to-cell variability were observed in Kat2a 
NULL cells at 4 months compared to Kat2a WT, suggesting that leukaemia is likely established 
by that time point. This supports the role of transcriptional variability in contributing to 
RUNX1-RUNX1T1(9a) leukaemia initiation. However, it is worth noting that the reduction in 
cell-to-cell transcriptional variability at 4 months-time point could be a technical artifact owing 










6.7 Inhibition of KAT2A rearranges chromatin accessibility pattern in Kasumi-1 cells 
 
Having studied the role of cell-to-cell transcriptional variability associated with loss of Kat2a 
in promoting cellular diversity and accumulation of leukaemia progenitor cells during RUNX1-
RUNX1T1(9a) pre-leukaemia, I wanted to understand the underlying causes of increased 
transcriptional variability during RUNX1-RUNX1T1(9a) pre-leukaemia transformation. Recent 
evidence suggests that transcriptional variability is consequential to inherent epigenetic 
variability and contributes towards disease relapse and diagnosis, (Landau et al., 2014; Pan et 
al., 2015; Li et al., 2016). Therefore, I interrogated whether this gain in transcriptional 
variability is associated with underlying epigenetic variability. For this, I analysed a pilot study 
conducted in Pina lab on Kasumi-1 cells, a human cell line representative of RUNX1-
RUNX1T1(9a) leukaemia where inhibition of KAT2A activity was achieved by using MB-3 as 
an inhibitor (Methods). These cells were then subjected to single-cell ATAC sequencing 
(scATAC-seq), a methodology to study variation in chromatin accessibility at single-cell level, 
based on Tn5 transposase activity (Buenrostro et al., 2015b). The library preparation was done 
by Pina lab members prior to my lab joining, using C1 Single-Cell Auto Prep System (Fluidigm, 
Inc.) (Methods).  
 
All generated libraries were subjected to paired-end sequencing. Adapter sequences were 
trimmed from FastQ files and the paired-end reads were aligned to the hg19 reference genome 
using Bowtie2 (Langmead and Salzberg, 2012). Duplicate reads were removed using Picard 
Tools (http://picard.sourceforge.net) and peak calling was done using MACS2 (Zhang et al., 
2008). Following peak calling, I obtained 74,284 peaks from control DMSO cells and 111, 898 
peaks from MB-3 treated cells (Fig 6.8). The higher number of peaks obtained in MB-3 treated 
cells could be a consequence of more cells subjected to sequencing compared to DMSO (38 
cells for DMSO and 50 cells for MB-3). To generate a combined matrix representing peaks 
from both the samples, these two peak sets were merged using Bedtools 2.27.0 (Quinlan and 
Hall, 2010). This generated a combined matrix with peak information from both DMSO and 
MB-3 with a total of 172,299 peaks. I used stringent filtering criteria for further analysis in 
order to exclude technical noise arising from single-cell data and due to the unequal number of 
cells sequenced for each sample. In order to assess reliable peaks, each peak was considered as 






a confident peak only when it is present in 15 out of 88 cells in total. The rest of the peaks were 
filtered out for downstream analysis. This strict filtering led to a total of 4,157 peaks which 
were used in downstream analysis. Post filtering, the peaks were subjected to differential 
accessibility analysis based on Fisher’s exact test and information gain (Methods). From this 
analysis, I identified significant differentially accessible peaks (p-adj <0.05, Bonferroni and 
Benjamin Hochberg correction). I obtained 50 peaks which were characterized as DMSO 
unique, 520 peaks which were characterized as MB-3 unique, and 3,587 peaks which were 
attributed as common peaks (Fig 6.8). Within the common peak subset, there were no 
significant differences in terms of differential accessibility upon inhibition of KAT2A.  
 
After identifying the unique and common subsets of peaks and confirming no differences 
within common subset, I looked at the peak accessibility frequency of the unique peak subsets 
(Fig 6.9A). The DMSO unique peaks showed an average peak frequency of 41.73% in DMSO 
cells, whereas MB-3 unique peaks had an average peak frequency of 29.96% in MB-3 cells, 
slightly lower than the frequency for DMSO unique peaks. As expected, the common peak 
subset showed similar accessibility in both DMSO and MB-3 treated cells, with an average 
accessibility of 21.75% in DMSO and 22.83% in case of MB-3 (Fig 6.9A). 
 
 







Figure 6.8: Single cell ATAC sequencing pre-processing and filtering.  
Schematic for single cell ATAC sequencing analysis. Pre-processing involved merging peaks using 
Bedtools, filtering out peaks which may introduce technical noise and performing differential 
accessibility analysis to further define peaks unique to DMSO (control), unique to MB-3 (treated), and 
common to both population of cells.  
 






To further characterize and understand the biological relevance of the individual subset of 
peaks, I annotated the peaks to nearby genes using Genomic Regions Enrichment of 
Annotations Tool (GREAT) (Mclean et al., 2010).  In control cells treated with DMSO, 41.66% 
of the unique peaks were found to be proximal to gene transcription start sites (TSS) (Fig 6.8B). 
Similarly, in MB-3 treated cells, 37.68% of peaks were proximal to TSS. However, the peaks 
distal to TSS (beyond 5kb), and likely may be attributed as cis-regulatory regions, displayed a 
higher accessibility in MB-3 treated cells where 38.69% of the distal peaks were annotated 
compared to 30.55% of the peaks in case of DMSO (Fig 6.9C). Overall, this also indicated that 
in case of control DMSO cells, there is a reduction in accessibility in distal peaks compared to 
proximal peaks whereas in case of MB-3 treated cells, both proximal and distal regulatory 
elements seem to be actively involved. This observation may indicate epigenomic 
reprogramming of KAT2A associated target genes. The common subset of peaks had a similar 
genomic region-gene association relationship as that of control cells (Fig 6.9D). 







Figure 6.9: GREAT analysis for region-gene associations.  
(A) Average peak frequency for DMSO unique peaks (purple), MB-3 unique peaks (yellow) and 
common peaks (blue) in MB-3 compared to DMSO, (B) GREAT analysis for DMSO unique peaks, 
where each peak is associated with a region defined by proximity to TSS, (C) GREAT analysis for MB-
3 unique peaks, where each peak is associated with a region defined by proximity to TSS, (D) GREAT 







































































































































































































6.8 MB-3 treated cells possess differential chromatin accessibility pattern 
 
Since inhibition of KAT2A did not show any effect on global chromatin accessibility patterns 
in the common subset of peaks, but indicated a differential regulatory reprogramming, I 
visualized the cells using dimensionality reduction analysis. The combined peak accessibility 
matrix is binary in nature, where 1 represents an accessible region and 0 represents an 
inaccessible region. Therefore, to compute cell to cell distances, I followed the approach of 
calculating Jaccard distance (Jaccard, 1901) (Methods). Jaccard distance is a dissimilarity 
measure which is the ratio between the number of peaks that are unique to a cell and the total 
number of peaks that are open in two cells. This measure allows us to derive a pairwise distance 
between two cells based on similarity of peak accessibility. After calculating the dissimilarity 
ratio for individual pairs of cells based on the accessible peaks, the generated matrix was 
utilized as an input for dimensionality reduction analysis using t-distributed stochastic 
neighbour embedding (t-SNE) (Van Der Maaten and Hinton, 2008). The tSNE plot generated 
highlighted DMSO and MB-3 treated cells as part of one cluster (Fig 6.10A). 
 
Further delving into this, I performed k-medoid clustering which employs the calculation of a 
central point of the cluster, termed as a medoid. The cells are further clustered based on their 
distance with the medoid. The medoid is calculated based on Jaccard distance as mentioned 
above. Upon clustering, DMSO cells grouped into a single cluster, whereas MB-3 cells formed 
two different clusters, indicating the presence of heterogeneity amongst the MB-3 population 
of cells (Fig 6.10B). The average peak frequency of MB-3 cluster I cells was ~30%, which was 
higher compared to control DMSO and MB-3 cluster II cells, which displayed an overall 
average peak frequency of ~20%. This suggested a variability in peak accessibility pattern upon 
inhibition of KAT2A using MB-3. This was an interesting observation and could potentially 
link to the differential epigenetic regulation of targets upon KAT2A inhibition. 
 







Figure 6.10: k-medoid clustering analysis.  
(A) Schematic for k-medoid clustering for all cells including DMSO (control) and MB-3 (treated). The 
analysis started from calculating Jaccard distance, performing dimensionality reduction analysis using 
tSNE, and overlaying cluster membership colours obtained from k-medoid clustering onto the tSNE 
plot, (B) k-medoid clustering highlighting three different clusters, namely, DMSO (purple), MB-3 I 
(yellow) and MB-3 II (green). 
 
6.9 Increase in transcriptional variability may be consequential to differential 
chromatin accessibility  
 
After performing dimensionality reduction analysis and observing differential chromatin 
accessibility pattern with MB-3 treated cells, I wanted to study different gene ontologies which 
may be reprogrammed differentially upon inhibition of KAT2A. For this, I performed 
A
B






differential accessibility analysis comparing the MB-3 I cluster with DMSO and MB-3 II 
cluster individually, using both Fisher’s exact test and information gain methods (methodology 
described previously). The differential peak analysis identified 3,067 peaks which were more 
accessible in MB-3 I cells compared to DMSO cells and 1,087 peaks more accessible in MB-
3 I cells compared to MB-3 II cells.  
 
To further understand the biological meaning of the higher accessibility peaks, I annotated the 
peaks to their closest genes using the annotatePeaks tool in HOMER (Duttke et al., 2019) 
(Methods). After annotating the peaks to their respective closest genes, I performed Panther 
gene ontology analysis for peaks that displayed higher accessibility in MB-3 cluster I compared 
to DMSO. This analysis revealed an enrichment in genes associated with cell cycle, DNA 
repair, protein ubiquitination and histone modifications (Fig 6.11A).  This was an interesting 
observation which was compatible with the increased accessibility observed at distal enhancer 
regions upon inhibition of KAT2A.  
 
Further, I wanted to understand whether the observed epigenetic variability upon MB-3 
treatment is associated with transcriptional changes. For this, I made use of scRNA-seq 
analysis conducted using RUNX1-RUNX1T1(9a) primary mouse pre-leukaemia samples. The 
genes associated with higher chromatin accessibility in MB-3 I cluster compared to DMSO, 
were converted to respective mouse gene IDs using BioMart (Kinsella et al., 2011). 
Transcriptional variability calculations were made using pairwise correlations on this set of 
genes (as described previously). Global analysis suggested an increase in transcriptional 
variability in Kat2a NULL cells compared to Kat2a WT at respective time points with a 
prominent increase at 2 months (Fig 6.11B). The leukaemia progenitors compartment also 
showed an increase in pairwise correlation coefficient compared to the rest of the cells (Fig 
6.11C), consistent with the observation in primary RUNX1-RUNX1T1(9a) pre-leukaemia. 
 
Having compared MB-3 I cluster with DMSO, I looked at the differential peaks in MB-3 I 
compared to MB-3 II. Again, I conducted peak annotation to nearest genes using HOMER and 
performed Panther gene ontology analysis. The gene expression programmes which were 
found to be enriched were similar to the above comparison with DMSO. These were namely 
cell cycle, DNA repair, protein ubiquitination, and histone modifications (Fig 6.11D). 






Integration with scRNA-seq data to calculate transcriptional variability indicated a similar 
trend of increase in pairwise distance upon Kat2a loss (Fig 6.11E). The leukaemia progenitor 
cells also showed an increase in transcriptional variability compared to the remaining 
population of cells (Fig 6.11F). These observations were compatible with the findings of 
epigenetic reprogramming upon KAT2A inhibition, and further suggest that transcriptional 
variability upon Kat2a loss may be consequential to inherent epigenetic variability.    
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Figure 6.11: Gene ontology analysis and integration with scRNA-seq data.  
(A) Panther gene ontology analysis for genes upregulated in MB-3 I cluster compared to DMSO (p-
adj<0.05*). Enriched categories include Cell cycle (purple), Protein ubiquitination (dark pink), 
Epigenetic/histone modifications (green) and DNA repair (light pink). (B) Transcriptional variability 
measurement for the upregulated genes in MB-3 I cluster based on pairwise correlation method using 
primary samples from scRNA-seq data (Kat2a WT 2 months as WT-2M, Kat2a NULL 2 months as 
NULL-2M, Kat2a WT 4 months as WT-4M, Kat2a NULL 4 months as WT-4M), (C) Transcriptional 
variability measurement for the upregulated genes in MB-3 I cluster based on pairwise correlation 
method in different population of cells identified using scRNA-seq data; LMPP, GMP and Leukaemia, 
(D) Panther gene ontology analysis for genes upregulated in MB-3 I cluster compared to MB-3 II (p-
adj<0.05*). Enriched categories include Cell cycle (purple), Protein ubiquitination (dark pink), 
Epigenetic/histone modifications (green) and DNA repair (light pink), (E) Transcriptional variability 
measurement for the upregulated genes in MB-3 I compared to MB-3 II cluster based on pairwise 
correlation method using primary samples from scRNA-seq data (Kat2a WT 2 months as WT-2M, 
Kat2a NULL 2 months as NULL-2M, Kat2a WT 4 months as WT-4M, Kat2a NULL 4 months as WT-
4M), (F) Transcriptional variability measurement for the upregulated genes in MB-3 I compared to 
MB-3 II cluster based on pairwise correlation method in different population of cells identified using 
scRNA-seq data; LMPP, GMP and Leukaemia. 
 
In this chapter, I studied the stepwise progression of RUNX1-RUNX1T1(9a) transformed Kat2a 
WT and Kat2a NULL pre-leukaemia cells using single cell pseudotime trajectory approaches. 
The analysis suggested Kat2a WT cells follow a linear trajectory whereas Kat2a NULL cells 
follow a branched trajectory. The multiple routes followed by Kat2a NULL cells are indicative 
of alterations in transcriptional landscape which further promote cell fate diversification during 
early stages of RUNX1-RUNX1T1(9a) pre-leukaemia transformation. There was an 
observation of abrupt transformation in Kat2a WT cells, which could be due to inability in 
capturing the transformed cells at intermediate stages of transformation or could be an artifact 
of the algorithm implemented in the Monocle 3 tool utilized for trajectory analysis. Monocle 3 
divides cells into larger and more well separated groups called partitions, using a statistical test 
from Alex Wolf and colleagues (Wolf et al., 2019), introduced as part of their Partition-based 
graph abstraction (PAGA) algorithm. While learning the single cell pseudotime trajectory each 
of these partitions eventually forms a separate trajectory. In case of genotype specific 
trajectories, all of the cells had fallen within the same partition as per the algorithm, hence, a 






single trajectory was obtained. However, in global trajectory analysis, by making use of default 
parameters, as done for genotype-specific trajectories, 3 different partitions were obtained 
which only allowed the algorithm to fit the trajectory within the compartment that followed a 
haematopoietic hierarchy, while excluding the rest of the compartments from the trajectory. To 
overcome this challenge, other methods for trajectory building, for example, TSCAN (Ji and 
Ji, 2019), could be used in future. However, it is worth considering that individual trajectory 
tools are based on fundamentally different algorithms (for example TSCAN utilizes minimum 
spanning tree whereas Monocle works on reverse graph embedding) which would make it 
extremely difficult to interpret and compare the analysis of one tool to the other. 
 
Due to unavailability of published scRNA-seq datasets similar to this study, different cell 
populations were identified based on the average expression of cell surface makers as per the 
definition of these populations in previous studies (Weissman and Shizuru, 2008; Doulatov et 
al., 2012). The presence of a higher percentage of Kat2a WT cells at 2 months, constituting 
LMPP-like population was consistent with the in vivo and in vitro observations from RUNX1-
RUNX1T1(9a) pre-leukaemia (Chapter-3). The presence of higher percentage of 4 months 
samples, both Kat2a WT and Kat2a NULL within GMP compartment is compatible with 
transformation hierarchy, as well as the increase in myeloid progenitor population observed in 
pre-leukaemia cells in vivo. 
 
The observation that RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells undergo B-cell 
and monocytic differentiation suggested that loss of Kat2a facilitates accessibility towards 
transformation prone cells by promoting cellular diversity. This was compatible with our 
previous observations, where MLL-AF9 transformed Kat2a NULL cells had also undergone 
monocytic differentiation, thereby promoting accessibility towards leukaemia stem-like cells 
(Domingues et al., 2020). Although scRNA-seq indicated the presence of B-cell differentiation 
at the 2 months time point which was compatible with the flow cytometry analysis, where B220 
expression was found to be prominently high in RUNX1-RUNX1T1(9a) transformed Kat2a 
NULL cells at plating 2 and no differences were observed between Kat2a WT and Kat2a 
NULL cells at plating 3. A similar observation was noted in the flow cytometry analysis for 
F4/80, a marker of monocytic differentiation. However, the insights from scRNA-seq 
suggested monocytic differentiation is present at both time points. The reason that no changes 






in monocytic differentiation could be noticed at plating 3 could highlight the fact that the 
conditioned methylcellulose medium in which CFC cultures were maintained supports the 
growth of myeloid progenitors and the terminally differentiated cells may not have been 
maintained well in this culture. Another reason for this could be the heterogeneity in the 4 
months sample where the cells captured using scRNA-seq within the monocyte compartment 
had the extent of transformation comparable to the cells collected at 2 months post 
transplantation. 
 
The observation of accumulation of leukaemia progenitors having RUNX1-RUNX1T1 
signature was in conjunction with the perpetuation of RUNX1-RUNX1T1(9a) transformed pre-
leukaemia clones observed in vivo. The gradual accumulation of leukaemia progenitors with 
time coincided with the progressive RUNX1-RUNX1T1(9a) transformation. This was in-line 
with the flow cytometry analysis of RUNX1-RUNX1T1(9a) transformed pre-leukaemic Kat2a 
WT and Kat2a NULL cells studied at 2 months and 4 months where an increase in GFP+c-
Kit+FcgR+ population, indicative of myeloid progenitors, was observed upon Kat2a loss. It 
would have been interesting to extend the analysis by isolating these cells using FACS sorting 
and further transplanting into C57/BL6 mice to study the leukaemia development with and 
without the presence of Kat2a, however, due to the lack of sufficient number of cells, this 
analysis could not be performed. 
 
The increase in cell-to-cell transcriptional variability was compatible with our previous 
observations in MLL-AF9 model (Domingues et al., 2020). However, the reduction in 
transcriptional variability from 2 months to 4 months could be either due to a technical artifact 
owing to small sample size or cellular variability contributing towards increase in 
transcriptional variability at the 2 months time point. Although it is difficult to dissect cell-to-
cell transcriptional variability in the presence of an underlying cellular diversity, I made an 
attempt using the Discrete distributional differential expression (D3E) tool (Delmans and 
Hemberg, 2016) which models the parameters of transcriptional bursting dynamics as an 
underlying cause of observed transcriptional variability. However, due to the absence of 
representative training simulation datasets in the D3E model, the results could not be interpreted 
with confidence. Future work may involve studying these parameters of transcriptional 






bursting experimentally using single molecule RNA FISH (smRNA-FISH) (Raj et al., 2008) 
or droplet digital PCR (ddPCR) analysis (Hindson et al., 2011).  
 
The insights obtained from scATAC-seq analysis suggested that the variability in accessible 
chromatin landscape may further lead to an enhanced cell-to-cell transcriptional variability. 
However, it is worth noting that the scATAC-seq analysis was associated with few caveats. 
One of these was the sample size, which was smaller and perhaps quite noisy, which could be 
addressed in future experiments. Another caveat associated with scATAC-seq is the sparse 
nature of data, due to which the peaks called using single cell data are not sufficiently reliable 
for downstream processing. To circumvent these challenges, performing bulk ATAC-seq in 
parallel on the same samples would enable calling of more reliable peaks which could be 
utilized for downstream analysis (Schep et al., 2017). 
 
Nonetheless, the epigenomic reprogramming observed upon inhibition of KAT2A in terms of 
redistribution of peaks accessible upon MB-3 treatment, suggested a collaborative role of distal 
and proximal regions in regulating the KAT2A associated target genes. However, it is worth 
noting that the differentially expressed genes upon Kat2a loss during RUNX1-RUNX1T1(9a) 
pre-leukaemia progression, namely ribosomal biogenesis, and mitochondrial ATP biosynthetic 
associated genes, did not show any changes in their chromatin accessibility pattern. This could 
be due to the fact that these transcriptional programmes may be specifically altered during pre-
leukaemia, whereas scATAC-seq data was generated from a representative established 
leukaemia cell line. The consistent capture of cell cycle and DNA repair machinery associated 
genes may suggest a cellular reprogramming dependent on differential chromatin signature or 
an enhanced DNA damage associated with RUNX1-RUNX1T1(9a) progression which are 







































My work in this thesis shows the mechanistic role of cell-to-cell transcriptional variability 
induced upon Kat2a loss in governing cellular fate diversification and hence promoting 
RUNX1-RUNX1T1(9a) pre-leukaemia transformation which can be further extended to other 
models of pre-leukaemia. This work represents a novel attempt at understanding the process of 
leukaemia initiation by introducing Kat2a loss as a regulator of transcriptional instability. This 
allowed in modelling pre-leukaemia stages and further associating the components of 
epigenetic variability in the form of chromatin accessibility in aiding disease progression. 
These observations have opened up a potential research area where the general contribution of 
Kat2a loss and consequent increase in transcriptional variability during pre-leukaemia can be 
further explored. These studies may further be extended to disease relapse, akin to disease 
initiation, where the presence of pre-leukaemia clones has been observed (Koeffler and Leong, 
2017). This would further allow the identification of regulatory modes or modules that 
contribute to AML progression in the absence of mutation. These regulatory modules may 
potentially be targetable therapeutically or constitute an indicative prognostic signature that 
may be used in the clinic for risk stratification. 
 
As stated earlier, AML is a heterogeneous disease entity with as many biological behaviours 
and natural histories as the mutation spectra observed in patients. It is worth noting that a 
proportion of leukaemias evolve through a prolonged pre-leukaemic phase. Understanding of 
the molecular mechanisms that may hinder or accelerate progression to overt leukaemia is 
central to the development of early diagnostic tools and early therapeutic intervention 
approaches. In this context, Kat2a depletion poses a fascinating model of perturbation of AML 
progression that can either prevent or accelerate leukaemia progression, depending on the stage 
of disease progression. Kat2a is central to transcriptional activation, particularly at the level of 
promoters (Domingues et al., 2020) and in cross-talk with the basic transcriptional machinery, 
and functions as part of distinct histone-modifying complexes (Arede et al., 2020). It is, in 
principle, a ‘druggable’ target (Domingues et al., 2020), and detailed understanding of Kat2a 
mechanisms of action in different forms of AML will inform drug design to complement 
conventional therapeutic schemes in a disease-specific and personalised manner for increased 






7.1 Kat2a loss may serve as a tool to study the process of transformation in other pre-
malignancies 
 
This thesis work sets up a paradigm in modelling the early steps of disease progression. The 
loss of Kat2a poses an excellent tool to understand the early steps of leukaemia progression 
which may further be extended to different pre-malignancies. Pre-leukaemia cell populations 
are marked by continuous acquisition and loss of specific mutations, sometimes occurring at 
different timepoints. This leads to simultaneous evolutionary convergence and divergence 
among particular clones and subclones during the course of disease. With the evolution of the 
disease, the composition of these cell populations changes remarkably, with selection occurring 
at different genetic and epigenetic levels. Moreover, these cell populations serve as a fantastic 
reservoir to understand early disruptions in epigenetic and transcriptional landscape.  
 
In line with this, my work focussed on characterizing and modelling the pre-leukaemia stages 
of RUNX1-RUNX1T1(9a) model of leukaemia. RUNX1-RUNX1T1 is characterized by a t(8;21) 
translocation event which leads to alteration of gene expression and haematopoietic cell 
proliferation but does not lead to development of leukaemia (Peterson and Zhang, 2004). This 
is in corroboration with the fact that RUNX1-RUNX1T1 has a weakly oncogenic effect and 
requires collaborating mutations to develop leukaemia. On the other hand, the spliced version 
RUNX1-RUNX1T1(9a), includes an extra exon, exon 9a, of the RUNX1T1 gene and encodes a 
C-terminally truncated RUNX1-RUNX1T1 protein of 575 amino acids. The expression of 
RUNX1-RUNX1T1(9a) is found to promote development of leukaemia in a mouse retroviral 
transduction–transplantation model (Yan et al., 2006).  
 
The pre-leukaemia clones in the RUNX1-RUNX1T1(9a) model were collected at 2 months and 
4 months post leukaemia-initiation and were characterized as cell populations that were GFP+ 
c-Kit+FcgR+. These cell populations were found to accumulate and expand within the 
progenitor cell compartment obtained from Kat2a NULL animals, suggesting that loss of 
Kat2a promotes accumulation of myeloid progenitors upon pre-leukaemia transformation. The 
definition of pre-leukaemia clones utilized in this study was compatible with the L-GMPs 
defined by Helin and colleagues in RUNX1-RUNX1T1(9a) leukaemia (Rasmussen et al., 2015). 






within the GFP+ cell compartment in Kat2a NULL cells isolated from spleen (Student’s t-test, 
p= 0.0642, data not shown), suggesting the presence of early progenitors. In addition to this, 
the overall distributions of different haematopoietic compartments in bone marrow cells 
including Gr1-Mac1-, c-Kit+Sca1-, c-Kit+Sca1+, and Cd34+FcgR+ cell populations were found 
to be altered, suggesting Kat2a associated changes in RUNX1-RUNX1T1(9a) pre-leukaemia 
hierarchy.  
 
Further, these pre-leukaemia cell populations were found to be associated with an enhanced 
clonal expansion capacity as reflected by serial replating assay. Kat2a NULL bone marrow 
cells transformed with RUNX1-RUNX1T1(9a) displayed a marked increase in self-renewal 
potential suggesting these cells have the capability to maintain the transformants which may 
have further expanded and consequently led to accelerated leukaemia progression. This was 
compatible with an in vitro colony forming assay performed on RUNX1-RUNX1T1(9a)+ 
transformed Kat2a WT and Kat2a NULL cells, which also showed an increase in replating 
capacity in Kat2a NULL cells. Interestingly, in a maintenance set-up where Kat2a knockout 
was performed post RUNX1-RUNX1T1(9a) transformation, self-renewal potential was 
significantly reduced. This observation was in line with a previous study conducted in our lab 
(Domingues et al., 2020) where reduction in colony-forming potential was observed in MLL-
AF9 induced leukaemia upon Kat2a loss, suggesting contrasting roles of Kat2a. These 
observations highlight that Kat2a impacts self-renewal in a stage-specific manner where its 
loss in transformed leukaemic cells decreases colony forming potential, whereas its loss in a 
disease initiation context enhances replating capacity.  
 
These pre-leukaemia cells were further found to have a linear increase in White Blood Cell 
(WBC) count consistently in both Kat2a WT and Kat2a NULL genotypes, which was 
compatible with the first phenotypic characterization study of RUNX1-RUNX1T1(9a) 
leukaemia (Yan et al., 2006). No changes were observed in haemoglobin level and platelet 
counts during the course of leukaemia development except a sharp decrease in Kat2a NULL 
animals at 44 weeks post transplantation. This may be due to aging or could be technical and 
may not be a consequence of pre-leukaemia burden as it does not show any association with 







The RUNX1-RUNX1T1(9a) leukaemias which developed were found to be in accordance with 
the classification of the haematopathology subcommittee of the Mouse Model of Human 
Cancers Consortium (MMHCC) (Kogan et al., 2002). The clinical characteristics of these mice 
were suggestive of AML without maturation. In line with the literature, the leukaemia cells 
obtained from RUNX1-RUNX1T1(9a) did not show a typical distribution of the three myeloid 
progenitor populations, including common myeloid progenitors (FcγRIIIloCD34+), granulocyte 
and macrophage progenitors (FcγRIIIhiCD34+), and megakaryocyte and erythroid progenitors 
(FcγRIIIloCD34−) within the progenitor compartment (c-Kit+ Sca-1−) (Yan et al., 2006) (Yan 
et al., 2004). All developed leukaemias had an unique profile highlighting different subset of 
markers confirming the multi-hit hypothesis of RUNX1-RUNX1T1(9a) leukaemia development 
(TCGA, 2013b).   
 
Our retroviral transduction-based transplantation model of RUNX1-RUNX1T1(9a) showed the 
first Kat2a WT animal to have developed leukaemia within 171 days post transplantation. This 
was compatible with available literature suggesting the development of RUNX1-RUNX1T1(9a) 
leukaemia within a timeframe of 120-200 days post transplantation (Bäumer et al., 
2014)(Hatlen et al., 2016)(Kobayashi et al., 2017). However, lower transduction efficiency in 
my transplantation experiments may have contributed towards longer latency period of 
RUNX1-RUNX1T1(9a)-induced leukaemogenesis. Upon loss of Kat2a, an acceleration in 
leukaemia progression was observed, with the first animal showing signs of leukaemia after 
104 days of transplantation. It is worth noting that my experiment was conducted in two 
separate cohorts of animals with separate transduction experiments conducted at different time 
frames. Although the transduction efficiency was variable between the two experimental set 
ups, nonetheless, in both cases a consistent acceleration in leukaemia progression in Kat2a 
NULL animals transformed with RUNX1-RUNX1T1(9a) overexpression plasmid was 
observed. Since the animals were only analysed until 1-year post-transplantation and the 
experiment was terminated thereafter, some RUNX1-RUNX1T1(9a) transformed Kat2a WT 
animals which may have started developing signs of leukaemia could not be analysed. 
 
RUNX1-RUNX1T1(9a) transformed leukaemic cells highlighted the presence of 20-30% of c-
Kit+Sca1- population within GFP+ cells in bone marrow, indicative of RUNX1-RUNX1T1(9a) 






This was in line with the observation in literature where the proportion of myeloid progenitors 
(Lin−Sca-1−c-Kit+) was greatly increased in GFP+ cells. Further, most GFP+ cells were found 
to have no expression of lineage markers associated with myeloid lineage like Gr-1 and Mac1, 
compatible with previous studies (Yan et al., 2006; Zuber et al., 2009).  
 
The RUNX1-RUNX1T1(9a) leukaemia burden studies for both Kat2a WT and Kat2a NULL 
animals showed that the transplanted mice had developed signs of anaemia, high white blood 
cell (WBC) count, abnormal differential counts and signs of cachexia and laboured breathing 
at the time of culling. These mice which developed leukaemia showed pale femurs, enlarged 
spleens and in some cases enlarged livers, but there was no indication of any clinical 
abnormalities in thymuses or lymph nodes. There was a high number of blast cells which was 
observed in the peripheral blood at terminal time point both in bone marrow and spleen (data 
not shown) compatible with previous characterization of RUNX1-RUNX1T1(9a) induced 
leukaemia burden (Yan et al., 2006) (Yan et al., 2004). No significant differences were 
observed in terms of overall leukaemia burden in Kat2a NULL relative to Kat2a WT animals, 
compatible with previous lab findings in case of MLL-AF9 leukaemia, where both Kat2a WT 
and Kat2a knockout (KO) leukaemic animals had similar disease burdens at the point of culling 
(Domingues et al., 2020). However, there was increasing trend in spleen size in RUNX1-
RUNX1T1(9a) transformed Kat2a NULL animals, perhaps indicating an early disease 
infiltration event which was merely strengthening the notion of accelerated RUNX1-
RUNX1T1(9a) leukaemia development upon loss of Kat2a.  
 
Overall, the combination of pre-leukaemia and leukaemia analysis of RUNX1-RUNX1T1(9a) 
in a Kat2a conditional knockout background suggested a perpetuation of pre-leukaemia clones 
upon Kat2a loss. These pre-leukaemia clones, as defined by GFP+c-Kit+FcgR+, showed an 
enhanced self-renewal potential and aided in accelerated leukaemia development in absence of 
Kat2a. Going forward, it would be interesting to explore the role of Kat2a in other pre-
leukaemia models specifically the ones initiated by RUNX1 mutation.   
 
One such model which could benefit from Kat2a based perturbation studies is Myelodysplastic 
syndrome (MDS). Myelodysplastic syndromes (MDS) are clonal disorders of haematopoietic 






abnormal myeloid differentiation leading to chronic cytopenias (reduction in number of mature 
blood cells) and to a variable risk of progression to AML (Itzykson and Fenaux, 2013). Even 
though the presence of various chromosomal abnormalities, mutations, and epigenetic changes 
have been observed in MDS progenitors, the earliest cellular stages at which pathogenic events 
occur is still not clear. Some studies in MDS have focused on the subset of patients with 
chromosomal 5q deletion (5q−) and have shown that stem cells in MDS harbour the deletion 
(Nilsson et al., 2007). Another study showed that these cells persist in the bone marrow (BM) 
of patients with 5q− during the process of treatment and can be predictive of relapses 
(Tehranchi et al., 2010). The number of recurrently mutated genes is greater in more advanced 
MDS subtypes, and acquisition of certain mutations including RUNX1 is associated with 
transformation to AML (Bejar et al., 2011). Splicing machinery associated genes have been 
found to be one of the most frequently impaired genes in MDS which can be identified in >50% 
of MDS patients (Bejar and Steensma, 2014). This is in line with my observations from 
individual analysis performed in both Kat2a WT and Kat2a NULL cells transformed with 
RUNX1-RUNX1T1(9a), where a downregulation of genes associated with splicing machinery 
was found to be associated with AML transformation. In addition to this, aberrant expression 
and mutation of multiple ribosomal proteins has been observed in MDS (Pellagatti et al., 2008) 
(McGowan et al., 2011) where rRNA expression is decreased in haematopoietic progenitor 
cells from MDS patients (Raval et al., 2012), compatible with my observations in RUNX1-
RUNXT1(9a) model upon Kat2a loss, suggesting that Kat2a loss can serve as a tool in 
modelling the early stages of 5q mediated MDS transformation.  
 
Another pre-leukaemic condition which has a predisposition towards different haematological 
and epithelial malignancies is Fanconi anaemia (FA). FA is a rare genetic condition 
characterized by congenital abnormalities, chromosome fragility, progressive bone marrow 
failure, and cancer susceptibility (Quentin et al., 2011). Most FA patients develop bone marrow 
failure throughout the course of the disease, usually during their first and second decades of 
life, and for the majority of patients the suspicion of FA is only made after the onset of 
pancytopenia (Shimamura and Alter, 2010). A strong predisposition towards haematological 
malignancies has been observed with cumulative probabilities of an FA patient developing 
MDS or AML being 30% to 40% by the age of 40 years (Alter, 2003). In a number of patients, 






urgent need of biomarker identification for disease prognosis. Epigenetic studies on FA have 
been mostly conducted on the role of histone deacetylation as well as hypomethylation in 
affecting FA-BRCA pathway during disease progression suggesting a dependency on 
epigenetic modifiers for disease progression (Belo et al., 2015). These observations support 
the notion that Kat2a loss may serve as a tool to study this pre-malignancy.  
 
Another model representing pre-leukaemia is ETV6-RUNX1, also known as TEL-AML1, one 
of the most frequent chromosomal translocations involving t(12;21)(p13;q22) in childhood 
Acute Lymphoblastic Leukaemia (ALL) with an incidence of approximately 25% (Sun, Chang 
and Zhu, 2017). This translocation occurs in haematopoietic stem cells and leads to the 
establishment of pre-leukaemic progenitor B-cell clones that persist in the bone marrow for 
several years. It has been shown that the translocation itself is insufficient to generate ALL and 
that secondary somatic mutations are necessary to activate the leukaemic phenotype (Sun, 
Chang and Zhu, 2017). The detection of the ETV6-RUNX1 fusion sequence in identical twins 
and in neonatal blood spots of children with ALL indicate that this gene fusion originates in 
the prenatal period (Ford et al., 1998). The transcription factor binding properties of ETV6-
RUNX1 have been mostly explored in context of RUNX1 where the binding of ETV6-RUNX1 
to RUNX1 target genes has been shown to potentially convert RUNX1 to a negative 
transcriptional regulator (Zelent, Greaves and Enver, 2004). A recent study by Enver group 
highlighted the gene expression programmes associated with ETV6-RUNX1 maintenance (cell 
cycle, E2F targets, MYC targets) (Wray et al., 2020) which coincided with the transcriptional 
programmes impaired upon Kat2a loss, suggesting that Kat2a loss may serve as an excellent 
tool to study this pre-leukaemia model. 
 
In parallel to this, in this thesis, pre-leukaemia studies were also conducted using the 
Idh1R132H model developed by our collaborator Prof. George Vassiliou’s laboratory at WT-
Sanger Institute, which we crossed into our conditional Kat2a knockout background. IDH1 
mutations have been identified as recurrent mutations during leukaemogenesis (Mardis et al., 
2009). The presence of these mutations is mutually exclusively of the transcription-factor 
fusions, suggests that they may have functional implications in the initiation of AML (TCGA, 
2013b; Papaemmanuil et al., 2016). Studies conducted on Idh1R132H are quite sparse, and the 






al., 2012b), indicating that additional collaborating mutations are required. Our analysis of 
Idh1R132H pre-leukaemia was also compatible with the literature, where an enhanced WBC 
count was observed but progression to acute leukaemia was not observed. However, the 
transplanted animals showed an accumulation of early progenitors upon Kat2a loss, 
characterized by c-Kit+Mac1-, compatible with the perpetuation of pre-leukaemic clones 
observed in RUNX1-RUNX1T1(9a) pre-leukaemia. 
 
The pre-leukaemia cells transformed with Idh1R132H were analysed post 4 weeks and 20 
weeks of leukaemia initiation. Upon phenotypic characterization of pre-leukaemia clones, no 
significant differences between the two genotypes were found in any of the haematopoietic 
compartments including HSCs, suggesting that loss of Kat2a at early stages of pre-leukaemia 
progression does not impact the BM cellularity. The KSL and KL population of cells followed 
a similar trend where no changes upon Kat2a loss were seen, however, an increasing trend in 
KL population was observed with time, in line with the previous literature suggesting 
accumulation of early progenitors during pre-leukaemia progression (Sasaki et al., 2012b). 
Further, these pre-leukaemia cell populations at 4 weeks were found to be associated with an 
enhanced clonal expansion capacity as reflected by serial replating assay, where Kat2a NULL 
bone marrow cells transformed with Idh1R132H had a marked increase in self-renewal 
potential suggesting these cells have the capability to maintain the transformants. Strikingly, 
no such differences were observed at 20 weeks post leukaemia initiation, suggesting that the 
enhanced colony forming capability of Kat2a NULL cells is an early effect upon Kat2a loss. 
Overall, Kat2a depletion serves as an excellent model to study early stages of pre-leukaemia 
progression as seen in case of RUNX1-RUNX1T1(9a) and Idh1R132H models which can be 
further extended to other pre-malignancy models including disease relapse. 
 
It is worth noting that the definition of pre-leukaemia is not strictly restricted to the cell 
populations having increased incidence of evolution into AML but also corresponds to the pre-
leukaemic clones which can exist at the time of complete morphologic remission after standard 
aggressive chemotherapy for AML (Koeffler and Leong, 2017). This phenomenon was first 
observed by Phil Fialkow and Claus Bartram in the early 1990s where they noted that about 
25% of the AML patients who achieved complete morphologic remission by chemotherapy 






Bartram, 1991). Since then, several high throughput sequencing studies have shown that 
individuals whose AML cells at diagnosis had mutations of either DNMT3A, IDH2, TET2, 
UAF1, or SRSF2 often had the same alteration at complete morphologic remission (Corces-
Zimmerman et al., 2014c; Garg et al., 2015; Klco et al., 2015; Sun et al., 2017). Surprisingly, 
the driver mutations in genes such as FLT3, RUNX1, RAS, NPM1, CEBPA, and WT1, 
although present at diagnosis of AML, were no longer found in complete remission. Ley and 
colleagues had reported that ~50% of the individuals whose AML cells carried DNMT3A, 
TET2, or IDH1/2 mutations at diagnosis continued to have the same mutation in >5% of the 
haematopoietic cells at complete morphologic remission, but the classical driver mutations (for 
example, NPM1, FLT3 and RAS) found at diagnosis were not detectable at remission (Klco et 
al., 2015). Another study performed by Dick’s group on a cohort of individuals whose AML 
blast cells had mutations of DNMT3A and NPM1 at both diagnosis and relapse indicated the 
presence of only the DNMT3A mutation upon morphologic complete remission (Shlush et al., 
2014b). In the same study, human bone marrow cells at diagnosis of AML were injected into 
immunodeficient mice where a total of 37% of samples did not engraft, 40% of samples 
recapitulated the AML blasts in the mice, but most interestingly, 23% of the samples produced 
multi-lineage engraftment that appeared normal. These multilineage engrafts had continued to 
have mutations of either DNMT3A or IDH1/2 suggesting that a preleukaemic clone exists even 
at diagnosis of AML(Shlush et al., 2014b). These observations highlight that Kat2a loss may 
serve as a tool in understanding the molecular mechanisms behind disease relapse models.  
 
7.2 Kat2a loss may serve as a tool to study mitochondrial metabolism 
 
The global differential gene expression analysis in combination with comparisons performed 
at individual time points indicated an enrichment in translation/ribosome biogenesis and 
mitochondrial ATP synthesis pathways upon Kat2a loss. These observations were compatible 
with a previous study conducted in our lab on MLL-AF9 leukaemia where loss of Kat2a 
downregulated gene expression pathways associated with translation/ribosome biogenesis and 
mitochondrial ATP synthesis (Domingues et al., 2020). These findings altogether suggested 
that loss of Kat2a may exert its effects through general pathways rather than leukaemia specific 






malignancies and can be further extended to study the impairment in ribosomal biogenesis and 
mitochondrial energetics in different malignancies.  
 
The time series comparison performed on RUNX1-RUNX1T1(9a) transformed Kat2a NULL 
cells suggested the presence of transcriptional instability in gene expression programmes 
associated with alternative splicing and cis-splicing, along with cell cycle regulation, protein 
modifications, and chromatin organization. The overall analysis highlighted that loss of Kat2a 
impacts translation/ribosomal biogenesis and mitochondrial ATP synthesis during early stages 
of pre-leukaemia transformation and potentially need those during pre-leukaemia maintenance. 
However, once the RUNX1-RUNX1T1(9a) pre-leukaemia is established, disease progression is 
dependent on alterations in cell cycle progression, post-transcriptional modifications, and 
epigenetic instability in the form of chromatin reorganization.  These insights were in 
agreement with literature where corruption of cell cycle regulation by RUNX1-RUNX1T1 is 
found to mediate leukaemia progression (Martinez-Soria et al., 2018). Previous work from the 
Bonifer group has also indicated the regulation of cell cycle genes and epigenetic 
reprogramming in terms of histone acetylation and transcription factor binding by RUNX1-
RUNX1T1 in t(8;21) leukaemia (Ptasinska et al., 2012). A recent preprint from Heidenreich 
lab in collaboration with Bonifer lab also suggested that RUNX1-RUNX1T1 affects alternative 
splicing of RNA in the t(8;21)-positive Kasumi-1 AML cells by controlling the choice of 
transcriptional start sites and by modulating expression of splicing components, suggesting a 
role for alternative splicing in RUNX1-RUNX1T1 leukaemogenesis (Grinev et al., 2021).  
 
Contrastingly, Kat2a WT cells were found to be mostly dependent on mitochondrial 
bioenergetics for pre-leukaemia transformation, highlighting the general significance of 
metabolic reconfiguration during pre-leukaemia transformation. From mitochondrial activity 
analysis of both Kat2a WT and Kat2a NULL cells undergoing transformation with RUNX1-
RUNX1T1(9a), an overall reduction in active mitochondrial mass was observed in Kat2a 
NULL cells relative to Kat2a WT cells. This reduction was not accompanied by any changes 
in mitochondrial potential. Further, the proportion of cells with low mitochondrial content was 
found to be higher within Kat2a NULL cells relative to Kat2a WT cells undergoing 
transformation with RUNX1-RUNX1T1(9a). This was in line with the inferences from 






leukaemia, indicating that reduction in mitochondrial activity upon Kat2a loss aids in RUNX1-
RUNX1T1(9a) pre-leukaemia transformation. 
 
The observation of reduced mitochondrial content during RUNX1-RUNX1T1(9a) pre-
leukaemia was in line with the Warburg theory laid down in 1924 (Hay, 2016a), which stated 
that cancer cells are highly dependent on glycolysis not so much for energy production, but 
rather as a platform to produce building blocks including nucleotides, amino acids, and electron 
carriers that are necessary for cancer progression (Hay, 2016b). The Warburg effect ensures a 
constant high activity of glycolysis and maintains the balance between energy supply and the 
anabolic functions of glycolysis and its deviations. This was in contrast with some of the 
findings on chronic myeloid leukaemia (CML) as well as AML where higher mitochondrial 
biogenesis and higher dependency on mitochondrial oxidation in leukaemia myeloblasts was 
observed compared with normal haematopoietic precursor cells (Green et al., 2010; Vakana et 
al., 2011; Farge et al., 2017; Mattes, Vellenga and Schepers, 2019). Strikingly, a recent study 
presented a slight variation to this notion (Marsin et al., 2000). The study suggested that 
decreased energy levels in cells activates AMP-activated protein kinase (AMPK), a crucial 
energy sensor, which promotes ATP production by increasing the activity and expression of 
proteins involved in catabolic processes including glycolysis and fatty acid oxidation, while 
conserving ATP by switching off biosynthetic pathways such as fatty acid, glycogen, and 
protein synthesis (Marsin et al., 2000)(Marsin et al., 2002). On these lines, a similar study 
conducted on MLL-AF9 leukaemia indicated that dietary restriction in mice harbouring MLL-
AF9-induced AML leads to activation of AMPK, which is essential to support leukaemia 
development. Thus, AMPK deletion significantly delays leukaemogenesis and depletes 
leukaemia-initiating cells by reducing glucose uptake and increasing oxidative stress and DNA 
damage. Notably, AML-initiating cells are particularly dependent on AMPK to suppress 
oxidative stress in the hypoglycaemic bone marrow environment and AMPK inhibition 
synergizes with dietary restriction to suppress leukaemogenesis (Saito et al., 2015). These 
studies altogether highlight that reduction in metabolic activity may be a hallmark of pre-
leukaemia transformation which may aid in maintenance of leukaemia-initiating cells. 
 
In this line, the impact of Kat2a on mitochondrial activity was also studied in Kat2a WT and 






mitochondrial mass was observed in Kat2a NULL cells. This was accompanied by an increase 
in relative proportion of Mito lo population. Along with alterations in mitochondrial mass, 
there was a subtle difference in mitochondrial membrane potential, where loss of Kat2a led to 
a reduction in mitochondrial membrane potential as read by fluorescent signal obtained from 
Mitostatus TMRE. These findings were in line with the observations from apoptosis analysis 
performed in MLL-AF9 transformed primary cell lines where an enhanced proportion of cells 
undergoing apoptosis were seen upon loss of Kat2a (Chapter-2). It is interesting how Kat2a 
mediated mitochondrial activity alterations may impact different models of leukaemia with 
similar effect upon Kat2a loss. Although these experiments both in RUNX1-RUNX1T1(9a) as 
well as MLL-AF9 models would have strongly benefited from including another replicate, in 
case of both models, the increasing trend in Mito lo cell population upon Kat2a loss seemed 
quite consistent suggesting that metabolic reconfiguration observation upon Kat2a loss may 
play an important role in context of both leukaemia initiation as well as maintenance model 
systems.  
 
A deeper insight into the biology of mitochondrial activity alterations was obtained by 
segregating the MLL-AF9 transformed cells into two categories- one with high active 
mitochondrial mass (Mito hi) and the other with lower active mitochondrial mass (Mito lo). 
An overall reduction in number of colonies was observed in Kat2a NULL cells compared to 
Kat2a WT cells, compatible with the global findings discussed in Chapter-6. The cells from 
Mito lo fractions formed less colonies compared to the respective Mito hi fractions for both 
genotypes, indicating that segregation of cells based on mitochondrial content may not have a 
genotype-specific effect. However, the colony forming potential of Kat2a WT Mito lo was 
found to be comparable with that of Kat2a NULL Mito hi and Kat2a NULL Mito lo, overall 
suggesting that Kat2a NULL phenocopies Kat2a WT Mito lo. 
 
In order to associate mitochondrial content with colony forming potential, I looked at the 
composition of these colonies based on a study from Lavau and colleagues (Lavau et al., 1997) 
defining types of colonies. The analysis showed a similar trend of reduction in compact 
colonies, the ones without any halo of migrating cells and thus representative of immature 
myeloid cells, as was observed globally in Kat2a NULL compared to Kat2a WT cells, in line 






colonies from Kat2a WT Mito lo was found to be comparable with that of Kat2a NULL Mito 
hi and Kat2a NULL Mito lo, overall suggesting that Kat2a NULL phenocopies Kat2a WT 
Mito lo, a trend compatible with total colonies. Furthermore, there was a significant reduction 
in mixed colony proportion, the colonies having a compact centre with a diffuse halo of 
differentiating progenitors, which was seen in Kat2a NULL Mito lo cells relative to Kat2a 
NULL Mito hi cells. The proportion of mixed colonies in Kat2a NULL Mito lo was comparable 
to the mitochondrial fractions in Kat2a WT cells. The proportion of dispersed colonies, 
comprising of large diffuse colonies without a clear centre, was the lowest in all the samples, 
consistent with the previous observations (Chapter-6). However, a trend towards an increase 
in the proportion of dispersed colonies was observed in case of Kat2a WT Mito lo, comparable 
with global Kat2a NULL cells, again indicating that Kat2a NULL phenocopies Kat2a WT 
Mito lo. Overall, the analysis allowed association of colony forming potential with the 
population of cells segregated on the basis of mitochondrial mass, compatible with previous 
observations by Simsek et al., which was based on in vitro colony forming assays and in vivo 
long-term repopulation assays, suggesting that separation of cells solely based on their 
metabolic profile markedly enriches for HSCs (Simsek et al., 2010). 
 
In line with this, the insights generated from single cell clonal cultures derived from individual 
mitochondrial fractions sorted from each genotype suggested a reduction in clonal expansion 
potential in Kat2a NULL cells relative to Kat2a WT cells transformed with MLL-AF9. This 
was compatible with the insights from colony forming assay described above as well as in 
Chapter-6. The cells from Mito lo fractions had reduced clonal expansion capacity compared 
to the respective Mito hi fractions for both genotypes, indicating that segregation of cells based 
on mitochondrial content may not have a genotype-specific effect. This was again in 
accordance with the colony forming assay observations described above, where both Mito lo 
fractions had reduced colony forming potential compared to their respective Mito hi fractions. 
This was also in line with the flow cytometry analysis (data not shown) where the viability of 
Mito lo fractions was compromised compared to respective Mito hi fractions suggesting that 
Mito lo fractions are hard to sustain in culture in vitro. Furthermore, the ability of a single cell 
to expand clonally was found to be comparable in Kat2a WT Mito lo with Kat2a NULL Mito 
total, again suggesting that loss of Kat2a may potentially phenocopy some of the aspects of 






analysis discussed above. These analyses altogether highlighted that loss of Kat2a leads to 
reduction in active mitochondrial mass which further impacts self-renewal potential and 
clonogenic expansion capacity of MLL-AF9 transformed cells in vitro. This was in line with 
the suggestion from literature that leukaemia stem cells showed increased mitochondrial mass 
with an increase in oxygen consumption and ATP production. These cells further exhibit 
increased fatty acid oxidation, consistent with high oxidative phosphorylation (OXPHOS) 
status and reduction in mitochondrial activity which led to enhanced anti-leukaemic effects 
(Bosc, Selak and Sarry, 2017). This was consistent with depletion of MLL- AF9 leukaemia 
stem-like cells in our study as a consequence of reduced mitochondrial activity upon Kat2a 
loss (Domingues et al., 2020).  
 
Notably, the observed reduced mitochondrial activity in RUNX1-RUNX1T1(9a) transformed 
Kat2a NULL pre-leukaemia cells may indicate alterations in metabolic landscape whereby the 
RUNX1-RUNX1T1(9a) transformed cells showed a reduction in mitochondrial respiration. 
This reduced dependency on mitochondrial respiration, in contrast to the above highlighted 
studies, may be associated with an enhanced cytoplasmic glycolysis (Simsek et al., 2010). 
Previous studies have indicated high glucose uptake rate displayed by AML cells (Cunningham 
and Kohno, 2016). In addition to this, studies have suggested that high levels of aerobic 
glycolysis at diagnosis were predictive for improved therapy response and survival of a small 
series of AML patients (Herst et al., 2011). Furthermore, a study conducted by Chen et al. 
showed that sera obtained from AML patients have a distinct glucose metabolic signature 
exhibiting significant alterations in six metabolites in this pathway. Among those, lactate, 2-
oxoglutarate, pyruvate, 2-HG, and glycerol-3-phosphate were found to be negatively 
associated with survival. There were no significant differences among distinct WHO AML 
subtypes, suggesting that this metabolic signature may be a consistent feature of AML 
independent of cytogenetic risk groups (Chen et al., 2014). Specifically, AML t(8;21) has been 
described to depend on glycolysis for its survival, which is further supported by the fact that 
the t(8;21) translocation positive Kasumi-1 cell line is highly sensitive to glycolysis inhibition, 
suggesting subtype specificity (Suganuma et al., 2010; Isa et al., 2018). A recent study further 
strengthened this notion by highlighting the role of ZBTB7A mutation frequently present in 
AML with t(8;21) translocation and correlated the loss of ZBTB7A with enhanced glycolysis 






that loss of ZBTB7A increases the expression of SLC glucose transporter genes as well as 
ENO2, PGM2, and PGM3, increasing glycolysis and sensitizing to glycolysis inhibition. 
Interestingly, inhibition of mitochondrial respiration revealed a profoundly increased 
glycolytic reserve in ZBTB7A knockout cells. They further showed that ZBTB7A can 
counteract RUNX1-RUNX1T1-dependent progenitor cell expansion through repression of 
glycolysis, opening up avenues for a targeted treatment of AML t(8;21) with metabolic 
inhibitors (Redondo Monte et al., 2020). However, it is worth noting that the reduced 
mitochondrial activity of  RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells may also be 
attributed to cells being in quiescent state and indicate their presence in disease relapse 
(Koeffler and Leong, 2017). 
 
Mitochondrial oxidative phosphorylation represents another aspect of mitochondrial 
bioenergetics which was found to be impaired upon Kat2a loss during RUNX1-RUNXT1(9a) 
pre-leukaemia. Mitochondrial DNA (mt-DNA) is composed of a double-stranded circular 
genome 16.6 kb in length without introns (Lang, Gray and Burger, 1999). It encodes 2 rRNAs, 
22 t-RNAs, and 13 of the 90 proteins in the mitochondrial respiratory chain. The 13 mt-DNA-
encoded proteins are translated by mitochondrial ribosomes within the mitochondrial matrix 
(Gaur et al., 2008). Mitochondrial ribosomes differ from eukaryotic cytosolic ribosomes in 
their structure and chemical properties (O’Brien, 2003). In addition, they use unique protein 
translation machinery including distinct initiation and elongation factors. These 13 mt-DNA-
encoded subunits of the electron transport chain are important for functional regulation of 
oxidative phosphorylation (Fukuda et al., 2007). 
 
In line with this, in this thesis, the role of mitochondrial translation was studied in both MLL-
AF9 and RUNX1-RUNXT1(9a) transformed Kat2a WT cells. For this, tigecycline, an inhibitor 
of mitochondrial translation was used. Tigecycline is a third generation tetracycline antibiotic 
that interferes with translation by blocking the interaction of aminoacyl-tRNA with the A site 
of the ribosome in mitochondria (as well as bacteria and eukaryotes) and has been proposed as 
a potential therapy in AML (Škrtić et al., 2011) (Lamb et al., 2015). The MLL-AF9 transformed 
Kat2a WT cells didn’t show any difference in colony forming potential upon treatment with 
Tigecycline, indicating that these cells may not be sensitive to mitochondrial translation 






a significant reduction in compact colonies representative of the colonies without any halo of 
migrating cells was observed, highlighting the presence of immature myeloid cells. These 
observations suggested that MLL-AF9 transformed cells may not be sensitive to tigecycline in 
terms of impacting the overall colony numbers, however, tigecycline treatment impacts the 
maintenance of self-renewal potential of these cells, highlighted by the reduced number of 
compact colonies. This reduction in compact colonies was accompanied by a gain in the 
proportion of non-compact colonies indicating that MLL-AF9 transformed Kat2a WT cells 
upon inhibition of mitochondrial translation activity may mimic some of the characteristics of 
Kat2a NULL cells. Thus, the inhibition of mitochondrial translation impacts the self-renewal 
potential of MLL-AF9 transformed Kat2a WT cells which is compatible with previous 
literature findings where tigecycline treatment impacts self-renewal of TEX and M9-ENL1 
AML cell lines and leads to a reduced repopulating ability of these treated cells observed in 
NOD/SCID Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice (Škrtić 
et al., 2011). 
 
The analysis was further extended to RUNX1-RUNX1T1(9a) leukaemia initiation set-up, where 
RUNX1-RUNX1T1(9a) transformed Kat2a WT cells upon treatment with tigecycline, showed 
reduced number of colonies at each plating suggesting that the cells undergoing transformation 
with RUNX1-RUNX1T1(9a) are sensitive to the inhibitor. This was consistent with previous 
studies (Rashkovan and Ferrando, 2019). Interestingly, post plating 3, which is when the 
percentage of RUNX1-RUNX1T1(9a) transformed cells is >99%, the number of colonies upon 
tigecycline treatment remained constant, perhaps indicating perpetuation of a particular 
population of cells. These cells perhaps reflect their dependency on glycolysis rather than 
oxidative phosphorylation as their primary source of energy, hence resistant to tigecycline 
treatment (Farge et al., 2017). These cell population upon characterization with flow cytometry 
indicated an increase in c-kit expression, in contrast to the observation in MLL-AF9 cells where 
no changes in c-kit expression was observed. This increase in c-kit expression in Kat2a WT 
cells undergoing transformation with RUNX1-RUNX1T1(9a) suggested an accumulation of 
immature myeloid progenitor cells, which was contrary to the observations in MLL-AF9 cells 
where an enhanced differentiation was observed upon tigecycline treatment, characterized by 
an increase in proportion of non-compact colonies. Although both the models highlight 






these observations may justify how Kat2a mediated impairment in mitochondrial biogenesis 
pathway associated genes may cause impairment in leukaemia stem-like cells in case of MLL-
AF9, whereas it leads to perpetuation of leukaemia initiating cells and further accelerate the 
disease progression in case of RUNX1-RUNX1T1(9a), suggesting a model-specific role.  
 
Overall, the analysis has an implication towards understanding the association of 
mitoribosomes in human pathologies using Kat2a perturbation. The defects in mitochondrial 
translational machinery can arise from mutations in the components of machinery, including 
tRNAs, aminoacyl-tRNA synthetases, translation factors, and ribosomal components (Vafai 
and Mootha, 2012; Boczonadi and Horvath, 2014), some of which have been documented 
before (Saada et al., 2007; Galmiche et al., 2011; Smits et al., 2011; Carroll et al., 2013). These 
mutations commonly cause instability of the protein, impaired assembly of the affected 
mitoribosomal subunit, a deficiency in oxidative phosphorylation, and a variety of severe 
phenotypes, including dysmorphism, lactic acidosis, neurological disorders, and 
cardiomyopathies, which are often fatal early in life.  
 
Since most of these proteins are involved in apoptotic signalling and the regulation of cell 
proliferation, their altered expression has been associated with the development of cancer 
(Greber and Ban, 2016; Kampen et al., 2020). Further to this, as indicated from the above 
experiments, elevated mitochondrial translation may be needed to provide the metabolic 
capacity to meet the energy requirements of cancer cells. Even though ATP production in 
cancer cells has long been thought to occur mostly by glycolysis in the cytoplasm (Hanahan 
and Weinberg, 2011), recent evidence has indicated that some types of cancer cells may rely 
heavily on oxidative phosphorylation in their mitochondria, utilizing metabolites provided by 
neighbouring glycolytic stromal cells (Pavlides et al., 2009) or by cancer cells in more poorly 
oxygenated regions of the cancer (Feron, 2009). In agreement with these ideas, the upregulation 
of a large number of mitoribosomal proteins has been observed in human breast cancer cells, 
but not in adjacent stromal cells, leading to the proposal that mitochondria fuel epithelial cancer 
cell metabolism (Sotgia et al., 2012). Therefore, targeting mitochondrial translation may be a 
promising strategy for cancer therapy (Lamb et al., 2015). Interfering with mitochondrial 
translation by treatment with tigecycline or the knock down of mitochondrial EFTu selectively 






suggesting that tigecycline may possibly be an anticancer agent (Järås and Ebert, 2011; Škrtić 
et al., 2011).  
 
7.3 Kat2a loss may serve as a model to study ribosomopathies 
 
The RUNX1-RUNX1T1(9a) pre-leukaemia transformation in Kat2a NULL cells also captured 
transcriptional instability in ribosomal biogenesis and cytoplasmic translation associated gene 
expression programmes. The consistent capture of these gene expression pathways in different 
comparisons during pre-leukaemia transformation as well as in the absence of Kat2a are 
compatible with insights from literature. Previous studies have shown that ribosomal 
biogenesis is corrupted during pre-leukaemia transformation in RUNX1 mutant haematopoietic 
Stem Progenitor cells (HSPCs) which correlated with lower rates of translation and a stress 
resistant phenotype, thus providing them with a selective advantage over normal HSCs in the 
bone marrow (Cai, Gao, Teng, Ge, et al., 2015). Further, studies have indicated that RUNX1-
RUNX1T1 binds to ribosomal DNA sequences and epigenetically regulates pre-rRNA 
synthesis (Bakshi et al., 2008). However, Kat2a associated impact on ribosomal biogenesis 
may be through Myc-dependent regulation of rRNA genes. Myc activates co-regulatory 
proteins, such as the transformation/transcription domain-associated protein (TRRAP) by 
binding to the promoter. TRRAP is part of the histone acetyltransferase (HAT) complex, which 
is responsible for targeting acetylation of histones through the acetyltransferase activity of the 
Kat2a, thereby impacting the transcription of rRNA genes (Gomez-Roman et al., 2003; Van 
Riggelen, Yetil and Felsher, 2010). Since, Kat2a directly targets Myc as shown by previous 
studies in our lab (Domingues et al., 2020), future studies may explore whether Myc dependent 
regulation of rRNA genes is via Kat2a mediated acetylation. 
 
On these lines, the impact of Kat2a loss was studied on protein synthesis rate using OP-Puro 
incorporation method (Hidalgo San Jose and Signer, 2019) where a significant reduction in 
OP-Puro high (Hi) cell population was observed within the Lin-c-kit+ compartment of cells in 
Kat2a NULL cells transformed with Idh1R132H mutation. This was also accompanied by a 
gain in OP-Puro low (Lo) cell population, suggesting that loss of Kat2a reduces translation rate 
in Idh1R132H pre-leukaemia cells. These observations were compatible with previous studies 






programmes was suggested, based on scRNA-seq analysis in MLL-AF9 transformed Kat2a 
NULL cells. Upon performing OP-Puro incorporation assay in a subset of leukaemia cells 
defined by Lin-Kit+Sca1-CD34+FCgR+ (L-GMPs), a reduction in protein synthesis was 
observed in Kat2a NULL cells (Domingues et al., 2020), in line with the insights from 
Idh1R132H pre-leukaemia cells. Altogether, the analysis suggested that depletion in ribosomal 
biosynthetic programmes can impact Kat2a mediated pre-leukaemia progression by providing 
a selective advantage to the transformed cells over normal HSCs in the bone marrow, 
compatible with the observation made by Speck and colleagues (Cai, Gao, Teng, Mason, et al., 
2015). 
 
The mechanistic association of impairment of ribosomal biosynthetic programmes during pre-
leukaemia transformation was confirmed using S6K1 inhibitor which acts on S6K1 isoform of 
p70 ribosomal S6 kinase and thus inhibits protein synthesis (Pearce et al., 2010). S6K1 is a 
member of the A, G, and C family of serine/threonine protein kinases and is a key regulator of 
cellular metabolism. S6K1-deficient mice are smaller than wild-type littermates and display 
hypoinsulinemia and glucose intolerance (SH, D and G, 2006). To mediate its effects on 
metabolic pathways, S6K1 phosphorylates a number of downstream substrates including the 
small ribosomal subunit protein S6 (rpS6) (Salmond et al., 2015). Kat2a WT cells undergoing 
transformation with RUNX1-RUNX1T1(9a) showed an enhanced colony forming potential at 
plating 2 upon S6K1 inhibition, compatible with the insights from scRNA-seq analysis 
suggesting that impairment of ribosomal biogenesis/cytoplasmic translation may contribute 
towards the acceleration in pre-leukaemia transformation. This increase in colony forming 
potential was lost markedly upon plating 3 indicating that inhibition of cytoplasmic translation 
is beneficial for RUNX1-RUNX1T1(9a) pre-leukaemia progression during early stages of 
transformation. Similar observations were made for Idh1R132H transformed Kat2a WT cells 
indicating that inhibition of cytoplasmic translation is beneficial for RUNX1-RUNX1T1(9a) 
and Idh1R132H pre-leukaemia progression during early stages of transformation.  
 
The analysis was further extended to study association with MLL-AF9 transformed cells based 
on the scRNA-seq data on MLL-AF9 leukaemias revealing ribosomal biogenesis/cytoplasmic 
translation amongst the top enriched categories which were found to be downregulated upon 






vitro upon S6K1 inhibition showed a reduction in colony forming potential, in line with the 
observation in MLL-AF9 model where loss of Kat2a aids in depletion of leukaemia stem-like 
cells (Domingues et al., 2020). Upon further characterization of colonies, a significant 
reduction in compact colonies, representative of immature myeloid cells, was observed which 
was complemented by a gain in mixed and dispersed colonies representing differentiated 
macrophages. Overall, the S6K1 inhibition study showed contrasting dependencies on 
ribosomal biosynthetic programmes in RUNX1-RUNX1T1(9a) and Idh1R132H pre-leukaemia 
models compared to MLL-AF9 maintenance model, consistent with the insights drawn from 
mitochondrial bioenergetics associated mechanistic experiments. The analysis suggested that 
early reduction in expression of genes associated with ribosomal biosynthetic programmes 
associated may contribute towards perpetuation of leukaemia initiating cells and further 
accelerate disease progression in RUNX1-RUNX1T1(9a). However, once the leukaemia is 
established, inhibition of ribosomal biogenesis assembly promotes cellular differentiation 
leading to delayed leukaemogenesis as observed in MLL-AF9 leukaemia, suggesting the stage-
specific role of ribosomal biosynthetic programmes during leukaemia progression. 
 
The mechanistic association of impairment in ribosomal biosynthetic programmes during 
RUNX1-RUNX1T1(9a) and Idh1R132H leukaemia initiation was consistent with the defects in 
ribosome biogenesis observed in different haematological malignancies including, Diamond-
Blackfan anaemia (DBA). DBA is a congenital syndrome associated with anaemia, physical 
malformations, and cancer (Vlachos et al., 2012b). In the majority of individuals with DBA, 
mutations or gene deletions of a subset of ribosomal proteins are found, with RPS19 mutations 
accounting for about 25% of all cases (Flygare et al., 2007; Devlin et al., 2010). The major 
mechanism of DBA disease progression is associated with haploinsufficiency of a ribosomal 
protein that disrupts the processing of pre-ribosomal RNA (pre-rRNA), leading to abortive 
ribosome biogenesis (Choesmel et al., 2007; Farrar et al., 2014). Individuals with DBA have 
an increased frequency of both solid cancers and leukaemia (Vlachos et al., 2012b), where 
specifically RPL5 or RPL11 loss-of-function have been observed to predispose DBA patients 
to cancer by loss of capacity to activate the TP53 tumour suppressor (Molavi, Samadi and 
Hosseingholi, 2019). DBA shows an enhanced erythroid defect which can be attributed to 
mutations in RPS19 and RPL11 which reduce Internal Ribosome Entry Site (IRES)-mediated 






models and patient samples (Horos et al., 2012). In contrast to this, impairment of ribosomal 
biogenesis upon Kat2a loss did not show defects associated with any haematopoietic 
compartment including in RUNX1-RUNX1T1(9a), Idh1R132H, and MLL-AF9 models of 
leukaemia (Domingues et al., 2020), suggesting that the observations might be disease-
specific.  
 
Somatic recurrent ribosomal protein mutations and deletions have also been detected in T-cell 
acute lymphoblastic leukaemia (T-ALL), where low frequency mutations in RPL11 are 
observed (Tzoneva et al., 2013b). In addition to this, heterozygous loss of RPL5 by deletions 
or inactivating mutations has been shown to occur in 2% of T-ALL samples whereas mutations 
or deletions in RPL22 were described in 4% of T-ALL samples indicating the disease 
progression to be dependent on reduced ribosomal activity (De Keersmaecker et al., 2013b; 
Liu et al., 2017). 20% of the relapsed chronic lymphoid leukaemia (CLL) patients show 
mutations in RPS15 thereby suggesting that reduced levels of mature ribosomes and lower 
overall translation weaken the cells and promote a quiescent state (Ljungström et al., 2016b; 
Bretones et al., 2018). These observations are overall compatible with the reduction in 
ribosomal activity in RUNX1-RUNX1T1(9a) pre-leukaemia upon Kat2a loss and indicate that 
Kat2a loss may serve as a model to study ribosomopathies as a cause of leukaemia 
transformation.  
 
7.4 Loss of Kat2a promotes cellular diversification with an increase in transcriptional 
variability 
 
Pre-leukaemia cells serve as reservoir of early haematopoietic multipotent progenitors which 
are capable of diversifying during the process of leukaemia development. This cellular 
diversification usually occurs in a discontinuous manner which further gives rise to discrete 
developmental stages, including progenitor and differentiated states, as well as discrete 
lineages and terminally differentiated types (Koeffler and Leong, 2017). This process of cell 
dynamics is somewhat similar to the stages of development and was first noted by C. 
Waddington in the 1940s. His landscape describes an iconic picture where a marble rolls down 
a surface, staying in valleys and seeking the lowest point. At watersheds, the valleys branch so 






developing cell in an embryo and the landscape epitomizes some more abstract set of 
constraints, thus clearly heralding the notions of stability and instability in the modern sense 
of dynamics (Wang et al., 2011). Indeed, it has recently become clear that Waddington’s 
epigenetic landscape in principle represents the dynamics of a system of gene regulatory 
interactions that impose constraints to and drive cell development (Huang, 2009; MacArthur, 
Maayan and Lemischka, 2009), giving a metaphor for the qualitative understanding of 
developmental processes of cells. However, similar understanding on how the dynamics of a 
gene regulatory circuit governs binary cell fate decisions aiding in pre-leukaemia to leukaemia 
progression is yet to be explored.  
 
The phenomenon of cellular diversification is an independent and reproducible phenomenon 
and has been seen in case of various developmental systems including embryonic and 
haematopoietic systems (Kamminga et al., 2000; Keller, 2005; Lüer and Technau, 2009). The 
consequent process of cell fate specification highlights the relationship between cell lineages 
and genetic programmes and can be defined as a sequence of instructions associated with a 
given fate, specific decision events, directionality, and a means of apportioning a defined 
numbers of cells to particular fates to generate proportionate tissues. Herein, the mammalian 
homolog of Gcn5, known as Kat2a, has been utilized as a tool to study binary cell fate decisions 
contributing towards pre-leukaemia to leukaemia progression. Kat2a is a well-established 
regulator of stochastic transcriptional regulation (Raser and O’Shea, 2004b), the deletion of 
which results in mutants possessing enhanced cell-to-cell transcriptional variability in gene 
expression as measured across a range of locus fluorescence reporters (Weinberger et al., 
2012b). The cell-to-cell transcriptional variability reflects the variability in the number of 
mRNA molecules produced from a given locus at a certain time point (Ko, 1991; Mcadams 
and Arkin, 1997). The same can be measured on the basis of snapshot analysis performed on 
gene expression studies (Sanchez, Choubey and Kondev, 2013). One of the major causes 
behind the phenomenon of cell-to-cell gene expression variability is the occurrence of 
transcription in the form of ‘bursts’ (Cai, Friedman and Xie, 2006). mRNA is produced from 
the promoter of a gene in the form of bursts, switching between periods of prolonged inactive 
(or ‘off’) states and short-lived active (or ‘on’) states (Thattai and Van Oudenaarden, 2001). 
Most gene loci reflect the phenomenon of transcriptional bursting with a characteristic size and 






individual bursts and burst frequency reflects the rate at which the promoter is engaged in 
active transcription (Peccoud and Ycart, 1995; Kumar, Singh and Kulkarni, 2015). These rates 
of binding and dissociation are majorly dependent on protein availability and the presence of 
other bound proteins. Both burst size and burst frequency contribute to mean gene expression, 
whereas transcriptional variability is more strictly dependent and shown to be anti-correlated 
with burst frequency (Hornung et al., 2012a). The size and frequency of bursts in yeast are 
increased through histone acetylation of genes and promoters, respectively (Weinberger et al., 
2012b). In this study, the presence of transcriptional variability was assessed during RUNX1-
RUNX1T1(9a) pre-leukaemia transformation upon Kat2a loss, based on a Spearman’s 
correlation coefficient measuring cell-to-cell variability.  
 
The global comparison indicated an increase in transcriptional variability upon loss of Kat2a 
at respective time points. The increase in transcriptional variability upon Kat2a loss was more 
evident at 2 months compared to 4 months, compatible with the cellular dynamics observed at 
early stages of pre-leukaemia transformation. Further, there was a reduction in transcriptional 
variability at 4 months compared to 2 months in both the genotypes, perhaps indicating that 
increase in cell-to-cell transcriptional variability is the hallmark of an early pre-leukaemia 
transformation event. The increase in transcriptional variability was compatible with the 
previous laboratory work on MLL-AF9 model of leukaemia where a significant increase in 
gene expression variability was measured by increase in coefficient of variation upon Kat2a 
loss. This increase in transcriptional variability in MLL-AF9 transformed Kat2a knockout 
leukaemias was evident at all levels of gene expression and associated with greater cell-to-cell 
dispersion in transcript levels (Domingues et al., 2020). The variability in transcript levels was 
attributed to a change in burst frequency but not in burst size, in line with the evident role of 
yeast orthologue, Gcn5 (Weinberger et al., 2012b). 
 
Cell-to-cell variation in gene expression and fluctuations over time in single cells have broad 
implications. This noisy gene expression is often perceived as undesirable and unpredictable; 
however, living systems are inherently noisy and are optimized to function in the presence of 
stochastic fluctuations (McAdams and Arkin, 1999).  The variability in gene expression is 
sometimes considered harmful as it distorts cell signals, corrupts circadian clocks, and disrupts 






Ehrenberg, 2000). On the other hand, some organisms can exploit stochasticity to introduce 
diversity into a population, as occurs with the lysis–lysogeny bifurcation in phage λ (Robb and 
Shahrezaei, 2014) or the DNA inversion mechanism in bacteria (Van de Putte and Goosen, 
1992). The variability in gene expression has also been directly implicated as a mechanism of 
cell fate choice in yeast (Blake et al., 2006b) and has been previously shown to be associated 
with normal transitions into haematopoietic lineage specification (Pina et al., 2012; Teles et 
al., 2013).  
 
The cell-fate decisions and lineage dependencies upon Kat2a loss were studied during RUNX1-
RUNX1T1(9a) pre-leukaemia transformation using pseudotemporal ordering. Pseudotemporal 
ordering of RUNX1-RUNX1T1(9a) transformed Kat2a WT cells resulted in a linear trajectory, 
starting from a cell population marked by c-Kit+Ly6ehiCd34+Flt3+, representing lymphoid 
primed multipotential progenitor candidates (LMPP) with a subset of cells highlighted by c-
Kit+Ly6ehiCd34+Flt3-, representing the presence of multipotent progenitors (MPP). These 
populations were identified based on previous literature insights (Weissman and Shizuru, 
2008)(Doulatov et al., 2012). This cell population characterized by LMPP-like and MPP was 
enriched in Kat2a WT cells collected at 2 months post transplantation, suggesting that these 
cells are still at the early stages of haematopoietic hierarchy and haven’t yet progressed to pre-
leukaemia transformation. These multipotent progenitors then showed a bifurcation, one arm 
of which was towards Granulocyte-Macrophage Progenitor (GMP)-like population highlighted 
by Ly6eloCd34+Fcgr3+, whereas the other arm showed the presence of monocyte-macrophage 
population characterized by Cd14+Cd74+Mafb+Mafg+. The GMP-like population was 
relatively more enriched in Kat2a WT cells collected 4 months post transplantation confirming 
the pre-leukaemia hierarchical progression of RUNX1-RUNX1T1(9a) transformed Kat2a WT 
cells. The monocyte-macrophage arm of the trajectory included Kat2a WT cells processed 2 
months post transplantation suggesting that differentiation of RUNX1-RUNX1T1(9a) 
transformed Kat2a WT cells towards monocytic lineage is an early event during RUNX1-
RUNX1T1(9a) pre-leukaemia transformation.  
 
Similarly, pseudotemporal ordering of RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells 
was performed which yielded a relatively branched trajectory. This was in contrast to the 






transcriptional profiles which further leads to varied cellular trajectories during the process of 
RUNX1-RUNX1T1(9a) pre-leukaemia transformation. The different subsets of cell population 
present in the Kat2a NULL trajectory overlaid with the cellular population identified in the 
trajectory pursued by Kat2a WT cells, including the presence of LMPP-like and MPP-like 
cells. However, I observed emergence of three different branches from LMPP-like cell 
population, two of which coincided with the Kat2a WT trajectory and were identified as GMP-
like and monocyte-macrophage-like. In this case, however, the proportion of cells belonging 
to monocyte-macrophage-like cell population were higher compared to Kat2a WT cells, 
indicating that loss of Kat2a may promote differentiation towards monocytic lineage during 
the process of RUNX1-RUNX1T1(9a) pre-leukaemia transformation.  
 
Overall, the analysis captured different compartments of haematopoietic hierarchy which led 
towards accumulation of RUNX1-RUNX1T1+ pre-leukaemic progenitor cells, in line with the 
insights obtained from in vivo analysis of RUNX1-RUNX1T1(9a) pre-leukaemia cells, where 
an accumulation of early myeloid progenitors denoted by GFP+c-Kit+FcgR+ was observed. The 
global trajectory analysis indicated a cell population marked by c-Kit+Ly6ehiCd34+Flt3+, 
representing lymphoid primed multipotential progenitor candidates (LMPP) with a subset of 
cells marked by c-Kit+Ly6ehiCd34+Flt3-, representing the presence of multipotent progenitors 
(MPP). These multipotent progenitors then showed a bifurcation, one arm of which was 
towards Granulocyte-Macrophage Progenitor (GMP)-like population marked by 
Ly6eloCd34+Fcgr3+, whereas the other arm showed the presence of monocyte-macrophage 
population as well as B-cell lymphocyte progenitors characterized by Cd14+Cd74+Mafb+Mafg+ 
and Cd79a+Cd19+Il7r+, respectively. The monocyte-macrophage arm along with B-cell 
lymphocyte progenitors present in the trajectory were enriched in Kat2a NULL cells processed 
2 months post transplantation suggesting that differentiation of RUNX1-RUNX1T1(9a) 
transformed Kat2a NULL cells towards monocytic and B-lymphocytic lineage is an early event 
during RUNX1-RUNX1T1(9a) pre-leukaemia transformation. The hierarchical organization of 
trajectory from LMPP to GMP coincided with the changes in cell-to-cell transcriptional 
variability with a marked reduction from LMPP-like to GMP. However, consistent with global 
observations, an increase in gene expression variability was observed in individual cell 







The early loss of Kat2a indicated cellular differentiation towards B-cell and monocytic lineages 
suggesting that loss of Kat2a is capable of diversifying the pre-leukaemic population of cells. 
These observations were experimentally validated by utilising an in vitro set-up where both 
Kat2a WT and Kat2a NULL cells were transduced with RUNX1-RUNX1T1(9a) and the levels 
of B220, a B-cell marker, were assessed using flow cytometry. The analysis indicated an 
increase in B-cell population upon Kat2a loss. A similar observation for F4/80, a monocyte 
marker, was made, where an increase in F4/80 expression was observed in Kat2a NULL cells 
undergoing transformation with RUNX1-RUNX1T1(9a). Strikingly, none of these observations 
held true in further re-platings, confirming that the differentiation towards B-cell and 
monocytic lineage is an early effect seen upon loss of Kat2a. However, it is worth noting that 
these observations may be consequent to the fact that these cells were maintained in myeloid 
culture conditions and continued serial replating selects for the cells with enhanced self-
renewal potential. The presence of monocytic differentiation upon Kat2a loss in RUNX1-
RUNX1T1(9a) pre-leukaemia was consistent with the previous work conducted in our lab 
where MLL-AF9 transformed cells in absence of Kat2a also showed an enhanced monocytic 
differentiation as marked by an enhanced expression of Cd11b monocytic marker (Domingues 
et al., 2020). The differentiation towards B-cell lymphocytic lineage was also in line with the 
literature insights pointing towards an aberrant expression of B-cell markers, like Cd19 and 
Cd79a, due to constituent expression of B-cell transcription factor PAX5 in t(8;21) patient-
derived cells, which binds to the promoter and enhancer of some of these genes and thus 
contributes towards their aberrant expression through epigenetic regulation (Walter et al., 
2010) (Kostareli et al., 2012). Moreover, the yeast homologue of Kat2a, known as Gcn5, has 
been found to participate in transcriptional regulation of the IgM H-chain gene via histone 
acetylation in immature B-cells, suggesting it’s key role in epigenetic regulation of B cell 
functions (Kikuchi et al., 2014b, 2014a). Overall, these insights were consistent with our 
observations in MLL-AF9 leukaemia where Kat2a depletion enhanced the probability of 
differentiation cell fate transitions (Domingues et al., 2020). This was also akin to previous lab 
observations on depletion of Kat2a in mouse embryonic stem cells where an increase in gene 
expression variability was negatively correlated with stabilization of pluripotency (Moris et 







Upon following the pre-leukaemia transformation hierarchy based on the progression of 
myeloid arm of bifurcation, pre-leukaemia progenitors were identified marked by c-Kit+Ly6e-
Fcgr3+, compatible with the characterization of pre-leukaemia in vivo. These cells were majorly 
enriched in Kat2a WT and Kat2a NULL cells studied at 4 months post-transplantation, thus 
highlighting an accumulation with respect to time. The gradual building-up of leukaemia 
progenitors with time coincided with the progressive RUNX1-RUNX1T1(9a) transformation. 
The increased accumulation of leukaemia progenitors upon Kat2a loss at respective time points 
was in line with the in vivo observation of accelerated leukaemia progression upon loss of 
Kat2a. These cells upon further characterization were found to have higher average expression 
of RUNX1-RUNX1T1 (Ptasinska et al., 2012) which were exclusively present in this 
compartment of cells, thus suggesting the presence of leukaemia-associated events. 
Furthermore, a gradual reduction in Kat2a targets was observed in the leukaemia progenitor 
cells relative to LMPP-like and GMP population highlighting Kat2a mediated events in this 
compartment of cells. Accordingly, the progression from GMP to pre-leukaemia was marked 
by an increase in gene expression variability, consistent with the presence of leukaemia 
associated events and in line with our previous observations in MLL-AF9 model of leukaemia 
(Domingues et al., 2020). Altogether, the trajectory analysis suggested the propensity of early 
progenitors to diverge towards RUNX1-RUNX1T1(9a) mediated transformation upon Kat2a 
loss, as evident from the accumulation of pre-leukaemia progenitors. 
 
One of the ways by which cells can change their state is by stochastic fluctuations that allow 
them to jump around the landscape without requiring any parameter changes (Moris, Pina and 
Arias, 2016b). These stochastic fluctuations are an intrinsic feature of some biological systems, 
especially with respect to transcription in which low numbers of transcription factors and DNA 
molecules can cause sporadic engagement of RNA polymerase and lead to discontinuous 
mRNA synthesis (Raj and van Oudenaarden, 2008) (Eldar and Elowitz, 2010) resulting in 
deviations from the stable cell state. Usually, these perturbations are small enough allowing 
the system to be back to its original stable state. On the other hand, these events could represent 
stochastic fluctuations of transcription factor levels over a threshold that proves sufficient to 
promote cell identity changes (Schröter et al., 2015). Such events have been observed in 






Stochastic fluctuations might also apply to embryonic stem cell populations and in general in 
eukaryotic stem cells (Arias and Hayward, 2006; Martinez Arias and Brickman, 2011). 
 
Strikingly, the proportion of cells belonging to GMP compartment including both Kat2a WT 
and Kat2a NULL population at 2 months was lower than the combined Kat2a WT and Kat2a 
NULL population of cells at 4 months pointing towards an abrupt transformation trajectory 
owing to the enhanced transcriptional variability observed upon trajectory analysis. This 
observation suggested that gene expression variability during pre-leukaemia transformation 
need not align through time along an ordered continuum and could instead be interpreted as a 
reflection of systemic features that allow a cell to stochastically rearrange its networks. It may 
also suggest that the actual transitions between states might be discontinuous, and that the 
observed cell-to-cell transcriptional variability in pre-leukaemia compartment may reflect the 
existence of a dynamic array of transcriptional states, with varied probability of transitions. 
Previous literature insights suggest that discontinuous fate decisions may occur in few systems 
including haematopoietic system in the case of early myelo-erythroid choices in mouse 
haematopoiesis and in human haematopoietic stem cells that can give rise to differentiated cells 
directly without going through multilineage intermediates (Pina et al., 2012; Notta et al., 2016). 
In fact, discontinuity in cell-fate trajectories has been observed upon loss of Kat2a in MLL-
AF9 leukaemia where Kat2a WT MLL-AF9 cells aligned along an almost linear trajectory. This 
was in contrast to Kat2a knockout MLL-AF9 leukaemia cells which were distributed along 
multiple differentiation trajectories. These multiple trajectories reflected multiple 
uncoordinated routes into cell fate decision-making, which were initiated but not coherently 
completed by cells depleted of stem cell potential (Domingues et al., 2020). Similar insights 
were obtained upon Kat2a depletion in mouse embryonic stem cells where Kat2a-inhibited 
cells were incapable of sustaining pluripotency, but lagged in their ability to proceed through 
lineage differentiation (Moris et al., 2018b).  
 
Altogether, the insights generated from lineage dependency studies suggested that loss of 
Kat2a enhances the propensity of cell fate transitions which results in increased molecular 
heterogeneity and stochastic fate choices. Kat2a loss likely facilitates rather than determines 
fate acquisition by increasing cell-to-cell gene expression variability and may function 






understanding the gene regulatory modules associated with individual cell state and during the 
process of diversification and may aid in a better molecular understanding of cell fate dynamics 
induced upon Kat2a loss during pre-leukaemia. 
 
7.5 Increase in transcriptional variability upon Kat2a loss may be consequential to 
differential chromatin accessibility  
 
The process of cell-fate decision making requires changes in transcriptional state of a cell. The 
transcription of a gene requires interaction with histone modifiers and chromatin remodellers, 
which further determine the accessibility of the transcription factors to the DNA and their 
binding stability (Moris, Pina and Arias, 2016b). The alterations in chromatin accessibility may 
act as a key to changing the coordinates of the transcriptional state of a cell (Swain, Elowitz 
and Siggia, 2002; Chalancon et al., 2012). For example, the binding of transcription factors 
can define cellular state by activating specific genes and thus define which gene regulatory 
modules will be active. To associate gene expression variability observed upon Kat2a loss with 
alteration in chromatin accessibility patterns, single-cell ATAC sequencing was performed. 
Single-cell Assay for Transposase Accessible Chromatin-sequencing or scATAC-seq is a 
method which employs Tn5 transposase, which simultaneously tags and fragments DNA 
sequences in open chromatin regions, and reveals the interplay between genomic locations of 
open chromatin, DNA-binding proteins, individual nucleosomes and chromatin compaction at 
single-cell resolution (Buenrostro et al., 2015b). The assay was performed on Kasumi-1 cells 
representative of the same primary genetic alteration, RUNX1-RUNX1T1(9a).  
 
Upon performing differential accessibility analysis using fisher exact test and information gain 
methods (Baker et al., 2019), 50 peaks were characterized as being unique to DMSO, 520 peaks 
unique to MB-3 and 3587 peaks which were attributed as common set of peaks. Strikingly, 
within the common subset of peaks, no significant differences were observed in terms of 
differential accessibility upon inhibition of KAT2A suggesting that attenuating KAT2A 
activity does not impact global chromatin accessibility in Kasumi-1 cells. This was 
unsurprising given the acetyltransferase activity of Kat2a and capability to act as a chromatin 
remodeller by stabilising transcription rather than initiating it (Jin et al., 2014). Although, this 






observed in RUNX1-RUNX1T1(9a) transformed Kat2a NULL cells at 4 months relative to 
Kat2a WT cells within the leukaemia progenitor compartment obtained from scRNA-seq data, 
likely due to establishment of leukaemia by that time point of sampling. However, unpublished 
analysis in the Pina lab using scRNA-seq of MB-3 treated Kasumi-1 cells highlighted enhanced 
cell-to-cell transcriptional variability upon inhibition of KAT2A. These findings overall 
indicated that increase in transcriptional variability cannot be solely attributed to differential 
chromatin accessibility patterns.  
 
The analysis conducted on understanding the region-gene associations suggested an overall 
rearrangement in the distribution of peaks upon KAT2A inhibition, based on their vicinity with 
TSS. In control samples treated with DMSO, 41.66% of the peaks were found to be proximal 
to TSS whereas in case of MB-3 treated cells, 37.68% of the peaks were proximal to TSS. 
However, an enhanced chromatin accessibility was observed at distal peaks upon KAT2A 
inhibition where 38.69% of the distal peaks were annotated compared to 30.55% of the peaks 
in control cells. This may indicate a crosstalk between the proximal and distal regulatory 
regions speculating about higher order chromatin organization of KAT2A associated targets. 
This was compatible with the previous observations in our lab where Kat2a loss in primary 
MLL-AF9 cells was found to be associated with mild increase in H3K9ac, a mark deposited by 
Kat2a, at candidate active enhancer regions. These candidate enhancer regions were identified 
by the presence of H3K27ac, suggesting a possible pattern of imbalance of H3K9ac regulation 
between promoters and enhancers (Domingues et al., 2020). 
 
Going forward, it will be interesting to develop an understanding towards this promoter vs 
enhancer specificity observed upon inhibition of KAT2A, in light of the enhancer-promoter 
interaction via CTCF binding. CTCF gene encodes a transcriptional regulator protein with 11 
highly conserved zinc finger domains. The using of different combination of eleven ZF 
domains allows this protein to bind different DNA sequence and interact with various protein 
factors (Ohlsson, Renkawitz and Lobanenkov, 2001) (Ren and Zhao, 2019). A recent study has 
suggested that there is a conserved subset of CTCF sites using prostate cancer as a model 
system, which are resistant to CTCF depletion. The authors have further proposed that these 
persistent CTCF sites are essential for constitutive higher order chromatin architecture and the 







CTCF binding sites are present widely in genome and a majority of them are located within 
Topologically Associated Domains (TADs), defined as megabase-sized local chromatin 
interaction domains (Nora et al., 2020). these intra-domain CTCF binding sites are in the close 
vicinity of potential enhancers of transcription, as marked by p300 and H3K4me1, and thus 
may influence the activity of enhancers (Ren and Zhao, 2019). A study performed on utilising 
chromosome conformation capture carbon copy (5C) technology in human cell lines 
specifically, GM12878, K562 and HeLa-S3 cells, found that a fraction of CTCF enriched distal 
elements significantly interact with gene promoters. These findings suggested that one of the 
main roles of CTCF in genome function may be to facilitate the interaction between regulatory 
sequences and promoters (Sanyal et al., 2012). Since distal enhancers must physically contact 
with their target promoters to carry out their activity, the nearby CTCF molecules may bring 
enhancers to the vicinity of their target promoters (Ren et al., 2017b; Nora et al., 2020). CTCF 
can mediate the enhancer-promoter contact through the interaction between CTCF bound 
nearby enhancers and cohesin loaded nearby promoters (Fudenberg et al., 2016; 
Merkenschlager and Nora, 2016). Liu and colleagues reported that regulatory elements-bound 
CTCF and cohesin can recruit the core promoter factor TAF3 and mediate its contact with 
promoters through TAF3-dependent loop formation in ES cells. They further showed that 
depletion of CTCF reduces the efficient recruitment of TAF3 to distal regulatory elements, 
compromises endoderm differentiation marker gene expression, such as Gata4, Afp, and 
Apoa1(Liu et al., 2011). Another example from a relatively recent study highlighted the 
interaction between CTCF and enzyme poly-ADP-ribose (PARP1), which allows 
establishment of inter-chromosomal contacts between active circadian loci and repressive 
chromatin at the lamina, thereby mediates circadian transcriptional plasticity (Zhao et al., 
2015). These studies highlighted the role of promoter-enhancer interaction facilitated by CTCF 
in changing the transcriptional landscape of cells. 
 
As discussed earlier, recent studies have indicated the role of promoter sequence, nucleosome 
positioning, epigenetic modifications, and three-dimensional genome organization 
contributing towards regulation of gene expression (Chalancon et al., 2012). On similar lines, 
gene expression variation may result from any fluctuation of above-mentioned factors, 






gene expression variability with CTCF mediated interactions where CTCF-bound T cell-
specific genes GATA3, CD90, CD28, CD5 displayed significantly increased expression 
variation in CTCF depleted cells (Ren et al., 2017b). However, the increased cell-to-cell 
variation of expression by knocking down of CTCF could also be accounted for by the 
heterogeneous CTCF knockdown efficiency across different cells. Conclusive evidence came 
from the deletion of a specific CTCF binding site at Thy1 locus, nearby a distal enhancer, using 
CRISPR/CAS9, which resulted in a significantly higher cell-to-cell variation of gene 
expression in the CRISPR knockout cells. The enhanced variability in gene expression by 
deletion of CTCF binding site at Thy1 locus was correlated with decreased Thy1 promoter-
enhancer interaction but not changes in the TAD structure, strongly suggesting a model that 
CTCF binding near the enhancer region stabilizes the interaction between the Thy1 promoter 
and its enhancers and thus reduces the cell-to-cell variation of Thy1 expression (Ren et al., 
2017b). These observations were compatible with the increase in cell-to-cell transcriptional 
variability observed in both MLL-AF9 and RUNX1-RUNX1T1(9a) models of leukaemia. These 
insights hold more relevance as H3K9ac-depleted promoters in Kat2a knockout MLL-AF9 
leukaemia cells had a significant association with CTCF binding leading to speculation that 
CTCF may be dislodged to enhancers and promote asymmetric distribution of histone 
acetylation marks, with dysregulation of locus control. 
 
Although inhibition of KAT2A did not reveal any global changes in chromatin architecture in 
Kasumi-1 cells, upon segregating the cells based on dimensionality reduction algorithm and 
further k-medoid clustering, the KAT2A inhibited cells corresponded to two different clusters. 
The presence of two different clusters upon KAT2A inhibition pointed towards the presence 
of differential peak footprint which may be consequential to the rearrangement in the 
distribution of peaks which were observed upon KAT2A inhibition. The peaks segregating 
these two clusters upon MB-3 treatment contributed towards cell cycle specifically G2/M 
transition as well as monocytic differentiation, suggesting diversification of cellular states upon 
KAT2A inhibition. This was compatible with insights from scRNA-seq obtained from RUNX1-
RUNX1T1(9a) pre-leukaemia. The higher accessibility peaks obtained upon comparing 
individual cluster with respect to control cells were biologically interpreted as the genes 
contributing to cell cycle, DNA repair, epigenetic modifications, and protein ubiquitination, in 






transformation. Interestingly, the genes associated with mitochondrial bioenergetics and 
ribosomal biosynthetic programmes, which were captured in scRNA-seq data generated from 
RUNX1-RUNX1T1(9a) pre-leukaemia, did not show up in scATAC-seq analysis. This could 
potentially be due to the fact that these are highly expressed genes and its unlikely to attribute 
small changes in gene expression to gain in chromatin accessibility. The regulation of these 
genes is likely to be more subtle. Moreover, the capturing of DNA repair associated genes may 
highlight the incidence of increase in DNA damage during the progression of RUNX1-
RUNX1T1(9a) leukaemia, in line with the notion that Kat2a/Gcn5 is required for double-strand 
break DNA repair (Salunkhe et al., 2018), and something which can be explored in detail in 
future. Although gH2AX staining did not suggest increased DNA damage upon Kat2a loss in 
case of Idh1R132H model of pre-leukaemia, this was one of the aspects of studying DNA 
damage and there may be other mechanisms of inducing DNA damage during pre-leukaemia 
transformation upon loss of Kat2a. The gene expression programmes including protein 
ubiquitination, cell cycle and epigenetic modifications were also captured consistently in time 
series comparison conducted using scRNA-seq data individually for Kat2a WT cells and Kat2a 
NULL cells during RUNX1-RUNX1T1(9a) pre-leukaemia progression and are compatible with 
literature on gene expression programmes impacted in RUNX1-RUNX1T1(9a) leukaemia 
(Ptasinska et al., 2012, 2014; Martinez-Soria et al., 2018; Nafria et al., 2020). Interestingly, 
some of these genes, specifically the ones contributing to higher cellular metabolism, were 
captured during the intermediate stages of RUNX1-RUNX1T1(9a) pre-leukaemia hierarchy of 
progression, potentially linking epigenomic rewiring to stochastic gene expression. 
 
This was further validated by integrating the information obtained from scATAC-seq analysis 
on Kasumi-1 cells with the scRNA-seq analysis performed on RUNX1-RUNX1T1(9a) pre-
leukaemia cells. For this, the genes having higher accessibility in one of the MB-3 clusters 
were utilized for pairwise distance measures using RUNX1-RUNX1T1(9a) pre-leukaemia 
scRNA-seq data. These genes showed an increase in cell-to-cell transcriptional variability in 
Kat2a NULL cells both at 2 months and 4 months with respective Kat2a WT cells, consistent 
with the previous observations from RUNX1-RUNX1T1(9a) pre-leukaemia. Further, these 
genes showed an increase in cell-to-cell transcriptional variability in leukaemia progenitor cells 
compared to LMPP-like and GMP-like population of cells, in line with the previous scRNA-






variability observed upon Kat2a loss during RUNX1-RUNX1T1(9a) pre-leukaemia 
progression, with differential chromatin accessibility. This association was compatible with 
previous literature findings where locally disordered methylation arising from stochastic 
process in primary leukaemia cells was associated with relatively more noisy transcriptional 
landscape suggesting an association between promoter methylation and gene expression 
(Landau et al., 2014). Another study conducted by Mason and colleagues showed that the genes 
containing shifts in epiallele composition at promoters exhibited significantly greater variance 
in their transcript abundance between relapse and diagnosis, as compared to genes without such 
epiallele shifts in their promoters. Further, the genes which were differentially expressed in 
AML relapse patients significantly associated with promoters harbouring epiallele shift than 
with promoter not harbouring epiallele changes (Li et al., 2016). 
 
However, the scATAC-seq analysis presented here has some caveats associated with small 
sample size leading to high technical noise. Although stringent filtering of cells might have 
helped in overcoming some of these, unfortunately, this also means that rare cell subsets having 
unique chromatin accessibility landscape may have been lost due to strict filtering. It is also 
worth noting that scATAC-seq data is highly sparse. A typical human scATAC-seq dataset 
contains 102-104 cells with 103-105 sequenced reads per cell. However, the number of cis-
regulatory elements (CREs) in the genome far exceeds 105 (Ji et al., 2020). Thus, in a typical 
cell, most CREs do not have any mapped read whereas for the CREs with reads, the number 
of mapped reads rarely exceeds two because each locus has no more than two copies of 
assayable chromatin per cell in a diploid genome (Schep et al., 2017; Ji et al., 2020). Also, the 
current scATAC-seq technology destroys cells during the assay and thus, one can only obtain 
a snapshot of a cell at one time point. However, molecular events such as transcription factor 
(TF)-DNA binding and their dissociation are temporal stochastic processes. The steady-state 
activity of a CRE in a cell is determined by the probability that such stochastic events occur 
over time. Since probability is a continuous measure, the overall activity of a CRE in a cell 
should be a continuous signal in principle. The sparse and nearly binary scATAC-seq data 
collected for each CRE at one single time point therefore cannot accurately describe the CRE’s 
continuous steady-state activity in a cell (Ji et al., 2020). These challenges can be circumvented 
to certain extent by estimating the probability from static observations using higher cell 






over time still makes scATAC-seq the most popular method for single-cell regulome mapping 
due to its relatively simple and robust protocol and unparalleled throughput (Zhou et al., 2019). 
 
Chromatin remodelling has been defined as one of the early candidates responsible for bursting 
nature of transcription. As eukaryotic genes are wrapped around histone proteins that form 
chromatin fibres, and chromatin can be remodelled from a tightly bound, transcriptionally inert 
structure to a more loosely bound, transcriptionally active conformation through the action of 
various chromatin-remodelling enzymes. Thus, random events of chromatin remodelling could 
result in random bursts of transcription. Some of the initial studies performed on this hypothesis 
had provided indications towards the alteration of chromatin-remodelling enzymes resulting in 
stochastic gene expression (Raser and O’Shea, 2004a) (Xu, Zawadzki and Broach, 2006). 
Genomic position including positional effects like measuring correlations between proximally 
located genes also appeared to have a strong effect on covariation in bursting between multiple 
genes which provided a link between chromatin-related events and stochastic gene expression 
by indirect means (Becskei, Kaufmann and Van Oudenaarden, 2005) (Raj et al., 2006). In 
agreement with this, the analysis presented here suggested an association between gene 
expression stochasticity with a gain in chromatin accessibility pattern during RUNX1-
RUNX1T1(9a) leukaemia progression. 
 
Recent advancements in single-cell approaches have shown that many eukaryotic genes are 
transcribed stochastically in bursts of specific sizes and frequencies (Raj et al., 2006) (Levsky 
et al., 2002) (Larsson et al., 2019), however, very few studies have made an attempt to elucidate 
the molecular mechanisms behind transcriptional bursting. One such study based on the 
analysis of 8,000 individual human genomic loci using time-lapse fluorescence microscopy 
indicated the role of promoter as the key regulator in defining transcriptional dynamics. The 
study strengthened the argument that transcriptional bursting dominates across the human 
genome, both burst frequency and burst size vary by chromosomal location, and transcriptional 
activators alter burst frequency and burst size, depending on the expression level of the locus 
(Dar et al., 2012). In this line, a study conducted by Naef’s lab on histone acetylation using 
Bmal1 promoter as their model system suggested that transcriptional bursting predominantly 
resulted from variations in burst frequency while the genomic position changed the burst size. 






being greatest at peak expression and lowest at trough expression, while remaining unaffected 
by the genomic location (Nicolas et al., 2018). Although the authors showed it directly for 
H3K27ac mark however, there was indirect evidence suggesting that H3K9ac would have a 
similar effect. This was compatible with our previous observation on Kat2a associated 
transcriptional burst frequency in the mouse MLL-AF9 model where loss of Kat2a led to a 
reduction in burst frequency of Kat2a-acetylated targets (Domingues et al., 2020). Several 
studies have proposed that promoter reactivation suppression is essential for controlling 
transcriptional bursting (Zoller et al., 2015), and promoter and enhancer elements regulate 
burst size and frequency, respectively (Fukaya, Lim and Levine, 2016b) specifically with 
H3K27ac mark being linearly associated with differential burst frequency (Larsson et al., 
2019). In contrast to this, few studies have indicated that enhancers are essential in regulating 
burst size, both by increasing bursting amplitude, equivalent to the rate of transcription 
initiation, and bursting length, indicative of the total time the enhancer stays in the ON state 
(Falo-Sanjuan et al., 2019). However, the molecular mechanism behind cis-regulatory 
elements (such as the TATA box) and chromatin accessibility at the core promoter in regulating 
transcriptional bursting kinetics has not been extensively explored yet except for a few studies 
providing a link between these factors and transcriptional dynamics (Hornung et al., 2012b) 
(Zoller et al., 2015). 
 
On these lines, my thesis work attempts at shedding light on understanding the potential impact 
of chromatin remodelling on transcriptional dynamics in context of disease initiation. This 
work suggests that the cell-to-cell transcriptional variability observed upon loss of Kat2a can 
accelerate pre-leukaemia transformation which further aids in leukaemia progression. Further, 
this enhanced cell-to-cell transcriptional variability may be associated with a gain in chromatin 
accessibility. Furthermore, the work highlights that the cell-to-cell transcriptional variability 
observed during early stages of pre-leukaemia transformation creates a cellular diversity, as 
evident from differentiation towards B-cell and monocytic lineages, with an increased 
accessibility towards cell states prone to transformation. These candidate cell populations upon 
transformation may benefit from low biosynthetic activity that promotes their progression to a 
leukaemic state (Fig 7.1). This work provides a benchmark in associating chromatin 
remodelling with transcriptional landscape during pre-leukaemia and has the potential to be 






Future work may involve studying the transcriptional bursting parameters upon inhibition/loss 
of KAT2A during pre-leukaemia progression. This can be achieved by employing techniques 
like single-molecule RNA FISH (smRNA-FISH) or Droplet digital PCR analysis for KAT2A 
targets at different time points during RUNX1-RUNX1T1(9a) pre-leukaemia progression. As 
inhibition of KAT2A altered the crosstalk between promoter and candidate enhancer regions, 
it would be interesting to study how these changes in epigenomic landscape regulate the burst 
size and burst frequency of Kat2a associated targets. Given that loss of Kat2a reduced the burst 
frequency of its associated targets in case of MLL-AF9 model of leukaemia (Domingues et al., 
2020), understanding the transcriptional parameters during RUNX1-RUNX1T1(9a) pre-
leukaemia would enable a detailed understanding of Kat2a mediated transcriptional variability 
in a disease stage specific manner. A change in burst size may indicate the potential promoter 
mediated regulation of Kat2a targets contributing to transcriptional variability, whereas 
alterations in burst frequency may suggest crosstalk with putative enhancer regions leading to 
enhanced transcriptional variability upon Kat2a loss. 
 
Although increase in transcriptional instability may seem contrary to an enhanced chromatin 
accessibility observed upon loss of Kat2a, however, this could potentially explain the 
observations related to cellular differentiation upon Kat2a loss as well as initiation of new gene 
programmes during stochastic speciation of pre-leukaemia cells. An alternative  explanation 
for increase in chromatin accessibility could be a loss of genome integrity by aberrant 
recruitment of replication licensing factors (Devbhandari et al., 2017; Kurat et al., 2017). With 
this in mind, future work could explore the applications of targeted DNA sequencing to study 
signs of DNA damage in candidate regulatory regions associated with Kat2a target genes. For 
this, the upstream regulatory regions of Kat2a candidate target genes could be amplified from 
RUNX1-RUNX1T1(9a) pre-leukaemia samples using PCR, and DNA sequencing could be 
performed on the PCR amplicons. The sequencing data thus generated could be used to study 
somatic variants accumulated in these regulatory regions during the process of pre-leukaemia 
progression. An increase in accumulation of somatic variants upon loss of Kat2a would suggest 
an association between loss of Kat2a and increase in genomic instability. 
 
Going forward, it will also be interesting to make use of epigenetic tools (e.g. dCas9-KAT2A 






enhancers and test molecular and functional consequences of the manipulation. To achieve this, 
guide RNAs against candidate regions of interest could be specifically designed to directly 
manipulate Kat2a mediated acetylation activity at those regions in representative cell lines like 
Kasumi-1. This will allow study of locus specific changes in transcriptional bursting 
parameters upon directing Kat2a mediated acetylation. This strategy will be instrumental in 
developing a mechanistic understanding of individual acetylation events and the ability of 
specific sequences to regulate transcriptional bursting activity. In the future, this knowledge 





























Figure 7.1 : Proposed model depicting transcriptional variability consequent to differential 
chromatin accessibility promoting leukaemia. 
The differential chromatin remodelling pattern obtained upon MB-3 treatment of Kasumi-1 cells 
suggesting an increase in cell-to-cell transcriptional variability (yellow coloured cluster was associated 
with enhanced accessibility), similar to the observation from scRNA-seq data obtained from RUNX1-
RUNX1T1(9a) pre-leukaemia. This increase in transcriptional variability leads to cell-fate 
diversification making transformation prone cells more accessible. These cells upon transformation 
through RUNX1-RUNX1T1(9a) overexpression then benefit though reduced ribosomal activity in order 
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Annexure-A: Analysis Scripts 
A.1 Single-cell RNA sequencing analysis 
Pre-processing and filtering  











## creating a Seurat object 
 
amlseu_500_3 <- CreateSeuratObject(raw.data = amlseu_500_3.data, 
min.cells = 53, min.genes = 500, project = "AML1_ETO") 
 







## calculating percentage mitochondrial content 
 
mito.genes <- grep(pattern = "^MT-", x = rownames(x = 
amlseu_500_3@data), value = TRUE) 
percent.mito <- Matrix::colSums(amlseu_500_3@raw.data[mito.genes, 
])/Matrix::colSums(amlseu_500_3@raw.data) 
 
## adding gene counts, UMI counts and percentage mitochondrial 
content as metadata 
 
pbmc <- AddMetaData(object = amlseu_500_3, metadata = percent.mito, 
col.name = "percent.mito") 





VlnPlot(object = amlseu_500_3, features.plot = c("nGene", "nUMI", 
"percent.mito"), nCol = 3) 
 
## plotting relationship between UMI counts and gene counts or 
mitochondrial content 
 
GenePlot(object = amlseu_500_3, gene1 = "nUMI", gene2 = 
"percent.mito") 
GenePlot(object = amlseu_500_3, gene1 = "nUMI", gene2 = "nGene") 
 
## Filtering cells with low and high threshold 
 
amlseu_500_3 <- FilterCells(object = amlseu_500_3, subset.names = 
c("nGene", "percent.mito"), low.thresholds = c(200, -Inf), 
high.thresholds = c(2500, 0.05)) 
 
Detection of variable genes 
amlseu_500_3 <- FindVariableGenes(object = amlseu_500_3, 
mean.function = ExpMean, dispersion.function = LogVMR, x.low.cutoff 
= 0.0125, x.high.cutoff = 3, y.cutoff = 0.5) 
 
length(x = amlseu_500_3@var.genes) ## getting the number of variable 
genes 
 
Differential expression calculation using DESeq2 
amlseu_500_3 <- SetAllIdent(object = amlseu_500_3, id = 'ident') 
 
diff_56_46_deseq <- FindMarkers(object = amlseu_500_3, ident.1 = 
'IN56', ident.2 = 'IN46', test.use = "DESeq2") 
 
amlseu_500_3 <- ScaleData(object = amlseu_500_3, vars.to.regress = 
c("nUMI", "percent.mito")). ## scaling the data 
 
Linear Dimensionality reduction analysis 
amlseu_500_3 <- RunPCA(object = amlseu_500_3, pc.genes = 
amlseu_500_3@var.genes, do.print = TRUE, pcs.print = 1:5, 
genes.print = 5) 
 





PCAPlot(object = amlseu_500_3, dim.1 = 1, dim.2 = 2) ## plotting PCA 
 
PCHeatmap(object = amlseu_500_3, pc.use = 10, cells.use = 500, 
do.balanced = TRUE, label.columns = FALSE) 
 
amlseu_500_3 <- JackStraw(object = amlseu_500_3, num.replicate = 
100, display.progress = FALSE) ## Jackstraw plot for estimating the 
significant PCs 
 
JackStrawPlot(object = amlseu_500_3, PCs = 1:12) ## visualizing 
Jackstraw plot 
 
PCElbowPlot(object = amlseu_500_3) ## elbow plot to determine the 
significant PCs 
 
Graph based clustering analysis 
amlseu_500_3 <- RunPCA(object = amlseu_500_3, pc.genes = 
amlseu_500_3@var.genes, do.print = TRUE, pcs.print = 1:5, 
genes.print = 5) 
 
amlseu_500_3 <- FindClusters(object = amlseu_500_3, reduction.type = 
"pca", dims.use = 1:10, resolution = 0.6, print.output = 0, save.SNN 
= TRUE) 
 
PrintFindClustersParams(object = amlseu_500_3) 
 
Non-linear dimensionality reduction analysis 
amlseu_500_3 <- RunTSNE(object = amlseu_500_3, dims.use = 1:10, 
do.fast = TRUE) 
TSNEPlot(object = amlseu_500_3) 
 
Creation of Cell Data Set object for pseudotime analysis using Monocle v3.0 
## reading barcodes from combined gene expression matrix 
 
amlseu_sample_sheet <- 
read.table("~/Desktop/mm10_2/total.barcodes_monocle.txt", sep = 
"\t") 
 





## reading gene IDs from combined gene expression matrix 
 
amlseu_gene_annotation_2 <- 
read.table("~/Desktop/mm10_2/total.genes_monocle.txt", sep = "\t") 
 
rownames(amlseu_sample_sheet) = amlseu_sample_sheet$V2 
 





pd_2 <- new("AnnotatedDataFrame", data = amlseu_sample_sheet) 
fd_2 <- new("AnnotatedDataFrame", data = amlseu_gene_annotation_2) 
 
amlseu_500_3_mono.data <- Read10X(data.dir = "~/Desktop/mm10_2/") 
 
## obtaining raw expression matrix using Seurat object 
 
amlseu_mono <- CreateSeuratObject(raw.data = amlseu_500_3_mono.data, 
project = "AMLETO_Monocle", min.cells = 53, min.genes = 500) 
expression_matrix <- amlseu_mono@data 
 
## creating a new cell data set object 
 
aml_m3_cds <- new_cell_data_set(expression_matrix, cell_metadata = 
amlseu_sample_sheet, gene_metadata = amlseu_gene_annotation_2) 
 
## performing pre-processing and normalization 
 
aml_m3_cds = preprocess_cds(aml_m3_cds, num_dim = 100) 
plot_pc_variance_explained(aml_m3_cds) 
 
## clustering the cells using k-means clustering 
 
aml_m3_cds <- cluster_cells(aml_m3_cds) 
plot_cells(aml_m3_cds) 
 
## colouring the cells based on sample ID 
 








colData(aml_m3_cds)$sampleID <- colo 
 
plot_cells(aml_m3_cds, color_cells_by = 'sampleID') 
 
Performing dimensionality reduction analysis 
aml_m3_cds <- reduce_dimension(aml_m3_cds, reduction_method = 
"tSNE") 
 
## clustering the cells using k-means clustering and overlaying on 
tSNE plot 
 
aml_m3_cds <- cluster_cells(aml_m3_cds, reduction_method = "tSNE") 
 
Pseudotime trajectory analysis 
## learning the trajectory 
 
aml_m3_cds <- learn_graph(aml_m3_cds) 
 
plot_cells(aml_m3_cds, color_cells_by = 'sampleID', 
label_cell_groups = FALSE, label_leaves = TRUE, label_branch_points 
= TRUE, graph_label_size = 1.5) 
 
## ordering the cells in pseudotime 
 
aml_m3_cds = order_cells(aml_m3_cds) 
 
plot_cells(aml_m3_cds, color_cells_by = "pseudotime", 
label_cell_groups = 'sampleID', label_leaves = FALSE, 
label_branch_points = FALSE, graph_label_size = 1.5) 
 
## obtaining the principal node  
 
get_earliest_principal_node <- function(aml_m3_cds, id = "IN46"){ 
+ cell_ids <- which(colData(aml_m3_cds)[,"sampleID"] == id) 





+ closest_vertex <- 
aml_m3_cds@principal_graph_aux[["UMAP"]]$pr_graph_cell_proj_closest_
vertex 
+ closest_vertex <- as.matrix(closest_vertex[colnames(aml_m3_cds), 
]) 





## ordering the cells relative to principal node 
 
aml_m3_cds = order_cells(aml_m3_cds, root_pr_nodes = 
get_earliest_principal_node(aml_m3_cds)) 
plot_cells(aml_m3_cds, color_cells_by = "pseudotime", 
label_cell_groups = FALSE, label_leaves = FALSE, label_branch_points 
= FALSE, graph_label_size = 1.5) 
 
Pairwise distance calculation 
# Subsetting required matrix of cells 
 
Non_LeuP_amlseu <- SubsetData(object = amlseu_500_3, ident.use = 
c('B-cells', 'LMPPs', 'CMPs', 'Monocytes')) 
 
# Calculate mean, CV and DM 
 
means_Non_LeuP <- rowMeans(as.matrix(Non_LeuP_amlseu@data)) 
cv2_Non_LeuP <- apply(as.matrix(Non_LeuP_amlseu@data), 1, 
var)/means_Non_LeuP^2 
dm_Non_LeuP <- DM(means_Non_LeuP, cv2_Non_LeuP) 
 
# Sort based on DM to identify top 500 highly variable genes 
 
dm_Non_LeuP_sorted <- sort(dm_Non_LeuP, decreasing = TRUE) 
top_500_Non_LeuP <- dm_Non_LeuP_sorted[1:500] 
 










# calculating spearman correlation 
Non_LeuP_spearman <- cor(x = as.matrix(Non_LeuP_subset_matrix), y = 
NULL, method = "spearman") 
 
# calculating distance, d 
d_Non_LeuP <- sqrt((1-Non_LeuP_spearman)/2) 
dim(d_Non_LeuP) 
 
# for plotting merging every cell type ‘d’ in single vector 
d_Non_LeuP_vector <- as.vector(d_Non_LeuP) 
d_NonLeuP_w_LeuP <- c(d_Non_LeuP_vector, d_LeuP_vector) 
sampid_NonLeuP_w_LeuP <- c(rep("Non-Leukaemic Progenitors", 
length(d_Non_LeuP_vector)), rep("Leukaemic Progenitors", 
length(d_LeuP_vector))) 
 
# making a dataframe for ‘d’ and ‘sampleID’ 




# assigning column names for defining aesthetics in ggplot 
colnames(total_NonLeuP_w_LeuP_dataframe) <- c("Pairwise_Distance", 
"Cell_Type") 
p_NonLeuP_w_LeuP_total <- ggplot(total_NonLeuP_w_LeuP_dataframe, 
aes(factor(Cell_Type), Pairwise_Distance)) 
p_NonLeuP_w_LeuP_total + geom_violin(aes(fill = factor(Cell_Type))) 
# colours based on cell type 
 
A.2 Single-cell ATAC sequencing analysis 
Filtering the lower quality cells 
## loading single-cell ATAC sequencing individual peak vs gene 





import numpy as np 
dmso_mb3_column_range=range(3,91) 
print dmso_mb3_column_range 













## to obtain peak information, chromosome start and stop location 
for each peak in input file 
 
dmso_mb3_peak_info=[] 
with open(dmso_mb3_file_name,'r') as f: 
  
 for line in f: 
  peak_info=line.split('\t')[0:3] 
  dmso_mb3_peak_info.append(peak_info) 
   
## to count number of 1's for each cell and impose a threshold of 
15% 1’s which is 13 in this case (15% of 88) 





## dmso_mb3_indices is a boolean array of length number of peaks 
## selecting those rows from peak info which have a value of indices 




for i in range(len(dmso_mb3_peak_info)): 
 if dmso_mb3_indices[i]: 
  dmso_mb3_filt_peak_info.append(dmso_mb3_peak_info[i])  
   
## dmso_mb3_indices is boolean array for obtaining data from 
dmso_mb3_data 
   
dmso_mb3_filt_peak_data=dmso_mb3_data[dmso_mb3_indices,:] 
 
## peak_info an array of chromosome location, start, stop 





## peak_data an array of all binary values for each cell and each 
peak 
## peak_info_string is a string having each value representing 
chromosome location, start and stop 
## peak_data_string is a string each value of which is 88 binary 




with open(dmso_mb3_filt_peak_data_file,'w') as f: 
 for i in range(len(dmso_mb3_filt_peak_info)): 
  peak_info=dmso_mb3_filt_peak_info[i] 
  peak_data=dmso_mb3_filt_peak_data[i,:] 
  peak_info_string='\t'.join(peak_info) 
  peak_data_string='\t'.join([str(val) for val in 
peak_data]) 
  f.write('\t'.join([peak_info_string,peak_data_string])) 
  f.write('\n') 
 
Jaccard distance calculation 
 
## loading filtered single cell ATAC sequencing matrix having peak 

















from scipy.spatial import distance 













## calculation of jaccard distance for individual cell with respect 
to each cell 
 
for i in range(dmso_mb3_columns): 









Dimensionality reduction analysis using tSNE 
## loading filtered single cell ATAC sequencing matrix having peak 





import numpy as np 

















from sklearn.manifold import TSNE 








import matplotlib.pyplot as plt 
 
## creating a list of colours which contains 1 for all DMSO cells 
 
dmso_mb3_colors=[1 for i in range(0,38)] 
 
## creating a list of colours which contains 2 for all mb3 cells 
 




## creating an array of 88 elements with initial 38 values as 1 and 






























from Pycluster import kmedoids 







for n in range(2,11): 
        
clusterid,error,nfound=kmedoids(dmso_mb3_jaccard_data,nclusters=n,np
ass=20) 
        print n. ## print the number of clusters 
        for val in clusterid: 
            print val,',', 
        print '\n'  
        print error 
        print nfound 
        print '\n\n' 
 











## generating transpose of dmso_mb3_data matrix 









from sklearn.manifold import TSNE 
from scipy.spatial import distance 
dmso_mb3_data_t_embedded=TSNE(n_components=2,metric=distance.jaccard






import matplotlib.pyplot as plt 
dmso_mb3_clusters=[21 , 21 , 21 , 21 , 53 , 21 , 21 , 21 , 21 , 21 , 
21 , 45 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 
, 21 , 45 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 21 , 
21 , 45 , 45 , 45 , 45 , 45 , 45 , 45 , 45 , 45 , 53 , 45 , 53 , 53 
, 45 , 53 , 53 , 53 , 45 , 45 , 45 , 53 , 45 , 53 , 53 , 53 , 21 , 
45 , 45 , 45 , 45 , 45 , 21 , 45 , 45 , 45 , 45 , 45 , 21 , 45 , 53 
, 53 , 53 , 45 , 45 , 45 , 45 , 45 , 45 , 45 , 21 , ] 
 








Calculation of differential accessibility peaks 
dmso_mb3_file_name="/home/sg823/scATAC_Kasumi_analysis3_01092018/dms
o_mb3_raw_15_filt_peaks.txt" 























 for j in dmso_mb3_infogain_data_col_range: 
  if dmso_mb3_infogain_data[i][j]==0: 
   count_zero+=1 
  else: 
   count_nonzero+=1 
  if j>37: 
   if dmso_mb3_infogain_data[i][j]==0: 
    count_g2zero+=1 
   else: 
    count_g2nonzero+=1 
  if j<=37: 
   if dmso_mb3_infogain_data[i][j]==0: 
    count_g1zero+=1 
   else: 





 entropy=scipy.stats.entropy(pk,base=2)  ## calculating global 
entropy 
  





 g1_entropy=scipy.stats.entropy(pk_g1,base=2)  
  



















 if p_g2nonzero-p_g1nonzero>threshold: 
  celltype=2 
   
 elif p_g1nonzero-p_g2nonzero>threshold: 





array,alpha=0.05,method='indep', is_sorted=False). ## calculation of 
adjusted p_value using Benjamin Hochberg method  
 
for i in dmso_mb3_row_range: 
 str_data = [str(val) for val in data_array[i]] 





















B.1: Definition of haematopoietic compartments for flow cytometry 
 
Cell population Gating strategy 
HSC Lin – cKit + Sca1 + CD34 - CD135 - 
MPP Lin – cKit + Sca1 + CD34 + CD135 - 
LMPP Lin – cKit + Sca1+ CD34 + CD135 + 
CMP Lin – cKit + Sca1 - CD34 +/lo CD16/32 lo 
GMP Lin – cKit + Sca1 + CD34 + CD16/32 hi 
MEP Lin – cKit + Sca1 + CD34 - CD16/32 - 
 
B.2: Primers for Genotyping 
 





















B.3: Primers to confirm excision/mutation recombination 
 


























B.4: List of antibodies and fluorescent dyes 
 
Antibody Fluorochrome Catalogue ID Clone Dilution Supplier 
Annexin V APC 640919 -  BioLegend 
CD45R/ B220 APC-Cy7 103223 RA3-6B2 1:50 BioLegend 
CD45R/ B220 PerCP-Cy5.5 103235 RA3-6B2 1:100 BioLegend 
CD117/c-Kit APC-Cy7 105826 2B8 1:50 BioLegend 
CD11b/Mac1 AF700 101222 M1/70 1:200 BioLegend 
CD14 PE-Cy7 123315 Sa14-2 1:100 BioLegend 
CD16/32/FcγR PE 101308 93 1:100 BioLegend 
CD24 BV510 101831 M1/69 1:100 BioLegend 
CD34 APC 128612 HM34 1:100 BioLegend 
F4/80 PE 123109 BM8 1:100 BioLegend 
Gr1 PB 108430 RB6-8C5 1:100 BioLegend 
Hoechst 33342 - H3570 - 1:10000 Invitrogen 
Hoechst 33258 - H3569 - 1:10000 Invitrogen 
Sca1 PE-Cy7 108114 D7 1:100 BioLegend 
Streptavidin BV421 405226 - 1:200 BioLegend 
Streptavidin BV605 405229 - 1:200 BioLegend 
CD45R/B220 (Lin) Biotin 103204 RA3-6B2 1:300 BioLegend 
Ter119 (Lin) Biotin 116204 Ter119 1:300 BioLegend 
Gr1 (Lin) Biotin 108404 RB6-8C5 1:300 Biolegend 
CD3e (Lin) Biotin 100304 145–2 C11 1:300 BioLegend 
CD11b (Lin) Biotin 101204 M1/70 1:300 BioLegend 







Reaction Buffer Kit 
AF647 azide A10277 - 1:500 Invitrogen 
 
B.5: List of cell culture reagents 
 
Reagent Catalogue ID Supplier 
RPMI R8758 Sigma 
IMDM I3390 Sigma 
DMEM D6429 Sigma 
FBS F9665 Sigma 
L-Glutamine G7513 Sigma 
Antimycotic A5955 Sigma 
Trypsin 59418C Sigma 
PBS D8537 Sigma 
Methylcellulose M3434 Stem Cell Technologies 
Mouse IL-3 213-13 Peprotech 
Mouse IL-6 500-P56 Peprotech 
Mouse SCF 500-P71 Peprotech 
 
B.6: List of Molecular Biology reagents 
 
Reagent Catalogue ID Supplier 
DNA extraction kit K1820-01 Invitrogen 
SYBR master mix UF-LSMT-B0701 Takyon 
PCR master mix 203643 Qiagen 
Agarose BP160-100 Fisher Bioregents 
BSA BP9700-100 Fisher Scientific 
SYBR safe DNA gel stain NBS-SV Invitrogen 
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